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ABSTRACT 
Human mesenchymal stem cells (hMSCs) have been identified as a promising cell-based therapy 
candidate to treat a number of unmet clinical indications, however, in vitro expansion will be 
required to increase the available number of cells and meet this demand. Scalable 
manufacturing processes, amenable to closed, single-use and automated technology, must 
therefore be developed in order to produce safe, effective and affordable hMSC therapies. To 
address this challenge, a controlled serum-free end-to-end microcarrier process has been 
developed for hMSCs, which is amenable to large-scale manufacture and therefore increasing 
economies of scale. Preliminary studies in monolayer culture assessed the level of variability in 
growth between five hMSC donors, which was found to have a variance of 25.3 % after 30 days 
in culture. This variance was subsequently reduced to 4.5% by the development of a serum-free 
monolayer culture process with the maintenance of critical hMSC characteristics and an 
increased number of population doublings. In order to transfer this into a scalable system, the 
serum and serum-free expansion processes were transferred into suspension by the addition of 
plastic microcarriers in 100 mL spinner flasks without control of pH or dissolved oxygen (DO). 
This achieved a maximum cell density of 0.08 ± 0.01 · 106 cells.mL-1 in FBS-based medium, 0.12 
± 0.01 · 106 cells.mL-1 in HPL-based medium and 0.27 ± 0.03· 106 cells.mL-1 in serum-free medium 
after six days. In order to drive consistency and yield into the manufacturing process, a process 
control system was developed for the FBS-based microcarrier expansion process in a 100 mL 
DASbox bioreactor platform to control DO, pH, impeller rate and temperature. Reduced impeller 
rates and DO concentrations were found to be beneficial, with a final cell density of 0.11 ± 0.02 
· 106 cells.mL-1 and improved post-harvest outgrowth and colony-forming unit (CFU) potential 
compared to uncontrolled microcarrier and monolayer culture. This controlled bioreactor 
expansion process was then applied to the previously developed serum-free microcarrier 
process, eventually achieving a final cell density of 1.04 ± 0.07 · 106 cells.mL-1, whilst retaining 
key post-harvest hMSC characteristics. Following the controlled serum-free expansion and 
harvest of hMSCs, a downstream and cryopreservation process was developed to assess the 
impact of prolonged holding times and subsequent unit-operations on hMSC quality 
characteristics. This showed that hMSCs are able to maintain key characteristics throughout the 
entire end-to-end process, demonstrating their potential for commercial scale manufacture. 
 
Key words: cell-based therapy, consistency, cryopreservation, downstream process 
development, human mesenchymal stem cell, manufacture, microcarrier, process control, 
regenerative medicine, serum-free. 
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1 Introduction 
 
Regenerative medicine is a growing field that aims to develop treatments to restore or maintain  
tissue function (Mason and Dunnill 2008; Mather et al. 2009) and draws upon therapies from 
all four pillars of healthcare: pharmaceuticals, biologics, devices and cell therapies (Mason and 
Manzotti 2009). Cell therapy is the therapeutic application of cells regardless of cell type or 
clinical indication – a platform technology (Mason et al. 2011) with global sales of well over £1 
billion and growth predicted to follow (Mason 2013). Human mesenchymal stem cells (hMSCs) 
have been identified as a promising cell-based therapy to target a number of unmet clinical 
indications such as heart disease and stroke, due to their ease of isolation, relative immune 
privilege and their ability to respond to local environmental cues, to release a cascade of trophic 
factors to initiate repair (Caplan 2009; Caplan and Correa 2011; Pittenger et al. 2015).   
 
For the majority of clinical indications, the transplantation of primary donor hMSCs may not be 
sufficient to achieve a therapeutic benefit and the expansion of cells in vitro will be required to 
address the shortage of functional cells available in the patient. The aim of these manufacturing 
processes is to significantly increase cell numbers without negatively affecting the therapeutic 
potential of the cell, which is known to deteriorate with time in culture (Hourd et al. 2008). It is 
possible that the commercial manufacturing lot size required to meet this need will be in the 
order of trillions of cells (Rowley et al. 2012a), though this is dependent on the dose 
requirements per patient and market size of each indication to be treated (Wappler et al. 2013). 
Many of the manufacturing processes for these cell-based therapies, for example Prochymal® 
(Osiris Therapeutics), are based on manual planar culture technology which has proven difficult 
to cost-effectively operate at the commercial scale. It is clear therefore, that this current manual 
planar culture technology will not be sufficient to meet this need and scalable manufacturing 
processes, amenable to closed, single-use and potentially automated technology, must be 
developed in order to produce safe, effective and affordable cell-based therapies.   
 
Humans MSCs are complex biological entities that are sensitive to their environment and display 
intrinsic variability within a tightly regulated industry. The two major sources of variation in the 
product are introduced by the process input material and process conditions (Williams et al. 
2012), which must be controlled in order to reduce product costs. A key aspect of reducing 
variation in the process input material will be reducing and eventually eliminating the use of 
fetal bovine serum (FBS) from the cell culture medium (Wappler et al. 2013). In addition to lot-
Chapter 1: Introduction 
 
 
2 | P a g e  
 
to-lot variability, there are further process constraints on the use of FBS such as limited supply, 
increasing costs, potential for pathogen transmission (Brindley et al. 2012) and reduced scope 
for process optimisation. All of these considerations mean that moving towards a serum-free 
process would be beneficial in the development of a scalable and consistent manufacturing 
process.    
 
A lack of online process control is a key barrier for the consistent manufacture of hMSC 
therapies, as it has the potential to reduce the variation associated with the process conditions 
during manufacture. Without effective process control metrics, expansion technology will suffer 
when attempting to maintain product consistency and will therefore incur a higher cost of 
production. Effective monitoring and control systems will provide assurance of continued 
suitability and process capability, under the guidance of quality risk management (International 
Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals 
for Human Use 2008). Process control systems for conventional bioreactor technology are well-
understood and have the potential to be adapted for the manufacture of hMSC therapies (Butler 
2005; Trummer et al. 2006) and subsequently reduce variation in the hMSC product.   
 
One of the key differences between traditional cell bioprocesses to manufacture therapeutic 
proteins and the development of cell-based therapy manufacturing processes is that the cellular 
identity and functional characteristics must be maintained throughout the entire process. This 
means that the development of scalable and cost-effective off-the-shelf hMSC manufacturing 
processes must consider the harvest, downstream processing and long-term preservation of the 
hMSC product and its functional characteristics. The successful development of these end-to-
end manufacturing processes should be systematically evaluated as a set of sequential unit-
operations, rather than developing each step of the process in isolation, as changes in the 
upstream process will have a fundamental impact on the product quality throughout the 
following process steps. Accordingly, the scalable end-to-end manufacture of hMSC therapies, 
to consistently obtain clinically relevant cell numbers of the desired quality for commercial 
production, remains a key challenge for the successful development of off-the-shelf hMSC 
manufacturing processes.         
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2 Literature Review  
 
Regenerative medicine and tissue engineering are expanding research areas in which living 
human cells and tissues are being developed as potential therapeutic products. Clinical 
applications of cell based therapies are wide ranging, but are predominantly aimed at 
degenerative conditions, organ failure, and tissue damage (Thomas et al. 2007). Of increasing 
interest in the field is the use of stem cells, which have demonstrated the potential to treat or 
even cure chronic diseases such as diabetes, cancer, cardiac disease and neurological disorders, 
effecting billions of people throughout the world (Mimeault and Batra 2006; Mimeault et al. 
2007). Stem cells are defined as cells that have the ability to perpetuate themselves through 
self-renewal with the ability to generate mature cells of a particular tissue (Reya et al. 2001). It 
is this ability to self-perpetuate and produce large quantities of therapeutically active cells that 
have generated significant interest around the use of stem cells to not only treat, but potentially 
cure many diseases.  
 
 
2.1 Historical perspective of stem cells 
The transplantation of bone marrow from healthy donors to treat patients for bone 
degeneration dates back to the 19th century (Goujon 1869) with abysmal results and no 
survivors. The research slowly continued and it was not until the pioneering work of Dr Edward 
“Don” Thomas in the 1950s that patients began to go into remission from leukemia, for which 
he won the Nobel Prize for Medicine in 1990. Despite the number of bone marrow 
transplantations, the discovery of mammalian bone marrow stem cells was not made until 1961 
at the University of Toronto by James Till and Ernest McCulloch who demonstrated that the 
number of marrow cells injected into a mouse produced a linear correlation with the number of 
colonies formed in the spleen (Till 1961; Till and McCulloch 1961). This work developed the 
hypothesis that each of these colonies was produced by a single cell or clone, which was verified 
by further experiments (Becker et al. 1963; Siminovitch et al. 1963). The impact of this research 
cannot be underestimated, as it was the first set of experiments to conclusively prove that bone 
marrow contained cells with clonogenic potential and sparked a new research area, which 
aimed to harness this potential and further the development of bone marrow transplantation 
(Tavassol.M and Crosby 1968). 
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Despite the realisation that bone marrow contained cells with the potential to proliferate in 
vivo, the presence of non-hematopoietic stem cells could not be confirmed until they were 
isolated. This critical step was taken in the late 1960s by a Russian scientist Alexander 
Friedenstein with colleagues at the University of Moscow. The group showed that “fibroblast-
like” clonogenic cells from rat bone marrow could be isolated from hematopoietic progenitor 
cells by adherence to tissue culture plastic as well as in vivo differentiation down the osteogenic 
lineage via heterotopic transplantation (Friedens.Aj et al. 1966). This proved vital in their 
development, as it provided not only the proof that these “stromal stem cells” are a distinct 
population in the bone marrow but also provided a method for isolation, allowing for more 
detailed studies to characterise these cells. Studies soon followed to show that discrete colonies 
could be formed from single cells, bringing about the concept of a bone marrow colony-forming 
unit fibroblast (CFU-f) (Friedens.Aj et al. 1970; Friedens.Aj et al. 1974; Friedenstein et al. 1976), 
as well as the ability to form multiple skeletal tissues (bone, cartilage, adipose and fibrous 
tissues) in vivo by the progeny of a single cell which Friedenstein and Owens termed  “osteogenic 
stem cells” (Friedenstein et al. 1987; Owen and Friedenstein 1988). 
 
It was not until the work of Arnold Caplan in the early 1990s that the potential for “mesenchymal 
stem cells” to regenerate skeletal tissues was considered for clinic indications (Caplan 1991). 
This idea of a cell therapy, whereby hMSCs could be taken from a patient, expanded ex vivo and 
returned to the same patient for therapeutic benefit (autologous therapy) initiated the need for 
in vitro expansion technologies to obtain these clinically relevant cell numbers, due to the rarity 
of these cells in vivo. This shift to in vitro isolation and culture meant that many more research 
groups could investigate hMSCs using conventional cell culture techniques combined with the 
highlighted potential for multiple target therapeutic indications. This led to the formation of the 
first cell therapy company Osiris Therapeutics (NASDAQ:OSIR) in 1992 who quickly began pre-
clinical development of an hMSC therapy for the treatment of Graft vs. Host disease (GvHD) 
along with continuing research in the field (Bruder et al. 1994; Wakitani et al. 1995; Jaiswal et 
al. 1997; Johnstone et al. 1998; Caplan and Dennis 2006a; Caplan 2007). It was not until 1999 
that the true potential of hMSC therapies received worldwide attention after Osiris Therapeutics 
published a research paper in Science suggesting a broad therapeutic utility for hMSCs 
(Pittenger et al. 1999). This breakthrough coincided with the isolation of human embryonic stem 
cells (hESCs) by James Thomson in 1998 (Thomson et al. 1998) which produced significant 
interest around the broad therapeutic potential of stem cells. On the crest of a wave, the stem 
cell world changed dramatically with hMSCs being proposed for the treatment of many 
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indications (mirroring hESCs), far outside of the original limits proposed by Friedenstein et al in 
the 1970s. 
 
This broad therapeutic utility is still being considered today, with cell therapy companies such 
as Mesoblast Ltd (Australia), Athersys Inc. (USA), Pluristem Therapeutics Inc. (Israel) and 
Celgene (USA) currently in clinical development with hMSCs products for the treatment of acute 
myocardial infarction, ischemic stroke, multiple sclerosis, limb ischemia, pulmonary disease and 
diabetes. Clearly there is a push to commercialise cell therapy products targeting these major 
indications, however, rigorous product characterisation must be considered to ensure hMSC 
have the functional ability to treat this broad range of clinical indications.  
 
 
2.1.1 The sobering years 
Reality soon hit at the turn of the millennium. The hype surrounding the potential of hMSCs to 
treat a vast number of clinical indications sparked by the work of Osiris Therapeutics (Pittenger 
et al. 1999) and the groundbreaking developments within embryonic stem cell research led 
many academic institutions to invest heavily in hMSC research. Conversely, the green shoots of 
industry that began to emerge in the 1990s soon disappeared as the failure rate of clinical trials, 
the huge cash-burn and increased bankruptcy of cell therapy companies caused investors to 
lose confidence in the industry and as a result, the capital value of publically traded companies 
plummeted from $2.5 billion in 2000 to $300 million by 2003 (Lysaght and Hazlehurst 2004).  
 
 
2.1.2 Induced pluripotent stem cells 
Fueled in part by the lack of government funding for embryonic stem cell research, academia 
was in search of an alternative cell line which would provide the benefits of a pluripotent cell 
line without the associated ethical constraints. Based on work by Sir John B. Gurdon at Oxford 
University in 1962 (Gurdon 1962), Shinya Yamanaka et al  of Kyoto University successfully 
reprogrammed murine (Takahashi and Yamanaka 2006) followed by human (Takahashi et al. 
2007) mature cells to become pluripotent using a technique known as somatic-cell nuclear 
transfer (SCNT) in 2006 and 2007, respectively. SCNT allows for the creation of primitive 
embryonic-like stem cells by combining the nuclei from a somatic cell with an enucleated egg 
potentially allowing for the development of patient-specific pluripotent stem cells (Byrne et al. 
2007), termed induced pluripotent stem cells (iPS cells).  
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The derivation of human iPS cells in 2007 had a significant impact on the stem cell world, with 
the US research funding for non-embryonic cell lines more than doubling by 2009. At the same 
time, embryonic stem cell research experienced no significant increase in research funding even 
following the US government’s decision to pass the Stem Cell Research Enhancement Act and 
reinstate federal funding for embryo-derived cells lines in 2009. It seems that as the field 
develops, iPS cells are increasingly taking the place of ESCs as the pluripotent cell of choice with 
reduced ethical constraints associated with the destruction and manipulation of human 
embryos.  
 
 
2.1.3 Industry and early adopters  
The development of iPS cells in 2006 coincided with a large number of biotechnology companies 
becoming involved in the commercialisation of hMSC therapies. This has led to a large jump in 
the number of clinical trials for hMSC therapies from 2008 with peak interest for cardiac repair, 
skeletal disorders and disease of the immune system (Li et al. 2014). The development of 
systems such as the Celution by Cytori Therapeutics, began to drive the commercial interest in 
developing autologous cell-based therapy clinical trials. These point-of-care devices allow for 
the isolation of a patient’s own adipose derived hMSCs in the clinic, for re-implantation in the 
same procedure under the regulatory policy of minimal manipulation (Trainor et al. 2014). This 
has the benefit of a shorter regulatory pathway compared to manufactured products which is 
considered to be desirable due to shorter perceived reimbursement timelines, therefore 
reducing the risk to investors (O'Cearbhaill et al. 2014). 
 
The minimum guidelines for defining hMSCs published in 2006 by the International Society for 
Cellular Therapies (ISCT) came at a time when many big companies where getting involved in 
hMSC therapies, a fantastic demonstration of the give and take between academia and industry 
that will be imperative to achieve successful commercialisation. Industry creates the need that 
academia is charged with fulfilling and although the argument is still active about the issue of in 
vitro characterisation of hMSCs, the ISCT went some way to addressing the issue and gave 
industry and academia direction on the minimum definition of what constitutes an hMSC, which 
will be discussed further in Section 2.2.4.    
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2.2 Mesenchymal stem cells 
Ever since the term mesenchymal stem cell was first introduced by Arnold Caplan in 1991 
(Caplan 1991), much excitement has been generated around the potential for hMSCs to treat 
and in some cases cure human disease.  This has been mainly due to their ease of isolation as 
well as their ability to proliferate ex vivo under the appropriate culture conditions. Human MSCs 
have now been reportedly isolated from many tissue types such as bone marrow (Friedens.Aj 
et al. 1966; Friedens.Aj et al. 1970; Pittenger et al. 1999), adipose tissue (Zuk et al. 2001; Zuk et 
al. 2002), umbilical cord (Wang et al. 2004) and cord blood (Erices et al. 2000; Kogler et al. 2004) 
with the therapeutic benefit thought to be achieved via a combination of: 
 
1. Modulation of the patients’ immune system. 
2. Release of trophic factors to stimulate native tissue regeneration.  
3. Reducing the inflammatory response. 
 
Part of the defining criteria for an hMSC is the ability to differentiate into different cell types 
(Figure 2.1) including osteoblasts, chondrocytes, adipocytes, neural cells and connective tissues 
(Pittenger et al. 1999; Pittenger and Martin 2004). Along with the desirable characteristics 
described above, hMSCs have also received a lot of attention due to their ability for donor 
mismatched transplantation without ectopic formation and their non-engraftment following 
treatment, achieving their mode of action via a “hit and run” mechanism (von Bahr et al. 2012). 
This introduced the possibility of off-the-shelf (allogeneic) hMSC therapies, whereby many 
doses can be manufactured from a single batch to treat multiple patients. This allows for 
increasing economies of scale and the development of a business model that is far more akin to 
current biopharmaceuticals, a highly attractive proposition for pharmaceutical companies.  
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Figure 2.1. Ability of mesenchymal stem cells in the bone-marrow cavity to self-renew (curved 
arrow) and to differentiate (straight, solid arrows) towards the mesodermal lineage. The 
reported ability to trans-differentiate into cells of other lineages (ectoderm and endoderm) is 
shown by dashed arrows, as trans-differentiation has not been fully demonstrated in vivo. 
Taken from (Uccelli et al. 2008) 
 
2.2.1 hMSC nomenclature 
The term “mesenchymal stem cell” proposes a ubiquitous in vivo potential that has yet to be 
fully demonstrated (Bianco et al. 2008; Bianco et al. 2013a; Bianco et al. 2013b). The term 
mesenchymal stem cell suggests that they can be derived from skeletal and non-skeletal tissues 
as well as having the ability to act as a “drugstore” (Caplan and Correa 2011) delivering trophic 
factors (Caplan and Dennis 2006b) when infused in vivo to successfully treat a multitude of 
diseases, including those effecting non-skeletal tissues (Pittenger and Martin 2004; Caplan 
2005). This multilineage potential of hMSCs has yet to be proven in vivo, with a limited amount 
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of positive human clinical data to support this broad therapeutic utility. By applying the 
appropriate chemical cues to cells in vitro one could form almost any human tissue type. A good 
example of this is bone morphogenetic protein (BMP) which can cause adult myocytes to form 
osteoblast-like cells (Yamaguchi et al. 1991; Katagiri et al. 1994), but does not demonstrate that 
these cells are functional. It is important, therefore, that the in vivo mechanism of action of 
hMSCs is well understood so that manufacturing processes can be developed in order to 
maximise these desired cell attributes.   
 
Human MSCs represent an entirely heterogeneous population of cells, making it very difficult to 
standardise and compare research since there is no universal method for positively selecting a 
homogenous population. Although efforts are being made to do so based on CD271+ cells from 
human bone marrow (Jones et al. 2006; Jones et al. 2010), it is unlikely that a single cell surface 
marker will define the entire functional hMSC population. It is important, however, that efforts 
are made to positively select the input material for hMSC manufacturing processes, as this will 
reduce variation in the product and facilitate the development of consistently efficacious 
therapies. That said, it is also possible that the infusion of a heterogeneous population of hMSCs 
is part of the therapeutic benefit, with different subpopulations of hMSCs contributing to the 
variety of clinical effects.     
 
Despite the many names given to hMSCs (Table 2.1) it is clear that much more work is required 
to fully understand and characterise these cells, to ensure that researchers in the field do not 
lose sight of the fact that these cells must demonstrate their therapeutic potential in vivo if the 
full potential of hMSC therapies is to be realised.  
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Table 2.1. Summary of the various names given to “hMSCs” demonstrating the uncertainty 
and conflict in the field as to the identity and function of these cells. 
Nomenclature Year  Reference 
Stromal Stem Cell 1966 
(Friedens.Aj et al. 1966; Friedens.Aj 
et al. 1970; Friedens.Aj et al. 1974; 
Friedenstein et al. 1976; Owen and 
Friedenstein 1988) 
Marrow Stromal Cell 1975 
(Kharlamova 1975; Prockop 1997; 
Woodbury et al. 2000) 
Osteogenic Stem Cell 1987 (Friedenstein et al. 1987) 
Mesenchymal Progenitor Cell 1988 
(Pensler et al. 1988; Johnstone et 
al. 1998) 
Mesenchymal Stem Cell 1991 
(Caplan 1991; Bruder et al. 1994; 
Pittenger et al. 1999; Caplan and 
Dennis 2006a; Caplan 2007) 
Skeletal Stem Cell 2001 
(Kuznetsov et al. 2001; Bianco and 
Robey 2004; Bianco et al. 2006; 
Bianco et al. 2010) 
Multipotent Adult Progenitor Cell 2001 
(Reyes and Verfaillie 2001; Jiang et 
al. 2002b; Schwartz et al. 2002) 
Multipotent Mesenchymal Stromal 
Cell 
2006 
(Dominici et al. 2006; Le Blanc 
2006; Horwitz 2008; Horwitz and 
Dominici 2008) 
Medicinal Signaling Cell 2010 (Caplan and Sorrell ; Caplan 2010) 
 
 
 
2.2.2 Isolation and sources 
Although much of the research has focused on bone marrow derived hMSCs, they can also be 
found and isolated from many other organs and tissues (Table 2.2).The work of Meirelles et al  
showed hMSC-like colonies derived from various tissues, all with similar morphology and 
immunophenotype even after several passages (Kolf et al. 2007). This raises the question: is 
there an hMSC niche that is common to all of these tissues?  
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Table 2.2. Summary of isolation sources for hMSCs. 
Source Reference 
Bone Marrow 
(Friedens.Aj et al. 1966; Friedens.Aj et al. 1970; 
Pittenger et al. 1999; Pittenger and Martin 2004) 
Adipose Tissue 
(Zuk et al. 2001; Zuk et al. 2002; Wang et al. 
2006) 
Placenta 
(Soncini et al. 2007; Brooke et al. 2009; Yu et al. 
2009; Timmins et al. 2012) 
Umbilical Cord 
(Wang et al. 2004; Sarugaser et al. 2005; 
Hartmann et al. 2010; Hatlapatka et al. 2011) 
Cord Blood 
(Erices et al. 2000; Kogler et al. 2004; Hong et al. 
2005; Moon et al. 2005) 
Muscle 
(Bosch et al. 2000; Qu-Petersen et al. 2002; 
Wada et al. 2002; Peault et al. 2007) 
Brain (Kang et al. 2010; Rowley et al. 2012a) 
Pancreas & Liver 
(Petersen et al. 1999; Faris et al. 2001; Oh et al. 
2002; Seaberg et al. 2004) 
Dermis (Toma et al. 2001; Shih et al. 2005) 
 
 
Studies have suggested that the hMSC niche could be of perivascular nature, due to the 
expression of α-smooth muscle actin (α-SMA) by all hMSCs isolated from various tissues 
(Meirelles et al. 2006) as well as CD45-/CD31-/Sca-1+/Thy-1+ cells found to be localised to 
perivascular sites (Blashki et al. 2006). Further supporting this theory, hMSCs have been found 
lining blood vessels in human bone marrow and dental pulp using markers Stro-1 and CD146 
(Shi and Gronthos 2003). Some researchers have taken it so far as to say that hMSCs are 
pericytes, due to their ability to repair many different tissues, outside of the mesoderm lineage 
(Doherty and Canfield 1999; Farrington-Rock et al. 2004; Caplan 2008). This would explain why 
hMSCs seemingly have the ability to home in on sites of injury as by this theory they would be 
localised to the perivascular niche of a particular tissue, in a position to initiate repair. It should 
be noted, however, that in vivo experiments have not shown that hMSCs are solely located in 
the perivascular niche.  
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Part of the evidence against the “pericyte” theory is that hMSCs isolated from various tissues of 
the same patient differ in terms of their differentiation potential, proliferative ability and 
functionality. It has been found that hMSCs from the umbilical cord have a higher proliferative 
capacity than those isolated from both adipose tissue and bone marrow although the number 
of hMSCs in the latter tissues is higher (Kern et al. 2006). In terms of differentiation potential, it 
has been shown that synovium-derived hMSCs display a greater potential for chondrogenic 
differentiation, whilst bone marrow derived hMSCs show the greatest potential for osteogenic 
differentiation (Sakaguchi et al. 2005). This shows that hMSCs isolated from different tissues 
have unique properties and therefore it is a reasonable assumption that the hMSC niche is not 
the same in every tissue. Further to this, hMSCs seem to display a higher differentiation 
potential for the tissues from which they were isolated, pointing towards a unique in vivo niche 
environment that they are adapted to maintain.  
 
 
2.2.3 Characterisation of hMSCs 
Scalable manufacturing processes for hMSC based therapies would benefit from online 
measurement and control of quality parameters (James 2011). Broadly speaking, these quality 
parameters can be broken up into identity, potency, purity and safety which must all be 
optimised during the manufacturing process (Carmen et al. 2012b). This characterisation of 
hMSCs is critical within a highly regulated healthcare environment, particularly considering that 
the regulatory framework was designed for the manufacture of chemical products, not 
biological products (Mason and Dunnill 2007). Process development must be based on a 
foundation of detailed characterisation data, to ensure the continuity of quality necessary for 
Good Manufacturing Practice (GMP) compliant cell therapy manufacturing (Mason and Hoare 
2006). To this end, robust tools and technologies for cell characterisation are imperative for the 
successful development of scalable cell therapy manufacturing processes (Bravery 2010).  
 
 
2.2.3.1 Identity of hMSCs 
The purpose of identity assays are to verify that the product in the master cell bank, working 
cell bank and final product at the manufacturing facility have the correct identity (FDA 2008b). 
In addition to this it is important to ensure that the manufacturing process has not had any 
adverse effects on the phenotype of the cell product within or between batches. This is 
particularly important when scaling up a process, modifying the process during development or 
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manufacturing at multiple sites as comparability of product identity must be demonstrated 
throughout. It is possible for these phenotypic changes to occur when process changes are made 
to reduce serum, increase culturing periods or modify harvesting protocols. There are a number 
of methods available to assess hMSC identity both quantitative and qualitative; however, many 
of these methods rely on an operator intervention and efforts should be made to develop online 
testing methods to facilitate automated and reproducible manufacturing controls.   
 
By far the most common method to assess hMSC identity, used by laboratories all over the world 
is by morphology. This simply involves looking at the cells down a microscope to verify the 
typical size and shape expected of hMSCs and has been previously used as a release test, for 
example Carticel®, an autologous cartilage therapy produced by Genzyme® (FDA 1997). Despite 
morphology being a good indication of cell identity, it is heavily reliant on operator judgment 
which is not validated and therefore introduces process variability. Regulatory authorities will 
require quantitative approaches for reliable product monitoring and release testing which 
morphology cannot provide alone. 
 
One method which has been widely used for some time in biological research to assess the cell 
surface phenotype is flow cytometry. Flow cytometry is a high-throughput analytical technique 
that can be used, amongst other applications, to study protein expression properties of a cell 
using fluorescently labeled monoclonal antibodies. This provides a qualitative method for 
characterising the hMSC population based on key positive and negative markers and has 
become a routine method for identifying stem cell populations from many tissue sources such 
as the eye and peripheral blood (Adams et al. 2009; Tarnok et al. 2010). Whilst these single 
marker methods are useful, they do not often take into account the expression of multiple 
surface markers simultaneously which provides a far better understanding of the target hMSC 
population by the co-positive (> 95%) and co-negative (< 5%) expression of surface antigens 
(Preffer and Dombkowski 2009; Chan et al. 2014a). Multiparameter (also known as multicolour) 
flow cytometry has been applied to clinical diagnostics and immunology, providing the high-
resolution information needed to identify subtle phenotypic differences with statistical 
robustness (Peters and Ansari 2011). Despite the potential of flow cytometry to deliver semi-
quantitative product data, there are a number of issues that mean that this information is not a 
definitive representation of identity. Flow cytometry requires the use of manufactured 
antibodies and in some cases fixing agents such as paraformaldehyde which mean that the 
measured cells cannot always be used for clinical applications. These types of destructive 
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measurement methods can only be applied to batch testing at the end of the process and are 
unlikely to be used for real-time process monitoring as they require a level of manual operator 
intervention to set up gating strategies. 
 
Polymerase chain reaction or PCR, is a method to amplify just a few copies of a piece of DNA or 
RNA over several orders of magnitude by successive heating and cooling cycles (Saiki et al. 1985; 
Saiki et al. 1988; Mullis et al. 1992). Briefly, short DNA fragments containing sequences 
complementary to a known region (or primers) are used to target a gene of interest. DNA 
polymerase is then used to assemble a new DNA strand based on the targeted primer region 
and the process repeated throughout the thermal cycles to initiate a chain reaction to 
exponentially amplify the desired gene sequence (Kubista et al. 2006). This genetic profiling of 
the desired hMSC population can be used to characterise the identity of a cell therapy product 
by obtaining a detailed  knowledge of the cell gene expression, indicating the cell’s potential for 
protein production (Stroncek et al. 2009). Quantitative PCR (qPCR) can be used to collect data 
in “real time” by attaching a fluorescent marker to each new strand of DNA, which can be 
monitored via illumination during the thermal cycling (Heid et al. 1996; Livak and Schmittgen 
2001). The use of PCR is reliant on a well-defined reference cell line to compare the genes of 
interest against or alternatively can be used to monitor the identity of a cell line throughout a 
manufacturing process to assess whether the process is causing changes to the cell identity. This 
can be achieved by developing a cell line and indication specific genetic panel or array, to target 
a number of key genes that will be important to the manufactured product and to ensure these 
genes are not affected by the process itself, in an economic and time efficient manner (Carmen 
et al. 2012b).  
 
Attempts have been made by the International Society for Cellular Therapies (ISCT) to 
standardise the defined minimum identity of hMSCs (Dominici et al. 2006; Rasini et al. 2013) 
and have focused on three key identity assays: 
 
1. Human MSCs must adhere to and proliferate on tissue culture plastic.  
2. Human MSCs must express CD105, CD73 and CD90, and lack expression of CD45, CD34, 
CD14 or CD11b, CD79α or CD19 and HLA-DR surface markers. 
3.  Human MSCs must demonstrate differentiation into osteoblasts, adipocytes and 
chondroblasts in vitro.  
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In addition to this, hMSCs must retain the desired karyotype throughout culture, to ensure 
genomic integrity of the cell for both research and therapeutic applications. Although this is a 
more important consideration for pluripotent cells such as embryonic stem cells (Lefort et al. 
2009), it is still important to ensure that hMSCs retain genetic stability during manufacture. 
Despite the number of methods currently available to assess the identity of hMSCs, there is still 
no consensus on their true in vitro identity. It is imperative that reliable cell therapy 
manufacturing processes are developed using fully characterised hMSC lines to first of all ensure 
processes are consistent but also to demonstrate that processes are comparable. It is important 
that hMSC characterisation panels take into account the target clinical indication, particularly 
for genetic assays, since the desired genetic expression will largely depend on the therapeutic 
use of the hMSC. Despite the introduction of this minimum identity criteria for hMSCs, it is clear 
that more rigorous characterisation is required to assess the quality of the product, based on 
the in vivo therapeutic mechanism of action (MOA).   
 
 
2.2.3.2 Potency of hMSCs 
Described by the US FDA as an appropriate measure of biological function, potency provides the 
basis for the in vitro measure of relative efficacy for a cell therapy product (Burger and Bravery 
2011; FDA 2011b). Potency assays should evaluate this biological function for a specific clinical 
indication, which is important for cell therapy products that are likely to use one manufacturing 
platform for multiple clinical indications, a strategy adopted by almost all companies developing 
hMSC-based products.  
 
Key to developing these potency assays is the cell therapy putative MOA, which identifies how 
the cell therapy delivers its therapeutic benefit, either by mesoderm differentiation potential 
(Caplan and Correa 2011), secretion of trophic factors (Caplan and Dennis 2006b), or 
immunomodulatory activity (Aggarwal and Pittenger 2005) but more likely a combination of all 
three as well as additional undefined mechanisms. Defining the indication specific MOA for 
hMSCs will have far reaching implications in the development of potency assays (FDA 2011b) 
and must be addressed to avoid “a race to the bottom” where the cheapest cell therapies will 
prevail, owing to the lack of product quality assessment for competing treatments.  
 
Ever since Arnold Caplan published research outlining the multilineage potential of hMSCs in 
1991 (Caplan 1991) it was envisaged that hMSC potency would be defined by differentiation 
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potential (Pittenger et al. 1999). The proposed hMSC MOA was by engraftment and 
differentiation into the target tissue type, most commonly osteoblasts within damaged bone as 
demonstrated by Prockop et al  (1995) and colleagues in mice (Pereira et al. 1995; Pereira et al. 
1998) and subsequently in humans by Horwitz et al  (Horwitz et al. 1999; Horwitz et al. 2002). 
This theory of hMSCs as progenitor cells solely for bone formation has faded, as pre-clinical 
animal models of hMSC therapies have shown therapeutic potential for disorders outside of the 
bone niche, such as myocardial infarction and neuronal diseases although this is contested by 
some (Herzog et al. 2003). In these clinical models, the documented engraftment of donor cells 
at the presumed site of activity was low or even completely absent (Horwitz and Dominici 2008). 
This mounting evidence that the therapeutic effect of hMSCs was not mediated by engraftment 
and terminal differentiation was further demonstrated by Le Blanc et al in 2012. Their group 
examined autopsy material from 18 patients who had received HLA-mismatched hMSCs and 
found no ectopic tissue formation as well as only detecting donor DNA in the lungs, lymph nodes 
and intestine at levels from 1/100 to <1/1000 (von Bahr et al. 2012).  
 
Despite this low level of engraftment, a substantial clinical benefit is seen from animal models 
and clinical trials resulting from the infusion of hMSCs, which begs the question, how are the 
hMSCs able to deliver clinical benefit without engraftment into native tissue? The idea that 
hMSCs act as trophic mediators to produce and deliver biologically active molecules to aid 
regeneration was introduced by Arnold Caplan in the early 2000s (Caplan and Dennis 2006b; 
Caplan 2009; Caplan and Correa 2011). It should be noted that this ability to secrete trophic 
mediators does not preclude the notion that hMSCs can act as progenitors in the local bone 
environment to induce regeneration via differentiation, but is part of the multitude of 
mechanisms in which hMSCs elicit a therapeutic benefit. 
 
Due to their native location in the bone marrow niche, hMSCs are able to secrete biochemical 
mediators from the lympho-hematopoietic system, such as stromal derived factor-1 (SDF-1 or 
CXCL12) (Ponomaryov et al. 2000), which initiates hematopoietic stem cells to home to the bone 
marrow niche (Peled et al. 1999). In terms of leukocyte mediated response, hMSCs are able to 
secrete interleukin (IL)-6, IL-7, IL-8, IL-11, IL-12, IL-14, IL-15, macrophage-colony-stimulating 
factor (M-CSF), Flt-3 ligand and stem cell factor (SCF) (Deans and Moseley 2000). Human MSCs 
can also be stimulated by these factors to produce alternative chemokines, for example 
stimulation with IL-1α induces hMSCs to express further IL-1α, leukemia inhibitory factor (LIF), 
granulocyte-colony-stimulating factor (G-CSF) and granulocyte-macrophage colony-stimulating 
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factor (GM-CSF) (Majumdar et al. 1998; Deans and Moseley 2000). Human MSCs have also been 
shown to secrete chemokine ligands, CCL2, CCL4, CCL5, CCL20, CX3CL1 and CXCL8 (Honczarenko 
et al. 2006).   
 
Much of the excitement around the use of hMSCs as a cell therapy has been due to their 
apparent ability to secrete biochemical mediators unrelated to the bone marrow niche, raising 
their potential to treat diseases from outside of their native environment. Subsets of hMSCs 
have been shown to secrete brain-derived neurotropic factor (BDFN), nerve growth factor (β-
NGF) (Crigler et al. 2006) and Nestin (Tondreau et al. 2004), suggesting potential to target 
neurological disorders. Further to this, hMSCs have been shown to induce angiogenesis via the 
secretion of vascular endothelial growth factor (VEGF) (Wang et al. 2006; Zisa et al. 2009) and 
basic fibroblast growth factor (bFGF) (Kinnaird et al. 2004), demonstrating the potential for 
hMSC therapies to treat cardiac and ischemic disorders. Although much of this work has been 
completed in vitro and it can be argued that this does not demonstrate the in vivo potential of 
hMSCs, however, clinical trials are well underway to assess the ability of hMSCs to treat 
disorders outside of the bone marrow niche with some promising early results. Considering that 
hMSCs represent a heterogeneous population of cells from the same source (Tremain et al. 
2001; Wagner et al. 2006) and also show heterogeneity between various isolation sources 
(Wagner et al. 2005; Kern et al. 2006), one can assume that the local stem cell environment 
plays a key role in the biochemical activity of hMSCs.  
 
A promising method for quantitatively determining hMSC potency is the colony-forming unit 
fibroblast (CFU-f). CFU-fs provide a measure of the biological activity of an individual cell, or 
clone and have been previously used in the quality assessment of hematopoietic cell-based 
products (Yang et al. 2005; Kasten et al. 2008). A potential drawback with the use of CFU-fs is 
that they require operator input in the form of colony counting and assessment, although this 
can be alleviated via bioluminescence which has been employed to quantify the number of 
colonies without operator intervention (Rich and Hall 2005). Further to this, it takes weeks of 
culture to assess whether hMSC have retained this potential and is therefore not amenable to 
online monitoring and feedback. Applying this technique to hMSCs may however provide a 
relatively inexpensive method for assessing biological activity that would require little material 
from the final product.  
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2.2.3.3 Purity of hMSCs 
Purity tests ensure that cell therapy products are free from unwanted material, such as 
endotoxins, unwanted cell types, residual proteins, mycoplasma or any other agents used in the 
manufacturing process (FDA 1997). For cell therapy applications, where the cell is the product 
there is potential for unwanted cell types to be present in the final product. This presents an 
issue when the final product in itself is a heterogeneous population of cells, generating the need 
for cell screening tools to positively select or negatively exclude desired and undesired cell types 
respectively. This becomes particularly important during the manufacture of pluripotent cell 
types which have the potential to differentiate into many undesired cell types given the 
appropriate chemical and mechanical cues. The particulate content in the final product must 
also be sufficiently reduced to ensure the purity of the hMSC therapy. Considering that hMSCs 
require a plastic surface to adhere to and proliferate on, manufacturing processes must 
minimise the level of plastic particulates in the final product, which will be particularly important 
for agitated processes, where the formation of such particulates is perceived to be higher than 
in static culture.      
 
One of the challenges associated with the manufacture of hMSC is in the use of animal products, 
typically in the form of foetal bovine serum (FBS) and trypsin which are still common within cell 
therapy manufacture (Brandenberger et al. 2011). The FDA Code of Regulations states that the 
animal serum levels must be reduced to below 1 ppm in the final formulation of a medicinal 
product (FDA 2002). There are no stated guidelines for the allowable levels of trypsin in product 
formulations (Carmen et al. 2012b), however, there is a push to eliminate the use of all xeno-
based products in cell therapy manufacture. As these purity release assays are developed, it is 
probable that multiplexed ELISA assays will be used to streamline the product release testing 
process (Ellington et al. 2010).  
 
 
2.2.3.4 Safety of hMSCs 
Product safety is of paramount importance in the successful development of a cell-based 
therapy as negative safety data will impact patient care and has been given the highest priority 
by regulatory bodies (FDA 1997). It is likely that sterility will need to be tested during the 
manufacturing process and as part of the product release testing panel for bacterial, viral and 
mycoplasma agents (Rayment and Williams 2010; Goldring et al. 2011). A further key aspect for 
ensuring product safety is in mitigating the risk of the cell therapy product containing unwanted 
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cell types, which could be tumorigenic, if the manufacturing process contains a differentiation 
step (Anisimov et al. 2005; Ben-David and Benvenisty 2011). It is likely that characterisation 
techniques such as qPCR and flow cytometry, in combination, will play a role in ensuring that 
the product does not contain those cell types that have the potential to form tumors in vivo 
(Lavon et al. 2004; Noaksson et al. 2005; Adewumi et al. 2007).  
 
In order to minimise the risk of safety implications in cell therapy products, closed processes 
(including supply chain materials and expansion) must be used and in some cases, disposable 
systems may be beneficial from a cost and risk basis. It is important to note that release tests to 
confirm product sterility can take up to 14 days to complete (FDA 2010), which is problematic 
for cell therapy products designed to undergo short term preservation. An accepted way to 
overcome this can be seen with the former cell product Provenge®, an autologous treatment 
for prostate cancer from Dendreon® (USA) which administers the cell product prior to the 
results of the sterility panel (FDA 1998). Finally, it is important that cell therapy products are 
tested for karyotypic abnormalities to ensure genetic stability of the product (Muntion et al. 
2012), although it is not known how critical these abnormalities are in vivo (Sun et al. 2008; 
Carpenter et al. 2009; Hwang et al. 2013; Ruan et al. 2014).  
 
Traditionally, it was thought that hMSCs would present safety issues with respect to 
immunogenicity if cells from one patient were infused into another, in the form of an allogeneic 
therapy (Pittenger and Martin 2004). It has been shown, however, that hMSCs display relative 
‘immune-privilege’, meaning that they do not initiate a full immune reaction in the same way as 
donated tissues and organs, with little major histocompatibility complex (MHC) class I molecules 
and no MHC II expression (Uccelli et al. 2006). Although there is growing evidence for this 
relative immune-privilege, hMSCs have not yet demonstrated absolute immune-privilege. 
Allogeneic hMSCs have shown donor-specific cellular immune responses in vivo by measurable 
anti-donor B cell mediated responses (Beggs et al. 2006; Isakova et al. 2010). This means that 
there is potential for minor immune response to allogeneic hMSC infusion and it is likely that it 
is dependent on hMSC delivery route (Isakova et al. 2014), with systemic infusion producing an 
increased allograft reaction.  
 
In contrast, hMSCs have demonstrated immunosuppressive potential via the inhibition of T cell 
proliferation (Di Nicola et al. 2002; Tse et al. 2003; Klyushnenkova et al. 2005). This ability will 
also be effective for the treatment of diseases causing an immune overreaction by modulating 
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the leukocyte population. This ability not only applies to hMSCs in their undifferentiated state, 
but has also been shown by hMSCs differentiated in vitro, which show that these differentiated 
cells do not elicit an allo-reactive lymphocyte proliferative response, supporting transplant of 
hMSCs between HLA-incompatible patients (Le Blanc et al. 2003). This relative immune-privilege 
is a large part of the reason that hMSCs have gained so much attention as a candidate for cellular 
therapies as reduction in patient immune response allows for biotechnology companies to 
pursue the ‘off-the-shelf’ business model, which is akin to current bio-pharmaceutical products.    
 
 
2.2.4 Serum-free expansion of hMSCs 
As stated previously, the levels of animal serum must be reduced to below 1 ppm in the final 
formulation of a medicinal product and therefore eliminating it from the hMSCs manufacturing 
process will be highly desirable. In addition to this,  there is a large amount of lot-to-lot 
variability between batches of animal serum, as well as a limited supply (Brindley et al. 2012), 
spiraling cost, potential for pathogen transmission, increased risk of recipient immune reaction 
(Spees et al. 2004) and reduced scope for process optimisation. Furthermore, FBS has been 
shown to contain immunogenic contaminants which have the potential to negatively impact 
post-transplant clinical results (Heiskanen et al. 2007), potentially increasing the regulatory 
burden placed upon these products. All of these considerations mean that moving towards a 
serum-free process would be beneficial in achieving scalable, tunable and consistent hMSC 
manufacturing processes. In addition, hMSCs grown in a serum-free medium have 
demonstrated increased proliferation rates, up-regulation of genes important to hMSC function 
and down-regulation of genes involved in the production of proinflammatory cytokines 
(Crapnell et al. 2013).  As such, there has been a trend towards reducing or eliminating serum 
from the process (Jung et al. 2012) and even towards developing completely serum and xeno-
free processes (Dos Santos et al. 2011b). 
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2.3 Clinical trial landscape for cell-based therapy 
A search of the clinical trial database yielded a total of 1342 active clinical trials that were judged 
to be true cell-based therapies from the BSI definition. The vast majority of these cell-based 
therapies are using hematopoietic cells (n=444), hMSCs (n=382), lymphocytes (n=253) and 
dendritic cells (n=91) (Figure 2.2). The use of tissue specific cells was less prevalent, representing 
114 of current cell-based therapy activity with a mixture of cell types such as chondrocytes 
(n=12), endothelial cells (n=15), fibroblasts (n=14), hepatocytes (n=16), islet cells (n=13) and 
neural cells (n=13).  
 
 
 
 
Figure 2.2. Number of currently active clinical trials by cell type and target clinical indication. 
Displaying broader cell type categories of Hematopoietic (Blue), Mesenchymal Stem Cells 
(Red), Immune Cells (Green), Tissue specific cells (Orange), Embryonic stem cells (Purple) and 
Other (Aqua). From (Heathman et al. 2015b)     
 
 
Figure 2.3 shows the diversity of cell isolation sources represented from hematopoietic and 
hMSC trials. The rapid increase in hMSC activity is clear, with 382 clinical trials in progress from 
a number of isolation sources most notably 237 of which are from the bone marrow, 61 from 
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umbilical cord and 59 from adipose tissue.  The use of pluripotent stem cell-derived products 
was rare, though there are six clinical trials involving embryonic stem cells. Interestingly, all six 
involve differentiation into retinal pigment epithelium cells and were initiated by industry: CHA 
Bio & Diostech in Korea (n=2), Advanced Cell Technology (n=3) and Pfizer in the UK (in 
collaboration with University College London). 
 
 
 
 
Figure 2.3. Current active cell therapy clinical trials showing the breakdown of the 
hematopoietic and mesenchymal stem cell groups the by cell isolation source. From 
(Heathman et al. 2015b) 
 
 
 
2.3.1 Disease indications targeted by cell-based therapy clinical trials  
It is clear that the most common target for cell-based therapy clinical trials is oncology, which 
represents 46% of all cell-based therapy clinical trials identified (Figure 2.2), due to the use of 
traditional blood cell and immune cell-based therapies for the treatment of various cancers. 
Aside from these traditional cell-based therapies, cardiology was the second largest clinical 
target with 88 clinical trials (Figure 2.2), 51 of which were using hMSCs (Figure 2.4). 
Immunological disorders remain a key target for cell-based therapies (Figure 2.5) with disorders 
such as graft vs. host disease (n=33), immune modulation following transplantation (n=17) and 
Crohn’s disease (n=16), as well as rheumatic disorders osteoarthritis (n=15), lupus 
erythematosus (n=9) and rheumatoid arthritis (n=6) currently in Phase 1 and above. 
Neurological indications also represented a significant target for novel cell-based therapies for 
indications such as multiple sclerosis, stroke and motor neuron disease (Figure 2.5). Figure 2.4 
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shows the broad therapeutic utility adopted for hMSCs, with clinical indications covering all 18 
clinical categories with the majority within cardiovascular, neurological and autoimmune 
indications predominantly in Phase 1. Likewise, tissue specific cells cover the majority of clinical 
indication categories, due to the diversity of cell populations within this category.  
 
 
 
 
 
 
Figure 2.4. Current active cell therapy clinical trials involving tissue specific cells (see Figure 
2.2) and mesenchymal stem cells showing target clinical indication and current clinical trial 
phase. From (Heathman et al. 2015b)  
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Figure 2.5. Breakdown of the most prevalent clinical targets from cell therapy clinical trials by 
target disease and clinical trial phase. From (Heathman et al. 2015b) 
 
 
2.3.2 Cell-based therapy clinical trial phase 
Considering the relative age of the industry, it is unsurprising that by January 2014 the majority 
of cell-based therapy clinical trials were in Phase 1, with 232 hMSC, 146 lymphocyte and 118 
hematopoietic cell clinical trials (Figure 2.6). There was however, an increase in hematopoietic 
cell clinical trials moving to Phase 2 with 187 compared to 116 in Phase 1. There were also four 
tissue specific cell-based clinical trials that reached post-market surveillance, or Phase 4 (Figure 
2.6). Most notable of these was the use of dermal fibroblasts for wound repair from Arita 
Medical (ReCellTM) and Organogenesis (ApligrafTM) as well as cell-based therapies to treat type 
2 diabetes and for cornea replacement. Figure 2.5 shows the major clinical categories by specific 
disease targets, with the vast majority targeting hematological malignancies within oncology, 
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with equal weighting in Phase 1 and Phase 2. Cardiovascular indications also had a similar 
number of clinical trials in Phase 1 and Phase 2, with 10 clinical trials in Phase 3 and above. 
Human MSC clinical trials were also well represented in Phase 2 (n=88) and were even seeing 
progression to Phase 3 (Figure 2.6).  Neurology and rheumatology based indications that involve 
hMSCs were mostly in Phase 1 (Figure 2.7), however clinical development using bone marrow-
derived hMSCs to treat acute coronary syndrome, Crohn’s disease and graft vs. host disease 
were progressing into Phase 2 and above, with clinical trials taking place all over the world.  
 
 
 
 
Figure 2.6. Breakdown of current active cell therapy clinical trials by cell group and trial phase. 
From (Heathman et al. 2015b) 
 
 
2.3.3 Clinical translation of mesenchymal stem cell-based therapies 
It is clear that outside of the traditional cell-based therapies using blood and immune cells to 
treat cancer, the majority of novel clinical trial activity was involving hMSCs. The rebranding of 
hMSCs has been used to generate intellectual property by defining a specific set of 
characterization criteria for the cell, for example, Athersys Inc. are developing a product termed 
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MultiStemTM, a Multipotent Adult Progenitor Cell (MAPC) therapy which has been patented 
under this name (Jiang et al. 2002a; Breyer et al. 2006).  
 
 
 
Figure 2.7. Current active cell therapy clinical trials involving mesenchymal stem cells showing 
target clinical indications by target disease and trial phase. From (Heathman et al. 2015b) 
 
 
2.3.4 Case study: product manufacture during Phase 1 clinical trial 
Since the discovery of embryonic stem cells in 1998 (Thomson et al. 1998), pluripotent stem 
cells have been considered a promising source of allogeneic stem cells for regenerative 
therapies. In 2010 Geron Co. went into Phase 1 clinical trials with an allogeneic hESC derived 
oligodendrocyte progenitor product for the treatment of spinal cord injury. Despite no adverse 
safety issues with this hESC derived therapy, Geron Co. halted the clinical trial citing financial 
and regulatory issues (Atala 2012). Currently, all of the clinical trials involving hESCs are targeting 
ophthalmology related indications, in Stargardt’s macular dystrophy and dry age-related 
macular degeneration. Advanced Cell Technologies are sponsoring three of these clinical trials 
in the UK and USA, treating these disorders with hESC-derived retinal pigment epithelium (RPE) 
cells. One of the key challenges in the manufacture of a pluripotent product is in the 
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differentiation of the hESC into the therapeutically active cell, which can dramatically impact 
product yield. The Advanced Cell Technologies RPE product is manufactured from the GMP-
grade MA09 hESC line, cultured on mitomycin-inactivated murine embryonic fibroblasts for 
three passages. Following the formation of embryoid bodies, pigmented RPE patches are 
isolated and purified (Lu et al. 2009), before further expansion and cryopreservation for clinical 
use. Product characterisation takes place in-process and post-cryopreservation, in the form of 
pathogen testing, karyotype analysis and purity (Schwartz et al. 2012). Much of this 
manufacturing process is labor-intensive and requires operator intervention, which may not be 
amenable to automated and scalable manufacture. Therefore, despite the positive safety data 
from these ESC clinical trials (Atala 2012), it is clear that there are many manufacturing 
challenges that must be overcome before these therapies can be translated through clinical trial 
and into commercial production.   
 
 
2.3.5 Case study: manufacture for commercial production 
It is clear from the clinical trial results in Figure 2.2, that the most prevalent clinical category for 
cell based therapies is oncology, with immune cells contributing to around half of these cell-
based therapies. Sipuleucel-T is an autologous active cell-based immunotherapy product 
designed to stimulate an immune response against prostate cancer from Dendreon Corporation 
(Seattle, USA) (Small et al. 2006). In 2010, Sipuleucel-T (Provenge®) became the first FDA 
approved autologous cell-based therapy, providing a scale-out service based approach to 
product manufacture and delivery. Patient cells are collected via leukapheresis (Kantoff et al. 
2010) and cold shipped to a manufacturing site, where the cells are manipulated under GMP 
conditions to isolate and activate the target immune cells. The activated cell-based immune 
therapy is then cold shipped back to the patient to be re-infused, which is repeated three times 
to deliver the full therapeutic dose. Dendreon Corporation (USA) operates patient logistics from 
a central location, with distributed manufacturing taking place at multiple sites across the USA. 
This product handling and manipulation is largely manual and has led to high product operating 
costs, increasing the product cost of goods and therefore creating a high reimbursement price, 
which is ~$100,000 per patient. Efforts have been made to reduce the cost of goods by 
implementing automated process steps, with the intention of reducing these high operating 
costs. This case study highlights the importance of considering functionally closed and 
automated scale out processes early in clinical development as this will reduce the overall cost 
of goods during commercial production (Hampson 2014).      
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A proposed clinical development pathway would be to produce Phase 1 material in a manual, 
semi-closed process which could then be transferred to a scalable, closed and automated 
manufacturing process following the success of the initial clinical trials. This model would allow 
for reduced capital investment to evaluate the product at Phase 1 but then would transfer the 
process in a timely manner, ensuring a scalable and cost effective product supply for late stage 
clinical development and commercial supply. Considering the high cost and increased risk of 
validating sterilization cycles, it is likely that these closed-processes will utilize disposable 
technology, mimicking current therapeutic protein process development (Kuczewski et al. 
2011).  
 
 
2.3.6 Progress from clinical development to product manufacture 
Industry progression towards the successful manufacture of cell-based therapies is evident by 
international cooperation on the formation of global reference ‘ruler’ standards and protocols 
to facilitate manufacturing comparability of hMSCs (Viswanathan et al. 2014). This will facilitate 
the development of consistent manufacturing processes across multiple sites and allow for a 
method to define each cell line. Defining desirable product characteristics is critical and will form 
the basis of release tests as well as setting the tolerances on the process, allowing for systematic 
product development and optimisation.    
 
A further sign that the commercial market for hMSC application is increasing in competiveness 
is the drive by companies such as Athersys Inc. (USA) and Mesoblast Ltd (Australia) to clearly 
differentiate their product and its production process from “generic” hMSCs. This phenomenon 
parallels the clinical development of MACITM (by Genzyme) and CCITM (by TiGenix) where 
companies actively sought to distance their products from legacy clinical data on the use of 
Autologous Chondrocyte Implantation (ACI), which was inconclusive in demonstrating cost 
effectiveness (Hourd et al. 2008). This approach to cell-based product development is largely 
driven by a fundamental lack of understanding of the product’s mechanism of action, as 
companies must differentiate their product to avoid a race to the bottom, whereby a lower cost 
therapy has an increased chance of reimbursement. Without the knowledge of the how these 
cell-based therapies elicit therapeutic benefit, manufacturing processes cannot be optimised to 
maximize this function and will inevitably be surpassed by lower cost therapies. Given the 
importance of regulation on the production of cell-based therapies, it is perhaps unsurprising 
that in the race to successfully commercialize cell products, companies have begun to raise the 
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regulatory bar as a tactic to disrupt competitor companies. This action has the potential to 
hinder smaller companies who do not have the financial resource to comply with this increasing 
regulatory burden.  
 
A further hallmark of the commercial progress of hMSC therapies is the move towards 
developing automated processes as well as the implementation of functionally closed 
manufacturing systems and consideration of the associated logistics, supply chain and cost of 
goods (Hampson et al. 2008). Significant UK government investment in the form of the Cell 
Therapy Catapult has been tasked with ‘de-risking’ cell-based therapy development for industry 
by providing a ‘centre of excellence’ to bridge the current translation gap in the industry (Mason 
and Manzotti 2010). Outside of the UK, additional institutes have been established to provide 
resources,  in Canada (Centre for Commercialization of Regenerative Medicine) and the USA 
(California Institute for Regenerative Medicine and the National Institutes of Health) to facilitate 
this translational process. Despite this progress, there remains a requirement for a better 
understanding of potential manufacturing platforms and how they can be best utilized for cell-
based therapy production.  
 
 
2.3.7 Expansion technologies to achieve clinical scale manufacture 
With cell-based therapies moving towards commercialization and multiple clinical trials in late 
stage development, it is clear that selecting suitable manufacturing technologies is becoming 
increasingly important. It is imperative that potential pitfalls in developing scalable 
manufacturing methods are identified at an early stage and strategies are implemented that can 
streamline this development pathway. A key consideration for streamlining this pathway is the 
tradeoff between clean room space and on-going commercial supply as patient numbers 
increase from clinical development to commercial production. For an autologous therapy if you 
were treating, for example, 100 patients in a typical two week process for a Phase 3 clinical trial, 
you would likely require four clean room facilities in order to separate each patient lot. This is 
assuming that the process is not entirely closed and therefore each lot must be segregated to 
avoid cross contamination. The issues then arise if the product is successful and commercial 
production is carried out using the same process for say 1,000 or even 10,000 patients per year, 
where the clean room and personnel requirements increase 10-fold or 100-fold respectively, 
making the product cost-prohibitive at this scale. This will drive the development of expansion 
platforms that are fully closed, so that multiple patient lots can be manufactured in the same 
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facility, greatly reducing fixed and operating costs as the product moves toward commercial 
production. Table 2.3 shows the number of doses per lot achievable for multiple expansion 
technologies currently available based on an allogeneic hMSC treatment for myocardial 
infarction (Hare et al. 2009) requiring 35 – 350 million cells per dose. This demonstrates the 
challenge of manufacturing an hMSC based product for 10,000 patients per year, given the 
number of doses per lot achievable using current expansion technology.  
 
 
Table 2.3. Potential scale per lot and harvest constraints for various cell therapy 
manufacturing platforms. From (Heathman et al. 2015b) 
 
 
 
A manufacturing process that reduces biological divergence will inevitably yield a more 
consistent and higher quality product. This biological divergence is typical of cell expansion 
processes, whereby small changes to the cell environment at the start of culture will lead to 
large changes by the time the product is harvested. This has been demonstrated for the culture 
of embryonic stem cells whereby changes to dissolved oxygen levels in the culture medium can 
lead to changes in cell growth characteristics (Wu et al. 2014) and differentiation potential 
(Prado-Lopez et al. 2010). This potential divergence can be limited by reducing the 
heterogeneity of the culture conditions via mixing, so that the cell microenvironment remains 
consistent throughout the culture. Technology that does not induce mixing such as T-flasks will 
potentially suffer from heterogeneity in physical, chemical and hence physiological conditions 
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(Nienow 2006), although it can also exist in other forms. Packed/fluidized-bed bioreactors, due 
to their high density will invariably suffer from axial concentration gradients as medium flows 
though the bed, particularly as the scale and cell density increases. Hollow fibre reactors have 
the potential to introduce heterogeneity via longitudinal concentration gradients as medium or 
dissociation reagent flowing down the bioreactor changes with distance through the fibre 
(under plug flow conditions). Although these factors could impact the consistency of the 
product, there is a lack of evidence to back this up and far more work will be required to fully 
understand and develop the various manufacturing processes for cell-based therapies.  
 
A lack of online process control is a key barrier for the consistent manufacture of cell-based 
therapies. Expansion technologies such as rotating flasks and multilayer flasks lack the capability 
for online cell visualization which could form the basis for a non-invasive control strategy based 
on cell coverage of a surface (Joeris et al. 2002). These technologies as well as T-flask automation 
currently lack the ability for online medium sampling which prohibits the control of key nutrient 
and metabolite concentrations, a staple of process control in the bioprocessing industry. 
Without an effective process control metric, expansion technology will suffer when attempting 
to maintain product consistency and will incur a higher cost for product validation. Process 
control strategies are poorly understood for novel cell expansion technologies, however they 
are routine in stirred tank bioreactors for current bioprocesses (Butler 2005; Trummer et al. 
2006). In addition to this, the physical characterization of the stirred reactor system is well 
understood and can also be directly translated from traditional bioprocesses (Vrábel et al. 2000; 
Langheinrich et al. 2002; Nienow 2006). This development is analogous to process analytical 
technology (PAT) (FDA 2004) in the current biopharmaceutical industry (Ganguly and Vogel 
2006) and could be used as a model for cell-based therapy process development.  
 
The efficient harvest of cell-based therapies represents one of the few deviations from 
traditional bioprocessing and must be designed based on cell sensitivity and the pooling time 
limitations of the product. Scale-out processes such as rotating flasks (Merten et al. 1997; 
Kedong et al. 2010), T-flasks (Thomas et al. 2007) and multilayer flasks (Abraham et al. 2011) 
will require high cell pooling times which will limit the effective scale to which these therapies 
can be manufactured as product quality will likely reduce during the pooling process (Table 2.3). 
For cell-based therapies that are surface-adherent, the dissociation of the cell from the surface 
is required during the expansion process. This unique constraint of cell-based therapy 
manufacture is often overlooked but has been considered for packed/fluidized bed (Kasuto et 
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al. 2014), hollow fibre (Antwiler et al. 2014) and stirred tank bioreactors (Nienow et al. 2014). 
Rocking-motion (Singh 1999; Mikola et al. 2007) and pneumatically driven bioreactors (Zeikus 
2009; Kim et al. 2013) have been previously employed for suspension cell culture. However, 
transferring these systems to surface-adherent cell types will likely require an additional process 
step to transfer the culture to a harvest vessel, allowing for increased agitation to promote 
efficient detachment and harvest of cells from microcarriers, which may not be sufficient in 
these systems (Lee et al. 2011). A further challenge will emerge if the cells are required to be 
dissociated during the process (i.e. if bead-to-bead transfer does not occur at a high enough 
rate to support one step expansion). This will add additional steps to the process and will likely 
influence the design and optimization of other aspects of the process, such as agitation strategy 
and culture medium. 
 
Although much work is yet to be done on calculating the optimum volume for expanding cell-
based products in stirred tank reactors, current estimates put the maximum value at around 
1000 liters (Rowley et al. 2012b). It should be noted however, that industrial scale mammalian 
cell culture, once considered to be limited to a similar scale is now routinely operated at greater 
than 10,000 liters (Nienow 2006). Similar gains in effective cells per batch can also be made by 
increasing the microcarrier concentration, which is currently far from optimal for suspension 
based systems (Rafiq et al. 2013b). One feature that is a fundamental aspect of all culture 
processes is the need to supply oxygen to the cells. Due to its limited solubility, this supply is 
required to be provided continuously. As the cell density increases, it becomes necessary to 
provide oxygen by sparging; typically with air, which also strips out the carbon dioxide produced 
(Sieblist et al. 2011). For free suspension animal cells, sparging has required the inclusion in the 
medium of protective agents, almost always the surfactant, PluronicTM F68, as the energy 
released from bursting bubbles damages the cells, resulting in a loss of cell viability (Nienow 
2006). The addition of a surfactant such as PluronicTM F68 reduces the adhesion of cells to these 
bubbles during sparging, reducing the prevalence of cell damage as the bubbles burst at the gas-
liquid interface.   Due to the fact that the cell densities reached to date and the specific oxygen 
uptake rate of hMSCs (Rafiq et al. 2013b) and hESCs (Oh et al. 2009) for example, are both low, 
such issues have not yet been addressed but will need to be as the density increases, especially 
since the presence of these protective agents in final product formulations may be an issue.  For 
pneumatically driven bioreactors (Zeikus 2009; Kim et al. 2013), bubbling gas is inherent to the 
way they function and therefore potential cell damage must be considered during the appraisal 
of expansion technology. 
Chapter 2: Literature Review 
 
 
33 | P a g e  
 
It is clear that other than stirred bioreactors, there is a distinct lack of comparable and peer 
reviewed data for the majority of manufacturing platforms discussed in this study. This could 
potentially be to the detriment of the field, as without reliable information to inform technology 
appraisal, process development is likely to default to stirred tank bioreactors due to the strong 
legacy data that exists for large scale mammalian cell culture. On the other hand, there is 
nothing to be gained by innovating unnecessarily. Many of the potential manufacturing 
platforms mentioned here were considered in the 1980s for culturing animal cells, when it was 
considered that because they lacked a cell wall, it would be impossible to do so in the presence 
of rotating stirrers.  Yet today, whether in single use systems (SUBs), at bench scale or the largest 
commercial scale, stirred bioreactors are commonplace in the biotechnology industry (Kehoe et 
al. 2010). Indeed, they are now being preferred industrially even for clone selection in 
robotically-controlled microbioreactors (ambrTM) at the 15 mL scale (Nienow et al. 2013).  
 
Although, several manufacturing systems are already available for the expansion and 
manipulation of therapeutically relevant cells, an optimal and universal manufacturing platform 
does not yet exist and may not be attainable due to the variety of cell types and clinical 
applications. With the exception of hMSCs, most therapeutically relevant cell types have only 
been demonstrated on a subset of the broad range of available platforms. Developers 
considering the range of available manufacturing technologies need to balance the competing 
pressures discussed. Nevertheless, the fact that both hMSC culture and harvest have now been 
effectively demonstrated in stirred bioreactors based on sound physical principles is 
encouraging, especially given the inherent flexibility and controllability of this technology; and 
its success with free suspension and adherent animal cells from the 15 mL to the 25,000 L scale. 
 
As an industry, cell-based therapies are still in the early stages of clinical development. It is clear 
that we must better understand the quality of our cell-based products in order to form a stable 
base for process evaluation and development. Investment in cell-based therapy manufacturing 
in the UK has created an urgent need to better understand these cell-based therapy products 
to facilitate successful manufacture based on strong clinical data demonstrating product 
efficacy. It is likely that there will be bespoke manufacturing processes for each of these cell-
based products as well as ‘generic’ cell-based therapy products driven by this fundamental lack 
of product understanding, with a move toward functionally closed and single-use technology 
(Simaria et al. 2014). 
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2.4 Aims and objectives 
It is clear that there is a significant amount of clinical activity around the use of hMSCs, driven 
by their potential to treat a variety of diseases that currently only have limited or palliative 
treatment options. Current manufacturing processes for these BM-hMSC therapies are largely 
based on manual expansion technology and therefore are not readily scalable to cost-effectively 
meet the patient need on a large-scale. Considering that the input to this process will need to 
be from multiple donors, it will be important to consider the impact of the variation in donor 
material as well as establishing a mechanism to select input material based on desired product 
attributes and drive consistency into the process at an early stage of development. In 
conjunction with this, variation in culture materials must also be controlled during development 
and moving towards a serum-free process provides a mechanism to reduce supply chain risk as 
well as reducing the batch-to-batch variation associated with FBS. Finally, the development of a 
process control strategy within an agitated microcarrier process has the potential to consistently 
produce BM-hMSCs within a process that has the potential to cost-effectively meet the batch 
sizes required at the commercial scale. Accordingly, the objectives of this work are as follows:      
 Characterise BM-hMSCs from multiple donors in monolayer culture to understand the 
variation in cell growth, metabolism and quality attributes.  
 Assess the impact of different culture media on the yield, quality and consistency of BM-
hMSC expansion.  
 Process transfer from the small-scale monolayer process to a potentially scalable 
microcarrier process under serum-free conditions.  
 Develop a process control strategy for the microcarrier culture of BM-hMSCs to 
maximise growth, consistency and BM-hMSC quality characteristics. 
 Develop a potentially scalable downstream and cryopreservation process to assess the 
impact of multiple integrated unit operations on BM-hMSC attributes. 
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3 Materials and Methods 
3.1 Materials 
All materials used were analytical grade or better. Sterilisation of liquids and equipment was 
achieved via autoclaving with a Systec VX-95 autoclave (Systec, Germany) at 121°C on a 40 
minute cycle.  Aqueous solutions were prepared using filtered water from a MilliQ ultrafiltration 
unit (Millipore, UK).  
 
3.2 Culture of human mesenchymal stem cells 
3.2.1 Medium formulation 
Human mesenchymal stem cells were cultured using three different medium formulations, 
firstly with Dulbecco’s Modified Eagle Medium (DMEM; Lonza, UK) supplemented with 10 % 
(v/v) foetal bovine serum (FBS) (Lot: RVC35874, Hyclone, Belgium) and 2 mM ultraglutamine 
(Lonza, UK). Complete growth medium was stored at 2 to 8°C and used within one month of 
preparation.  
 
For culture using human platelet lysate (HPL), Dulbecco’s Modified Eagle Medium (DMEM; 
Lonza, UK) was supplemented with 2, 5 and 10 % (v/v) HPL (StemulateTM, Cook Regentec, USA) 
and 2 mM ultraglutamine (Lonza, UK). Complete growth medium was stored at 2 to 8°C and 
used within one month of preparation. 
 
For serum-free culture, the growth surface of T-flasks was coated with 0.4 µg.cm-2 PRIME-XV® 
human fibronectin (FN) (Irvine Scientific, USA) and cultured in PRIME-XV® SFM (Irvine Scientific, 
USA) as per manufacturer’s instructions. Growth medium was stored at -18°C and thawed 
immediately before use. The selection of PRIME-XV® SFM was made following a pre-screen of 
six commercially available serum-free media.    
 
 
3.2.2 Acquisition and isolation of BM-hMSCs 
Bone marrow derived mesenchymal stem cells were purchased or donated as mononuclear cells 
(MNCs) from Lonza (USA) after the patient had given informed consent (Table 3.1). MNCs from 
Lonza were initially plated at a cell density of 100,000 MNCs.cm-2 with the first medium 
exchange taking place after 48 hours and every 72 hours thereafter. Cells donated from 
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Southampton University were received at passage 1 and initially plated at a density of 5000 
cells.cm-2 with a medium exchange taking place every 72 hours. The five BM-hMSC donors were 
selected at random in order to obtain a sample from representative BM-hMSC donors so that 
process development would account for input material from multiple, random donors.   
 
 
Table 3.1. Summary of the BM-hMSC line donor information as well as the chosen 
nomenclature to identify the various donor cell lines. Bone marrow derived mesenchymal 
stem cells were purchased1 or donated2 as mononuclear cells. 
BM-hMSC line 
Nomenclature 
Donor Age 
(years) 
Donor Gender Donor Ethnicity Lot Number 
2M0 20 MALE CAUCASIAN 4625A 
1M1 27 MALE BLACK 080004A 
1M2 19 FEMALE BLACK 071313B 
1M3 24 MALE CAUCASIAN 701150B 
1M4 25 FEMALE HIPANIC 0000327825 
 
 
3.2.3 Cryostorage  
BM-hMSCs were cryopreserved at passage 0 to passage 3 at a density of either 1 x 106 or 2 x 106 
cells.mL-1 in a freeze medium containing 90% (v/v) FBS (Lot: RVC35874, Hyclone, Belgium) and 
10% (v/v) dimethylsulphoxide (DMSO). Cells suspended in 1 mL freeze medium were placed into 
2 mL cryovials, placed in a freezing container (Panasonic, UK) and stored in a -80 °C freezer to 
cool at a rate of 1 °C.min-1. After 24 hours, cells were placed in the vapour phase of a monitored 
liquid nitrogen cryostorage bank for long term storage.  
 
 
3.2.4 Resuscitation  
A cryovial of BM-hMSCs was removed from liquid nitrogen storage and rapidly thawed in a 
water bath at 37 °C until a sliver of ice remained. The contents of the vial were pipetted drop 
wise into 10 mL of culture medium pre-warmed to 37 °C, centrifuged at 220 g for 5 minutes at 
room temperature, supernatant aspirated and re-suspended in 5 mL of fresh pre-warmed 
culture medium. Cells were counted using the method below and seeded into a T-flask at 5000 
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cells.cm-2 with the appropriate volume of pre-warmed culture medium (see Table 3.2), labeled 
and placed into a humidified incubator at 37 °C in air containing 5% CO2 for culture.  
 
 
3.2.5 T-Flask culture of human mesenchymal stem cells 
Cells were grown in T-flasks seeded at 5,000 cells.cm-2 in a humidified atmosphere at 37°C in air 
containing 5% CO2. A complete medium exchange was performed after 72 h culture and cells 
were passaged at day 6 of culture. On passage, the hMSCs were washed with Ca2+ and Mg2+ free 
phosphate buffered saline (PBS) (Lonza, UK). PBS free from Ca2+ and Mg2+ was used in order to 
reduce cell adhesion and enzyme denaturation caused by the presence of these components in 
the PBS. Cells were then incubated for 5 min with trypsin (0.25 %)/EDTA solution (Lonza, UK) or 
TrypLE Express (Life Technologies, UK) for serum-free culture to aid cell detachment from the 
surface. The dissociation reagent was then inactivated by the addition of fresh growth medium 
equivalent to three times the volume of the trypsin solution used for cell detachment. This cell 
suspension was centrifuged at 220g for 5 min at room temperature, the supernatant discarded 
and the remaining pellet re-suspended in an appropriate volume of culture medium. Viable cells 
were counted using a NucleoCounter NC-3000 automated mammalian cell counter 
(Chemometec, Denmark) and an appropriate number of cells were then re-seeded into a fresh 
T-flask. 
 
 
Table 3.2. Volume of culture medium and Trypsin used in monolayer culture of BM-hMSCs 
Culture Vessel 
Growth Surface Area 
(cm2) 
Medium Volume 
(mL) 
Trypsin Volume  
(mL) 
24 well plate 1.9 0.5 0.15 
12 well plate 3.8 1 0.25 
6 well plate 9.5 3 0.50 
T-25 25 5 1 
T-75 75 15 3 
T-175 175 35 7 
T-225 225 50 9 
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3.3 Microcarrier culture of human mesenchymal stem cells 
 
3.3.1 Microcarrier preparation 
To sterilise the microcarriers, 1.39 grams of polystyrene P102-L microcarriers (SoloHill, UK) and 
15ml of distilled water were added to each flask, giving a microcarrier surface area of 500 cm2. 
The flasks were sealed and autoclaved at 121 °C for 40 mins. The supernatant was then aspirated 
and 20 ml of sterile culture medium was added to each flask and incubated at room temperature 
for at least 20 mins to coat the microcarrier surface in serum protein. The supernatant was once 
again aspirated and replaced with 100ml of fresh culture medium and placed into a humidified 
incubator at 37 °C in air containing 5% CO2 for culture. The microcarrier type used in these 
studies was selected following a screening of multiple commercially available microcarriers.   
 
 
3.3.2 Spinner flask preparation  
The glass surfaces of 100 mL Spinner flasks (diam. T = 60 mm) (BellCo, USA) were siliconised 
with Sigmacote (Sigma-Aldrich, UK) to prevent cell attachment to the glass surface. Spinner 
flasks were operated with a magnetic, horizontal stirrer bar and a vertical paddle (diam. D = 50 
mm).  
 
 
3.3.3 Spinner flask operation  
Each spinner flask was seeded with 3 million BM-hMSCs (6000 cells.cm-2) and left to settle in a 
humidified incubator at 37 °C and 5% CO2 in air, for one hour. After this initial period the spinner 
flasks were placed on a magnetic stirrer plate (Bell-EnniumTM Compact 5, USA), at an impeller 
speed of 30 rpm, the minimum speed required to achieve microcarrier suspension (Rafiq et al. 
2013a). The spinner flasks side-arm caps were loosened (to allow for gas exchange) and were 
incubated at 37 °C in a humidified atmosphere of 5% CO2 in air. A 50% medium exchange was 
performed every three days. 1 ml samples of the medium from the spinner flasks were taken 
daily as well as samples of fresh medium on days when a medium exchange occurred. The 
medium samples were centrifuged at 220g for 5 minutes and 1 ml of the supernatant is removed 
to ensure that no microcarriers were present.  Daily samples of the cell suspension were also 
taken for cell counting using the NucleoCounter NC-3000 method below. 
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3.3.4 Spinner flask harvest  
On the sixth day of culture the BM-hMSCs were harvested from the spinner flasks using a 
previously published method (Nienow et al. 2014). The microcarriers were left to settle at the 
bottom of the spinner flasks, the supernatant was aspirated and the microcarriers were washed 
in 50 ml of Ca2+ and Mg2+ free PBS for 3 minutes at an impeller speed of 30 rpm. The 
microcarriers were left to settle once more and the PBS aspirated before adding 50 mL of Trypsin 
for 7 minutes at an impeller speed of 150 rpm (ending with 5 seconds at 200 rpm). The Trypsin 
was then quenched with 50 ml of medium and a 2 mL sample placed in a single well of a 6 well 
plate for analysis under a light microscope to assess detachment efficiency. The remainder of 
the solution was filtered through a 60 μm Steriflip Filter Unit (Merck Millipore, Germany) to 
separate the microcarriers from the cells and medium. The cell suspension was centrifuged, the 
supernatant aspirated and the cell pellet re-suspended in culture medium. A cell count was then 
performed using a NucleoCounter NC-3000 to assess the overall BM-hMSC growth and the 
culture harvest efficiency.  
 
 
3.3.5 DASGIP DASbox bioreactor culture 
DASGIP, DASbox bioreactors (Figure 3.1), were used for all controlled bioreactor experiments, 
with a working volume of 100 ml and a vessel diameter (T) of 63 mm.  The bioreactor was 
equipped with a 3-blade 30°-pitch down pumping impeller (diameter, D = 30.25 mm, Figure 3.2), 
a temperature probe, a dissolved oxygen (dO2) probe (Hamilton, UK) a pH probe (Hamilton, UK), 
an off-gas analyser (Eppendorf, Germany) and two sample ports.  The DASbox system was set 
up, calibrated and controlled using Eppendorf, DASGIP control unit and accompanying software.  
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Figure 3.1. DASGIP DASbox Controlled stirred bioreactor system 
 
 
 
 
Figure 3.2. DASGIP DASbox impeller and geometry 
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The DASbox system was operated with headspace aeration to achieve sufficient gas supply, 
unless otherwise stated. For sparged culture, the gas inlet port was lowered into the culture 
medium with an aeration rate of 0.1 VVM. For sparged bioreactor cultures, Antifoam C (Sigma, 
UK) was made up to a concentration of 2% (v/v) in water and sterilised by autoclaving. Antifoam 
was added to the bioreactors to reduce foaming at a concentration of 0.01% (v/v) per day. If 
PluronicTM F68 (Life Technologies, UK) was used in culture as a shear protectant, it was added 
directly into the culture medium at a concentration of 0.1% (v/v) as per the manufacturer’s 
instructions.  
 
To allow for sampling and harvest of the culture medium in the DASbox bioreactor without 
requiring the microcarriers to settle, one of the DASbox sample ports was modified (Figure 3.3). 
Briefly, a 40 µm nylon mesh was placed over the sample port and held in place using silicone 
sample tubing which prevented the microcarriers from entering the sample port during culture 
and harvest. This modification was made prior to autoclave sterilisation of the bioreactor so that 
the nylon mesh and tubing was sterilised during the autoclave process.         
 
 
 
Figure 3.3. DASGIP DASbox impeller and sample port modification (red arrow)  
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3.3.6 DASGIP DASbox bioreactor harvest 
To initiate the microcarrier harvest process, the DASbox control was switched off and the 
microcarriers allowed to settle. The spent culture medium was extracted through the modified 
sample port (Figure 3.2) and the microcarriers were washed twice in 50 ml of Ca2+ and Mg2+ free 
PBS. The PBS was aspirated before adding 80 mL of dissociation reagent for 10 minutes at an 
impeller speed of 375 rpm (ending with 5 seconds at 400 rpm). The dissociation reagent was 
then quenched with 70 ml of medium and a 2 mL sample placed in a single well of a 6 well plate 
for analysis under a light microscope to assess detachment efficiency. The remainder of the 
solution was filtered through a 60 μm Steriflip Filter Unit (Merck Millipore, Germany) to 
separate the microcarriers from the cells and medium. The cell suspension was centrifuged, the 
supernatant aspirated and the cell pellet re-suspended in culture medium. A cell count was then 
performed using a NucleoCounter NC-3000 to assess the overall BM-hMSC growth and the 
culture harvest efficiency.  
 
 
3.3.7 Downstream processing and cryopreservation from microcarrier culture 
Following detachment and separation from the microcarriers, BM-hMSCs were held in culture 
medium for four hours to simulate an expected process pooling time. Harvested cells were then 
suspended in Prime-XV™ Cryopreservation medium (Irvine Scientific, USA) at 2x106 viable 
cells.ml-1. Cells were equilibrated in freezing medium for 30 minutes at room temperature and 
aliquots (0.5 ml) were loaded into 1.8 ml cryovials during equilibration. Vials were cooled at 4°C 
for 5 minutes then cooled with a Stirling cryocooler (EF600, Asymptote, UK) set to cool at -
1°C.min-1 to -80°C. Cooled vials were stored under liquid nitrogen vapour for at least one month. 
Vials were rapidly thawed in a 37°C water bath and cells recovered by growth medium dilution 
followed by centrifugation. The resultant cell pellet was suspended in growth medium then the 
cells were seeded into T-flasks to monitor outgrowth and into fibronectin-coated multiwell 
plates to assess cell adhesion. 
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3.4 Analytical Techniques 
 
3.4.1 NC-100 determination of viable cell number 
Human MSC viability was determined via propidium iodide (PI) exclusion using a NucleoCounter 
NC-100 automated mammalian cell counter. Briefly, the non-viable cell number was determined 
by direct measurement of the cell suspension using a NucleoCassette (Chemometec, Denmark) 
containing PI (with the assumption that viable cells exclude the PI) and run on the 
NucleoCounter NC-100. The total cell number was obtained by first mixing 50 μL of the cell 
suspension with 50 μL of NucleoCounter Buffer A (Chemometec, Denmark) to permeabilise the 
cell membrane, vortexing for 3 seconds and leaving for a minimum of 10 seconds. Next, 50 μL 
of NucleoCounter Buffer B (Chemometec, Denmark) was added to the solution for stability and 
the solution aspirated using a NucleoCassette (Chemometec, Denmark) and run on the 
NucleoCounter NC-100 to obtain the total cell number (taking into account the 3x dilution). To 
calculate the viable cell number, the non-viable cell number was subtracted from the total cell 
number and multiplied by the cell re-suspension volume. 
 
 
3.4.2 NC-3000 determination of viability, mean cell diameter and cell aggregation 
The cell suspension was taken up into a Via-1 Cassette and loaded into the NucleoCounter NC-
3000 automated mammalian cell counter (Chemometec, Denmark) to determine mean cell 
diameter, viability (via acridine orange uptake and DAPI exclusion) and percentage cell 
aggregation.  
 
 
3.4.3 NC-3000 determination of cell number from microcarrier culture 
For microcarrier cultures, cells were counted directly from microcarrier culture, whilst still 
attached to the microcarrier surface.  The total cell number was obtained by first mixing 200 μL 
of the cell-microcarrier suspension with 100 μL of NucleoCounter Buffer A (Chemometec, 
Denmark) to permeabilise the cell membrane, vortexing for 30 seconds and leaving for a 
minimum of 10 seconds. Next, 100 μL of NucleoCounter Buffer B (Chemometec, Denmark) was 
added to the solution to stabilise, vortexed for 10 seconds and the solution taken into a Via-1 
Cassette (Chemometec, Denmark) and run on the NucleoCounter NC-3000 to obtain the total 
cell number (taking into account the 2x dilution). 
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3.4.4 Demonstration of multilineage potential  
The assessment of BM-hMSC multilineage potential was made according to the International 
Society for Cellular Therapies (ISCT) guidelines (Dominici et al. 2006; Rasini et al. 2013) which 
states that human mesenchymal stem cells should demonstrate the ability to differentiate down 
the osteogenic, adipogenic and chondrogenic lineages.  
 
A StemPro osteogenesis kit (Life Technologies, UK) was used to verify BM-hMSC osteogenic 
potential combined with dual staining of calcium and alkaline phosphatase; briefly the 10 mL 
osteogenic supplement was thawed at room temperature and added to 90 mL of the supplied 
basal medium and stored at 4-8°C. Cells were seeded in a 12 well plate at 5 x 103 cells cm-2 with 
DMEM and placed into an incubator at 37°C for 72 hours, after which 1 mL osteogenic 
differentiation medium was added to each well. The cells are then returned to the incubator 
with a medium exchange taking place every 2 to 3 days. After 28 days under differentiation 
conditions the medium is removed, cells were rinsed once in PBS and fixed in a 1 mL solution of 
4% (v/v) PFA for 5 minutes at room temperature. After fixation, cells were washed with distilled 
water and 1 mL 2.5% (v/v) silver nitrate (Sigma, UK) is added to each well for 30 minutes. Cells 
were rinsed three times with distilled water and a fast violet solution (Sigma, UK) containing 4% 
(v/v) napthol AS-MX phosphate alkaline (Sigma, UK) was added to the cells for 45 minutes at 
room temperature in the dark. Finally, cells were washed three times in distilled water and 
visualised under a light microscope.  
 
A StemPro chondrogenesis kit (Life Technologies, UK) was used to verify BM-hMSC 
chondrogenic potential combined with Alcian blue staining of extracellular matrix containing 
glycosaminoglycans. Briefly, the 10 mL chondrogenic supplement was thawed at room 
temperature and added to 90 mL of the supplied basal medium and stored at 4-8°C. 
Chondrogenic differentiation involves the formation of a micromass of BM-hMSCs, generated 
by seeding multiple 5 μl cell suspensions at 1.6 x 107 cells.ml-1 into a 12 well plate. The 12 well 
plate is placed into a humidified incubator at 37°C for 20 minutes, after which 2 mL 
chondrogenic differentiation medium is added to each well. The cells were then returned to the 
incubator with a medium exchange taking place every 2 to 3 days. After 14 days under 
differentiation conditions the medium was removed, cells are rinsed once in PBS and fixed in a 
2 mL solution of 4% (v/v) paraformaldehyde (PFA) (Sigma, UK) for 20 minutes at room 
temperature. After fixation, cells were rinsed in PBS and stained with 1% Alcian blue (w/v) 
(Sigma, UK) in 0.1 N hydrochloric acid (HCl) (Sigma, UK), passed through 0.2 μm filter (Nalgene, 
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UK) and incubated for 30 minutes at room temperature. After incubation, cells were rinsed 
three times with 0.1 N HCl, distilled water is added to dilute the acidity and cells were visualised 
under a light microscope (Nikon Eclipse TS-100, UK).  
 
A StemPro adipoogenesis kit (Life Technologies, UK) was used to verify BM-hMSC adipogenic 
potential combined with Oil Red O staining of lipid vacuoles; briefly the 10 mL adipogenic 
supplement was thawed at room temperature and added to 90 mL of the supplied basal 
medium and stored at 4-8°C. Human MSCs were seeded in a 12 well plate at 1 x 104 cells cm-2 
with growth medium and placed into an incubator at 37°C for 24 hours, after which 1 mL 
adipogenic differentiation medium was added to each well. The cells were then returned to the 
incubator with a medium exchange taking place every 2 to 3 days. After 21 days under 
differentiation conditions the medium was removed, cells rinsed once in PBS and fixed in a 1 mL 
solution of 4% (v/v) PFA for 20 minutes at room temperature. A stock solution of 0.3% (w/v) Oil 
Red O (Sigma, UK) was prepared in 99% isopropanol, stable for one year at room temperature. 
The working Oil Red O solution was prepared by mixing 3 parts Oil Red O stock solution with 2 
parts distilled water, passed through a 0.2 μm filter and incubated for 10 minutes at room 
temperature (stable for 2 hours). After fixation, cells were rinsed with distilled water and 1mL 
60% (v/v) isopropanol was added to each well for 5 minutes, removed and 1 mL of filtered Oil 
Red O working solution is added for 5 minutes at room temperature. Oil Red O solution is 
removed, cultures were rinsed with distilled water three times or until water is clear and 
visualised under a light microscope.   
 
 
3.4.5 Immunophenotype by multiparameter flow cytometry  
Detached BM-hMSCs were suspended at 0.5 x 106 cells.ml-1 in culture medium, loaded into a 96 
well plate (200µl per well) and centrifuged for 5 minutes at 300 g. The aspirate was removed 
and the cells re-suspended, washed in flow cytometry stain buffer (R&D Systems, UK) and 
centrifuged for 5 minutes at 300 g. The cells were stained for 20 minutes in the dark at room 
temperature with fluorescent monoclonal antibodies against CD34 (PE-CY5), CD45 (APC-Cy7), 
CD73 (PE-Cy7), CD90 (APC), CD105 (PE), HLA-DR (FITC) (BD Biosciences, UK) along with 
corresponding isotype controls. After incubation the cells were washed twice with staining 
buffer as before and 200µl of stain buffer is used to re-suspend the samples before analysis.   
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All data was obtained using a Guava EasyCyte 8HT flow cytometer (Merck Millipore, UK) 
equipped with 488nm and 640nm lasers running guava SoftIncyte acquisition software (v2.5). A 
minimum of 10,000 gated (forward scatter/side scatter) events were recorded for each sample. 
Compensation values were determined using anti-mouse Ig, κ antibody capture beads 
(CompBeads, BD Bioscience, UK) according to the manufacturer’s instructions. Post-acquisition 
analysis and compensation was performed with FlowJo v7.6.5 (TreestarInc, USA) software. 
 
 
3.4.6 Nutrient and metabolite analysis  
To assess the metabolic activity of the BM-hMSCs during culture, 1 mL medium samples were 
taken from each culture vessel (T-flask, spinner flask or bioreactor), stored initially at -18°C and 
transferred to -80°C for permanent storage. Multiple medium samples were thawed, 
randomised and analysed for glucose, lactate and ammonium using the BioProfile FLEX (Nova 
Biomedical, USA). Alternatively, the medium sample were thawed and analysed for glucose, 
lactate, ammonia, lactate dehydrogenase (LDH) and total protein using the Cedex Bio-HT 
metabolite analyser (Roche, Germany).    
 
 
3.4.7 Plastic adherence and morphology by phase contrast microscopy  
According to the minimum criteria as defined by the ISCT (Dominici et al. 2006; Rasini et al. 
2013), BM-hMSCs must adhere to tissue culture plastic. During the culture of BM-hMSCs this 
ability to adhere to tissue culture plastic has been assessed via daily imaging of the BM-hMSCs 
over multiple passages. In conjunction with this, qualitative morphology analysis of the BM-
hMSCs is carried out by taking a representative image of each T-75 flask on every day of culture 
throughout serial passage. This information was then used to assess changes in BM-hMSC 
morphology throughout the multiple passages as well as morphological differences between 
the various donor BM-hMSC cell lines.  
 
 
3.4.8 Quantitative osteogenic potential of BM-hMSCs  
Osteogenesis was quantified by BM-hMSC collagen production using the Sircol Assay (Biocolour, 
UK) following osteogenic differentiation. Collagen standards of acid-soluble collagen Type I at 0, 
0.1, 0.2 and 0.4 g.L-1 were used to quantify the collagen production. BM-hMSCs were seeded at 
10,000 cells.cm-2 in a 12 well plate with previously described cell culture medium; after 3 days 
culture growth medium was exchanged to PRIME-XV® Osteogenesis Serum-Free Medium (Irvine 
Scientific, USA) and cultured for 9 days with a medium exchange taking place every 3 days. To 
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quantify the collagen production cells were fixed with a solution of 5% acetic acid (v/v) (Sigma, 
UK) and 9% formaldehyde (v/v) (Sigma, UK) for 30 minutes at room temperature. The monolayer 
was washed and Sircol Dye Reagent (Biocolour, UK) was added to each well for 30 minutes, 
removed and the cell monolayer was washed with Acid-Salt Wash Reagent (Biocolour, UK). 
Alkali Reagent (Biocolour, UK) was added to each well to release the collagen-bound Sircol Dye 
Reagent and the resulting solution along with the collagen standard was quantified on a 
microplate reader (BMG Labtech, UK) at an absorbance of 555 nm. 
 
 
3.4.9 Colony forming unit-fibroblast (CFU-f) efficiency 
To assess the CFU-f efficiency, BM-hMSCs were seeded in a T-flask at 10 cells.cm-2 and cultured 
with a medium exchange every 3-5 days. Following 14 days culture, cells were washed with PBS 
and fixed in 4% formaldehyde (v/v) (Sigma, UK) for 30 minutes. Colonies were stained with 1% 
crystal violet (Sigma, UK) in 100% methanol (w/v) for 30 minutes. Stained colonies that were 
made up of more than 25 cells were recorded as CFU-fs. 
 
 
3.4.10 RNA isolation 
Total RNA was collected using TriFastTM Reagent (Peqlab, Germany) according to the 
manufacturer’s instructions. Potential genomic DNA contamination was removed by digestion 
with DNase (Life Technologies, Germany) followed by reverse transcription at 50 °C for 60 min 
using Superscript III (Life technologies, Germany) and 250 ng Oligo(dT)18-primer (Life 
Technologies, Germany).   
 
 
3.4.11 Quantitative real-time-polymerase chain reaction (PCR) analysis 
Quantitative real-time PCR was done with SYBR GreenER qPCR Supermix Universal (Life 
Technologies, Germany), additionally added 1x SybrGreenI (Life Technologies, Germany) and 
0.2 µM primer each on the DNA engine Opticon2 (Biorad, Germany) using these cycling 
conditions: Primary denaturation at 95 °C for 3 min, followed by 35 cycles: 95°C for 30s, 60°C 
for 30s (36B4, p21, CCL2) / 55 °C (Oct4) and 72°C for 30s followed by fluorescence measurement. 
The following primers for cell markers were used: CCL2 (recruits monocytes, memory T cells, 
and dendritic cells to the sites of inflammation produced by either tissue injury or infection, 
NM_002982.3) (Fw) 5¢-CCA AGG GCT CGC TCA GCC AGA TGC-3¢, (Re) 5¢-CGG AGT TTG GGT TTG 
Chapter 3: Materials and Methods 
 
 
49 | P a g e  
 
CTT GTC CAGG-3¢; p21 (regulates the cell cycle and mediates cellular senescence, 
NM_000389.4) (Fw) 5¢-CCG CCT GCC TCC TCC CAA CT-3¢, (Re) 5 ¢-GAG GCC CGT GAG CGA TGG 
AA-3¢, OCT4 (pluripotent marker associated with self-renewal of undifferentiated cells, 
NM_002701.4) (Fw) 5¢-GAG GAG TCC CAG GAC ATC AA-3¢, (Re) 5¢-CAT CGG CCT GTG TAT ATC 
CC-3¢ and VEGF (associated with vascularization and growth of blood vessels, 
NM_001171623.1) (Fw) 5¢- GGAAGGAGCCTCCCTCAGGGTTTCG -3¢, (Re) 5¢- 
GCCGGAGTCTCGCCCTCCGG -3¢. Serial dilutions of plasmid standards were used as positive 
controls and for quantification. Expression was normalized to the reference gene 36B4 
(ribosomal protein large P0 RPLP0, NM_001002.3). 
 
 
3.4.12 Short tandem repeat (STR) analysis  
Short Tandem Repeat analysis was completed by LGC Standards (UK) under their cell line 
authentication program. 
 
 
3.4.13 Post-thaw BM-hMSC adhesion and F-actin staining  
For the cell adhesion assay, cultured cells were washed with PBS then fixed and permeabilised 
with BD Cytofix/Cytoperm™ kit at 4°C for up to 1 week. After repeated washing, cellular F-actin 
was stained with 100 nM Alexa Fluor® Phalloidin with 100 nM 4',6-diamidino-2-phenylindole 
counterstain for 30 minutes in the dark. Stained cells were visualized with a Nikon Eclipse TS100 
fluorescence microscope (Nikon Instruments Europe B.V. UK). Cells were harvested during 
outgrowth and diluted 1:1 with viability stain (10 nM calcein-AM + 50 µg/ml propidium iodide 
in PBS) and incubated at 37°C for 7 minutes in 96 well plates. Stained cells were counted using 
a Guava EasyCyte 8HT flow cytometer using a standardized analysis protocol with GuavaSoft 2.6 
(Merck Millipore, UK). 
 
 
 
3.5 Statistical analysis 
Results were deemed to be significant if P < 0.05 using a 2 tailed Students T-test in SPSS (IBM, 
USA) statistical software. 
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3.6 Equations 
Equation 1: Specific growth rate 
𝑆𝑝𝑒𝑐𝑖𝑓𝑖𝑐 𝑔𝑟𝑜𝑤𝑡ℎ 𝑟𝑎𝑡𝑒, µ =  
ln(
𝐶𝑥(𝑡)
𝐶𝑥(0)
⁄ )
∆𝑡
  
Where µ is the net specific growth rate (h-1), Cx(t) and Cx(0) are the cell numbers at the end and 
start of the exponential growth phase, respectively and t is time (h).  
 
 
Equation 2: Fold increase 
𝐹𝑜𝑙𝑑 𝑖𝑛𝑐𝑟𝑒𝑠𝑎𝑒 =  
𝐶𝑥(𝑓)
𝐶𝑥(0)
  
Where Cx(f) is the final cell number at the end of passage and Cx(0) is the initial cell number at 
the start of passage.  
 
 
Equation 3: Population doublings 
𝑃𝑜𝑝𝑢𝑙𝑎𝑡𝑖𝑜𝑛 𝐷𝑜𝑢𝑏𝑙𝑖𝑛𝑔𝑠, 𝑃𝑑 =
1
log  (2)
∙ log (
𝐶𝑥(𝑡)
𝐶𝑥(0)
)  
Where Pd is the number of population doublings, Cx(t) and Cx(0) are the cell numbers at the end 
and start of the exponential growth phase, respectively. 
 
 
Equation 4: Doubling time 
𝐷𝑜𝑢𝑏𝑙𝑖𝑛𝑔 𝑡𝑖𝑚𝑒, 𝑡𝑑 =  
ln 2
𝜇
  
Where td is the cell doubling time (h) and µ is the net specific growth rate (h-1). 
 
 
 
Equation 5: Specific metabolite consumption and production rate 
𝑆𝑝𝑒𝑐𝑖𝑓𝑖𝑐 𝑚𝑒𝑡𝑎𝑏𝑜𝑙𝑖𝑡𝑒 𝑓𝑙𝑢𝑥, 𝑞𝑚𝑒𝑡 = (
𝜇
𝐶𝑥(0)
) ∙ (
𝐶𝑚𝑒𝑡(𝑡)−𝐶𝑚𝑒𝑡(0)
𝑒𝜇𝑡−1
)  
Where qmet is the net specific metabolite consumption or production rate, µ is the specific 
growth rate (h-1), Cx(0) is the cell number at the end of the exponential growth phase, Cmet(t) 
and Cmet(0) are the metabolite concentrations at the end and start of the exponential growth 
phase, respectively and t is time (h).  
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Equation 6: Yield of lactate from glucose 
𝑌𝑖𝑒𝑙𝑑 𝑜𝑓 𝑙𝑎𝑐𝑡𝑎𝑡𝑒 𝑓𝑟𝑜𝑚 𝑔𝑙𝑢𝑐𝑜𝑠𝑒, 𝑌 𝐿𝑎𝑐
𝐺𝑙𝑢𝑐
= (
∆[𝐿𝑎𝑐]
∆[𝐺𝑙𝑢𝑐]
)  
Where YLac/Glc is the yield of lactate from glucose, ∆[Lac] is the lactate production over specific 
time period and ∆[Glc] is the glucose consumption over same time period. 
 
 
Equation 7: Colony-Forming Unit Fibroblast (CFU-f) Efficiency 
𝐶𝐹𝑈𝑓 𝐸𝑓𝑓𝑖𝑐𝑖𝑒𝑛𝑐𝑦 = (
𝑁𝑐(0)
𝑁𝑐(𝑡)
) ∙ 100  
Where Nc(0) and Nc(t) are the number of cells seeded and the number of colonies formed, 
respectively. 
 
Equation 8: Mean specific energy dissipation rate 
The mean specific energy dissipation rate during culture at NJS (numerically equal to the specific 
power, (P/M)JS imparted to the medium) is given by: 
(𝜀?̅?)𝐽𝑆 = (𝑃 𝑀⁄ )𝐽𝑆 =  𝑃𝑂 ∙ 𝜌𝐿 ∙ 𝑁𝐽𝑆
3 ∙ 𝐷5 𝑀𝐽𝑆⁄   
Where Po is the impeller power number (dependent on the impeller type), D is the impeller 
diameter, ρL is the fluid density, kg.m-3 and MJS is the mass of medium and microcarriers in the 
vessel. 
 
Equation 9: Kolmogorov scale 
The Kolmogorov scale, λK is given by: 
 
(𝜆𝐾)𝐽𝑆 = (𝜈
3 (𝜀𝑇)𝐽𝑆 𝑚𝑎𝑥⁄ )
1 4⁄
 
 
Where εT max is the maximum local specific energy dissipation rate close to an impeller and ν is 
the kinematic viscosity.  
 
Equation 10: Reynolds number 
 
𝑅𝑒 = 𝑁 ∙ 𝐷2 ∙ 𝜌𝐿 𝜇⁄  
 
Where Re is the Reynolds number, N is the impeller speed (s-1), D is the impeller diameter (m), 
ρL is the fluid density (kg.m-3) and µ is the fluid viscosity (kg.ms-1). 
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3.7 Equipment and suppliers 
Becton Dickinson, UK 
 BD FACSCanto II 
 
BellCo, USA  
 Bell-EnniumTM Compact 5 position magnetic stirrer platform  
 100 mL spinner flasks   
 
BMG Labtech, UK 
 Omega plate reader 
 
Chemometec, Denmark  
 NucleoCounter NC-100 automated mammalian cell counter 
 NucleoCounter NC-3000 automated mammalian cell counter 
 
Eppendorf, UK  
 DASGIP DASbox controlled bioreactor system 
 Eppendorf 5804 Centrifuge    
 
Hamilton, Germany  
 DASbox OxyFerm dissolved oxygen probe  
 DASbox EasyFerm pH probe   
 
Merck Millipore, UK 
 Guava EasyCyte 8HT flow cytometer  
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Nikon Instruments, UK  
 Nikon TS-100 inverted microscope 
 Fluorescent Inverted microscope   
 
Nova Biomedical, USA  
 BioProfile FLEX Bioanalyser   
 
Roche, Germany 
 Cedex Bio-HT metabolite analyser 
 
 
Thermo Scientific, UK  
 Benchtop centrifuge Megafuge 16 
 Herasafe KS Class II Biosafety Cabinet  
 Heraeus HERAcell 150 CO2 Incubator   
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4 Characterisation of BM-hMSCs from Multiple Donors 
 
4.1 Chapter introduction 
Autologous cell-based therapies, where the cell donor and recipient is the same individual, are 
patient specific and their manufacture must be scaled-out to ensure that patient material is 
segregated and cross-contamination of material is avoided. Scale-out of autologous therapies 
will likely necessitate multiple manufacturing facilities, creating the need for local automation 
and the demonstration of comparability between these sites (Hourd et al. 2014a; Rafiq et al. 
2015a). The main advantage of autologous cell-based therapies is the lack of immune rejection 
associated with donor transplant material, eliminating the need for immunosuppressive 
medication, which would add significant cost to the treatment. Autologous therapies may also 
benefit from the development of point-of-care devices, where functional closed devices can be 
used to manufacture cell-based therapies at the bedside. These typically involve the isolation 
and enrichment of cells directly from the patient and are returned on-site as “minimally 
manipulated” therapies. Despite these advantages, many challenges remain in the development 
and commercialisation of autologous cell-based therapies. It is possible that the route of the 
target disease might be with the patient’s own cells and it would therefore be better to avoid 
using them, or indeed the patient is unable to undergo the procedure required for cell isolation. 
Furthermore, issues surrounding the quality test burden and logistics add to the complexity for 
the production and delivery of a cost effective autologous cell-based therapy and failure of 
product batches would be likely to lead to an inability to treat patients.  
 
Regenerative cell-based therapies where the donor and the recipient are different individuals 
are termed “allogeneic”. This creates an off-the-shelf business model, which is far more akin to 
current biopharmaceuticals, representing an attractive commercial opportunity. Assuming cell 
products can be stored long-term i.e. their manufacture is decoupled from delivery to the 
patient; the cells can be made available on demand. In contrast to autologous therapies, 
allogeneic products have the potential to be scaled-up, potentially benefitting from the 
economies of scale experienced by traditional bioprocesses (Jung et al. 2012; Rafiq et al. 2013b). 
As such, manufacturing technologies employed for allogeneic therapies are likely to differ in 
terms of nature and scale including the use of traditional scale-up technology such as stirred-
tank bioreactors. Allogeneic therapies will however create a product that is “more than 
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minimally manipulated”, which means that the regulatory pathway requires far more time and 
resource to complete.   
 
For the development of both autologous and allogeneic cell-based therapies, the 
characterisation of the input material from different donors will be necessary to assess any 
potential variation in the manufacturing and delivery process. The aim of this Chapter, 
therefore, is to characterise the input material for a BM-hMSC therapy bioprocess and then 
assess the implications for the development and operation of a large scale “more than minimally 
manipulated” cell-based therapy bioprocess.  
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4.2 Growth characteristics of BM-hMSCs from multiple donors 
 
4.2.1 Experimental overview 
The development of both patient specific and off-the-shelf BM-hMSC manufacturing processes 
will have to consider the effect of donor variation and therefore it is important to assess the 
potential impact of this variation on the process. With this in mind, an experiment was designed 
to compare the growth and metabolite flux of five BM-hMSC lines over five passages (30 days) 
in small-scale monolayer culture.  Four T-75 flasks were seeded for each donor BM-hMSC line 
in accordance with the protocol described in Section 3.2.5 and passaged every six days for a 
total of five passages. At passage the viable cell number was determined (Section 3.4.1) and the 
growth kinetics calculated (Equation 1). The culture medium supplemented with FBS (Section 
3.2.1) was exchanged after three days and daily medium samples were taken and analysed for 
glucose, lactate and ammonium as in Section 3.4.6 on the Nova BioProfile FLEX. The metabolite 
concentrations and per cell metabolite flux was then calculated from these measurements 
(Equation 5 and 6).     
 
 
4.2.2 Human MSC growth kinetics over multiple passages  
It will be important to consider the growth kinetics of multiple BM-hMSC donors for 
manufacturing processes that require cell expansion, in order to meet the cell numbers required 
for each product dose. The specific growth rate of each of the donor BM-hMSC lines can be seen 
in Figure 4.1, with clear differences between them. Cell lines M0, M2 and M4 generally 
maintained their expansion potential over the five passages with the specific growth rate of M0 
decreasing by only 0.066 ± 0.007 day-1, M2 decreasing by 0.056 ± 0.009 day-1 and M4 decreasing 
by 0.069 ± 0.018 day-1 from passage four to passage eight. In contrast, BM-hMSC lines M1 and 
M3 showed a dramatic reduction in growth kinetics over the expansion period with M1 
decreasing by 0.138 ± 0.022 day-1 and M3 decreasing by 0.123 ± 0.043 day-1 over the same time 
period. The specific growth rates measured here are in the range of other studies of BM-hMSCs 
and many display the same reduction in growth kinetics throughout expansion (Sethe et al. 
2006; Higuera-Sierra et al. 2009). This reduction in growth kinetics as the number of population 
doublings increases is largely due to the onset of cellular senescence (Estrada et al. 2013; Carlos 
Sepúlveda et al. 2014). This onset of cellular senescence is induced through replicative 
exhaustion, DNA damage, or other stresses (Tchkonia et al. 2013) and is irreversible in primary 
BM-hMSCs, limiting the expansion potential during manufacture.     
 
Chapter 4: Characterisation of BM-hMSCs from Multiple Donors 
 
 
57 | P a g e  
 
 
Figure 4.1. Growth potential of the five BM-hMSC lines over five passages. Showing (A) 
Cumulative population doublings; (B) Variation in cumulative population doublings across all 
six BM-hMSC lines; (C) Specific growth rate; (D) Fold Increase. (Data shows mean ± SD, n = 4). 
 
 
As mentioned in Section 4.1, autologous cell-based therapy products must be scaled-out to 
meet demand and the process must have the capability to deal with innate variation that exists 
when manufacturing each product batch from a different donor. With this in mind, the variation 
in input material should be assessed in order to inform product and process development, 
increase efficiency and reduce costs (Naing et al. 2015a). The variation in growth kinetics of the 
five BM-hMSC lines can be seen in Figure 4.1, with 13.74 ± 0.33 cumulative population doublings 
achieved by M0 over 30 days in culture, compared to M3 which only achieved 7.81 ± 0.32 over 
the same period of time. The measured variation in growth kinetics will likely have implications 
for BM-hMSC products that require culture expansion, as a minimum number of cells will be 
required to be generated within a set time frame, to meet the specification of the product. With 
such differences in the growth of BM-hMSCs between donors this makes the manufacture of 
autologous cell-based products a real challenge and solutions have been proposed to alleviate 
this, such as reducing the expansion of the product and utilising functionally closed automated 
manufacturing devices (Hourd et al. 2014b). The implications of this difference in growth 
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kinetics will also impact the logistics and timing, as the process will typically have to operate at 
the “worst-case-scenario”. Table 4.1 shows the variation in process time for each of these donor 
BM-hMSC lines for a theoretical process with the batch requirement of 350 million BM-hMSCs 
(Heathman et al. 2015b). The range in the process time between these donor BM-hMSC lines 
for this hypothetical product is over 13 days, creating potential batch timing issues when 
manufacturing products from multiple patients. This also creates differences in the medium 
utilisation to achieve each patient dose, for example M1 requires almost double the volume of 
medium per million cells compared to M0 (Table 4.1). This will likely impact of the overall cost 
of goods for patient specific processes, as medium and particularly the serum component of 
medium is likely to be a key cost driver during process scale-out (Brindley et al. 2012). Table 4.1 
also shows the inter batch range for each of these donor BM-hMSC lines, with cells requiring 
higher processing times showing increased batch variation (Figure 4.2). Increased inter batch 
range has the potential to reduce productivity as process timing will need to be flexible enough 
to accommodate this variation and production rates are likely to be decreased.     
 
The logistics of isolating cells from the patient, processing these cells and returning them to the 
patient will have to take place in a limited time period, for example, Provenge® (Dendreon 
Corporation, USA) a non-expanded cell-based therapy has a processing time of up to 18 hours. 
Process timings must therefore be clearly defined which will be challenging when the difference 
in growth kinetics is so variable and the process must be run assuming the minimum possible 
expansion rate of the product to avoid creating a production bottleneck. The implications of this 
are that low growth rate cells greatly reduce the efficiency of the process, which is likely to 
increase the cost of developing autologous cell-based products.     
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Table 4.1. Process time required to manufacture a theoretical batch of 350 million BM-hMSCs 
demonstrating variation in process time between and within donor material. Assumptions – 
Starting population of 2M BM-hMSCs, expanded in a T-flask process.    
BM-hMSC 
line 
Per dose of 350 million BM-hMSCs 
mL culture media 
per million cells 
Process Time 
(days) 
Number of 
Passages 
Inter Batch Range 
(days) 
M0 14.2 3 0.5 87 
M1 23.3 4 5.0 159 
M2 17.6 4 1.6 117 
M3 27.4 5 6.8 151 
M4 18.7 4 0.9 129 
 
 
 
The development of allogeneic cell-based therapies represents an off-the-shelf business model 
more akin to current biopharmaceutical production. These allogeneic processes can be scaled-
up to treat multiple patients from a single batch which is likely to increase the cost-effectiveness 
of the product due to increasing economies of scale, simpler supply logistics and larger amounts 
of material for quality control (QC)/quality assurance (QA) testing in comparison to autologous 
processes. Material from multiple donors must therefore be assessed in order to create a 
master cell bank with enough material to manufacture cells to meet the commercial demand 
for the cell-based therapy.  
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Figure 4.2. Correlation showing that the BM-hMSC donors with increased process times to 
achieve a therapeutic dose of 350 million cells have increased variation between batch 
production runs 
 
 
Figure 4.1b shows the box and whisker plots for the variation across five BM-hMSC lines, which 
increases with passage number and time in culture. The divergence in cell growth will create an 
issue for processes with a high expansion ratio, as a consistent process will be harder to obtain 
the longer the cells are in culture. This highlights the importance of developing a process control 
strategy that is capable of reducing this divergent culture, minimising the time required for in 
vitro expansion, or ideally producing a convergent process, once it is transferred to a large-scale 
bioreactor system.  
 
The divergence in growth characteristics of BM-hMSCs from multiple donors has implications 
for the development of allogeneic cell-based therapy manufacturing processes, as they will 
require a high cell expansion ratio at large scale in order to produce sufficient cell numbers to 
meet the product demand. Furthermore, as the cells are cultured for a longer period of time, 
the number of manipulations increases, which has the potential to introduce increased 
variability into the process. Automated and closed processes have the potential to reduce the 
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inherent variability in each of these process manipulations and are likely to play a key role in the 
development of allogeneic cell-based therapies.     
 
The development of an allogeneic product also necessitates a master cell bank, from which the 
final product can be manufactured (Wuchter et al. 2014). The cost of developing a master cell 
bank is typically high and cannot be recovered until the product receives market approval, 
adding to the funding gap in development of allogeneic cell-based therapies. The quality and 
consistency of the master bank is critical, as once it has been created it cannot be changed and 
therefore a high level of product and process understanding is required, coupled with rigorous 
safety and quality testing to ensure that the product in the master cell bank is suitable for the 
manufacture of the cell-based therapy product. The key advantage of an allogeneic process over 
an autologous process, however, is that the cellular material in the master cell bank can be 
selected based on rigorous product screening to control the variation in process input material. 
This will allow for increased consistency in desired product attributes throughout the 
manufacturing process, driving down the cost of these therapies as they increase in scale.    
 
 
4.2.3 Human MSC metabolite flux over multiple passages  
The relative metabolite production rate and nutrient consumption rate can be seen in Figure 
4.3, with the per cell metabolite flux showing differences across the five BM-hMSC lines over 
the 30 days in culture. The net glucose consumption rate for the BM-hMSC lines remained 
relatively stable throughout the 30 days of culture with the exception of M3, which showed an 
increase at the end of the culture period. The increase in net glucose consumption of M3 is 
linked with an increase in the net lactate production rate (Figure 4.3b). This is primarily 
associated with a reduction in the proliferative rate of the M3 cell line towards the end of the 
culture process. Variation in net metabolite flux across the cell lines has implications for the 
operation and control of autologous bioprocesses, as this will change the required nutrient 
feeding strategy employed during the manufacturing process.  
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Figure 4.3. Metabolite consumption and production of the five BM-hMSC lines over five 
passages. Showing (A) Specific glucose consumption rates; (B) Specific lactate production 
rates; (C) Specific ammonium production rates; (D) Specific yield of lactate from glucose.  
(Data shows mean ± SD, n = 4)  
 
 
The increase in the lactate production of M3 (Figure 4.4) has the potential to cause the build-up 
of toxic components that would need to be limited either by dilution (medium exchange) or 
removal from the process. If the levels of nutrient utilisation and metabolite production vary 
between donors in this way, control systems must be developed and integrated within the 
manufacturing process with the ability to neutralise this effect and maintain a consistent 
process, which will be critical for the successful regulation of an autologous manufacturing 
process. As well as metabolites, process parameters such as dissolved oxygen concentration and 
pH should also be controlled as they will have a profound impact on the critical product 
attributes (Lavrentieva et al. 2010c), which could be different for each donor BM-hMSC line. 
Control of nutrients and metabolites will become particularly important if the bioreactor 
process is operated at high cell densities, as the consumption of nutrients and production of 
metabolites will occur at an increasing rate. 
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Figure 4.4 shows the live metabolite concentrations of glucose, lactate and ammonium over the 
five experimental passages for each of the donor BM-hMSC lines. During the expansion process 
for BM-hMSCs, it is important that the concentration of glucose is maintained as it represents 
the main carbon source for anaerobic glycolysis, the primary metabolic pathway for glucose 
utilisation of BM-hMSCs (Higuera-Sierra et al. 2009). The concentration of glucose generally 
reaches a minimum at day six of culture, as the number of cells.ml-1 reaches a maximum. M0 
showed the lowest concentration of glucose which occurred on day six of the first experimental 
passage at 2.80 ± 0.26 mmol.L-1. In contrast to this, BM-hMSC donor M3 reached a minimum 
glucose concentration on day six of experimental passage five with 2.88 ± 0.12 mmol.mL-1 when 
the cell growth rate was at its lowest. This is likely due to the increased cellular stress as the BM-
hMSCs undergo senescence and consuming increasing amounts of glucose, with reducing the 
available glucose concentration in culture shown to reduce this onset of senescence (Lo et al. 
2011). 
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Figure 4.4. Metabolite consumption and production showing the difference between the BM-
BM-hMSC lines over five passages. Daily medium samples were taken and analysed for 
glucose, lactate and ammonium concentration. (Data shows mean ± SD, n = 4) 
 
 
In addition to the maintenance of glucose concentration during culture, the levels of lactate and 
ammonium must be minimised as they have the potential to inhibit the growth of the BM-
hMSCs. These have previously been determined experimentally to be greater than 20 mmol.L-1 
for lactate and 2 mmol.L-1 for ammonium (Schop et al. 2009b).  As with the minimum 
concentration of glucose, the concentration of lactate generally reaches a maximum at day six 
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of culture, as the number of cells.ml-1 reaches its maximum. M0 produced the highest 
concentration of lactate which occurred on day six of the first experimental passage with 4.96 
± 0.17 mmol.L-1. In contrast to this, BM-hMSC donor M3 reached a maximum lactate 
concentration on day six of experimental passage four with 5.36 ± 0.48 mmol.mL-1 when the cell 
growth rate was at its lowest. This is again likely due to the increased cellular stress as the BM-
hMSCs undergo senescence, consuming increasing amounts of glucose and concurrently 
producing increasing amounts of lactate. Despite the increase, this concentration of lactate is 
still below the inhibitory level of 20 mmol.L-1 as determined previously for BM-hMSCs.  
 
Similarly, the concentration of ammonium generally reaches a maximum at day six of culture, 
as the number of cells.ml-1 reaches its maximum. M0 produced the highest concentration of 
ammonium on day six of the first experimental passage with 0.80 ± 0.01 mmol.L-1. Again, in 
contrast to this, BM-hMSC donor M3 reached a maximum ammonium concentration on day six 
of experimental passage three with 0.79 ± 0.07 mmol.mL-1. Despite the increase throughout 
culture, this concentration of ammonium is still well below the inhibitory level of 2 mmol.L-1 as 
determined previously for BM-hMSCs, demonstrating in all instances that the medium exchange 
regime employed in this monolayer process is sufficient to maintain the required levels of 
glucose, lactate and ammonium required for sustained BM-hMSC expansion.  
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4.3 Identity of BM-hMSCs from multiple donors 
 
4.3.1 Experimental overview  
Perhaps one of most important aspects of the manufacture of cell-based therapy products is 
the definition and measurement of cell characteristics (Williams et al. 2012). These can be 
broken down into identity, potency, purity and safety which must all be considered during 
product development (Carmen et al. 2012a). The identity of BM-hMSCs must be maintained 
throughout the expansion process and establishing a baseline for the monolayer process is 
important to ensure the donor cells meet the minimum criteria of a BM-hMSC. The BM-hMSC 
morphology has been assessed during the expansion process outlined in Section 4.3, using a 
representative phase contrast microscopy image of the BM-hMSCs adhered to the surface of a 
tissue culture flask. Additionally, the tri-lineage differentiation potential of each BM-hMSC 
donor has been assessed after five experimental passages (total of seven cell passages) using 
the protocol outlined in Section 3.4.4 with representative images taken of each donor. 
Multicolour flow cytometry has been used to assess the co-expression of surface markers on 
the BM-hMSCs after five passages, using the protocol in Section 3.4.5. Finally, the genotype of 
three of the BM-hMSC donors has been verified by short tandem repeat (STR) analysis after five 
experimental passages to ensure the BM-hMSC cultures have remained genetically stable and 
have not become contaminated during subsequent culture.     
 
 
4.3.2 Morphology of BM-hMSCs from multiple donors  
Morphology has been used for decades as a qualitative assessment of BM-hMSC identity and 
has also been used as part of the release test for approved cell-based therapies, for example 
Carticel® (Genzyme, USA) includes morphology as part of their wider product release tests. 
Figure 4.5 shows the difference between the morphology of the BM-hMSC lines after five days 
in culture, with clear differences between them. Despite this, the majority of the BM-hMSC 
donors display the spindle-shaped, elongated morphology outlined by Pittenger et al (Pittenger 
et al. 1999), particularly at day six of monolayer culture.  
  
The implications for this difference in cell morphology can be appreciated when considering that 
an adherent cell manufacturing process will be based upon a fixed surface area for cell 
expansion.  With such differences in cell morphology in terms of size and alignment, the 
effective number of cells per square centimeter of these two cell lines when confluent varies 
greatly, creating an issue for these manufacturing processes based upon a fixed surface area. In 
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these processes, the final cell number at harvest will vary greatly between patients due to these 
morphological differences. Considering that manufacturing processes for autologous cell-based 
therapies will likely have a minimum number of cells per dose, this variation will greatly increase 
the risk of suffering product batch failure as this minimum number of cells per dose may not be 
met. Increased batch failure rate will likely increase the inherent risk and inevitably the cost of 
autologous cell-based therapy products. In addition to the challenges relating to the number of 
cells obtainable per unit area, the cell size will likely play a role in the downstream processing 
and delivery of the cells to the patient.  
 
The isolation procedure and subsequent positive selection of input material for these patient 
specific processes will be critical in reducing the failure rate of these manufacturing processes. 
Robust and reproducible isolation protocols need to be established to minimise variability of 
source material and selection criteria based on desired product attributes should be identified 
at an early stage of development. These isolation and selection processes will likely reduce 
process variation by placing controls on the input to the process, which will be critical to the 
success of these personalised cell-based therapies.   
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Figure 4.5. Phase contrast images showing the difference in BM-hMSC morphology 
throughout six days of culture   
 
 
As well as the cost implications of a product batch failure it is also important to consider the 
implications of such an occurrence in terms of not being able to treat a patient with an 
autologous therapy (Hampson et al. 2008). This represents a limitation to the use of such 
therapies and creates a challenge that has not been experienced with traditional medical 
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treatments. Depending on the severity of the clinical indication, this has the potential to cause 
complications and repetition of the isolation, expansion and delivery process may not be 
possible. It is clear that autologous therapies represent an opportunity to deliver cell-based 
therapies from a scale-out process and require innovation beyond current biopharmaceutical 
manufacture, however, subtle differences in this approach as highlighted above must be 
considered during product development and commercialisation. 
 
 
4.3.3 Tri-lineage differentiation of BM-hMSCs from multiple donors  
In addition to the BM-hMSC plastic adherence described in Section 4.3.2, BM-hMSCs from all 
donors must demonstrate the ability to differentiate down the osteogenic, chondrogenic and 
adipogenic lineages in vitro as defined by the International Society of Cellular Therapy (ISCT) 
(Dominici et al. 2006). This qualitative demonstration of tri-lineage differentiation potential for 
all donor BM-hMSCs can be seen in Figure 4.6, despite the differences discussed in Section 4.2. 
The BM-hMSCs cultured in chondrogenic medium as micromasses have stained positive for the 
presence of glycosaminoglycans (GAGs) with Alcian Blue, indicative of chondrogenic 
differentiation. In addition, BM-hMSCs cultured in adipogenic medium have formed lipid 
vacuoles (stained with Oil Red-O) and BM-hMSCs cultured in osteogenic medium have 
demonstrated the production of alkaline phosphatase and calcium, stained black with silver 
nitrate. 
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Figure 4.6. Tri-lineage differentiation potential of BM-hMSC lines using phase contrast 
microscopy. Showing osteogenic differentiation by staining for alkaline phosphatase and 
calcium deposition, adipogenic differentiation by staining with Oil Red O and chondrogenic 
differentiation by staining with Alcian Blue. 
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4.3.4 Immunophenotype of BM-hMSCs from multiple donors  
The development of a multiparameter flow cytometry method to assess the co-expression of 
surface markers on BM-hMSCs represents a step forward in immunophenotype analysis (Chan 
et al. 2014a). The simultaneous expression of positive and negative surface markers identities 
the cell population that meets all of the immunophenotype requirements, providing enhanced 
analytical resolution over the conventional method of assessing a single marker at a time. In 
addition, by taking a multiparameter approach, the phenotype analysis of BM-hMSCs requires 
fewer cells and reagents as well as a decreased operator time representing a significant cost and 
time saving during the process.    
 
Despite the differences in cell growth and net metabolite flux described in Section 4.1, all of the 
BM-hMSC lines displayed the expected immunophenotype by the positive co-expression of 
CD73, 90 and 105 and negative co-expression of CD34 and HLA-DR at the start and end of the 
culture process (Table 4.2). This level of expression has been maintained above 90% for all of 
the BM-hMSC donors across five experimental passages and 30 days in culture, demonstrating 
that cellular changes in growth kinetics and net metabolite flux do not have an effect on the 
expression of BM-hMSC surface markers.  
 
 
 
Table 4.2. Multiparameter flow cytometry showing percentage co-expression of CD90+, 
CD73+, CD105+, CD34- & HLA-DR- of each BM-hMSC line at day 0 (passage 1) and after day 30 
(passage 5). Mean value ± SD, in all cases 10,000 events were measured. 
BM-hMSC line Day 0 (P3) Culture Day 30 (P8) Culture 
M0 98.97 ± 0.19 % 97.78 ± 2.26 % 
M1 96.21 ± 0.22 % 95.97 ± 0.42 % 
M2 98.19 ± 0.09 % 95.13 ± 2.53 % 
M3 93.60 ± 2.51 % 96.56 ± 0.42 % 
M4 98.14 ± 0.94 % 93.17 ± 1.60 % 
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Figure 4.7. Exemplar multiparameter flow cytometry plots showing co-expression of CD90+, 
CD73+, CD105+, CD34- & HLA-DR- at the start (passage 1, top) and end (passage 5, bottom) of 
expansion.  
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4.3.5 Short tandem repeat analysis of BM-hMSCs  
Short tandem repeat (STR) analysis of M2, M3 and M4 BM-hMSC lines shows that they have 
retained the 16 key loci they are expected to express, indicating that these cell lines have 
retained the characteristic genotype throughout the entire culture process (Figure 4.8).     
 
 
 
Figure 4.8. Short tandem repeat analysis of M2, M3 and M4 BM-hMSC lines at the end of the 
expansion process demonstrating retention of the 16 loci that are characteristic of BM-hMSCs.      
Chapter 4: Characterisation of BM-hMSCs from Multiple Donors 
 
 
74 | P a g e  
 
4.4 Characterisation of BM-hMSCs from multiple donors 
 
4.4.1 Experimental overview  
As mentioned previously, the measurement of cellular characteristics is of critical importance 
for the successful development of BM-hMSC manufacturing processes. The M2, M3 and M4 BM-
hMSC lines have been taken forward for further characterisation as M2 and M4 had similar 
growth characteristics from Section 4.2 and M3 had much lower growth potential over the five 
passages. To assess the colony forming unit fibroblast (CFU) potential, four T-75 flasks for each 
of these donor lines were taken through eight experimental passages and at the end of each of 
these passages remaining cellular material from each T-75 flask was plated into two T-25 flasks 
for CFU analysis as described in Section 3.4.9. In conjunction with this, at passages three, seven 
and ten, remaining cellular material from each of the four flasks was plated into three wells of 
a 12-well plate and quantitatively assessed for osteogenic potential as described in Section 
3.4.8. The development and validation of this protocol can be found in Appendix A.        
 
 
4.4.2 Colony forming unit-fibroblast potential of BM-hMSCs from multiple donors  
It is widely acknowledged that a better understanding of the mechanism by which BM-hMSCs 
elicit their therapeutic action will be required before processes can be developed in order to 
preserve or potentially maximise it. Figure 4.9 shows the colony forming (CFU) efficiency of 
three of the BM-hMSC lines, M2, M3 and M4. Despite similarities in growth kinetics between 
M2 and M4 their ability to form colonies over ten passages in culture is very different, which 
would pose a challenge if the products were being assessed under the same QA guidelines. If 
the product does not meet the QA specification defined during clinical development, the 
product batch will be failed, creating significant consequences for both autologous and 
allogeneic processes. As allogeneic manufacturing processes are operated at larger batch sizes, 
the failure to meet the product release criteria will result in the loss of a large amount of 
invested capital, increasing the financial risk in the process. In contrast, the implications of a 
product batch failure during an autologous cell-based therapy process are that the patient will 
go untreated. Depending on the severity of the clinical indication targeted, this has the potential 
to be fatal, which will have severe implications for the health of the patient.    
 
It can also be seen from Figure 4.9 that the CFU potential of M2, M3 and M4 decreases 
throughout the monolayer expansion process, which is particularly apparent for M3 and M4. 
This provides valuable information about the relative quality of the BM-hMSC lines as despite 
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demonstrating similar growth kinetics and net metabolite flux, M2 and M4 have shown very 
different colony forming characteristics. The trend of BM-hMSCs showing decreasing CFU 
potential through culture also has implications for the development of large-scale processes 
with a higher cell expansion ratio, as desired attributes must be maintained in the final product.        
 
 
 
Figure 4.9. Further characterisation of three of the BM-hMSC lines throughout culture 
showing the differences in the colony forming unit fibroblast efficiency. (Data shows mean ± 
SD, n = 4) 
 
 
4.4.3 Quantitative osteogenic potential of BM-hMSCs from multiple donors  
The osteogenic potential of M2, M3 and M4 has also been quantified using collagen production 
under nine days of osteogenic differentiation (Figure 4.10). As with the colony forming unit 
fibroblast efficiency, the relative production of collagen under osteogenic conditions reduced 
significantly for M3 and M4 from passage three to passage ten, whilst the collagen production 
from the M2 cell line remained lower throughout culture. The loss in BM-hMSC multi-potency 
during in vitro expansion has previously been related to a loss of in vivo bone formation 
(Siddappa et al. 2007), which could be used as a critical-to-quality attribute (CQA) for a clinical 
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indication relating to bone tissue regeneration. Considering the rapid loss in activity after 
passage three, this would potentially limit the use of culture expanded BM-hMSCs for this type 
of clinical indication.     
 
 
 
Figure 4.10. Further characterisation of three of the BM-hMSC lines throughout culture 
showing the differences in the quantification of the collagen deposition after nine days under 
osteogenic conditions. Data shows mean ± SD, n = 4, ** denotes p < 0.01.  
 
 
It has been shown previously that donor age and gender has an effect on the function of BM-
hMSCs (Siegel et al. 2013), particularly relating to their ability for immunoregulation in vivo 
(Galipeau 2013). With these intrinsic donor characteristics having such an effect on the 
functionality of the cell-based therapy products, it is important to understand how they will 
affect the final product. To maintain the consistency required within the process, it will likely be 
necessary to pre-screen donor material for both autologous and allogeneic products prior to the 
expansion process. By taking this approach it might be possible to reduce the impact of the 
variability in donor BM-hMSCs described, however, the ethical implication of pre-selecting 
patients for autologous cell-based therapies must be carefully considered.  
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4.5 Implications of multiple donors in bioprocess development 
 
4.5.1 Demonstrating comparability 
Any changes to the manufacturing process during clinical development will require validation of 
the process to ensure it remains comparable before and after the change. Validating process 
changes will require significant time and resource, as well as the development of functional 
assays to demonstrate that there has been no change to the safety or function of the cell-based 
therapy product. In addition to making process changes, comparability must also be 
demonstrated if a cell-based therapy product is to be manufactured at multiple facilities (Hourd 
et al. 2014b). Multisite manufacture has the advantage of reducing the capital cost for scaling 
out product manufacture to meet commercial demand as well as reducing the inherent risk of 
having a single manufacturing facility. 
 
The process of demonstrating product comparability is not a trivial one and must go beyond the 
conventional in-process and product release characterisation, requiring a large amount of 
process and product data during development to act as a stable foundation from which to 
demonstrate product comparability. At the core of this dataset is the establishment of a set of 
product CQAs linked to the product mechanism of action for a specific clinical indication. 
Demonstrating this level of product comparability for a process that is expanding cells from 
multiple donors will be challenging, as variability in the input material will reduce the process 
consistency. In addition to this, with a divergence in BM-hMSC growth as seen in Figure 4.1b, 
increasing the number of product population doublings will make the process of demonstrating 
comparability more challenging still. Driving a consistent process will therefore be a logical first 
step towards developing these comparable processes, with reliable control strategies forming 
the basis for this consistency. Another aspect of ensuring consistency is sufficient control on the 
process input materials such as reagents, culture medium and disposables.  
 
As can be seen from Figure 4.9 and Figure 4.10, the characteristics of each of these cell lines 
changes throughout the culture process. Depending on the target indication and the set of CQAs 
for the cell-based therapy product, this will make the demonstration of process comparability 
challenging for expanded cell-based therapy products. Each of the product characteristics 
monitored during this study have shown a reduction as the number of cell population doublings 
increases, a clear sign that reducing the expansion ratio of the product where possible will 
improve the chances of maintaining product functionality and demonstrating comparability. 
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Understanding these process changes could be greatly improved by a detailed analysis of the 
metabolic activity of these products. Figure 4.3 shows the net metabolite flux of glucose, lactate 
and ammonium, however, understanding the metabolic intermediates such as pyruvate would 
also aid in demonstrating that process changes have not inadvertently affected the product 
characteristics, an important aspect of process comparability.  
 
 
4.5.2 Process analytical technology (PAT) 
As highlighted above, defining and measuring relevant product characteristics forms a critical 
part of developing successful manufacturing processes for cell-based therapies. If these 
processes are to be successfully transferred to a scalable manufacturing platform, these 
parameters must not only be measured, but must be integrated into online monitoring and 
control strategies. Process analytical technology or PAT is a system for analysing and controlling 
manufacturing processes through measurement of product attributes to ensure final product 
quality, proposed by the Food and Drug Administration (FDA) (Services 2004). 
 
This process can be broken down into three distinctive steps (S. Rathore et al. 2009): 
1. Understanding of the product quality attributes and how process parameters affect 
them.  
2. Ability to analyse quality attributes and monitor critical process parameters.  
3. Control of the critical process parameters to achieve consistent product quality.  
 
It will therefore be desirable to begin to measure online parameters in order to develop control 
systems to ensure that the product characteristics described in Section 4.4 remain consistent. 
These relevant process parameters are likely to include a combination of cell growth, medium 
temperature, pH, pO2 and pCO2, which are commonplace in current biopharmaceutical 
production processes (Cierpka et al. 2013). In addition to this, process parameters such as 
metabolite concentrations (glucose, lactate, ammonia and glutamine) can play a role in product 
understanding during the manufacturing process and should be controlled to ensure consistent 
product quality. The benefit of operating a production process under the guidance of PAT will 
likely be a reduction in product variability, which will reduce the likelihood of product batch 
failure. Having a detailed product understanding using online measurements also introduces 
the possibility for real-time release testing of product batches, which will reduce costs by 
reducing the quality test burden at the end of the process.   
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4.6 Chapter conclusions 
Characterising input material from different BM-hMSC donors has allowed for an assessment of 
the effect of variation on developing cell-based therapy manufacturing processes. Identifying 
the divergent nature of the growth of multiple BM-hMSC donor lines has been identified as a 
potential issue for the development of both autologous and allogeneic processes where cell 
expansion is required. Furthermore, measuring multiple quality characteristics of these BM-
hMSC lines throughout culture has demonstrated a reduction in quality as the population 
doubling level increases, which must be considered as these processes are scaled.   
 
Developing manufacturing processes from multiple BM-hMSC donors will require an 
understanding of the effect of donor characteristics on expanded autologous and allogeneic 
cell-based therapy bioprocesses. Measuring informative product attributes that are 
characteristic of the desired therapeutic effect for each clinical indication will facilitate the 
development of consistent manufacturing processes and will play a key role in unlocking the 
value of demonstrating process comparability, allowing for any necessary process changes and 
multisite manufacturing models.        
 
Having identified this variation between BM-hMSC donors and discussed the implications for 
patient specific and off-the-shelf manufacturing processes, steps must be taken to reduce this 
early in process development. With this in mind and considering the potential scalability issues 
associated with the use of FBS, altering the medium formulation for this monolayer expansion 
process prior to process transfer and scale-up will be an important step in limiting the impact of 
this donor variation. In addition to this, the growth medium is likely to have an influence on the 
growth and quality attributes of the BM-hMSCs, which will increase process yield and cost-
effectiveness.  
 
Publications arising from this Chapter: 
Heathman TRJ, Rafiq QA, Chan AK, Coopman K, Nienow AW, Kara B, Hewitt CJ. Characterisation 
of human mesenchymal stem cells from multiple donors and the implications for large scale 
bioprocess development. Biochemical Engineering Journal, (2015) (in press) 
 
Chan AK, Heathman TRJ, Coopman K, Hewitt CJ. Multiparameter flow cytometry for the 
characterisation of extracellular markers on human mesenchymal stem cells. Biotechnology 
letters, (2014) 36 (4): 731-41. 
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5 Improving the Yield and Consistency of BM-hMSC Expansion 
 
5.1 Chapter introduction 
Achieving the consistent manufacture of medicinal products is a key requirement for regulatory 
approval and begins with assessing and reducing process variation where possible (Williams et 
al. 2012). Driving a consistent process will demonstrate a state of control over the product and 
provides a foundation for comparability, whereby process changes during clinical development 
can be validated and the product can be manufactured at multiple sites.  
 
A key aspect of these manufacturing processes is the culture medium in which the cells are to 
be expanded, which is typically supplemented with fetal bovine serum (FBS) (Wappler et al. 
2013). In addition to lot-to-lot variability, there are further process constraints on the use of FBS 
such as limited supply (Brindley et al. 2012), potential for pathogen transmission and 
immunological reactions against bovine antigens (Kocaoemer et al. 2007). Human platelet lysate 
(HPL) has been proposed as a viable alternative, whereby blood platelets are lysed to release 
growth factors such as platelet-derived growth factor (PDGF), epidermal growth factor (EGF), 
transforming growth factor-β (TGF-β) and fibroblast growth factor (FGF) which then supplement 
the BM-hMSC growth medium (Lubkowska et al. 2012). This can be used as a patient specific 
supplement from their own blood plasma or pooled from multiple donors, for example 
Stemulate™ manufactured by Cook Regentec (USA). Furthermore, HPL has already been 
reported as a superior substitute to FBS for the in vitro expansion of BM-hMSCs (Schallmoser et 
al. 2010) and has been shown to maintain stem cell characteristics and multipotent capacity 
(Doucet et al. 2005).  
 
Rather than simply replacing the serum source in culture medium, it is highly desirable to 
develop serum-free medium formulations and avoid a number of the aforementioned 
constraints on serum-based processes (Heathman et al. 2015d). Serum-free culture has  also 
been previously shown to be amenable to scalable expansion technology such as microcarriers 
and stirred bioreactors, producing higher BM-hMSC yields per unit time than serum-based 
processes, which will be important for driving down the production cost of BM-hMSC therapies 
(dos Santos et al. 2011a). That said, the current cost of serum-free medium for research is 
generally higher than serum-based medium, however, as the demand increases and higher yield 
processes can be developed, these costs will likely be reduced over time.   
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Considering the innate biological variability that exists between donors and the importance of 
ensuring a consistent manufacturing process, driving this philosophy into process development 
at an early stage is critical. Therefore, the aim of this Chapter is to demonstrate how the 
development of a serum-free expansion process can drive increased consistency and yield of 
BM-hMSC manufacture between donors and explore the benefits this can bring as the process 
scale increases.  
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5.2 Growth characteristics of BM-hMSCs in different media 
 
5.2.1 Experimental overview 
Given the importance of the medium formulation on the expansion of BM-hMSCs and on the 
development of scalable processes, three different medium formulations have been assessed 
for their effect on the yield, quality and consistency of two BM-hMSC lines. From Chapter 4, the 
M2 BM-hMSC line has been selected for this study due to the higher growth and quality 
characteristics, as well as, M3 which displayed the lowest growth kinetics and a sharp reduction 
in cellular characteristics. The three medium formulations are as follows (see Section 3.2.1): 
 
1. DMEM supplemented with 10% foetal bovine serum (FBS) 
2. DMEM supplemented with 10% human platelet lysate (HPL) 
3. Irvine Scientific PRIME-XV® MSC Serum-free medium (SFM) 
 
Prior to this study, the concentration of HPL in DMEM was screened to assess the level required 
for similar growth characteristics to 10% FBS (found to be 10% HPL), the results of which can be 
found in Appendix B. The selection of PRIME-XV® SFM was made following a pre-screen of six 
commercially available serum-free media and the PRIME-XV® SFM was tested for compatibility 
with BM-hMSCs prior to these experiments, the results of which can be found in Appendix C. 
Four T-75 flasks were seeded for each BM-hMSC line, in each medium formulation giving a total 
of 24 flasks that were cultured for 36 days in accordance with the protocol described in Section 
3.2.5. At passage the viable cell number, mean cell diameter and percentage cell aggregation 
was determined (Section 3.4.2) and the growth kinetics calculated (Equation 1). The culture 
medium supplemented with either FBS or HPL was exchanged after three days and SFM was 
exchanged every two days. Daily medium samples were taken and analysed for glucose, lactate, 
ammonia, lactate dehydrogenase (LDH) and total protein as in Section 3.4.6 on the Cedex Bio-
HT. Metabolite analysis was transferred from the BioProfile FLEX to the Cedex Bio-HT as more 
medium components could be measured using the Cedex Bio-HT with increased accuracy and 
higher throughput. The metabolite concentrations and per cell metabolite flux was then 
calculated from these measurements (Equation 5 and 6).     
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5.2.2 Growth kinetics over multiple passages 
Human mesenchymal stem cells are currently under clinical investigation for the treatment of 
many diseases, with the majority of these off-the-shelf therapies typically requiring more than 
one billion cells per patient (Prasad et al. 2011; Maziarz et al. 2015). In order for manufacturing 
processes to meet this demand, a large cell expansion ratio will be required to treat many 
patients from the same batch. Figure 5.1 shows the relative difference between a serum-free 
medium (SFM), PRIME-XV®, and medium supplemented with fetal bovine serum (FBS) or human 
platelet lysate (HPL) in terms of BM-hMSC growth. It is clear that the SFM offers a significantly 
higher proliferation rate over FBS and HPL (p < 0.001) with a maximum specific growth rate of 
0.471 day-1 compared with 0.244 day-1 in FBS and 0.334 day-1 during the 36 day expansion 
process (Figure 5.2). This increased growth rate corresponds to a final median cumulative 
population doubling level of 18.15 in the SFM compared with 8.93 in FBS and 9.91 in HPL culture 
across the two donors at the end of the 36 day expansion process.  
 
 
 
Figure 5.1. Cumulative population doublings of the two BM-hMSC lines over 36 days of 
expansion in FBS, HPL and SFM. Showing the increased consistency and yield in SFM over 36 
days and increased consistency and yield in HPL over 18 days compared to FBS-containing 
medium. Data shows mean ± SD, n=4 
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This represents an increase of around 600 times the number of cells under the SFM culture 
compared with FBS culture over this expansion period, which dramatically increases the 
effective product yield and potential scalability of the SFM process to meet the needs of a large 
scale off-the-shelf cell-based therapy.  
 
Cells that experience nutrient deprivation typically spend longer in the G1 phase of the cell cycle, 
resulting in slower proliferation (Jorgensen and Tyers 2004). The fact that the PRIME-XV® 
medium supported a more rapid cell growth therefore indicates that it may provide a better 
nutritional balance or activates growth regulation pathways such as the PI(3)K pathway, than 
the FBS-containing medium under the medium exchange regime employed here. 
 
 
 
Figure 5.2. Specific growth rate of the two BM-hMSC lines over 36 days of expansion in FBS, 
HPL and SFM. Showing the increased consistency and yield in SFM and the decline in growth 
rate of BM-hMSCs in HPL culture. Data shows mean ± SD (n=4)  
 
5.2.3 Mean cell diameter of BM-hMSCs over multiple passages 
The cell diameter of the BM-hMSCs throughout the expansion process in FBS, HPL and the SFM 
culture has been measured to determine whether this attribute remains consistent. It can be 
seen from Figure 5.3 that the BM-hMSCs cultured in the SFM have a smaller diameter 
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throughout the expansion process compared to FBS and HPL, which in volumetric terms equates 
to around half the size (assuming complete sphericity). The increase in cell diameter of M2 and 
M3 towards the end of the culture process is associated with a reduction in growth rate (Figure 
5.4) and therefore stability in cell diameter throughout culture will be important in order to 
maintain BM-hMSC growth kinetics. Figure 5.4 shows the relationship between the mean cell 
diameter of the BM-hMSC population against the growth kinetics of the subsequent passage. 
This demonstrates that the smaller BM-hMSCs generally have higher growth kinetics, which has 
been reported previously (Majore et al. 2009; Christodoulou et al. 2013). In addition to growth, 
BM-hMSC size is also linked to aging of BM-hMSCs and loss in differentiation potential (Stolzing 
and Scutt 2006; Wagner et al. 2010) and therefore increasing size can also be used as a surrogate 
marker of BM-hMSC senescence.  
 
 
 
Figure 5.3. Mean cell diameter of the two BM-hMSC lines throughout 36 days of expansion in 
FBS, HPL and SFM. Showing the reduced mean cell diameter under SFM and an increase in HPL 
throughout culture. Data shows mean ± SD (n=4)   
 
Importantly, the osmolality of the FBS-based, HPL-based and PRIME-XV® SFM are similar (0.31, 
0.31 and 0.29 Osmol.kg-1, respectively), further indicating that the difference in cell size noted 
in Figure 5.3 is not a simple matter of a change in osmotic balance, although it should be noted 
that the osmolality of the PRIME-XV® SFM is closer to human physiological conditions 
(Cheuvront et al. 2014).  Although the reasons for this relationship are not clear, it can 
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nonetheless provide a basis for evaluating the stability of the BM-hMSCs throughout expansion 
and provide as an early indication that cell growth kinetics may begin to reduce. The smaller cell 
size experienced in the SFM will also allow for higher number of cells per area, an important 
attribute for adherent cell expansion, however, the implications of this smaller size on the 
functional properties must be assessed during product pre-clinical and subsequent clinical 
development.  
 
 
 
Figure 5.4. Correlation showing the relationship between mean cell diameter and specific 
growth rate of BM-hMSCs during the following passage, R2=0.8705. Data shows (n=144) 
 
 
The size of the BM-hMSC also has the potential to affect the post-transplant safety profile of 
the therapy and the impact of the process conditions on this attribute should be considered in 
relation to the delivery method (Ge et al. 2014). If the cell-based therapy is to be delivered by 
intra-arterial infusion, there is a potential risk of microembolisms and decreased cerebral blood 
flow which must be mitigated by altering the cell dose, infusion volume and velocity (Cui et al. 
2015). The size of freshly isolated stem cells is ~11 µm and can be transported through 
capillaries, while expansion has previously been shown to increase the size to ~20 µm 
obstructing microvascular vessels after infusion (Moelker et al. 2007). Considering that BM-
hMSCs cultured under FBS reached a maximum cell diameter of 18.4 µm compared with SFM 
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with a maximum cell diameter of 15.5 µm, the smaller cell diameter achieved under SFM would 
offer advantages of reduced risk of these complications. Cells of around 15 µm have previously 
been shown to carry reduced risk of restricting cerebral blood flow, with larger cells requiring a 
reduced dose and infusion rate (Janowski et al. 2013).  
 
5.2.4 Net metabolite flux per BM-hMSC 
The net metabolite flux of glucose and lactate has been measured in FBS, HPL and SFM culture 
over the expansion process to better understand the relative consistency between the donor 
BM-hMSCs with time in culture. Figure 5.5 shows the per cell flux of glucose for FBS, HPL and 
SFM culture, with a range of per cell glucose flux of 24.29, 28.77 and 8.81 pmol.cell-1.day-1 for 
FBS, HPL and SFM expansion, respectively. This is concurrent with the relative flux of lactate per 
cell (Figure 5.6), with a range of 22.47, 25.76 and 2.11 pmol.cell-1.day-1 for FBS, HPL and SFM 
expansion, respectively.  
 
 
 
Figure 5.5. Per cell metabolite flux of two BM-hMSC lines over 36 days of monolayer 
expansion in FBS, HPL and SFM. Showing increasing per cell glucose consumption rate through 
culture in FBS and HPL. Data shows mean ± SD (n=4)      
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This increased range in per cell metabolite flux in FBS and HPL is primarily due to increased 
variability between donors at the end of the expansion process and is associated with a 
reduction in BM-hMSC growth and increase in cellular senescence that is not experienced in the 
SFM, despite the higher number of population doublings.  
 
 
Figure 5.6. Per cell metabolite flux of two BM-hMSC lines over 36 days of monolayer 
expansion in FBS, HPL and SFM. Showing increasing per cell lactate production rate through 
culture in FBS and HPL. Data shows mean ± SD (n=4)      
 
 
Figure 5.7 shows the ammonia flux per cell of M2 and M3 in FBS, HPL and SFM. This shows a 
similar increase in the ammonia production rate towards the end of HPL expansion that was 
experienced with the glucose consumption and lactate production rates. This reaches a 
maximum of 6.92 ± 0.38 pmol.cell-1.day-1 after 36 days expansion in M3, which is almost double 
the production rate measured in SFM. The yield of lactate from glucose (Figure 5.8) in SFM was 
typically below 1 mol.mol-1, suggesting a combination of anaerobic glycolysis and oxidative 
phosphorylation to drive energy production (Ozturk and Palsson 1991; Cruz et al. 1999). The 
higher yield of lactate from glucose in FBS and HPL suggests increased utilisation of anaerobic 
glycolysis, suggesting that the BM-hMSC cultured in SFM more efficiently utilise glucose for 
energy production (Schop et al. 2008).  
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Figure 5.7. Per cell metabolite flux of two BM-hMSC lines over 36 days of monolayer 
expansion in FBS, HPL and SFM. Showing increasing per cell ammonia production rate through 
culture in HPL. Data shows mean ± SD (n=4)       
 
 
 
Figure 5.8. Yield of lactate from glucose of two BM-hMSC lines over 36 days of monolayer 
expansion in FBS, HPL and SFM. Demonstrating that BM-hMSCs use glucose via anaerobic 
glycolysis in all conditions. Data shows mean ± SD (n=4) 
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The net flux of metabolites has the potential to form part of a panel of measurements for the 
purposes of demonstrating comparability, whereby process changes can be evaluated for their 
impact on cellular characteristics. This understanding of the cell during the expansion process 
will also be a valuable tool during process scale-up to ensure that the interaction between the 
cell and its environment has not changed during technology transfer. This highlights the 
importance of process analytical technology (PAT), which can be employed to monitor and 
control process and product attributes to ensure consistency and quality in the final product. It 
can be seen from Figure 5.5 and Figure 5.6 that there is reduced per cell consumption of glucose 
and production of lactate in SFM culture, which is likely to be a beneficial product attribute as 
the process is scaled. This will be particularly apparent once suspension-based expansion 
processes routinely reach high cell densities (in excess of 1x106 cell.mL-1), where the buildup of 
waste products such as lactate have the potential to inhibit the expansion process. Considering 
that the culture medium is likely to contribute to a significant portion of the cost of goods for 
BM-hMSC production, product attributes that reduce the usage of culture medium will be 
increasingly beneficial at the large scale.     
 
The increased consistency between donor BM-hMSC lines in terms of per cell metabolite flux is 
a further demonstration that the cells cultured in the SFM conditions show reduced inter-donor 
variation, an important consideration given the large amount of variation experienced in cell-
based therapy manufacture. Although this has been demonstrated here for basic metabolites, 
there is scope to extend this analysis to a larger panel of metabolic intermediates to provide a 
detailed understanding of the impact of the process on the BM-hMSC metabolic characteristics 
during scale up. The reason for this increased consistency in the SFM has yet to be explored in 
the literature, however, the combination of BM-hMSCs cultured on fibronectin with serum-free 
growth medium has previously shown to activate the platelet-derived growth factor receptor, 
which is essential for cell migration (Veevers-Lowe et al. 2011). Activation of BM-hMSCs in this 
way provides a potential mechanism for the cell characteristics to converge, as the BM-hMSCs 
are actively forced to utilise specific cellular pathways, as opposed to serum-based culture 
where an abundance of various proteins are available to the cells. This combination of a 
fibronectin coating with growth medium supplemented with platelet-derived growth factor has 
been used previously to positively select for smaller, highly proliferative cell populations from 
bone-marrow, termed multipotent adult progenitor cells (MAPCs) (Breyer et al. 2006). This 
positive selection process could also be contributing to the increase in consistency measured in 
several different characteristics under serum-free conditions as discussed further below.    
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5.2.5 Live metabolite flux over multiple passages 
The measurement of live metabolite concentrations throughout culture is important to ensure 
that the medium exchange regime employed is sufficient to supply the required nutrients and 
limit the concentrations of metabolites that have the potential to limit cell growth. Figure 5.9 
show the concentration of glucose in each medium formulation for both BM-hMSC donors, 
demonstrating that the concentration of glucose did not fall below 2 mmol.L-1 at any point 
during the 36 days of expansion in FBS, HPL or SFM.   
 
Figure 5.9. Live glucose concentration of two BM-hMSC lines over 36 days of monolayer 
expansion in FBS, HPL and SFM. Showing reduced glucose concentration in HPL and lower 
glucose utilisation of BM-hMSCs in SFM. Data shows mean ± SD (n=4)       
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Similarly, the concentration of lactate in the culture medium must be reduced to avoid inhibition 
of BM-hMSC growth and characteristics which has previously been determined to be 35.4 
mmol.L-1 for BM-hMSCs (Schop et al. 2009b). It can be seen from Figure 5.10 that the maximum 
level of lactate for FBS and HPL culture was 6.67 ± 0.06 and 9.44 ± 0.66 mmol.L-1, respectively. 
In contrast, the maximum level of lactate in SFM was far lower at 3.22 ± 0.19 mmol.L-1, more 
than an order of magnitude lower than the previously determined inhibitory level.    
 
 
Figure 5.10. Live lactate concentration of two BM-hMSC lines over 36 days of monolayer 
expansion in FBS, HPL and SFM. Showing increased lactate concentration in HPL and lower 
lactate concentration in SFM. Data shows mean ± SD (n=4)     
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The concentration of ammonia in the culture medium must also be reduced to avoid inhibition 
of BM-hMSC growth and characteristics which has previously been determined to be 2.4 
mmol.L-1 for BM-hMSCs (Schop et al. 2009b). It can be seen from Figure 5.11 that the maximum 
level of ammonia for FBS and HPL culture was 0.70 ± 0.05 and 0.87 ± 0.05 mmol.L-1, respectively. 
In this instance, the maximum level of ammonia in SFM was higher at 0.90 ± 0.02 mmol.L-1, 
however, still half the previously determined inhibitory ammonia level for BM-hMSCs.    
 
 
Figure 5.11. Live ammonia concentration of two BM-hMSC lines over 36 days of monolayer 
expansion in FBS, HPL and SFM. Showing similar levels of ammonia concentration in FBS, HPL 
and SFM. Data shows mean ± SD (n=4)  
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Cell damage was evaluated by measuring a combination of lactate dehydrogenase (LDH) 
(Lavrentieva et al. 2010a) and total protein released. Figure 5.12 and Figure 5.13 show these 
concentrations throughout culture, which indicate only a minimal increase in LDH and no 
change in the subsequent total protein concentration. The only appreciable increase in LDH 
concentration occurred in SFM at the first passage from the baseline of around 3 U.L-1 up to 
10.13 ± 1.56 U.L-1.  
 
 
Figure 5.12. Live lactate dehydrogenase (LDH) concentration of two BM-hMSC lines over 36 
days of monolayer expansion in FBS, HPL and SFM. Showing increased LDH concentration in 
SFM at increased cell densities. Data shows mean ± SD (n=4)  
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This is in conjunction with the highest cell density during the expansion process and therefore 
should be monitored, particularly during bioreactor culture where it is desirable to have high 
BM-hMSC densities to increase product yields. This combined measurement demonstrates that 
cell death was minimal throughout the expansion process, making the fold expansion data a 
reliable estimate of net proliferative rate.   
 
 
Figure 5.13. Live total protein concentration of two BM-hMSC lines over 36 days of monolayer 
expansion in FBS, HPL and SFM. Showing no increase in concentration throughout expansion, 
indicating a low amount of BM-hMSC death. Data shows mean ± SD (n=4)       
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5.3 Identity of BM-hMSCs in different medium formulations 
 
5.3.1 Experimental overview 
The identity of BM-hMSCs must be sustained throughout the expansion process and ensuring 
that this is the case for all potential culture media or changes to the process is important during 
process development. To achieve this, the tri-lineage differentiation potential of both BM-hMSC 
donors in each media condition has been assessed after six experimental passages using the 
protocol outlined in Section 3.4.4 with representative images taken in each condition. 
Multicolour flow cytometry has also been used to assess the co-expression of surface markers 
on the BM-hMSCs after six passages, using the protocol in Section 3.4.5. Finally, the genotype 
of three of the BM-hMSC donors has been verified by short tandem repeat (STR) analysis after 
six experimental passages to ensure the BM-hMSC cultures have remained genetically stable 
and have not become contaminated during subsequent culture.     
 
 
5.3.2 Tri-lineage differentiation potential of BM-hMSCs in different formulations 
As defined by the International Society of Cellular Therapy (ISCT) (Dominici et al. 2006), BM-
hMSCs from both donors in each medium formulation must demonstrate the ability to 
differentiate down the osteogenic, chondrogenic and adipogenic lineages in vitro. This 
qualitative demonstration of tri-lineage differentiation potential for all donor BM-hMSCs can be 
seen in Figure 5.14. The BM-hMSCs cultured in chondrogenic medium as micromasses have 
stained positive for the presence of glycosaminoglycans (GAGs) with Alcian Blue, indicative of 
chondrogenic differentiation. In addition, BM-hMSCs cultured in adipogenic medium have 
formed lipid vacuoles (stained with Oil Red-O) and BM-hMSCs cultured in osteogenic medium 
have demonstrated the production of alkaline phosphatase and calcium, stained black with 
silver nitrate. Figure 5.14 shows that BM-hMSCs have demonstrated this potential for both of 
the BM-hMSC donors in all three medium formulations, which demonstrates that changing the 
medium formulation has not had an adverse impact on the in vitro differentiation potential of 
the BM-hMSCs.   
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Figure 5.14. Tri-lineage differentiation potential of the two BM-hMSC lines in FBS, HPL and 
SFM using phase contrast microscopy. Showing osteogenic differentiation by staining for 
alkaline phosphatase and calcium deposition, adipogenic differentiation by staining with Oil 
Red O and chondrogenic differentiation by staining with Alcian Blue 
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5.3.3 Immunophenotype of BM-hMSCs in different medium formulations 
In addition to the tri-lineage differentiation potential in Section 5.3.2, BM-hMSCs must also 
demonstrate the expression of both positive and negative surface markers in accordance with 
the ISCT criteria. Table 5.1 shows the percentage co-expression of CD90+, CD73+, CD105+, 
CD34- & HLA-DR- of the two BM-hMSC lines in FBS, HPL and SFM at the start and end of the 
expansion process.  
 
Table 5.1. Multiparameter flow cytometry showing percentage co-expression of CD90+, 
CD73+, CD105+, CD34- & HLA-DR- of two BM-hMSC lines in FBS, HPL and SFM at day 0 (passage 
3) and after day 36 (passage 9). Mean value ± SD, in all cases 10,000 events were measured 
 
 
Despite the differences in cell growth and net metabolite flux described in Section 5.2, all of the 
BM-hMSC lines displayed the expected immunophenotype by the positive co-expression of 
CD73, 90 and 105 and negative co-expression of CD34 and HLA-DR at the start and end of the 
culture process. This level of expression has been maintained above 90% for all of the BM-hMSC 
donors across six experimental passages and 36 days in culture, demonstrating that cellular 
changes in growth kinetics and net metabolite flux do not have an effect on the expression of 
BM-hMSC surface markers. Further to this, the flow cytometry plots can be seen in Figure 5.15 
for M2 and Figure 5.16 for M3 at the end of the expansion process. This confirms the co-
expression of the required immunophenotype markers and also shows a difference in 
population distribution for the different conditions, with BM-hMSCs cultured in SFM displaying 
a tighter distribution of marker expression.  
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Figure 5.15. Multiparameter flow cytometry plots for M2 in FBS, HPL and SFM after 36 days 
of expansion showing co-expression of CD90+, CD73+, CD105+, CD34- & HLA-DR- 
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Figure 5.16. Multiparameter flow cytometry plots for M3 in FBS, HPL and SFM after 36 days 
of expansion showing co-expression of CD90+, CD73+, CD105+, CD34- & HLA-DR- 
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5.3.4 Short tandem repeat analysis of BM-hMSCs in different medium formulations 
Short tandem repeat (STR) analysis of M2 and M3 BM-hMSC lines in FBS, HPL and SFM after 36 
days culture can be seen in Figure 5.17. This shows that they have retained the 16 key loci they 
are expected to express, indicating that these cell lines have retained the characteristic 
genotype throughout the entire culture process in all conditions.  
 
 
 
Figure 5.17. Short tandem repeat analysis of M2 and M3 BM-hMSC lines in FBS, HPL and SFM 
after 36 days of expansion demonstrating retention of the 16 loci that are characteristic of 
BM-hMSCs  
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5.4 Characterisation of BM-hMSCs in different medium formulations 
 
5.4.1 Experimental overview 
The measurement of cellular characteristics is of critical importance for the successful 
development of BM-hMSC manufacturing processes, particularly when assessing the impact of 
different process conditions such as medium formulations, on the product. The BM-hMSC 
morphology has been assessed in each medium formulation during the expansion process, using 
a representative phase contrast microscopy image of the BM-hMSCs adhered to the surface of 
a tissue culture flask. In addition to this, RNA expression of four key BM-hMSC genes were 
assessed at passage three, six and nine of culture for each BM-hMSC line in each medium 
formulation. The following primers for cell markers were used: CCL2 (recruits monocytes, 
memory T cells, and dendritic cells to the sites of inflammation produced by either tissue injury 
or infection, p21 (regulates the cell cycle and mediates cellular senescence), OCT4 (pluripotent 
marker associated with self-renewal of undifferentiated cells) and VEGF (associated with 
vascularization and growth of blood vessels). Expression was normalized to the reference gene 
36B4 and plotted against the number of cumulative population doublings.  
 
To assess the colony forming unit fibroblast (CFU) potential of M2 and M3 in each medium 
formulation, four T-75 flasks for each of these donor lines were taken through six experimental 
passages and at the end of passage three, six and nine remaining cellular material from each T-
75 flask was plated into two T-25 flasks for CFU analysis as described in Section 3.4.9. In 
conjunction with this, remaining cellular material from each of the four flasks was plated into 
three wells of a 12-well plate and quantitatively assessed for osteogenic potential as described 
in Section 3.4.8. The output of each of these assays was plotted against cumulative population 
doublings to provide to normalised assessment of colony forming and osteogenic potential of 
each BM-hMSC line.   
 
 
5.4.2 Morphology of BM-hMSCs in different medium formulations 
Figure 5.18 shows the difference in BM-hMSC morphology between donor lines in FBS-based 
culture that is reduced in HPL and SFM culture, with smaller spindle-shaped cells. This increased 
consistency between donors in cellular morphology observed in HPL and SFM has benefits for 
the development of manufacturing processes based on a fixed surface area. This will be 
particularly apparent for patient specific therapies, where the number of obtainable cells per 
square centimeter will determine the final cell yield of the product batch. 
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Figure 5.18. Day six phase contrast images showing the more consistent morphology between 
M2 and M3 in HPL and SFM compared to FBS expansion   
 
 
 
 
Considering that manufacturing processes for these cell-based therapies will likely have a 
minimum number of cells per dose, this reduced variation under HPL and SFM will greatly 
reduce the risk of suffering a product batch failure, increasing the cost-efficiency of the process. 
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5.4.3 Genetic expression of BM-hMSCs in different medium formulations 
It is also important that the BM-hMSCs retain the expression of key genes throughout the 
expansion process, as they are likely to play a key role in the product performing its function in 
vivo. In general, BM-hMSCs cultured under SFM conditions retained the expression of all four 
genes analysed, indicating that the believed positive selection occurring to generate the more 
homogenous population in SFM, is not impacting the expression of key genes.  
 
 
 
Figure 5.19. Quantitative RT-PCR analysis showing RNA expression of CCL2 gene in FBS, HPL 
and SFM expansion against cumulative population doublings for the two BM-hMSC lines. 
cDNA is normalized to housekeeping gene 36B4 
 
 
The comparative analysis of the CCL2 gene for both BM-hMSC lines in FBS, HPL and SFM can be 
seen in Figure 5.19. This shows that the RNA expression of this gene has been maintained in all 
conditions despite the differences in the number of population doublings. The CCL2 gene has 
been implemented in the recruitment of T-cells, monocytes and dendritic cells to the sites of 
inflammation (Guilloton et al. 2012) and is therefore an important gene to maintain for clinical 
indications that require a level of immune modulation. Immunomodulatory properties of BM-
hMSCs play a key role in their therapeutic potential (Le Blanc et al. 2004; Le Blanc et al. 2008), 
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suppressing tissue rejection by inhibiting the response of the patient’s lymphatic cells. A number 
of companies such as Athersys Inc. (USA), Tigenix (Belgium), Pluristem Therapeutics Inc. (Israel) 
and Mesoblast Ltd (Australia) are developing BM-hMSC products to target clinical indication 
relating to immune modulation, demonstrating the increased emphasis that industry has placed 
on the immunomodulatory mechanism of action that BM-hMSCs have previously 
demonstrated. 
 
 
 
Figure 5.20. Quantitative RT-PCR analysis showing RNA expression of P21 gene in FBS, HPL 
and SFM expansion against cumulative population doublings for the two BM-hMSC lines. 
cDNA is normalized to housekeeping gene 36B4 
 
Figure 5.20 shows the relative expression of P21, a gene relating to cellular aging and 
senescence (Chen et al. 2011) and has not unduly increased throughout the expansion process 
in SFM, HPL or FBS culture. This demonstrates that the onset of senescence toward the end of 
the expansion process in FBS and HPL in this instance did not occur in conjunction with the up-
regulation of the P21 gene as has been demonstrated previously (Estrada et al. 2013).  
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Figure 5.21. Quantitative RT-PCR analysis showing RNA expression of Oct4 gene in FBS, HPL 
and SFM expansion against cumulative population doublings for the two BM-hMSC lines. 
cDNA is normalized to housekeeping gene 36B4 
 
 
Oct4 is a marker of pluripotency, mainly associated with embryonic stem cells, but has 
previously demonstrated expression in BM-hMSCs (Riekstina et al. 2009). Maintenance of Oct4 
under SFM expansion (Figure 5.21) demonstrates the continued ability of the cells to self-
proliferate at high population doubling. It has previously been demonstrated that BM-hMSCs 
selected by serum deprivation are a subpopulation of very early progenitor cells with enhanced 
expression of Oct4 and several other genes characteristically expressed in embryonic cells 
(Pochampally et al. 2004). This demonstrates an advantage of BM-hMSCs culture in SFM, with 
the expression of pluripotent markers being important for the clinical application of cell-based 
products that undergo cellular differentiation. It can also be seen from Figure 5.21 that the 
expression of Oct4 decreased in FBS and HPL for the BM-hMSC line that underwent senescence 
towards the end of the expansion process. This should be monitored during the expansion 
process to ensure that it does not affect the therapeutic potential of the BM-hMSC therapy, as 
the retention of functional material is vital for the development of successful expansion 
processes. 
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Figure 5.22. Quantitative RT-PCR analysis showing RNA expression of VEGFA gene in FBS, HPL 
and SFM expansion against cumulative population doublings for the two BM-hMSC lines. 
cDNA is normalized to housekeeping gene 36B4 
 
Figure 5.22 shows the expression of VEGF across both BM-hMSC lines in all medium conditions 
over the monolayer expansion process. VEGF has been shown to be a highly important gene in 
the promotion of angiogenesis by BM-hMSCs (Beckermann et al. 2008), which will be important 
in a number of clinical indications, particularly for cardiac repair (Gao et al. 2007), a key target 
for a number of BM-hMSC-based therapies. Despite a higher relative expression of VEGF in BM-
hMSCs cultured in SFM, there is a decrease in the expression of VEGF in FBS, HPL and SFM as 
the number of population doublings increases, which should be further investigated if the BM-
hMSC product requires a high level of cumulative population doublings and is to be used for 
clinical indications requiring angiogenesis.  
 
 
5.4.4 Colony forming potential of BM-hMSCs in different medium formulations 
There is currently much discussion about the true identity and desired characteristics of BM-
hMSCs for clinical applications and how they elicit their therapeutic mechanism of action 
(Bianco et al. 2013b). Despite this, some hints come from a Graft-versus-host disease (GVHD) 
study showing that just a few passages can make a significant difference to the product efficacy. 
Human MSCs from passages 1-2 compared to passages 3-4 showed a decrease in patient survival 
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and response while no in vitro differences were found (von Bahr et al. 2012).  Despite this 
uncertainty in the application of BM-hMSCs, there is still a need to rigorously characterise the 
cellular product during the development of an expansion process to ensure the process itself is 
not having a detrimental impact on the product characteristics whilst yield is increased. It is 
important that assay development takes place in parallel with clinical development so that the 
prediction of clinical effect for a specific target indication can be correlated to process 
measurements in vitro.        
 
As BM-hMSC expansion processes move through the development phase, there is an increasing 
need to assess the characteristics of the product in relation to the number of population 
doublings the cells have undergone and is favorable under the current regulatory guidelines. 
This has the benefit of normalizing cell expansion data as passage number does not take into 
account the seeding density of the cells or the relative expansion level of the product in each 
condition. Using population doubling level versus cellular characteristic in this way allows for a 
fair comparison between conditions and is also far more amenable to comparisons with scale-
up technology such as bioreactors, when the term passage does not readily apply.  
 
 
Figure 5.23. Colony forming efficiency of the two BM-hMSC lines against number of 
population doublings throughout the expansion process in FBS, HPL and SFM. Demonstrating 
the increased consistency between BM-hMSC lines in SFM compared to FBS and HPL-based 
medium 
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Figure 5.23 shows the colony forming potential of the BM-hMSC donor lines under FBS, HPL and 
SFM culture against the number of population doublings. This demonstrates that the colony 
forming potential decreases through the expansion process as the number of population 
doublings increases, which hints at the challenges that exist when developing large scale 
manufacturing processes, which are likely to require lot sizes in excess of a trillion cells (Rowley 
et al. 2012b).  
 
 
Despite this, BM-hMSCs cultured in SFM retained a similar level of colony forming potential at 
a high number of population doublings and importantly, the consistency between the two BM-
hMSC donor lines was far greater than in FBS and HPL.  What our data therefore suggests is that 
the SFM condition used, PRIME-XV®, in conjunction with growth on fibronectin, is able to 
support the generation of a more homogenous cell population in terms of colony forming 
potential as well as cell size and growth rate, possibly through a positive selection process or 
the maintenance of asymmetric division.  Indeed, an increased presence of CFU-Fs in an BM-
hMSC population has previously been noted when using an optimized defined medium 
formulation as compared to DMEM supplemented with FBS (Jung et al. 2010). Furthermore, 
Wagner and colleagues (Wagner et al. 2006) compared two serum-containing media noted that 
one was able to support a more homogenous morphology than the other. This maintenance of 
consistency between donors will be important for both patient specific and off-the-shelf 
therapies and will reduce the likelihood of suffering product batch failure during quality testing. 
This will result in a reduced cost at the large scale, as the capital invested per batch will be high 
but more importantly for patient specific therapies, a batch failure would result in a patient 
going without treatment, which would be highly undesirable.  
 
 
5.4.5 Quantitative osteogenic potential of BM-hMSCs in different formulations 
As with the colony forming potential in Figure 5.23, the quantitative osteogenic potential of the 
BM-hMSCs in each medium formulation has been evaluated. Similarly, the same trend is also 
presented in Figure 5.24, which shows that the osteogenic potential of the BM-hMSCs 
decreasing as the number of population doublings increases. This is also supported by in vivo 
clinical data (Yamachika and Iida 2013) for these indications as well as for additional indications 
outside of the BM-hMSC niche (Moll et al. 2014a).   It is important to assess the impact of the 
expansion process on quality attributes early in development, as it will determine the maximum 
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allowable expansion ratio of the product for each particular indication, which will in turn 
influence the overall cost and scale of the therapy. 
 
 
 
 
Figure 5.24. Osteogenic potential of two BM-hMSC lines against number of population 
doublings throughout the expansion process in FBS, HPL and SFM. Demonstrating the 
maintenance in osteogenic potential of both BM-hMSC lines in SFM at a high number of 
population doublings.       
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5.5 Considerations for consistency in bioprocess development  
One of the key driving factors for the overall production cost of a BM-hMSC therapy, as well as 
medium cost, will likely be in the level of donor to donor variability experienced during the 
manufacturing process, leading to increased process time and risk of batch failure. The donor 
lines selected for this study had previously demonstrated large differences in cellular 
characteristics (Chapter 4), which will particularly impact the successful development of patient 
specific BM-hMSC therapies.  
 
 
 
Figure 5.25. Box and whisker plots showing the consistency in growth kinetics of two BM-
hMSC lines over 18 days and 36 days expansion in FBS, HPL and SFM. Demonstrating the 
increased variation in FBS and HPL over 36 days of expansion and the maintenance of 
consistency in SFM expansion.  
 
 
Figure 5.25 shows the inconsistency between the growth characteristics of these BM-hMSC 
lines, with a range of 0.234 day-1 in FBS, 0.386 day-1 in HPL and 0.216 day-1 in SFM following the 
36 day expansion process, demonstrating a diverging process occurring in HPL culture. In 
contrast to this variance experienced in HPL culture and despite a higher number of cumulative 
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population doublings, the SFM culture process had a corresponding range of only 1.45 
population doublings between these donors and batch runs after 36 days in culture. This 
indicates that SFM is highly amenable to a large scale expansion process, where a high number 
of product population doublings are required. Further to this, HPL has demonstrated consistent 
BM-hMSC growth characteristics over 18 days of expansion, which indicates that is represents 
a viable alternative to FBS for patient specific manufacturing processes where a lower number 
of population doublings are required.    
 
 
Table 5.2. Process time required to manufacture a theoretical batch of 350 million BM-hMSCs 
demonstrating variation in process time between and within donor material that is reduced 
in HPL and further reduced in SFM. (From 2 million BM-hMSCs starting material).  
 
 
 
For the development of a patient specific cell-based therapy, where the inter donor variability 
has to be accounted for during manufacture, this reduction in product variance offers a 
significant benefit to the process. Reducing the divergence in donor cell characteristics will 
alleviate potential bottlenecks in the isolation, expansion and delivery process, an important 
consideration for cell-based therapy process development. In conjunction with this, a more 
consistent expansion process will reduce the risk of suffering a product batch failure, which for 
a patient specific therapy will mean that the patient will fail to be treated. Table 5.2 shows the 
variability between the two BM-hMSC lines for a hypothetical process requiring a batch size of 
350 million cells from a starting population of two million cells (Heathman et al. 2015b). This 
demonstrates the increased consistency that can be achieved in the SFM and HPL process 
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between production batches and between donors, with a reduction in range from 19.4 days in 
the FBS process to 4.5 days in the HPL process and 0.9 days in the serum free process. This also 
has advantages for off-the-shelf therapies, as it is possible to select material for the expansion 
process by pre-screening BM-hMSCs and discarding those that do not display sufficient growth 
kinetics. Under the SFM condition, both of the BM-hMSC lines displayed similar process times 
between donors and a reduced inter donor range. This has the potential to lead to reduced costs 
in the process development phase as fewer donor lines will be excluded (and therefore require 
testing) compared to FBS culture and will be available for the production process. The reduced 
process time to achieve this batch size in the serum free condition will also be advantageous for 
reducing the overall medium costs, as product batches can be manufactured in reduced time.  
 
  
 
 
Figure 5.26. Box and whisker plots showing the consistency in mean cell diameter of two BM-
hMSC lines over 18 days and 36 days expansion in FBS, HPL and SFM. Demonstrating the 
increased variation in FBS and HPL over 36 days of expansion and the maintenance of 
consistency in SFM expansion. 
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Furthermore, an increase in achievable cell number per batch will also increase the material 
available for quality release testing which is an important consideration of patient specific 
therapies as each patient batch must be independently tested prior to release. A study by 
Deskins and colleagues also demonstrated that three independent in vitro assays based on 
growth rate, proliferative potential and ATP content were able to predict in vivo performance, 
with BM-hMSCs performing above average in all three assays having increased in vivo 
regenerative abilities (Deskins et al. 2013).          
 
 
Human MSCs cultured in SFM had a cell diameter of 14.65 ± 1.7 µm (median ± range) compared 
to FBS culture with a cell diameter of 16.6 ± 2.8 µm (median ± range) and HPL culture also at 
16.6 ± 3.9 µm (median ± range). The variability in cell diameter throughout expansion in FBS and 
HPL-based medium (Figure 5.26) could have further implications for the delivery process in 
terms of cell concentration and infusion rate, which would likely have to be standardized during 
clinical development. As well as an increase in BM-hMSC productivity, this demonstrates a 
further advantage of SFM culture of BM-hMSCs in terms of cell size consistency over a 36 day 
expansion process. In addition to this, BM-hMSCs expanded in SFM demonstrated a reduction 
in post-harvest cell aggregation (Figure 5.27), which will be beneficial for the downstream and 
formulation process steps. 
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Figure 5.27. Box and whisker plots showing the post-harvest aggregation of five or more cells 
in FBS, HPL and SFM. Demonstrating the reduced BM-hMSC aggregation in SFM expansion 
compared to FBS and HPL. Data shows n = 144.  
 
 
Associated with the reduction in inter-donor variability, further reductions in process input 
variability can be made by placing controls on the supply of raw materials. Considering the 
potential issues surrounding the limited availability and batch-to-batch variability of FBS 
(Brindley et al. 2012), the development of defined, serum-free medium formulations will further 
drive consistency into the manufacturing process. In this model, culture medium can be 
manufactured to a specific formulation, ensuring inter-batch consistency and reducing overall 
costs by scaling up the medium manufacturing process and benefitting from increasing 
economies of scale. This is in contrast to a manufacturing process based on FBS, where the cost 
of the culture medium will increase as the process is scaled through clinical development into 
commercial scale production. It should be said, however, that the development of a defined 
medium formulation should be based on a rigorous product understanding, so that desired 
product attributes are maximized and not impacted by the various medium components. These 
desired product attributes could range from growth kinetics all the way to functional attributes, 
which will depend on the target clinical indication.   
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5.6 Chapter conclusions 
The development of consistent manufacturing processes remains a key challenge that must be 
overcome to ensure the successful translation of cell-based therapies. This serum-free medium 
has demonstrated the potential to reduce the variability of input material to these processes, 
which will allow for increased control over process consistency. By developing this serum-free 
process, the yield and consistency of BM-hMSC expansion has been increased between donors, 
which offers large advantages in the development of both off-the-shelf and patient specific cell-
based therapies. The convergence of BM-hMSC characteristics throughout an expansion process 
demonstrates a level of control over the product manufacture, which has the potential to 
increase the cost effectiveness and reduce the risk in these processes.   
 
 
Now that alternative medium formulations have been identified that have the potential to 
increase product yield and consistency, these can now be transferred to a scalable microcarrier 
based process. This will drive a level of scalability into the process, as a suspension based system 
can benefit from increasing economies of scale, whilst having the potential to meet the BM-
hMSC lot-sizes required for the commercial production of an off-the-shelf therapy.  
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6 Transfer of the BM-hMSC Expansion Process into Suspension 
 
6.1 Chapter introduction 
The addition of microcarriers has been used to culture adherent cells such as BM-hMSCs in 
suspension (Schop et al. 2008; dos Santos et al. 2011a; Chen et al. 2013; Rafiq et al. 2013a) 
allowing for process scale up, where online monitoring and control systems can be used to 
deliver a consistent and cost-effective BM-hMSC product. Stirred-suspension bioreactors are 
currently employed for mammalian cell culture in biopharmaceutical production and therefore 
their design and operation are well-understood (Nienow 2006), with the potential to meet the 
expected manufacturing demands of large-scale BM-hMSC therapies.    
 
A key aspect of reducing variation in the process will be reducing and eventually eliminating the 
use of fetal bovine serum (FBS) from the cell culture medium (Wappler et al. 2013). In addition 
to lot-to-lot variability, there are further process constraints on the use of FBS such as limited 
supply (Brindley et al. 2012), spiraling cost, potential for pathogen transmission, increased risk 
of recipient immune reaction (Spees et al. 2004) and reduced scope for process optimisation. 
Furthermore, FBS has been shown to contain immunogenic contaminants which have the 
potential to negatively impact post-transplant clinical results (Heiskanen et al. 2007), potentially 
increasing the regulatory burden placed upon these products. All of these considerations mean 
that moving towards a serum-free process would be beneficial in achieving scalable, tunable 
and consistent BM-hMSC manufacturing processes. In addition, BM-hMSCs grown in a serum-
free medium have demonstrated increased proliferation rates, up-regulation of genes 
important in BM-hMSC function and down-regulation of genes involved in the production of 
proinflammatory cytokines (Crapnell et al. 2013).   
 
Unlike traditional suspension-based bioprocesses, cell harvesting from the microcarrier surface 
is critically important as the quality characteristics of BM-hMSCs must be retained throughout 
this process. Harvesting involves two stages, detachment of BM-hMSCs from microcarriers 
followed by microcarrier separation from the BM-hMSC product (Nienow et al. 2014). After 
separation, cell-based products will undergo a holding time prior to downstream processing and 
formulation in order to pool the product. Product quality can deteriorate with prolonged 
holding time (Pal et al. 2008) and should be considered during process development. The large 
scale manufacture of an allogeneic BM-hMSC product will require long term product storage to 
decouple production from delivery, in a business model akin to current biopharmaceuticals. 
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Therefore, cryopreservation of BM-hMSCs must be carefully considered to ensure the 
therapeutic potential of the BM-hMSC product does not deteriorate prior to delivery (Moll et 
al. 2014b).     
 
The aim of this Chapter therefore was to develop a microcarrier expansion process for BM-
hMSCs in serum-based medium and to subsequently transfer this into a serum-free process. The 
integration of sequential unit operations for the serum-free BM-hMSC production process from 
expansion through to cryopreservation will also be evaluated to provide an important study in 
the development of a scalable end-to-end manufacturing process for BM-hMSC therapies.  
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6.2 Developing an agitated microcarrier process in serum-based medium 
 
6.2.1 Experimental overview 
Following the successful development of a monolayer expansion process in serum and serum-
free medium, with increased consistency and yield between donor BM-hMSC lines M2 and M3, 
this process must be transferred to a scalable expansion process with the potential to meet the 
lot-sizes required for commercial production of an off-the-shelf therapy. The first stage of this 
will be to transfer the serum-based monolayer process to microcarrier culture in suspension. 
For this, four 100 mL spinner flasks were cultured in FBS and HPL-containing medium with BM-
hMSC lines M2 and M3 for six days, to replicate a similar process to monolayer (Section 3.3). 
Daily medium samples were taken for analysis of glucose, lactate and ammonia, lactate 
dehydrogenase and total protein with cell counts performed on day three of culture (four 
samples were analysed per spinner flask as per Section 3.4.3). The culture medium was 
exchanged on day three for both FBS and HPL culture (Section 3.3.3). At harvest, the BM-hMSC 
were removed from the microcarriers and separated according to Section 3.3.4. The BM-hMSCs 
harvested from each condition were then assessed for mean cell diameter (3.4.2), tri-lineage 
differentiation potential (Section 3.4.4) and immunophenotype (Section 3.4.5). In addition to 
these identity measurements, BM-hMSC quality characteristics of colony forming efficiency 
(Section 3.4.9), osteogenic potential (Section 3.4.8) and outgrowth potential were also assessed 
post-harvest. Following this process, a comparison was made between these microcarrier and 
previous monolayer growth and post-harvest characteristics to assess the impact of transferring 
the BM-hMSC expansion process into suspension.   
 
 
6.2.2 Growth kinetics of BM-hMSCs in agitated microcarrier culture 
For a large number of clinical indications, BM-hMSCs will need to be manufactured on a large 
scale in order to reduce the cost of production and to meet the market need for the treatment. 
Microcarriers have previously been demonstrated to support the proliferation and harvest of 
BM-hMSCs in suspension (dos Santos et al. 2011a; Chen et al. 2013; Rafiq et al. 2013a) and 
therefore have the potential to be operated up to and beyond the thousand liter scale. 
    
The growth kinetics of BM-hMSCs will also play a part in reducing costs, as accommodating BM-
hMSCs with a lower expansion potential will reduce annual production rates (Heathman et al. 
2015c; Naing et al. 2015a). Figure 6.1 shows the growth rate of the two BM-hMSC donors over 
six days in culture in both FBS and HPL-containing medium. The growth kinetics of the two donor 
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BM-hMSC lines in the HPL-based medium is significantly higher (p < 0.01) than the FBS-
containing medium for both of the BM-hMSC lines, in particular M3 showed extremely low 
growth kinetics in FBS with 0.44 ± 0.18 population doublings over the six day growth period. 
This increase in growth kinetics for BM-hMSCs during microcarrier culture has also been 
demonstrated at 5% HPL compared with 10% FBS (Sunil et al. 2014).  
 
 
 
 
Figure 6.1. Growth kinetics of BM-hMSCs cultured on microcarriers in FBS-containing medium 
and HPL-containing medium for six days showing increased growth kinetics in HPL (p < 0.01). 
(A) Specific growth rate and (B) cumulative population doublings. Data shows mean ± SD n=4. 
 
 
The increased consistency between donors gives significant advantages to the manufacturing 
process as increased production rates and reduced batch failure rates are likely to reduce the 
overall cost of the product. It can be seen from Figure 6.1 that the lag phase experienced by BM-
hMSCs in FBS culture between day 0 and day 3 is not present when the cells are cultured in HPL, 
which is the likely cause of the difference in growth kinetics over the six day period. The reason 
for this may be due to an increase in the attachment rate of the cells which in turn shortens the 
lag phase prior to cell division taking place. This link between attachment efficiency and cell 
growth is well established (Mitchell et al. 2014) and the level of relevant attachment proteins 
present in HPL is typically higher than in FBS, which will contribute to this effect (Bieback 2013). 
The attachment of the BM-hMSCs to the culture surface is particularly important for suspension 
culture, where the cells and microcarriers are constantly agitated throughout the culture period.   
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6.2.3 Metabolite flux of BM-hMSCs in agitated microcarrier culture 
The net metabolite flux of the cells in microcarrier culture has been measured for M2 and M3. 
Figure 6.2A shows the glucose consumption of BM-hMSCs in FBS and HPL culture, which was 
between 11.13 – 15.32 pmol.cell-1.day-1 with no significant difference measured across these 
conditions. The lactate production rate is shown in Figure 6.2B, which again shows a similar level 
of production between FBS and HPL. This suggests that the BM-hMSCs in both conditions are 
using similar metabolic pathways, as confirmed by the yield of lactate from glucose (Figure 
6.2D). This is in contrast to previous studies using serum-free medium which demonstrated that 
BM-hMSCs tend to favor the relative production of ammonia over lactate during microcarrier 
culture under serum-free conditions (dos Santos et al. 2011a). There was however a reduction 
in the production of ammonia for M2 in HPL to 1.20 ± 0.03 pmol.cell-1.day-1, suggesting altered 
amino acid use, which may be related to the need for precursors (e.g. glutamine and asparagine) 
supporting purine and pyrimidine biosynthesis (Higuera et al. 2012). 
 
 
 
Figure 6.2. Per cell metabolite flux of two BM-hMSC lines over six days microcarrier expansion. 
Showing (A) per cell glucose consumption rate, (B) per cell lactate production rate, (C) per cell 
ammonia production rate and (D) Yield of lactate from glucose. Data shows mean ± SD (n=4).      
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Cell death was evaluated by measuring a combination of lactate dehydrogenase (LDH) 
(Lavrentieva et al. 2010a) and total protein released into the culture medium. Figure 6.3 shows 
these concentrations throughout culture, which show no increase in the LDH or total protein 
concentrations for both M2 and M3 in FBS and HPL-based culture. This demonstrates that cell 
damage was minimal throughout the microcarrier expansion process, despite the process 
change from static to agitated culture.  
 
 
Figure 6.3. Nutrient and metabolite flux of BM-hMSC expansion on microcarriers. Total 
protein (A) and lactate dehydrogenase concentration (B) are shown for FBS and HPL-
containing medium for M2 and M3. Data shows mean ± SD, n = 4 
 
 
6.2.4 Post-harvest characterisation of BM-hMSCs from agitated microcarrier culture 
The post-expansion detachment and separation of the BM-hMSCs from the microcarriers is of 
critical importance for a scalable production process, as cellular attributes must be maintained 
throughout the process (Nienow et al. 2014; Nienow et al. 2015b). A previously developed 
harvesting protocol (Nienow et al. 2014) was modified for this study by replacing trypsin-EDTA 
with TrypLE Express for the HPL culture to ensure the process was animal-component free. The 
post-harvest viability from both donor BM-hMSC lines in FBS and HPL was > 95%, demonstrating 
that this harvest process did not have a detrimental impact on the membrane integrity of the 
cells. It is important that BM-hMSC characteristics are also maintained following this 
detachment and separation process from the microcarriers.  
 
Figure 6.4 shows the effect of the microcarrier process on BM-hMSC attributes compared to 
pre-expansion for colony forming efficiency, osteogenic potential, specific outgrowth rate and 
mean cell diameter. The colony forming efficiency of the BM-hMSCs following the microcarrier 
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expansion and harvest process generally saw an increase compared to pre-expansion, with a 
significant increase for M2 in HPL (p < 0.05). Similarly, the specific outgrowth rate and mean cell 
diameter have been maintained post-harvest, demonstrating that the microcarrier process has 
not affected these BM-hMSC characteristics. In contrast, the osteogenic potential of the BM-
hMSC decreased for all conditions (p < 0.01), which should be further investigated if the BM-
hMSCs are to be used for clinical indications relating to the production of collagen. There is the 
potential however, for this type of clinical indication, that biodegradable microcarriers could be 
directly implanted as a cell-scaffold construct to support the regeneration of bone tissue (Gao 
et al. 2015), removing the need for cell harvest altogether.     
 
 
Figure 6.4. Post-harvest BM-hMSC quality compared to pre-expansion demonstrating 
retention of key attributes, showing (A) colony forming efficiency, (B) osteogenic potential, 
(C) specific outgrowth rate and (D) mean cell diameter. Data shows mean ± SD (n=4).  
 
The BM-hMSCs harvested from the microcarrier process must also retain their identity in 
accordance with the ISCT criteria. Figure 6.5 shows the tri-lineage differentiation potential of 
the BM-hMSC following microcarrier expansion in HPL down the adipogenic, osteogenic and 
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chondrogenic lineages. This demonstrates that the BM-hMSCs have retained their tri-lineage 
differentiation potential following microcarrier expansion in HPL.  
 
 
Figure 6.5. Tri-lineage differentiation potential of BM-hMSC lines using phase contrast 
microscopy. Showing adipogenic differentiation (A) by staining with Oil Red O, osteogenic 
differentiation (B) by staining for alkaline phosphatase and calcium deposition and 
chondrogenic differentiation (C) by staining with Alcian Blue 
 
 
In addition to a demonstration of the tri-lineage differentiation potential, BM-hMSC harvested 
from the microcarrier process must also retain their immunophenotype. Figure 6.6 shows the 
multiparameter flow cytometry plots of post-harvest BM-hMSCs demonstrating the maintained 
positive co-expression of CD105, CD90 and CD73 throughout the microcarrier expansion 
process. Further to this, BM-hMSC have retained the negative co-expression of CD45, CD34, 
CD11b, CD19 and HLA-DR following the microcarrier expansion process. This demonstrates that 
the BM-hMSCs have retained the desired immunophenotype throughout the microcarrier 
process as has been demonstrated during the monolayer expansion process.   
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Figure 6.6. Post-harvest multiparameter flow cytometry plots showing co-expression of 
CD90+, CD73+, CD105+, CD44+, CD34-, CD45-, CD11b-, CD19- & HLA-DR- from microcarrier 
culture 
 
 
This demonstrates that HPL is a viable alternative to FBS for the microcarrier culture of BM-
hMSCs and has the potential to be taken forward to support further process development and 
scale-up. The increased consistency in growth between donors in HPL will also benefit the 
development of both patient specific and off-the-shelf BM-hMSC therapies, allowing for 
increased production rates and shorter processing times.            
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6.2.5 Comparison of BM-hMSCs in monolayer and agitated microcarrier culture 
One of the key challenges in the successful development of scalable cell therapy manufacturing 
processes, is in the process transfer away from traditional manual monolayer processes. The 
decision of when in the development cycle to complete these bridging studies and move toward 
a scalable process should be carefully considered and many companies have suffered as a result 
of waiting until the end of clinical development, prior to commercial production. The advantages 
of automated and closed processing systems in driving scalable production by reducing costs 
should not be underestimated (Williams et al. 2012; Hampson 2014), with suspension based 
systems being a lead candidate, as they are routinely operated in this manner. This process 
transfer from monolayer to microcarrier culture will aim to assess the impact of the new process 
on the product attributes, to ensure they are comparable between the processes, avoiding the 
need to repeat clinical work, which will cost significant time and capital. 
 
 
Table 6.1. Comparison of monolayer and microcarrier culture of BM-hMSCs in FBS and HPL-
containing medium showing the improved process transfer under HPL. Statistics show 
significance between monolayer and microcarrier condition. * denotes p < 0.05 and ** 
denotes p < 0.01.  
 
 
Obtaining similar growth kinetics of the BM-hMSCs from the monolayer and microcarrier 
processes is also important, as this will affect the number of BM-hMSCs that can be 
manufactured per unit time, which will reduce the number of batches produced per year. Table 
6.1 shows the comparison of the monolayer and microcarrier process for M2 and M3 in FBS and 
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HPL-based culture. The growth rate of BM-hMSCs in FBS-based culture showed a significant 
reduction from monolayer to microcarrier culture for both BM-hMSC lines (p < 0.05 and p < 
0.01), which is particularly apparent for M3, with a reduction from 0.14 ± 0.02 to 0.05 ± 0.02 
day-1. This would create challenges during process scale up within a suspension based system 
and would necessitate careful selection of donor material for master cell banks, to ensure it is 
amenable to this potential change in process conditions from static to agitated culture. It is likely 
that this widening of the gap in growth kinetics between the static monolayer process and 
agitated microcarrier culture is due to the efficiency of cell attachment, which becomes more 
important within the agitated environment.  
 
 
In contrast to FBS-based culture, HPL proved more effective in supporting the transfer of the 
process from static to agitated conditions with only a slight reduction in the growth kinetics of 
M3 and no significant difference between the monolayer and microcarrier growth kinetics of 
M2. This demonstrates the potential of HPL to be used as a medium supplement within 
monolayer culture as well as for suspension culture of BM-hMSCs. Table 6.1 also shows that the 
colony forming efficiency, mean cell diameter and outgrowth rate have not been reduced for 
the microcarrier process which will be important during process transfer and scale up toward 
commercial production. It is also evident from Table 6.1 that the yield of lactate from glucose  
is more similar when comparing monolayer and microcarrier culture in HPL with FBS, which 
suggests a maintenance of the glycolytic pathway during microcarrier culture (Pattappa et al. 
2011). All of this means that HPL represents a beneficial alternative to FBS for monolayer 
expansion processes and further process transfer into suspension based systems. This has 
implications for both patient specific and off-the-shelf BM-hMSC therapies in terms of 
increasing yield and reducing costs of therapies that are currently in development.                   
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6.3 Development of a fibronectin coating process for microcarriers 
 
6.3.1 Experimental overview 
As has been discussed previously, the development of serum-free manufacturing processes will 
be important the drive the consistent and cost-effective production of BM-hMSC therapies. 
Considering the yield and consistency gains that have been achieved in serum-free monolayer 
culture and the successful process transfer of the serum-based process into suspension via the 
addition of microcarriers, it was important to also transfer the serum-free process into 
microcarrier culture. The key difference between the serum-based and the serum-free process 
for the culture of BM-hMSCs is in the fibronectin treatment of the tissue culture flask to provide 
the necessary attachment proteins to enable cell proliferation. This process is well established 
for monolayer culture, however, additional challenges to this coating process for microcarrier 
culture mean that a new process must be developed to ensure the adequate coating of the 
microcarriers and enable BM-hMSC expansion under serum-free conditions.    
 
The first experiment in this process was to assess the impact of fibronectin coating in monolayer 
in FBS-based culture. This is to provide a baseline for microcarrier coating in FBS-based culture 
so that the initial microcarrier coating development can be completed in FBS-based medium as 
this provides a far more cost-effective process development pathway. Four T-75 flasks were 
coated with 0.4 µg.cm-2 of PRIME-XV® Fibronectin and cultured in FBS-containing medium 
alongside four uncoated T-75 flasks for three passages. At the end of each passage, the viable 
cell number and mean cell diameter was determined and the growth kinetics were calculated. 
In addition, the three hour attachment efficiency was determined at the end of each passage 
for coated and uncoated T-25 flasks. 
 
In order to determine the concentration of fibronectin to coat the microcarriers, an experiment 
was designed to compare different concentrations of fibronectin in PBS prior to culture. Table 
6.2 shows the volume and concentrations of fibronectin used for each of the tested coating 
protocols for microcarriers. Four spinner flasks were cultured for each coating concentration for 
six days (see Section 3.3.3) and harvested according to Section 3.3.4 to determine the final cell 
number. Following this, post-harvest characterisation was completed to verify BM-hMSC 
immunophenotype and tri-lineage differentiation potential. In addition, an experiment was 
conducted to ensure that the fibronectin substrate did not coat the internal glass surface of the 
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spinner flask, which would allow BM-hMSCs to attach and proliferate on the internal surface of 
the flask. This was not found to be the case and these results can be found in Appendix D.      
 
Table 6.2. Fibronectin coating protocol for microcarrier culture 
Final coating 
concentration 
(µg.cm-2) 
Microcarrier surface 
area (cm2) 
Concentration of 
fibronectin (µg.mL-1) 
Volume of coating 
solution (mL) 
0.4 500 5 40 
0.2 500 2.5 40 
0.1 500 1.25 40 
 
 
The coating protocol was as follows: 
1. Depending on microcarrier surface area required, the appropriate amount of 
polystyrene plastic microcarriers was weighed as per the manufacturer’s instructions 
and transferred to a spinner flask vessel. (1.4 g provided 500 cm2 of microcarrier growth 
area). 
2. 25-30 mL of distilled water was added and the spinner flask was autoclaved.  
3. After autoclaving, the water was aspirated from the spinner flask. 
4. The appropriate amount of coating substrate was added according to Table 6.2 and the 
spinner flask was agitated at NJS (30 rpm) for two hours at room temperature.  
5. The microcarriers were washed once with PBS, 100 mL of SFM was added and the flask 
was transferred to in an incubator prior to BM-hMSC inoculation.  
 
Following this initial screening study in FBS, the best performing fibronectin concentration was 
taken forward to assess the performance in serum-free culture, with both human fibronectin 
(FN) and recombinant fibronectin (MatrIS-F). In addition to the pre-coating protocol described 
above, the potential for a direct coating process was also assessed. The advantage of this would 
be that it would shorten the process time, as well as alleviating the need to validate the coating 
process which would need to be de-coupled from the expansion process to reduce the risk in 
suffering a quality assurance failure, which would impact the subsequent process operation. 
The protocol for this direct coating was as follows: 
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1. Depending on microcarrier surface area required, the appropriate amount of 
polystyrene plastic microcarriers were weighed as per manufacturer’s instructions and 
transferred to a spinner flask vessel. (1.4 g provided 500 cm2 of microcarrier growth 
area). 
2. 25-30 mL of distilled water was added and the spinner flask was autoclaved.  
3. After autoclaving, the water was aspirated from the spinner flask. 
4. Fibronectin was added to 40 mL of SFM to give a final concentration of 1.25 µg.mL-1, 
which was agitated at 30 rpm for two hours at room temperature. 
5. Finally, 60 mL of fresh SFM was added and the flask was transferred to an incubator 
prior to BM-hMSC inoculation.  
After six days of culture, the four spinner flasks for each condition were harvested according 
to Section 3.3.4 and the cell number determined prior to post-harvest BM-hMSC 
characterisation.  
 
 
6.3.2 Fibronectin coating of FBS culture in monolayer  
The first part of developing a microcarrier coating process for serum-free culture was to assess 
the effect of culturing BM-hMSCs on fibronectin in FBS-containing medium in monolayer. This 
is because the initial development of a microcarrier coating process took place in FBS-based 
culture and it is important to obtain a baseline in monolayer to compare these results to the 
microcarrier coating protocol. Figure 6.7 shows the results of the monolayer fibronectin coating 
protocol in FBS-based medium. It can be seen from Figure 6.7 that the fibronectin coating of the 
tissue culture flasks led to a significantly increased growth rate of the BM-hMSCs at passage 
four (p < 0.01), passage five (p < 0.05) and passage six (p < 0.01). The specific growth rate of BM-
hMSCs at passage five was 0.258 ± 0.034 day-1 for non-coated and 0.316 ± 0.018 day-1 in 
fibronectin coated flasks, which can be used for comparison against the microcarrier coating, 
following an adaption passage.   
 
It has previously been shown that BM-hMSCs adhered to fibronectin strongly potentiate 
platelet-derived growth factor receptor (PDGFR)-β phosphorylation and focal adhesion kinase 
(FAK) activity. This leads to the regulation of actin reorganisation and increased cell migration, 
which is important during culture as well as therapeutically, for the remodelling of vasculature 
(Veevers-Lowe et al. 2011) and has been shown to enhance osteogenesis (Li et al. 2013). In 
addition to the increased growth characteristics of BM-hMSCs, the mean cell diameter of the 
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BM-hMSCs cultured on fibronectin was also significantly reduced for the first two passages (p < 
0.05), which is in accordance with the previous findings in Section 5.2.3, which showed that a 
reduced cell diameter was associated with increased growth kinetics.  
 
An indication that fibronectin enhances the attachment of BM-hMSCs can be seen in Figure 6.7, 
which is significantly higher for the first two passages (p < 0.05) compared to uncoated tissue 
culture plastic. It is also evident that the consistency in BM-hMSC attachment is improved when 
cultured on fibronectin, which will be important for the development of BM-hMSC 
manufacturing processes, particularly on microcarriers, where the cell attachment is particularly 
important under agitated conditions (Rafiq et al. 2015b).    
 
 
Figure 6.7. Fibronectin coating in FBS monolayer culture at a concentration of 0.4 µg.cm-2 
showing the specific growth rate, cell diameter and attachment efficiency of BM-hMSCs over 
three passages. Demonstrating the increased attachment and growth kinetics of BM-hMSCs 
cultured on fibronectin. Data shows mean ± SD, n=4. * denotes p < 0.05 
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6.3.3 Fibronectin coating of microcarriers in FBS culture   
Now that a baseline for fibronectin coating has been established in monolayer culture, a 
comparison of coating concentrations can be evaluated in microcarrier culture using FBS-
containing medium. The results of this study can be seen in Figure 6.8, which shows the fold 
increase in BM-hMSCs at fibronectin concentrations of 0, 0.1, 0.2 and 0.4 µg.cm-2, 
demonstrating an increase in growth rate at lower concentrations of fibronectin. As with the 
monolayer culture previously, coating the microcarriers in fibronectin produced a significant 
increase in growth kinetics (p < 0.05), demonstrating that the microcarriers are being 
successfully coated with the fibronectin substrate at all concentrations. 
 
Part of the reason for the improved growth kinetics at lower fibronectin concentrations can be 
seen in Figure 6.9, which shows the high level of microcarrier aggregation that occurs, 
particularly at a fibronectin coating concentration of 0.4 µg.cm-2. The consequence of increase 
microcarrier aggregation is that the available surface area for BM-hMSCs to expand on is 
reduced, resulting in a lower cell number at the end of six days in culture. In contrast, the level 
of microcarrier aggregation at 0.1 µg.cm-2 was comparable to the level of aggregation observed 
in the uncoated control.               
 
 
Figure 6.8. Fibronectin coating of microcarriers at different concentrations in FBS showing the 
increased BM-hMSC expansion rate at reduced fibronectin concentrations. Data shows mean 
± SD, n=4 
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In terms of a direct comparison between monolayer and microcarrier culture of BM-hMSCs, the 
uncoated monolayer condition had a growth rate of 0.258 ± 0.034 day-1, compared to 0.147 ± 
0.2 day-1 in microcarrier culture, a reduction of 0.111 day-1. In contrast, the difference in growth 
kinetics between monolayer and microcarrier culture for the fibronectin coated condition was 
0.059 day-1. This increased comparability in BM-hMSC growth kinetics between monolayer and 
microcarrier culture for fibronectin coated surfaces is likely a result of the improve attachment 
efficiency seen in Figure 6.7, as effective cell attachment becomes increasing important on 
microcarriers under agitated conditions. This characteristic of fibronectin coated microcarrier 
culture makes developing a serum-free microcarrier process a highly attractive proposition, 
considering the improved BM-hMSC growth and quality characteristics seen for monolayer 
culture in Chapter 5.   
 
 
Figure 6.9. Phase contrast images showing the aggregation of BM-hMSCs and microcarriers 
with fibronectin coating at different concentrations in FBS 
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To ensure that the fibronectin coating of microcarrier does not affect the identity characteristics 
of the BM-hMSC, immunophenotype, tri-lineage differentiation and morphology have been 
assessed in accordance with the International Society for Cellular Therapy (ISCT) criteria 
(Dominici et al. 2006). Figure 6.10 shows the compliance of the BM-hMSCs with the ISCT criteria, 
by adherence to tissue culture plastic, demonstrating the same morphology post-harvest in 
fibronectin coated and uncoated culture and differentiation down the osteogenic, adipogenic 
and chondrogenic lineages. The post-harvest BM-hMSC immunophenotype can be seen in 
Figure 6.10 which shows the co-expression of positive markers CD73, 90 and 105 as well as the 
expression of CD34 and HLA-DR at less than 2 % (Chan et al. 2014b). 
 
 
Figure 6.10. Post-harvest characterisation showing retention of BM-hMSC morphology, 
immunophenotype and tri-lineage differentiation potential for fibronectin coated 
microcarrier culture in FBS-based medium  
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6.3.4 Fibronectin coating strategy for microcarriers in SFM 
Following the successful demonstration of fibronectin coating of microcarriers in FBS-containing 
medium, the process was validated for serum-free culture using the lowest fibronectin 
concentration of 0.1 µg.cm-2. The reason for this was because it demonstrated similar growth 
characteristics to 0.2 µg.cm-2 (p > 0.05) whilst requiring half the amount of fibronectin, 
representing a significant cost saving for the process. For the development of the fibronectin 
coating process for microcarriers in SFM, human derived fibronectin (FN) will be used in 
conjunction with recombinant fibronectin (MatrIS-F) to assess the relative performance of the 
two fibronectin sources. The reason for this is that the development of defined manufacturing 
processes will require the use of non-animal and non-human derived components to reduce the 
risk of pathogen transmission as well as reducing the variability between batches of substrates 
(Unger et al. 2008). This means that the use of recombinant proteins, such as fibronectin in 
future BM-hMSC processes will be favourable and therefore it is important to assess whether 
they are amenable to the microcarrier process at an early stage in development. Further to this, 
if a similar performance can be demonstrated between human-derived fibronectin and 
recombinant fibronectin, then the rest of this development can be carried out using the more 
cost-effective fibronectin source, with the knowledge that if future development requires a 
recombinant protein source, the process can be successfully transferred in a timely fashion.    
 
 
 
Figure 6.11. The effect on BM-hMSC growth and cell diameter of pre-coating microcarriers 
versus directly adding the coating substrate into the medium for FBS and SFM-based 
expansion. Coating at 0.1 µg.cm-2 using human-derived (FN) and recombinant (MatrIS-F) 
fibronectin.  Data shows mean ± SD, n=4 
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Figure 6.11 shows the results for this development using PRIME-XV® SFM with pre-coating of 
the microcarriers in PBS and directly adding the fibronectin into the culture medium to avoid 
the additional process of coating the microcarriers. It can be seen from Figure 6.11, however, 
that directly adding the attachment substrate into the culture medium does not effectively 
support the proliferation of BM-hMSCs, with almost no growth over the six days of culture in 
SFM. This means that despite the advantages of eliminating the need to pre-coat the 
microcarriers, it is necessary to do so when expanding BM-hMSCs in SFM. The contrast between 
FBS and SFM in this instance is due to the increased presence of attachment proteins in FBS, 
which are able to support the attachment and proliferation of BM-hMSCs even when ineffective 
microcarrier coating occurs when the fibronectin is directly added to the culture medium. 
 
 
 
Figure 6.12. Post-harvest outgrowth showing the reduced outgrowth rate of cells cultured on 
microcarriers with attachment substrate added into the medium. Data shows mean ± SD, n=4 
 
 
It was also evident from Figure 6.11 that the growth kinetics of BM-hMSCs in SFM were 
drastically enhanced compared to FBS in microcarrier culture, as was seen in monolayer culture 
in Chapter 5. The mean cell diameter of BM-hMSCs in SFM was also lower than BM-hMSCs in 
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FBS culture, which was particularly evident for the BM-hMSCs cultured on pre-coated 
microcarriers (Figure 6.11). The fact that the post-harvest mean cell diameter of BM-hMSCs in 
the direct coating condition was significantly higher (p < 0.01) than in the pre-coating condition 
is further evidence that the BM-hMSCs in this condition were not able to successfully attach to 
the microcarriers.    
 
Figure 6.12 shows the post-harvest outgrowth kinetics of BM-hMSCs from each of the 
microcarrier conditions, which shows the reduced outgrowth kinetics of BM-hMSCs cultured on 
microcarriers that were directly coated from the culture medium. This is a further indication 
that the direct coating method for the microcarriers is having a detrimental impact on the BM-
hMSCs, which should be avoided during the manufacturing process. All of this evidence shows 
that for the successful expansion of BM-hMSCs in SFM, that pre-coating the microcarriers with 
fibronectin will be required at a concentration of 0.1 µg.cm-2, which can now be taken forward 
to develop a serum-free microcarrier process for the expansion of BM-hMSCs.   
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6.4 Development of a serum-free microcarrier process for BM-hMSCs 
 
6.4.1 Experimental overview 
Following the successful development of a fibronectin coating protocol for microcarriers in SFM, 
a full investigation of the serum-free culture of BM-hMSCs on microcarriers was completed. For 
this, four 100 mL spinner flasks were cultured in FBS-containing medium with BM-hMSC line M2 
and four were cultured in SFM following the microcarrier coating protocol described in Section 
6.3 for six days. Daily medium samples were taken for analysis of glucose, lactate, ammonia, 
lactate dehydrogenase and total protein with cell counts performed on day three of culture 
(four samples were analysed per spinner flask as per Section 3.4.3). The culture medium was 
exchanged on day three for FBS culture and every two days for SFM culture (Section 3.3.3). At 
harvest, the BM-hMSCs were removed from the microcarriers and separated according to 
Section 3.3.4. The BM-hMSCs harvested from each condition were then assessed for mean cell 
diameter (3.4.2), tri-lineage differentiation potential (Section 3.4.4) and immunophenotype 
(Section 3.4.5). In addition to these identity measurements, BM-hMSC quality characteristics of 
colony forming efficiency (Section 3.4.9) and outgrowth potential were also assessed post-
harvest.   
 
It is important that the development of BM-hMSC production processes also consider the 
downstream implications of the process and in particular the cryopreservation of the product, 
as many of these off-the-shelf therapies will require long term storage. Part of this was 
considering the time it will take to process bioreactor material on a large scale and integrating 
these realistic downstream processing times into the process prior to cryopreservation. With 
this in mind, a four hour holding time was incorporated into the SFM process post-harvest, with 
this BM-hMSC product taken forward into a serum-free cryopreservation process (Section 
3.3.6). Following this cryopreservation process, BM-hMSCs were thawed and assessed for 
adhesion and F-actin content (Section 3.4.13).     
 
 
6.4.2 Process map of the serum-free BM-hMSC microcarrier process 
Process mapping is a key part of systematic process development and allows for a structured 
development methodology centered on the concept of integrated unit operations and is being 
adopted in current biopharmaceutical manufacture (ICH 2005). Breaking a process down into 
unit operations allows for the detailed analysis of each process sub-unit, which can be assessed 
in terms of its impact on the product characteristics. This flags potential issues or bottlenecks in 
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the process which can then be systematically resolved. Figure 6.13 shows our simplified process 
map, which forms the basis for our integrated serum-free BM-hMSC production process, 
allowing us to develop individual unit operations to eventually achieve a larger yield of high 
quality product. The timing of the microcarrier-fibronectin coating step has been highlighted as 
a potential bottleneck, which cannot take place immediately prior to the expansion step. A 
quality risk management approach has highlighted that the quality assurance of the microcarrier 
coating could not take place in-process, as a failure event would severely impact subsequent 
unit operations. This will be addressed during future process development as this unit operation 
would have to take place in advance to decouple the coating step from the BM-hMSC expansion, 
reducing the inherent risk in the process.         
 
 
 
Figure 6.13. Process map for the serum-free expansion, harvest, downstream processing and 
preservation of BM-hMSCs on microcarriers. 
 
A further benefit of the process map is that it allows for interchangeability of unit operations 
that may not be sufficiently scalable for future product requirements. An example of this in the 
current process is the use of vacuum filtration and centrifugation to separate the BM-hMSCs 
from the microcarriers, which would be a challenge to operate at large scale. Therefore, during 
future development, scalable technology would be assessed for the separation and 
concentration step such as tangential-flow filtration. The effect of this unit operation must be 
assessed in terms of the impact on the product characteristics, to ensure product quality is not 
compromised. This assessment should be done in a timely manner, as the implications of 
changing process unit operations late in clinical development can be prohibitive. Therefore by 
taking this systematic development methodology and utilising process mapping, potential 
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bottlenecks and scalability issues can be alleviated at an early stage of development, avoiding 
costly changes as processes move through clinical development.         
 
 
6.4.3 Growth kinetics of BM-hMSCs in serum-free microcarrier culture 
As described previously, intensive process scale-up will be required to meet the clinical and 
commercial need for these large-scale allogeneic therapies. For instance, for a typical clinical 
indication like myocardial infarction, the dose requirements will be in the range of 35 – 350 
million BM-hMSCs per patient (Hare et al. 2009).  
 
 
 
Figure 6.14. Growth kinetics of BM-hMSCs cultured on microcarriers in FBS-containing 
medium and serum-free medium. Showing (A) Total viable cell number and (B) Specific growth 
rate. Data shows mean ± SD N=3 
 
 
The BM-hMSCs were expanded on non-porous plastic microcarriers in 100 mL spinner flasks 
over six days in FBS-containing medium and PRIME-XV SFM®. To facilitate cell attachment 
without the presence of serum (Hayman et al. 1985), plastic microcarriers were pre-coated with 
fibronectin before expansion under serum-free conditions. For BM-hMSCs expanded in spinner 
culture with FBS-containing medium, a final cell density of (8.58 ± 1.37) x 104 cells.mL-1 (mean ± 
SD, n=3) was reached, corresponding to a fold expansion of 2.86 ± 0.46 (Figure 6.14). In contrast, 
BM-hMSCs expanded in serum-free medium reached a final cell density of (3.01 ± 0.27) x 105 
cells.mL-1, corresponding to a fold increase of 10.04 ± 0.88 over the same time period (Figure 
6.15). Operating under serum-free conditions gave a 350% increase in BM-hMSC yield, which is 
significantly higher than serum-based culture (P < 1·10-6). This difference represents a significant 
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step forward in increasing the lot-size of BM-hMSC expansion and is comparable to studies 
which have achieved a BM-hMSCs density on microcarriers of 1 – 2 x 105 cells.mL-1, also under 
serum-free conditions (Santos et al. 2011; dos Santos et al. 2014). It was also observed that the 
BM-hMSC growth kinetics under serum-free microcarrier culture (0.384 ± 0.014 day-1) were 
significantly higher (p < 0.0001) than serum-free monolayer culture (0.323 ± 0.011 day-1). This 
increase could also be improved further by adding more surface area during the microcarrier 
culture, reducing the surface area limitation experienced under serum-free conditions.  
 
 
 
Figure 6.15. Growth kinetics of BM-hMSCs cultured on microcarriers in FBS-containing 
medium and serum-free medium. Showing (A) Cell concentration and (B) cumulative 
population doublings. Data shows mean ± SD N=3 
 
 
Despite this improvement in BM-hMSC yield under serum-free conditions, the expansion unit 
operation is clearly far from optimal. Figure 6.16 shows the large amount of microcarrier 
aggregation that occurred in serum-free culture, which limited the effective surface area 
available for expansion. The growth kinetics in Figure 6.14B and Figure 6.15B, where the BM-
hMSC growth between days 3 to 6 was reduced compared to day 0 to 3 in serum-free culture, 
is also suggestive of surface area limitation. It is likely that microcarrier aggregation is caused by 
a combination of accelerated cell growth, the microcarriers reaching effective confluence and 
the medium sampling process which requires the microcarriers to settle. These potential 
mechanisms will need to be addressed moving forward as aggregation not only has the potential 
to reduce cell yield but can also accentuate cell microenvironment heterogeneity (Baraniak et 
al. 2012) resulting in a cell product of inconsistent quality, although this did not occur here.         
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Figure 6.16. Microcarrier culture of BM-hMSCs on day 5 showing representative images of 
cell-microcarrier aggregation. Image of microcarriers in spinner flask with FBS-containing 
medium (A) and serum-free medium (B). Live/dead cell stain of BM-hMSCs on microcarriers 
in FBS-containing medium (C) and serum-free medium (D). Live cells stained with Calcein AM 
fluorophore (GREEN) and dead cells are stained with ethidium homodimer (RED). 
 
 
6.4.4 Metabolite flux of BM-hMSCs in serum-free microcarrier culture 
Metabolite analysis of microcarrier-based suspension culture of BM-hMSCs showed differences 
in the metabolic pathway usage relating to lactate and ammonia production between FBS-
containing and serum-free cultures. In FBS-containing medium, BM-hMSCs favoured the relative 
production of lactate over ammonia, whereas the relative production of ammonia over lactate 
was favoured with BM-hMSCs cultured in serum-free conditions (Figure 6.17). This finding is 
consistent with the monolayer process evaluated in Chapter 5.  
 
Chapter 6: Transfer of the BM-hMSC Expansion Process into Suspension 
 
 
143 | P a g e  
 
 
Figure 6.17. Nutrient and metabolite flux of BM-hMSC expansion on microcarriers. Glucose, 
lactate and ammonia concentrations in FBS-containing medium (A) and serum-free medium 
(B). Data shows mean ± SD, N=3 
 
 
 
Figure 6.18 shows that the per cell production of lactate was lower in serum-free culture at 
12.63 ± 0.59 pmol.cell-1.day-1 (mean ± SD, n=3) compared with 20.81 ± 4.88 pmol.cell-1.day-1, 
whereas the production of ammonia was 2.82 ± 0.15 pmol.cell-1.day-1 in serum-free, compared 
to 3.31 ± 0.10 pmol.cell-1.day-1 in FBS-containing culture.  The estimated yield of lactate from 
glucose over the entire culture period was 1.91 ± 0.03 and 1.76 ± 0.04 mol.mol-1 for FBS-
containing and serum-free culture, respectively. It is considered that the observed differences 
in these metabolic profiles are predominantly related to proliferative rate in this instance. The 
increased proliferative rate coupled with the smaller cell size makes DNA a larger proportion of 
the total cell biomass under serum-free conditions. Increased ammonia production suggests 
altered amino acid utilisation, which may be related to the increased need for precursors (e.g. 
glutamine and asparagine) supporting purine and pyrimidine biosynthesis (Higuera et al. 2012). 
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Figure 6.18. Specific consumption rate per cell of glucose (A) and production rate per cell of 
lactate (B), ammonia (C) and lactate dehydrogenase (D) for FBS-containing medium and 
serum-free medium.  Data shows mean ± SD (N=3). 
 
It is clear that a more detailed metabolic analysis is required and the development of culture 
medium should consider the impact of these metabolic pathways on cell characteristics. The 
reduced consumption of glucose and production of lactate per cell under serum-free conditions 
does however provide an advantage over serum-based culture, as the usage and build-up of 
metabolites has the potential to inhibit cell growth as the yield and scale increases. 
 
 
Figure 6.19. Nutrient and metabolite flux of BM-hMSC expansion on microcarriers. Total 
protein (A) and lactate dehydrogenase concentration (B) are shown for FBS-containing and 
serum-free medium. Data shows mean ± SD, N=3 
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Growth limiting concentrations of lactate and ammonia for BM-hMSCs, reported as 35.4 mM 
and 2.4 mM, respectively (Schop et al. 2009a), were not reached in any of our microcarrier 
cultures. Cell death was evaluated by measuring a combination of lactate dehydrogenase (LDH) 
(Lavrentieva et al. 2010a) and total protein released. Figure 6.19 shows these concentrations 
throughout culture, which indicate only a minimal increase in LDH and no change in the total 
protein released. This demonstrates that cell death was minimal throughout the expansion 
process, despite the increase in microcarrier aggregation, making the fold expansion data a 
reliable estimate of net proliferative rate. 
 
 
6.4.5 Harvest of BM-hMSCs from serum-free microcarrier culture 
The post-expansion detachment and separation of the BM-hMSC product from the microcarrier 
surface, whilst retaining the cell quality, is of critical importance for a scalable production 
process. The sequential expansion and harvest of BM-hMSCs represents an important step in 
the successful integration of these unit operations and has been demonstrated previously in 
FBS-based culture (Nienow et al. 2014). The same harvest protocol was modified for this study 
by replacing trypsin-EDTA with TrypLE Express for the serum-free culture to ensure the process 
was animal-component free. It was also observed that though microcarrier aggregation and cell 
number in the serum-free process was significantly greater than FBS-based culture, this 
difference did not limit the effectiveness of the harvest protocol and the BM-hMSCs were 
successfully detached from the microcarrier surface (Figure 6.20), with post-harvest cell viability 
(based on membrane integrity) of 99.63 ± 0.03 % (mean ± SD, n=3).  
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Figure 6.20. Post-expansion harvest of BM-hMSCs from microcarriers showing successful BM-
hMSC detachment from microcarriers (A). Post-harvest viability shows high number of intact 
BM-hMSCs for FBS-containing medium and serum-free medium. Data shows mean ± SD, N=3. 
 
 
 
After separating the cells from the microcarriers by vacuum filtration, the BM-hMSCs were held 
in culture medium at room temperature to simulate a potential large-scale batch pooling time 
before centrifugation, freezing medium equilibration and cryopreservation. This holding step 
was considered important for a cell-based product, as a BM-hMSC holding time of greater than 
six hours has been shown to negatively impact cellular quality (Pal et al. 2008), which could 
impose limits on the potential scalability of the bioprocess, depending on the sensitivity of the 
cell-based product. This holding process can be broken down into the microcarrier harvest (two 
hour process) and microcarrier-cell separation with an ambient hold in culture medium (two 
hour process). These steps are followed by suspension and equilibration of the cell product in 
freeze medium for up to one hour at 4°C prior to cryopreservation, which should be an 
acceptable exposure time for mixing and dosing thousands of vials or bags with suitable 
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manifold filling systems (Rowley et al. 2012a). Tangential-flow filtration has the potential to 
wash and concentrate cell products at the large scale within this two hour window (Pattasseril 
et al. 2013), meaning that the combined harvest, downstream and preservation timings in this 
study would still be relevant as the process is scaled-up further.                   
 
 
6.4.6 Post-harvest identity of BM-hMSCs from serum-free microcarrier culture 
To ensure that the microcarrier-based expansion and harvest unit operations have not had a 
detrimental effect on identity and quality, BM-hMSC characteristics have been evaluated 
immediately post-harvest. The primary objective for this is to demonstrate that the BM-hMSCs 
conform to the International Society for Cellular Therapy (ISCT) criteria (Dominici et al. 2006). 
Figure 6.21 shows the compliance of the BM-hMSCs with the ISCT criteria, by adherence to 
tissue culture plastic, demonstrating the same morphology post-harvest as was demonstrated 
pre-expansion and differentiation down the osteogenic (Figure 6.21E), adipogenic (Figure 6.21F) 
and chondrogenic (Figure 6.21G) lineages. The post-harvest BM-hMSC immunophenotype can 
be seen in Figure 6.21H which shows the co-expression of positive markers CD73, 90 and 105 at 
greater than 99 % as well as the expression of HLA-DR at less than 2 % (Chan et al. 2014b). There 
was an increase in the positive expression of CD34 above the 2% positive threshold, which can 
be attributed to an increase in non-specific antibody binding caused by the culture of BM-hMSCs 
on a fibronectin substrate and has previously been reported to be positive for adipose derived 
BM-hMSCs (Wagner et al. 2005). 
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Figure 6.21. Post-harvest BM-hMSC characterisation. (A) pre-expansion and (B) post-harvest 
BM-hMSC morphology in FBS-containing medium. (C) pre-expansion and (D) post-harvest BM-
hMSC morphology in serum-free medium. Tri-lineage differentiation of BM-hMSCs showing 
(E) osteogenic, (F) adipogenic and (G) chondrogenic potential post-harvest in serum-free 
medium. Multiparameter flow cytometry showing dual gating of CD73, 90, 105, 34 and HLA-
DR for BM-hMSCs post-harvest from serum-free microcarrier culture (H). 
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6.4.7 Post-harvest characterisation of BM-hMSCs from agitated microcarrier culture 
The successful development of a BM-hMSC manufacturing process relies on the characterisation 
of product identity and quality at each unit operation (Carmen et al. 2012a). The development 
of clinical indication specific BM-hMSC quality assays has proved to be complex, owing to their 
unique and multifactorial putative mechanism of action. Without definitive quality assays, the 
field relies on surrogate assays to measure cell attributes that are known to be related to aspects 
of BM-hMSC quality. Figure 6.22A shows the outgrowth of BM-hMSCs before, during and after 
expansion, with no decline in the proliferative potential observed across these unit operations. 
This suggests that BM-hMSCs have not experienced detrimental conditions during the 
microcarrier expansion and harvest process that could have affected their proliferation 
potential (Sethe et al. 2006).  
 
 
 
 
Figure 6.22. Post-harvest BM-hMSC quality compared to pre-expansion demonstrating 
retention of key attributes, showing (A) specific growth rate, (B) colony forming efficiency, (C) 
mean cell diameter and (D) forward/side scatter of cell populations confirming difference in 
mean cell diameter. 
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Colony forming potential has been highlighted as an important assay for the quality of BM-hMSC 
preparations (Pochampally 2008) and is known to deteriorate during culture (Schellenberg et al. 
2012). Figure 6.22B shows the maintenance of colony forming potential from pre-expansion to 
post harvest for both conditions, which further demonstrates that the BM-hMSCs have not been 
damaged during the harvest and separation process.  
       
The size of BM-hMSCs in culture is known to increase as they undergo cellular senescence 
(Wuchter et al. 2014), and should therefore be tracked throughout expansion and harvest to 
ensure it remains stable. Figure 6.22C demonstrates that the mean cell diameter remained 
stable throughout culture, with significantly smaller BM-hMSCs produced under serum-free 
culture (p < 0.05). Without the availability of a robust potency assay to determine the 
implications of a smaller cell size in serum-free culture, it is not known how this will affect in 
vivo BM-hMSC quality attributes. Despite this, clinical work has demonstrated that smaller BM-
hMSCs reduce the potential for vascular obstructions and stroke following the intra-artery 
injection of cells (Ge et al. 2014), as well as reducing capillary entrapment (Dreher et al. 2013). 
These observations suggest that a smaller cell size may not only be beneficial in terms of 
obtaining a higher number of cells per area for expansion, but might also be advantageous in 
product delivery. This possibility raises a question of whether the therapeutic potential of the 
cell is related to size and whether we need to think not only in terms of cell number but also in 
terms of product biomass for production and delivery of cell therapies. Cellular enlargement has 
been associated with the development of professional secretory cells such as plasma cells 
(Shaffer et al. 2004), with more organelles and increased protein synthesis. Considering that 
protein secretion is a putative mechanism of action of BM-hMSCs in vivo, the relation of cell size 
to secretory capability of BM-hMSCs should be clinically evaluated post-delivery.    
 
 
6.4.8 Downstream and preservation from a serum-free microcarrier process 
The BM-hMSCs harvested from serum-free spinner cultures were preserved using a serum-free 
freezing medium and a slow-freezing cryopreservation process. After thawing, cell viability (by 
membrane integrity) decreased to 75.8 ± 1.4% as a consequence of the cryopreservation 
process (Figure 6.23A). However, this value remains above the FDA guideline for cell-based 
therapies of 70% (FDA 2008a). A similar number of cells were recovered after three hours in 
culture, based on their sustained adherence to fibronectin without loss of membrane integrity 
(Figure 6.23A). It is important to note that this post-thaw recovery is comparable to studies 
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where BM-hMSCs have been immediately processed from monolayer culture (Liu et al. 2010), 
without the microcarrier harvest, filtration and holding time steps.   
 
 
 
Figure 6.23. Post-thaw BM-hMSC recovery following serum-free cryopreservation, showing 
(A) post-thaw recovery and 3 hour cell attachment based on PI exclusion. Post-thaw BM-hMSC 
outgrowth (B) following serum-free cryopreservation. Data shows mean ± SD (N=3). 
 
 
Despite the initial cell loss post-thaw, a 500 % increase in cell yield was obtained after 7 days in 
monolayer culture (compared with 800 % for unpreserved post-passage control), demonstrating 
that recovered cells were able to proliferate normally (Figure 6.23B). Recovered cells also 
displayed comparable morphology to unpreserved cells after 3 hours and 24 hours of culture on 
fibronectin, with signs of matured cell-matrix interactions, cell elongation (indicative of motility) 
(Huttenlocher and Horwitz 2011) and recovery of F-actin networks (Figure 6.24). These 
observations demonstrate that BM-hMSCs can be cryopreserved and recovered from a 
microcarrier expansion, harvest and holding process, with comparable cell yields to traditional 
monolayer harvest and immediate cell preservation.     
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Figure 6.24. Post-thaw BM-hMSC recovery following serum-free cryopreservation, showing 
formation of F-Actin cytoskeleton (A) 3 hours, (B) 24 hours post thaw (C) 3 hours post-passage 
control and (D) 24 hours post-passage control. Phase contrast images show day 2 BM-hMSC 
morphology post-thaw (E) and post passage control (F). Scale bar = 250 µm. 
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6.5 Chapter conclusions 
This Chapter has demonstrated that the serum-based monolayer BM-hMSC expansion process 
developed in Chapter five can be directly transferred into suspension via the introduction of 
microcarriers. This is an important process transfer step as the development of a scalable 
microcarrier expansion process has the potential to take advantage of increasing economies of 
scale to cost-effectively manufacture BM-hMSCs at the lot-sizes required for commercial 
production. Furthermore, the increased yield and donor consistency that was experienced for 
the monolayer process in HPL, has also directly transferred to the microcarrier process, 
indicated that this improved efficiency has the potential to be carried through increasing 
process scales, with preliminary process development and BM-hMSC donor screening taking 
place in small scale monolayer processes. In order for this microcarrier process to be operated 
under serum-free conditions, a fibronectin coating process has been developed for microcarrier 
culture. This has revealed that a lower concentration of fibronectin is more advantageous for 
microcarrier process which will be important to reduce the cost of goods in BM-hMSC 
manufacturing processes. It has been identified that the microcarriers must be pre-coated with 
fibronectin prior to the expansion process which will necessitate the validation and potential 
storage conditions for fibronectin coated microcarriers, to ensure the process is compatible with 
critical manufacturing principles.     
  
This Chapter has also demonstrated the feasibility of a serum-free microcarrier process for the 
expansion, harvest and preservation of BM-hMSCs. The integration of multiple process unit 
operations is an important step in developing a microcarrier-based expansion process capable 
of meeting the lot sizes required for clinical applications. The BM-hMSC identity and quality have 
been maintained throughout every unit operation of this integrated process, culminating with 
the successful recovery of BM-hMSCs from the cryopreservation step. Mapping has provided a 
robust process understanding from end-to-end, which can be broken down into individual unit 
operations and optimised for BM-hMSC yield, quality and consistency.  
 
The systematic development of a process control strategy for the expansion unit operation will 
form a key part of driving increased yield and consistency into the process, as well as the 
identification and mitigation of bottlenecks to further streamline the process. The focus of the 
following Chapter therefore, will be the development of a process control strategy for the 
microcarrier expansion of BM-hMSCs that can be integrated into this serum-free production 
process.            
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7 Process Control Strategy for BM-hMSC Microcarrier Culture 
 
7.1 Chapter introduction 
The addition of microcarriers has been used to culture adherent cells such as BM-hMSCs in 
suspension (Chapter 6) allowing for process scale-up, where online monitoring and control 
systems can be used to deliver a consistent and cost-effective BM-hMSC therapy. Further to 
this, stirred-suspension bioreactors are currently employed in biopharmaceutical production 
and therefore their design and operation are well-understood (Nienow 2006), with the potential 
to meet the expected manufacturing demands of large-scale BM-hMSC therapies (Heathman et 
al. 2015b). The supply of oxygen to the BM-hMSCs in these microcarrier suspension processes 
is essential and is typically achieved by headspace aeration as the oxygen uptake rate of BM-
hMSCs is relatively low (Rafiq et al. 2013a; Heathman 2015). That said, however, as the volume 
of the bioreactors and cell densities increase, it is likely that the sufficient supply of oxygen will 
require aeration directly into the culture medium via a sparger, which could be potentially 
detrimental to the BM-hMSCs (Nienow et al. 1996; Nienow et al. 2015a).  
 
One of the key aspects of a successful manufacturing process is in the reduction of product 
variation, which is particularly challenging when the cell is the final product. Variation can be 
introduced into the product by both the process input material and the process conditions 
(Williams et al. 2012). The input to the process must be controlled by strict BM-hMSC isolation 
techniques and potentially cell selection steps to improve product input consistency (Naing et 
al. 2015b), although these are typically poorly defined for BM-hMSCs. Additionally, the raw 
materials, such as the culture medium, must be controlled to further reduce variation and the 
development of defined medium formulations without the use of animal serum has been 
proposed as a mechanism to achieve this (Heathman et al. 2015e). The use of serum-free 
medium with microcarriers for the expansion of BM-hMSCs has previously been demonstrated 
for uncontrolled processes (dos Santos et al. 2011a; Heathman et al. 2015a; Tan et al. 2015) and 
therefore represents a viable alternative for large-scale serum free manufacture of BM-hMSCs. 
The monitoring and control of process parameters such as pH and dissolved oxygen for these 
suspension bioreactor systems will be important to reduce the variation introduced by the 
process conditions. This will be critical in order to drive consistent and cost-effective 
manufacturing processes for BM-hMSC therapies and therefore should be integrated into early 
bioprocess development.  
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The US Food and Drug Administration (FDA) has released guidance documents on the use of 
process control and real time release testing for pharmaceutical manufacturing (FDA 2009). This 
guidance has highlighted the importance regulators are placing on continual process 
improvement and enhanced understanding as a fundamental aspect of process development 
and control. Process analytical technology or PAT is a system for analysing and controlling 
manufacturing processes through measurement of product attributes to ensure final product 
quality, proposed by the FDA (FDA 2004). It will therefore be desirable to utilise these PAT 
technologies and measure online parameters in order to develop control systems to ensure that 
the product characteristics remain consistent. These relevant process parameters are likely to 
include a combination of cell growth, medium temperature, pH, pO2 and pCO2, which are 
commonplace in current biopharmaceutical production processes (Cierpka et al. 2013). 
 
The aim of this Chapter therefore, is to develop a process control strategy for the microcarrier 
culture of BM-hMSCs in suspension in order to drive increased consistency and yield into the 
process. The impact of this process control strategy on process economics and product 
consistency will be assessed for two BM-hMSC donors in both FBS-based and serum-free 
medium and compared to previously uncontrolled monolayer and microcarrier-based 
suspension BM-hMSC expansion processes in Chapter 5 and Chapter 6.       
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7.2 Effect of agitation rate on BM-hMSC expansion 
 
7.2.1 Experimental overview 
Following the successful development of a suspension-based microcarrier process for the 
expansion of BM-hMSCs, a control strategy should be developed to increase the yield and 
consistency in the process. The first step in this is to investigate the effect of the impeller speed 
on BM-hMSC growth and characteristics in order to determine the optimum agitation strategy 
for the microcarrier culture process. For this, three DASbox culture vessels per condition were 
cultured for six days in FBS-based medium (see Section 3.3.5) at 80, 115, 150 and 225 rpm in 
accordance with Table 7.1, which shows the characterisation of the bioreactor system at each 
impeller speed. It is important to note that the DASbox culture vessels do not contain baffles, 
however, the bioreactor system was assumed to be baffled due to the number of probes in the 
vessel in relation to the culture volume. The pH control set-point was 7.4, the dissolved oxygen 
concentration was controlled to 100 % and the temperature was controlled to 37 °C. Prior to all 
experiments, the control system on the DASGIP DASbox bioreactor platform was adjusted to 
ensure it remained stable, the process of which can be seen in Appendix E.  
 
During culture, daily medium samples were taken for analysis of glucose, lactate, ammonia, 
lactate dehydrogenase and total protein with cell counts performed each day (four samples 
were analysed per bioreactor as per Section 3.4.3). The culture medium was exchanged on day 
three of culture. At harvest, the BM-hMSCs were removed from the microcarriers and separated 
according to Section 3.3.6. The BM-hMSCs harvested from each condition were then assessed 
for mean cell diameter (Section 3.4.2), tri-lineage differentiation potential (Section 3.4.4) and 
immunophenotype (Section 3.4.5). In addition to these identity measurements, BM-hMSC 
quality characteristics of colony forming efficiency (Section 3.4.9) and outgrowth potential were 
also assessed post-harvest.   
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Table 7.1. Physical characterisation of the DASGIP DASbox bioreactor platform at the various 
impeller speeds used in this study. For an impeller diameter of 0.03 m and a bioreactor 
diameter of 0.063 m. 1) from reference (Nienow et al. 2015b)    
Impeller 
rate 
(rpm) 
Culture 
volume 
(ml) 
Power 
number1 
Max 
dissipation 
rate/average 
dissipation 
rate1 
Reynolds 
number 
Impeller 
speed (s-1) 
Max specific 
energy 
dissipation 
rate (W/kg) 
Kolmogorov 
scale of 
turbulence 
(µm) 
80 100 1.5 18 1439 1.33 0.016 90 
115 100 1.5 18 2068 1.92 0.046 68 
150 100 1.5 18 2697 2.50 0.103 56 
225 100 1.5 18 4046 3.75 0.346 41 
 
 
 
7.2.2 Human MSC growth kinetics on microcarriers 
In order to support the successful expansion of BM-hMSCs on microcarriers in suspension 
bioreactors, it will be critically important to employ an agitation strategy that suspends the 
microcarriers without causing damage to the cells throughout scale-up. In order to quantify this, 
the impact of different impeller speeds on the growth of BM-hMSCs on microcarriers has been 
assessed. In conjunction with this, the physical parameter of the bioreactor system have been 
calculated to provide a strong theoretical basis for this comparison, which can be seen in Table 
7.1. The controlled bioreactor system was operated at 100 % dissolved oxygen for each impeller 
rate, with the pH maintained at 7.4, which is commonly used for BM-hMSC culture (Wuertz et 
al. 2009).  
 
Figure 7.1 shows the effect of the various impeller speeds on BM-hMSC growth from daily 
samples over six days, with the highest impeller speed of 225 rpm leading to the lowest BM-
hMSC growth. This is confirmed by the post-harvest cell counts in Figure 7.2, which shows that 
there is significantly increased (p < 0.05) BM-hMSC growth at lower impeller speeds. The 
minimum impeller speed to suspend the microcarriers (NJS) was visually determined to be 115 
rpm, which explains why the daily cell counts at 80 rpm were lower than expected, as the 
microcarriers and cells were not entirely suspended. Maintaining the microcarriers and cells in 
suspension is critical to ensure that the effective mass and heat transfer can take place (Nienow 
1997) and therefore the impeller speed in this microcarrier-based bioreactor system should be 
at least 115 rpm. 
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Figure 7.1. Effect of bioreactor impeller speed on BM-hMSC growth over six days of culture in 
the DASbox controlled bioreactor, showing the increased growth kinetics at NJS. Control set-
points are 100% dissolved oxygen tension and pH 7.4 with headspace aeration. Data shows 
mean of n = 3 
 
 
Table 7.1 shows the characterisation of the bioreactor system at different impeller speeds with 
a calculation of the Kolmogorov microscale of turbulence for each impeller speed. Considering 
that the size of the microcarriers used in this study are in the range of 125-212 µm, Table 7.1 
shows that the Kolmogorov scale turbulent eddies at each of the investigated impeller speeds 
is much less than the size of the microcarriers but bigger than a cell. Kolmogorov theory suggests 
that the eddies most likely to cause damage are those of the size of the suspended entity i.e. 
eddies which are the same size as the microcarriers (Cherry and Papoutsakis 1986), with the 
energy of the eddies being transferred to the surface of the microcarriers. This results in high 
local velocity gradients between the microcarriers and the fluid, and the highest shear rates on 
the cells. Work by Croughan et al  (1987) has investigated the impact of this microscale of 
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turbulence on cells grown on microcarriers, with cell damage becoming significant when the 
microscale was less than or equal to about two-thirds the size of the microcarriers (Croughan et 
al. 1987). Based on the minimum microcarrier size used in this study it would suggest that the 
BM-hMSC growth kinetics would be affected at a turbulent eddy size of < 83 µm, which is the 
eddy size calculated for impeller speeds of 115 – 225 rpm, where the BM-hMSC growth kinetics 
were reduced compared with 80 rpm where the eddy size was 90 µm. However, in the latter 
case, the cells and microcarriers were not fully suspended at this impeller speed. This drop in 
growth rate clearly suggests that the impact of poor mass transfer to the cells due to the lack of 
suspension is more  damaging than that due to fluid dynamic stress even though the microscale 
is only ~  55 % of the size of the microcarrier at 115 rpm.        
 
 
 
Figure 7.2. Effect of bioreactor impeller speed on post-harvest BM-hMSC number after six 
days of culture in the DASbox controlled bioreactor, showing the increased BM-hMSC number 
at lower impeller speeds. Data shows mean ± SD, n = 3 
 
The spinner flask process employed an agitation strategy that gave a Kolmogorov microscale of 
183 µm (Hewitt et al. 2011), representing double the eddy size calculated for the culture process 
at 80 rpm here. A key difference between the spinner flask process and the DASbox process is 
that the DO and pH are controlled in the DASbox rather than simply relying on a buffer in the 
culture medium and environment regulation in an incubator. The control of the medium pH will 
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be important during manufacture, particularly as the cell densities and metabolite 
concentrations increase. Despite the much higher eddy size in the spinner flask process, the 
post-harvest BM-hMSC number was similar at 8.69 ± 0.58 · 106 (Chapter 6) compared to an 
impeller speed of 80 rpm which had a post-harvest cell number of 9.68 ± 1.94 · 106 under a 
similar culture process. It should also be noted that the growth kinetics at an impeller speed of 
150 rpm was similar (p > 0.05) to that measured at NJS, which is beneficial as it allows for similar 
BM-hMSC growth kinetics at an increased energy dissipation rate of 0.103 W.kg-1 compared with 
0.046 W.kg-1 at an impeller speed of 115 rpm (NJS), allowing for increased process flexibility 
during scale-up.    
 
 
7.2.3 Human MSC metabolite flux on microcarriers 
The relative flux of metabolites is an important parameter to measure and understand during 
the expansion process as it has the potential to form part of a process control system, based 
upon BM-hMSC characteristics. Figure 7.3 shows the lactate dehydrogenase (LDH) and total 
protein concentration at the various impeller speeds throughout the culture process, which do 
not increase as the impeller speed in changed. If cell damage was occurring during the culture 
process, the levels of LDH and total protein would increase as the cell cytoplasmic membrane 
rupture and release protein and LDH into the culture medium (Lavrentieva et al. 2010b). The 
differences in BM-hMSC growth kinetics discussed in Section 7.2.2 due to changes in impeller 
speed are therefore not attributed to cellular damage by membrane disruption in this instance.  
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Figure 7.3. Live metabolite concentrations of lactate dehydrogenase (LDH) and total protein 
at various impeller speeds demonstrating little increase in concentrations throughout 
expansion indicating a low level of cellular damage. Data shows mean ± SD, n = 3 
 
 
It has been demonstrated previously however, that increasing the shear stress in flow chambers 
during BM-hMSC culture leads to the inhibition of proliferation, in association with maintaining 
cells in G0/G1 phase of the cell cycle (Luo et al. 2011). Additionally, the reduction in growth 
kinetics at higher impeller speeds could be caused by an inhibition of BM-hMSC attachment and 
re-attachment to the microcarriers during the growth phase. Whatever the mechanism for the 
reduced growth rate of BM-hMSCs on microcarriers at increased impeller speeds, it is not 
caused by direct cell damage as is commonly assumed.  
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In addition to LDH and total protein concentration, the glucose, lactate and ammonia 
concentrations have been measured daily during the culture process for each impeller speed 
(Figure 7.4). The glucose concentration decreased to a minimum of 2.06 ± 0.45 mmol.L-1 at an 
impeller rate of 80 rpm, supporting that the post-harvest cell number was highest in this 
condition. The lowest reduction in glucose concentration was for 225 rpm, with a day six 
concentration of 4.08 ± 0.43 mmol.L-1 demonstrating a reduced glucose uptake at lower BM-
hMSC growth rates. In addition to this, the lactate concentration reach a maximum of 7.73 ± 
0.57 mmol.L-1 on day six of culture at an impeller speed of 80 rpm, with a similar trend for each 
impeller rate as for the glucose concentration. In contrast to this, the change in ammonia 
concentration was more similar across all of the impeller speeds, suggesting that ammonia 
production was less dependent on BM-hMSC growth than glucose and lactate during the culture 
process.  
 
The net flux of each metabolite can be seen in Figure 7.5, which shows a similar level of per cell 
glucose consumption and lactate production across each impeller speed. This is an indication 
that the low BM-hMSC growth at an impeller speed of 225 rpm is not a result of cellular 
senescence, as the glucose consumption and lactate production per cell has previously been 
shown to increase if this is the case (Heathman et al. 2015c). The increased ammonia production 
at an impeller speed suggests altered amino acid utilisation, which may be related to the 
increased need for precursors (e.g., glutamine and asparagine) supporting purine, and 
pyrimidine biosynthesis (Higuera et al. 2012). The yield of lactate from glucose for impeller 
speeds of 80, 115 and 150 rpm was around 2 mol.mol-1 which indicates that the cells mainly 
metabolise glucose via the inefficient glycolytic pathway instead of the energy efficient 
oxidative phosphorylation pathway (Higuera-Sierra et al. 2009).  
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Figure 7.4. Live metabolite concentrations of glucose, lactate and ammonium for various 
impeller speeds showing the increased metabolic activity at lower agitation rates. Data shows 
mean ± SD, n = 3 
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The impeller speed of 225 rpm had a yield of lactate from glucose of 2.70 ± 0.73 mol.mol-1 which 
is above the theoretical maximum yield of 2 mol.mol-1 (Glacken 1988). This suggests that an 
additional carbon source, most likely glutamine, is being metabolised to produce lactate and 
ammonia, resulting in higher lactate yields and an increase in the per cell ammonia flux (Rafiq 
et al. 2013a) seen in Figure 7.5.      
 
 
 
Figure 7.5. Metabolite consumption and production rate of BM-hMSCs at various impeller 
speeds. Showing glucose consumption, lactate production, ammonia production and the yield 
of lactate from glucose. Data shows mean ± SD, n = 3 
 
 
 
7.2.4 Post-harvest characterisation of BM-hMSCs 
In addition to the growth kinetics and metabolite flux, it is important to assess the post-harvest 
BM-hMSC characteristics to ensure that the process and harvest conditions have not had a 
detrimental impact on the quality of the cell (Nienow et al. 2014). The BM-hMSCs were 
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harvested from the microcarrier surface and separated prior to characterisation according to a 
previously published protocol for the DASGIP DASbox bioreactor platform (Nienow et al. 2015b).  
 
 
 
Figure 7.6. Post-harvest outgrowth rate of BM-hMSCs at various impeller speeds showing the 
increased outgrowth kinetics of BM-hMSCs from the controlled bioreactor compared to pre-
expansion and post-spinner culture. Data shows mean ± SD, n = 3 
 
 
The specific outgrowth rate can be seen in Figure 7.6 which shows that the BM-hMSC post-
harvest outgrowth rate was similar across all of the impeller speeds investigated. Similarly, this 
suggests that the impeller speed of 225 rpm has not triggered a senescent state in the BM-
hMSCs or caused detriment to their outgrowth potential. This is further evidence to support the 
hypothesis that the reduction of BM-hMSC growth kinetics on microcarriers at high impeller 
rates is due to inefficient cell-microcarrier attachment, rather than cell damage due to 
increasing shear forces. It can also be seen from Figure 7.6 that the post-harvest outgrowth 
kinetics of BM-hMSCs from the controlled DASbox bioreactor system at all impeller speeds were 
higher than either before expansion and post-harvest from the uncontrolled spinner flask 
process. This is an indication of the positive impact the controlled bioreactor process is having 
on the BM-hMSC characteristics which will be important for future bioprocess scale-up and 
development.       
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Figure 7.7. Post-harvest mean diameter of BM-hMSCs at various impeller speeds showing the 
reduced mean BM-hMSC diameter of BM-hMSCs from the controlled bioreactor compared to 
pre-expansion. Data shows mean ± SD, n = 3 
 
 
Associated with the increase in post-harvest outgrowth, the BM-hMSCs cultured in the DASbox 
bioreactor platform had a reduced mean cell diameter for all impeller speeds compared to pre-
expansion and post-harvest from uncontrolled spinner flasks. As well as being associated with a 
decrease in BM-hMSC growth rate, an increase in cell size has been linked to aging of BM-hMSCs 
and loss in differentiation potential (Stolzing and Scutt 2006; Wagner et al. 2010) and therefore 
a reduction in BM-hMSC size through controlled microcarrier expansion will be beneficial to the 
manufacturing process.  
 
Colony forming potential has been highlighted as an important assay for the quality of BM-hMSC 
preparations (Pochampally 2008) and is known to deteriorate during culture (Schellenberg et al. 
2012; Heathman et al. 2015c). Figure 7.8 shows the maintenance of colony forming potential 
from pre-expansion to post-harvest at all impeller speeds, which further demonstrates that the 
BM-hMSCs have not been damaged during the expansion and harvest process.  
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Figure 7.8. Post-harvest colony forming efficiency of BM-hMSCs at various impeller speeds 
showing a similar colony forming potential of BM-hMSCs across all conditions. Data shows 
mean ± SD, n = 3 
 
 
To ensure that the microcarrier-based expansion and harvest unit operations have not had a 
detrimental effect on BM-hMSC identity, the immunophenotype has been evaluated 
immediately post-harvest. The primary objective for this is to demonstrate that the BM-hMSCs 
conform to the International Society for Cellular Therapy (ISCT) criteria (Dominici et al. 2006). 
The post-harvest BM-hMSC immunophenotype for an impeller speed of 225 rpm can be seen in 
Figure 7.9 which shows the co-expression of positive markers CD73, 90 and 105 as well as the 
negative expression of HLA-DR and CD34 (Chan et al. 2014b). Table 7.2 shows the percentage 
co-expression of each of these markers, which is greater than 95% for impeller speeds of 80, 
150 and 225 rpm, confirming maintenance of BM-hMSC immunophenotype.  
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Figure 7.9. Exemplar multiparameter flow cytometry plots showing co-expression of CD90+, 
CD73+, CD105+, CD34- & HLA-DR- for an impeller speed of 225rpm 
 
 
 
 
 
Table 7.2. Post-harvest multiparameter flow cytometry showing percentage co-expression of 
CD90+, CD73+, CD105+, CD34- & HLA-DR- at various impeller speeds. Mean value ± SD, in all 
cases 10,000 events were measured 
Impeller speed (rpm) % co-expression of CD73+, 90+, 105+, 34- and HLA-DR- 
80 96.50 ± 0.14 
150 96.80 ± 0.28 
225 95.80 ± 0.14 
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7.3 Effect of dissolved oxygen concentration on BM-hMSC expansion 
 
7.3.1 Experimental overview 
In addition to the bioreactor impeller speed, the optimum dissolved oxygen (DO) concentration 
control set-point must be determined for BM-hMSC expansion on microcarriers. For this, three 
DASbox culture vessels per condition were cultured for six days (see Section 3.3.5) at 100, 75, 
50, 25 and 10 % dissolved oxygen in FBS-based medium. The pH control set-point was 7.4, the 
impeller speed was controlled to 115 rpm and the temperature was controlled to 37 °C. Prior to 
all experiments, the control system settings on the DASGIP DASbox bioreactor platform were 
adjusted to ensure it remained stable, the process of which can be seen in Appendix E.  
 
During culture, daily medium samples were taken for analysis of glucose, lactate, ammonia, 
lactate dehydrogenase and total protein with cell counts performed each day (four samples 
were analysed per bioreactor as per Section 3.4.3). The culture medium was exchanged on day 
three of culture. At harvest, the BM-hMSCs were removed from the microcarriers and separated 
according to Section 3.3.6. The BM-hMSCs harvested from each condition were then assessed 
for mean cell diameter (Section 3.4.2), tri-lineage differentiation potential (Section 3.4.4) and 
immunophenotype (Section 3.4.5). In addition to these identity measurements, BM-hMSC 
quality characteristics of colony forming efficiency (Section 3.4.9) and outgrowth potential were 
also assessed post-harvest.   
 
 
7.3.2 The importance of dissolved oxygen control in bioreactor operation  
Almost all of the current technology for BM-hMSC expansion utilise open, laboratory scale 
processes such as T-flasks wherein controlling, monitoring, and evaluating the impact of key 
parameters on target cell output and productivity is difficult (Kirouac and Zandstra 2008). 
Control of process parameters such as dissolved oxygen during the manufacturing process will 
be vital in maximising product consistency and ensuring that the process is scalable. A large part 
of this ability to control the process conditions is in maintaining a closed process during 
expansion, which not only reduces contamination risk but is vital in maintaining the desired 
culture environment of the BM-hMSCs and avoid fluctuations in these critical process 
parameters. Much of the current literature on low oxygen concentration or hypoxia (Table 7.3) 
culture of BM-hMSC use hypoxic incubators that maintain a low oxygen environment (an oxygen 
concentration in the gas phase lower than that found in atmospheric air) rather than controlling 
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the process conditions, with process manipulations taking place at atmospheric oxygen 
concentrations.  
 
 
Table 7.3. Definitions of culture and physiological oxygen concentrations in relation to 
atmospheric and dissolved oxygen concentrations.  
Atmospheric 
Oxygen 
Concentration (v/v) 
Dissolved Oxygen 
Concentration (%) 
In vitro 
Nomenclature 
In vivo 
nomenclature 
20 – 21 100 Normoxia Hyperoxia 
2 -5  10 - 25 Hypoxia Normoxia 
 
 
Figure 7.10 shows the impact of exposing low oxygen experiments to atmospheric oxygen within 
an agitated bioreactor process. This demonstrates that for a DO set-point of 5 % (1.05 % 
atmospheric oxygen), after a one hour exposure of the culture to atmospheric conditions (21 % 
atmospheric oxygen equivalent at saturation to 100 % dissolved oxygen), creates a deviation to 
a maximum DO concentration of 77.9 %, which takes a further 294 minutes to return back to 5 
% DO with continual headspace aeration with 1.05% atmospheric oxygen. Considering the 
number of manipulations that occur during culture, for example, daily sampling and medium 
exchange, this mode of operation causes large and prolonged fluctuations in dissolved oxygen 
concentrations experienced by the BM-hMSCs. Considering that this study has taken place in 
agitated conditions with headspace aeration, it represents a best case scenario, as in static 
monolayer culture without headspace gassing these deviations in DO would be larger with an 
increased set-point recovery time. This is a potential reason why there is so much discrepancy 
within the published literature of BM-hMSCs cultured in low oxygen concentration 
atmospheres.    
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Figure 7.10. Implications of exposing low dissolved oxygen (DO) experiments (5 and 25%) to 
atmospheric conditions in a biological safety cabinet for 1, 5 and 60 minutes. Demonstrating 
the importance of continuous closed process control during bioreactor culture. Bars represent 
the set-point recovery time to 5 or 25% DO and diamonds represent the maximum DO 
concentration reached during each exposure and recovery period.    
 
 
7.3.3 Human MSC growth kinetics on microcarriers 
Following the initial experiment to assess the effect of the bioreactor impeller rate on BM-hMSC 
expansion on microcarriers, the impeller speed of 115 rpm has been selected for future 
bioreactor experiments. This speed was chosen because it allowed for the suspension of the 
microcarriers, without causing detriment to the BM-hMSC growth kinetics or post-harvest 
characteristics. 
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Figure 7.11. Effect of dissolved oxygen concentration on BM-hMSC growth over six days of 
culture in the DASbox controlled bioreactor, showing the increased growth kinetics at lower 
dissolved oxygen concentrations. Control set-points are 115rpm impeller speed and pH 7.4 
with headspace aeration. Data shows mean of n = 3 
 
 
Dissolved oxygen concentration has been previously shown to have an impact on BM-hMSC 
growth and cell characteristics (Grayson et al. 2006), with much debate around the use of the 
terms “normoxia” (100 % DO) and “hypoxia” (typically < 25 % DO) (Rafiq et al. 2013c). Figure 
7.11 shows the effect of various controlled dissolved oxygen concentrations on BM-hMSC 
growth on microcarriers over six days of culture, with increased growth kinetics at lower 
dissolved oxygen concentrations. This is confirmed by Figure 7.12 , which shows the post-
harvest cell number in each dissolved oxygen concentration, with significantly higher BM-hMSC 
numbers (p < 0.05) at 10 and 25 % DO compared with 100 % DO. There is currently no common 
consensus on whether low oxygen concentrations are beneficial for BM-hMSCs, with some 
studies demonstrating improved growth (Dos Santos et al. 2010) and function (Basciano et al. 
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2011), whilst others demonstrate diminished BM-hMSC characteristics (Rafiq et al. 2013c) in 
monolayer culture. This data therefore, provides an indication that BM-hMSC growth 
characteristics are improved at low dissolved oxygen concentrations, in a controlled 
microcarrier expansion process.        
 
 
 
Figure 7.12. Effect of dissolved oxygen concentration on post-harvest BM-hMSC number after 
six days of culture in the DASbox controlled bioreactor, showing the increased BM-hMSC 
number at lower dissolved oxygen concentrations. Data shows mean ± SD, n = 3 
 
7.3.4 Human MSC metabolite flux on microcarriers 
It is again important to assess the effect of changing DO concentrations on the relative 
metabolite flux of the BM-hMSC during microcarrier expansion. Figure 7.13 shows the live 
concentrations of glucose, lactate and ammonia over the six days of expansion, with increased 
consumption of glucose and production of lactate in low dissolved oxygen concentrations, in 
accordance with the increased BM-hMSC growth rate in Section 7.3.3. In contrast, Figure 7.13 
shows that the production of ammonia in 10 and 25 % DO was reduced compared with higher 
DO concentrations, despite the increased BM-hMSC number at the lower dissolved oxygen 
concentration. As with the impeller speed experiment, the LDH and total protein concentrations 
have been measured to assess whether any BM-hMSC stress or damage has been caused by the 
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different DO concentrations. Figure 7.14 shows these concentrations throughout culture, which 
have not unduly increased over the six day period, although the 100 % DO condition has 
demonstrated the highest level of total protein and LDH, despite having the lowest number of 
BM-hMSC through culture. This reduction in the release of LDH has previously been associated 
with a reduction in cell necrosis for a DO concertation of 7 %, compared to BM-hMSCs cultured 
at 100 % DO (Lavrentieva et al. 2010b). A reduction in cell necrosis at low dissolved oxygen 
concentrations would be beneficial for BM-hMSC manufacturing processes, as cell death has 
the potential to activate a cascade of negative cell responses that would reduce the purity of 
the final product and would therefore be undesirable (Festjens et al. 2006).  
 
The per cell flux of glucose, lactate, ammonia and the yield of lactate from glucose can be seen 
in Figure 7.15 for BM-hMSC culture on microcarriers at various controlled DO concentrations. 
This shows a significantly higher glucose and lactate production rate (P < 0.05) for a dissolved 
oxygen concentration of 10 %. This is in agreement with previous studies for BM-hMSCs cultured 
in monolayer conditions at reduced DO concentrations (Brown et al. 2007; Dos Santos et al. 
2010; Rafiq et al. 2013c), which demonstrates that the cell metabolism is switching from 
oxidative phosphorylation to anaerobic glycolysis (likely due to oxygen limitation in the culture 
medium) as well as an up-regulation of the glucose transport into the cells in low DO culture. 
Furthermore, the level of glucose consumption and lactate production for BM-BM-hMSCs is also 
comparable to these studies with around 15 pmol.cell-1.day-1 and 30 pmol.cell-1.day-1, 
respectively. It is important to note that this result for controlled microcarrier culture is 
consistent with the literature on the monolayer expansion of BM-hMSCs at low DO 
concentrations, demonstrating that despite the change in process conditions from monolayer 
to microcarrier culture, the metabolite flux of BM-hMSC remains comparable which is important 
during process development (Archibald et al. 2015).   
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Figure 7.13. Live metabolite concentrations of glucose, lactate and ammonium for various 
dissolved oxygen concentrations showing the increased metabolic activity at lower dissolved 
oxygen concentrations. Data shows mean ± SD, n = 3 
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The flux of ammonia can also be seen in Figure 7.15, which shows a significant reduction (p < 
0.05) for both 25 and 10 % DO to around 2.5 pmol.cell-1.day-1, compared to 100 % DO. This is 
again in agreement with previous studies (Dos Santos et al. 2010) and supports a more efficient 
cell metabolism under low DO culture conditions. A reduction in the production in ammonia at 
low DO concentrations for microcarrier culture is also advantageous for process operation, as 
the build-up of toxic compounds to inhibitory levels will become less of an issue (Schop et al. 
2009b).     
 
 
 
Figure 7.14. Live metabolite concentrations of lactate dehydrogenase (LDH) and total protein 
at various dissolved oxygen concentrations demonstrating little increase in concentrations 
throughout expansion indicating a low level of cellular damage. Data shows mean ± SD, n = 3 
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The yield of lactate production from glucose can also be seen in Figure 7.15, which shows a 
reduction in yield to 1.21 ± 0.37 mol.mol-1 at 25% DO, but a subsequent increase at 10 % DO to 
2.27 ± 0.26 mol.mol-1 compared with 100 % DO. This is once again in agreement with studies of 
BM-hMSC culture at low oxygen concentrations in monolayer involving BM-hMSCs (Dos Santos 
et al. 2010; Rafiq et al. 2013c) but is significantly higher than BM-hMSCs derived from the 
umbilical cord at both high and low DO concentrations (Lavrentieva et al. 2010b). Considering 
the importance of the in vivo niche environment on hMSC characteristics, it is possible that this 
difference in cell metabolism at different dissolved oxygen concentrations is due to relative 
differences in the in vivo oxygen concentrations in the bone-marrow and umbilical cord tissues 
(Mohyeldin et al. 2010).   
 
 
 
Figure 7.15. Metabolite consumption and production rate of BM-hMSCs at various dissolved 
oxygen concentrations. Showing glucose consumption, lactate production, ammonia 
production and the yield of lactate from glucose. Data shows mean ± SD, n = 3 
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7.3.5 Post-harvest characterisation of BM-hMSCs 
As with the investigation of the effect of various impeller speeds, it is important to assess 
whether microcarrier expansion at reduced DO concentrations is not unduly effecting the post-
harvest BM-hMSC characteristics, despite the improved growth kinetics seen in section 7.3.3. 
Figure 7.16 shows the outgrowth rate of BM-hMSCs harvested from microcarrier culture at the 
various DO concentrations compared to pre-expansion and post-harvest from uncontrolled 
spinner flasks at 100 % DO. This shows significantly higher (p < 0.05) outgrowth kinetics for BM-
hMSCs across all controlled bioreactor expansion conditions compared to pre-expansion and 
post-harvest from the spinner flasks. In addition to this, BM-hMSCs cultured at 10 % DO 
demonstrated significantly higher (p < 0.05) outgrowth kinetics compared to all other controlled 
DO concentrations. This suggests that the controlled expansion of BM-hMSCs on microcarriers, 
particularly at low dissolved oxygen concentrations, is having a positive impact on the 
outgrowth kinetics of BM-hMSCs.  
 
    
 
Figure 7.16. Post-harvest outgrowth rate of BM-hMSCs at various dissolved oxygen 
concentrations showing the increased outgrowth kinetics of BM-hMSCs from the controlled 
bioreactor particularly at low dissolved oxygen compared to pre-expansion and post-spinner 
culture. Data shows mean ± SD, n = 3 
Chapter 7: Process Control Strategy for BM-hMSC Microcarrier Culture 
 
 
180 | P a g e  
 
In accordance with the increase in outgrowth kinetics, the mean cell diameter of BM-hMSCs 
cultured in controlled bioreactor conditions in Figure 7.17 is significantly (p < 0.05) lower than 
pre-expansion and post-harvest from uncontrolled spinner flasks. The benefits to the 
manufacturing process of producing smaller BM-hMSCs has previously been discussed 
(Heathman et al. 2015e) and smaller cells are commonly associated with increased proliferation, 
greater colony-forming efficiency and longer telomeres (Samsonraj et al. 2015). Likewise, BM-
hMSC culture at low DO from different sources may also display different functional 
characteristics and can modulate the autocrine or paracrine activity of a variety of cytokines and 
growth factors in BM-hMSCs (Das et al. 2010).   
 
   
 
Figure 7.17. Post-harvest mean diameter of BM-hMSCs at various dissolved oxygen 
concentrations showing the reduced mean BM-hMSC diameter of BM-hMSCs from the 
controlled bioreactor compared to pre-expansion and post-spinner culture. Data shows mean 
± SD, n = 3 
 
 
The post-harvest colony-forming (CFU) efficiency of BM-hMSCs from the controlled bioreactor 
process at various DO concentrations can be seen in Figure 7.18, which shows a similar level of 
CFU efficiency for BM-hMSC harvested form 50 and 100 % DO conditions, compared with pre-
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expansion and post-spinner culture. In contrast, the post-harvest CFU efficiency of BM-hMSC 
from 10 and 25 % DO was significantly higher (p < 0.05) than pre-expansion and post-harvest 
from spinner flasks. An increase in CFU efficiency of BM-hMSCs at low dissolved oxygen is widely 
reported and has been shown to be independent of hypoxia inducible factor (HIF) expression in 
BM-hMSCs (Tamama et al. 2011).  
 
 
 
Figure 7.18. Post-harvest colony forming efficiency of BM-hMSCs at various dissolved oxygen 
concentrations showing an increased colony forming potential of BM-hMSCs at reduced 
dissolved oxygen concentrations. Data shows mean ± SD, n = 3 
 
 
 
To ensure that the microcarrier-based expansion and harvest unit operations have not had a 
detrimental effect on BM-hMSC identity, the immunophenotype has been evaluated 
immediately post-harvest. The primary objective for this is to demonstrate that the BM-hMSCs 
conform to the International Society for Cellular Therapy (ISCT) criteria (Dominici et al. 2006). 
The post-harvest BM-hMSC immunophenotype for a dissolved oxygen concentration of 10% can 
be seen in Figure 7.19 which shows the co-expression of positive markers CD73, 90, 44 and 105 
as well as the negative expression of CD45, 34, 11b, 19 and HLA-DR, demonstrating that low 
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oxygen culture of BM-hMSCs in a controlled microcarrier process does not affect the 
immunophenotype of the BM-hMSCs.   
 
 
 
Figure 7.19. Exemplar multiparameter flow cytometry plots showing co-expression of CD90+, 
CD73+, CD105+, CD44+, CD34-, CD45-, CD11b-, CD19- & HLA-DR- for a dissolved oxygen 
concentration of 10%   
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7.4 Effect of sparging on BM-hMSC expansion 
 
7.4.1 Experimental overview 
Despite that fact that sufficient oxygen can be supplied to the culture medium by headspace 
aeration at the 100 mL volume and cell densities investigated here, it is acknowledged that this 
may not be the case as the bioreactor process is scaled-up and cell-densities increase. In order 
to address this early in process development, the effect of aeration via a sparger in the culture 
medium has been investigated with and without PluronicTM F68, a commonly used cell 
protectant in suspension-based mammalian cell culture. Evidence suggests that PluronicTM F68 
has the potential to accumulate in mammalian cells during culture (Gigout et al. 2008), which 
would be undesirable for cell-based therapy applications and therefore its use should be limited 
where possible. For this investigation, three DASbox culture vessels per condition were cultured 
for six days (see Section 3.3.5) with an aeration rate of 0.1 VVM (gas volume flow per unit of 
liquid volume per minute). The dissolved oxygen was controlled to 100 %, the pH control set-
point was 7.4, the impeller speed was set to 115 rpm and the temperature was controlled to 37 
°C.  
 
During culture, daily medium samples were taken for analysis of glucose, lactate, ammonia, 
lactate dehydrogenase and total protein with cell counts performed each day (four samples 
were analysed per bioreactor as per Section 3.4.3). The culture medium was exchanged on day 
three of culture. At harvest, the BM-hMSC were removed from the microcarriers and separated 
according to Section 3.3.6. The BM-hMSCs harvested from each condition were then assessed 
for mean cell diameter (3.4.2), colony forming efficiency (Section 3.4.9) and outgrowth 
potential.   
 
 
7.4.2 Aeration strategies in BM-hMSC bioreactor process development 
Agitation and aeration strategies will play a key role in the successful development of 
microcarrier based bioreactor processes for BM-hMSC manufacture, particularly as the scale of 
operation increases. Due to the fact that the specific oxygen demand and the cell densities 
achieved so far in BM-hMSC microcarrier culture are low, the oxygen demand of the cells in 
current benchtop bioreactors can be met by passing gas mixtures through the headspace. At 
the bench scale the relatively large surface area to volume ratio means that headspace aeration 
alone is sufficient to meet this demand, however on the commercial scale, as the available gas-
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liquid interface area is inversely proportional to scale, this will become more of a challenge 
(Nienow 2006). 
 
In order to address the oxygen supply issue, aeration directly into the culture medium via the 
incorporation of a sparger has been used for large scale mammalian cell culture, where the cell 
oxygen demand is an order of magnitude higher than BM-hMSCs (Rafiq et al. 2013a) and cell 
densities are greater than 5 · 106 ml-1 (Nienow 2003). The introduction of sparging into 
bioreactor culture also creates new challenges such as the addition of antifoam (Mostafa and 
Gu 2003) into the medium, which has been previously shown to significantly reduce the mass 
transfer properties of the system (Lavery and Nienow 1987). It is also widely accepted that cell 
damage due to sparging is primarily a result of bubbles bursting at the medium-air interface, 
where the local energy release is sufficient to damage the cell. Polymers such as PluronicTM F68 
are widely used to decrease this cell damage and improve bioreactor performance in traditional 
mammalian cell suspension processes (Oh et al. 1989; Kilburn and Webb 2000). This 
improvement in performance by the addition of PluronicTM F68 is a result of its ability to reduce 
the hydrophobicity of the cell surface, preventing cell-bubble attachment and subsequent 
damage due to these bubbles bursting at the surface (Meier et al. 1999). 
 
It is likely that the microcarrier culture of BM-hMSCs will encounter a number of these issues as 
the bioreactor scale and cell densities achieved increase throughout development. Therefore 
investigating the potential consequences will be important early in development. Furthermore, 
considering that the use of protective components, such as PluronicTM F68 have been successful 
for free suspension cell culture, it is possible that they will not be appropriate for the suspension 
culture of BM-hMSCs attached to microcarriers, as in this case the cells are administered directly 
to the patient and are subject to increased regulation.  
 
 
7.4.3 Human MSC growth kinetics on microcarriers 
The growth rate of BM-hMSC on microcarriers in a controlled bioreactor process has been 
assessed in order to compare the effect of sparging at 0.1VVM with and without PluronicTM F68 
to headspace aeration. Figure 7.20 shows this BM-hMSC growth rate over six days of bioreactor 
expansion, demonstrating that headspace aeration (1.70 ± 0.45·105 cell.mL-1) supports 
significantly higher (p < 0.05) growth kinetics compared to sparged culture with (0.52 ± 0.15·105 
cell.mL-1) and without (0.84 ± 0.18·105 cell.mL-1) PluronicTM F68. This is the first indication that 
aeration directly into the culture medium via a sparger has a detrimental impact on the 
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expansion of BM-hMSCs on microcarriers. Furthermore, the improved performance experience 
by free suspension cell culture due to the addition of PluronicTM F68 does not apply to the 
microcarrier system investigated here, which has also been demonstrated for an alternative cell 
type (Liu et al. 2004). 
 
 
 
Figure 7.20. Effect of sparging with and without PluronicTM F68 on BM-hMSC growth over six 
days of culture in the DASbox controlled bioreactor, showing the reduced growth kinetics 
when sparging. Control set-points are 115rpm impeller speed, 25% dissolved oxygen and pH 
7.4. Data shows mean ± SD, n = 3 
 
 
 
This results suggests that the detrimental impact of sparging on the microcarrier culture of BM-
hMSCs is not due to cell-bubble attachment, with cell damage caused by subsequent bubble 
bursting at the gas-liquid interface as is the case with free suspension cell culture (Meier et al. 
1999). The key difference with the microcarrier culture of BM-hMSCs compared to free 
suspension cell culture is that the cells must adhere to the microcarrier surface prior to growth. 
The addition of PluronicTM F68 into the culture medium in this system is in fact having a 
detrimental impact on the growth of BM-hMSCs (Figure 7.20), which perhaps is not surprising 
given that the mechanism of PluronicTM F68 is to reduce the cell hydrophobicity, thus reducing 
the affinity of the BM-hMSCs to attach to surfaces. Further evidence of this can be seen in Figure 
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7.21, which shows the attachment rate of the BM-hMSCs to the microcarriers during the six 
days of culture. This figure shows that the attachment rate of the BM-hMSCs is reduced in 
sparged culture compared to headspace aeration, suggesting that introducing bubbles into the 
bioreactor system is disrupting the BM-hMSC attachment process. Additionally, the inclusion of 
PluronicTM F68 in the culture medium is further reducing the attachment rate of the BM-hMSCs 
to the microcarriers in suspension, in accordance with the mechanism described above. This 
reduced attachment rate of BM-hMSCs is likely to be contributing to the reduced growth 
kinetics seen under sparged conditions for BM-hMSCs culture on microcarriers. There is 
potential however, that headspace aeration could be used for the initial attachment phase and 
sparged aeration could then be used as the BM-hMSC density and subsequent oxygen demand 
increases throughout the process.   
 
 
 
 
Figure 7.21. Attachment efficiency of BM-hMSC on microcarriers in the DASbox bioreactor 
system during sparger and headspace aeration strategies. Showing the reduced attachment 
rate of BM-hMSCs under sparged conditions. Data shows mean ± SD, n = 3 
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7.4.4 Human MSC metabolite flux on microcarriers 
In addition to growth kinetics, the metabolite flux has been monitored throughout culture to 
assess the impact that sparging is having on the consumption and production of metabolites 
throughout microcarrier culture. Figure 7.22 show the concentrations of glucose, lactate and 
ammonia throughout the six days of expansion for sparged and headspace aeration culture. This 
shows that despite the reduced growth kinetics seen in sparged culture in Section 7.4.3, the net 
flux of glucose, lactate and ammonia is similar for all conditions and did not reach previously 
determined inhibitory levels at any point (Schop et al. 2009b).    
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Figure 7.22. Live metabolite concentrations of glucose, lactate and ammonium at the different 
aeration strategies demonstrating a similar level of metabolic activity. Data shows mean ± SD, 
n = 3 
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Figure 7.23. Live metabolite concentrations of lactate dehydrogenase (LDH) and total protein 
at the different aeration strategies demonstrating little increase in concentrations throughout 
expansion indicating a low level of cellular damage. Data shows mean ± SD, n = 3  
 
 
As with the previous experiments, the LDH and total protein concentrations have been 
measured to assess whether any BM-hMSC stress or damage has been caused by sparged 
aeration. Figure 7.23 shows these concentrations throughout culture, which have not increased 
over the six day period in any condition. This is further evidence to suggest that introducing 
sparged aeration into the culture is not causing cell damage by bubble bursting, as the level of 
LDH and total protein would be increasing throughout culture if cell damage was occurring, 
which is the likely reason why the addition of PluronicTM F68 into sparged culture is not 
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improving the BM-hMSC growth kinetics on microcarriers. Considering that cell damage is not 
occurring during sparged aeration, it seems that the reduction in growth kinetics during sparging 
is caused by the reduction in attachment rate seen in Section 7.4.3.   
 
 
 
Figure 7.24. Metabolite consumption and production rate of BM-hMSCs at different sparging 
strategies. Showing the increased lactate and ammonia production for sparged culture. Data 
shows mean ± SD, n = 3 
 
 
The per cell flux of each metabolite can be seen in Figure 7.24, which shows a similar level of 
net glucose consumption per cell in headspace and sparged aeration during culture. In contrast, 
the production of ammonia to above 3 pmol.cell-1.day-1 and lactate to above 20 pmol.cell-1.day-
1 in sparged culture was significantly higher (p < 0.05) than from headspace aeration. The 
increase in the per cell production of lactate and ammonia has previously been associated with 
a reduction in growth kinetics of BM-hMSCs throughout an expansion process (Heathman et al. 
2015c).  
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7.4.5 Post-harvest characterisation of BM-hMSCs 
As with the previous experiments, it is important to assess whether the reduced growth 
characteristics of BM-hMSC in sparged aeration culture is also resulting in detrimental post-
harvest BM-hMSC characteristics, as this will be critical for successful development of 
commercial BM-hMSC manufacturing processes. The post-harvest characteristics of the BM-
hMSCs from the sparged and headspace aeration strategies can be seen in Figure 7.25, showing 
the relative post-harvest cell number, outgrowth rate, colony-forming potential and mean cell 
diameter.  
 
 
 
Figure 7.25. Post-harvest BM-hMSCs number, colony forming efficiency, outgrowth rate and 
mean cell diameter in different aeration strategies. Showing the reduced harvest cell number, 
mean BM-hMSC diameter and colony forming potential of BM-hMSCs from sparged culture. 
Data shows mean ± SD, n = 3 
 
 
The post-harvest BM-hMSC number confirms the findings in Section 7.4.3, that a significantly 
higher (p < 0.05) number of BM-hMSCs were produced under headspace aeration, compared to 
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sparged aeration in the controlled bioreactor process. Figure 7.25 shows that the post-harvest 
BM-hMSC mean diameter is increased for sparged culture, with a significant increase (p < 0.05) 
seen for sparged aeration with the addition of PluronicTM F68. This increase in post-harvest cell 
size is associated with a reduction in BM-hMSC attachment and subsequent growth rate with 
the addition of PluronicTM F68, as was seen in Section 7.2.4 for an impeller speed of 225 rpm. In 
addition to the increased post-harvest BM-hMSC diameter, the addition of PluronicTM F68 into 
the sparged culture lead to a reduction in BM-hMSC outgrowth kinetics as well as a significant 
reduction (p < 0.05) in the CFU potential of the BM-hMSCs. This reduction raises concerns about 
the use of PluronicTM F68 in the culture of BM-hMSCs on microcarriers and its inclusion in cell-
based therapy manufacturing processes should be carefully considered to ensure it is not having 
a detrimental impact on the growth or quality of the cell product.   
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7.5 Controlled expansion of BM-hMSCs in serum-free 
 
7.5.1 Experimental overview 
Now that a process control strategy has been developed for the microcarrier culture of BM-
hMSCs, this can be transferred to the serum-free microcarrier process developed in Chapter 6. 
For this, three DASbox culture vessels per condition were cultured for six days (see Section 3.3.5) 
for BM-hMSC donors M2 and M3 in SFM and FBS-based medium. From the previous studies in 
this Chapter, the pH control set-point was 7.4, the dissolved oxygen was controlled at 10%, the 
impeller speed was controlled to 115 rpm and the temperature was controlled to 37 °C.  
 
During culture, daily medium samples were taken for analysis of glucose, lactate, ammonia, 
lactate dehydrogenase and total protein with cell counts performed each day (four samples 
were analysed per bioreactor as per Section 3.4.3). The culture medium was exchanged on day 
three of culture for FBS and every two days for SFM. At harvest, the BM-hMSC were removed 
from the microcarriers and separated according to Section 3.3.6. The BM-hMSCs harvested from 
each condition were then assessed for mean cell diameter (Section 3.4.2), tri-lineage 
differentiation potential (Section 3.4.4) and immunophenotype (Section 3.4.5). In addition to 
these identity measurements, BM-hMSC quality characteristics of colony forming efficiency 
(Section 3.4.9) and outgrowth potential were also assessed post-harvest.  In addition to this, the 
effective yield was calculated in terms of cells per volume of medium used per day, to determine 
the efficiency of the controlled process compared to uncontrolled in both FBS and SFM for the 
two donor BM-hMSC lines. The consistency between the BM-hMSC donors was also assessed 
by calculating the coefficient of variation for the controlled and uncontrolled processes.  
 
 
7.5.2 Human MSC growth kinetics on microcarriers 
Following the successful development of a process control strategy in FBS-based culture, it is 
important to assess the effect of this new control strategy on the serum-free (SFM) microcarrier 
expansion of the two BM-hMSC donors developed in Chapter 6. Figure 7.26 shows the growth 
kinetics of the two donor BM-hMSC lines in controlled bioreactors in FBS and SFM, with 
significantly increased growth kinetics for both BM-hMSC donors in SFM to a final cell 
concentration of 7.11 ± 0.90 · 105 cell.mL-1 for M2 and 6.13 ± 1.82 · 105 cell.mL-1 for M3. This 
represents a 300 % increase in the BM-hMSC yield across the two donors in SFM, which will be 
advantageous in driving cost-effective BM-hMSC manufacturing processes. The increase in 
growth kinetics in a controlled SFM microcarrier process presented here is in accordance with 
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previously published data for monolayer culture in Chapter 5 (Heathman et al. 2015e) and 
uncontrolled spinner flask culture in Chapter 6 (Heathman et al. 2015a).  
 
 
 
Figure 7.26. Serum-free and FBS expansion of two BM-hMSC donors over six days in the 
DASbox controlled bioreactor, showing the increased growth kinetics under serum-free. 
Control set-points are 115rpm impeller speed, 10% dissolved oxygen and pH 7.4. Data shows 
mean ± SD, n = 3 
 
 
The harvest efficiency of BM-hMSC from the FBS-based process was 91.5 ± 8.9 % across both 
donors, which is comparable to previous studies which demonstrated > 95% harvest efficiency 
for a spinner flask based harvesting process (Nienow et al. 2014). This also demonstrates the 
effectiveness of the scalable harvesting method developed on sound engineering principles, as 
despite the change in bioreactor platform, maintaining the same specific energy dissipation rate 
and Kolmogorov microscale of turbulence in the DASbox bioreactor platform has yielded a 
similar BM-hMSC harvest efficiency (Nienow et al. 2015b). The overall harvest efficiency of the 
BM-hMSCs from the SFM process, however, was 76.5 ± 2.9 %, significantly lower than the 
previous FBS-based microcarrier processes. This is most likely due to the significantly increased 
BM-hMSC densities achieved under serum-free conditions, reducing the effectiveness of the 
separation process. Figure 7.27 shows that the harvest procedure employed has successfully 
removed the BM-hMSCs from the microcarriers in the SFM process. Therefore, the reduction in 
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harvest efficiency can be attributed to losses during the subsequent cell-microcarrier separation 
step and cell concentration.  This separation problem will clearly have to be addressed moving 
forward, as increased cell densities will be required in order to drive cost-effective 
manufacturing processes and harvesting efficiencies will have fundamental impact on final 
product yields. Part of this success will be in developing scalable downstream technology, 
capable of reducing losses in the process step of separating the BM-hMSCs from the 
microcarriers after detachment.   
 
 
 
Figure 7.27. Phase contrast image of microcarriers post-harvest from the SFM process. 
Demonstrating that the BM-hMSCs have been successfully removed from the microcarriers 
during the harvesting process.   
 
 
It is evident from Figure 7.28 that the attachment efficiency of BM-hMSCs to the microcarriers 
is improved for both donors in the SFM expansion process, with > 75 % attachment efficiency 
after one day. In contrast, the controlled FBS-based process had an attachment efficiency of < 
Chapter 7: Process Control Strategy for BM-hMSC Microcarrier Culture 
 
 
196 | P a g e  
 
70 % for both donors after one day, with a reduced attachment in the subsequent four days of 
expansion. Given the implications of poor cell-microcarrier attachment described above, 
particularly as the process increases in scale, this higher level of attachment represents a key 
advantage of the SFM process compared to the FBS-based microcarrier process.  
 
 
 
Figure 7.28. Attachment efficiency of two BM-hMSC donors on microcarriers in the DASbox 
bioreactor system in FBS and SFM expansion. Showing the increased attachment rate of BM-
hMSCs in SFM. Data shows mean ± SD, n = 3 
 
 
7.5.3 Human MSC metabolite flux on microcarriers 
Metabolite analysis of the controlled microcarrier culture of BM-hMSCs showed differences in 
the metabolic pathway usage relating to lactate and ammonia production between FBS-
containing and serum-free cultures. Figure 7.29 shows the relative consumption of glucose, 
production of lactate and ammonia, as well as the yield of lactate from glucose in FBS and SFM 
for two donor BM-hMSC lines. In FBS-based expansion the consumption of glucose was 9.86 ± 
1.49 pmol.cell-1.day-1 for M2 and 8.37 ± 1.94 pmol.cell-1.day-1 for M3, whereas for SFM expansion 
the consumption of glucose was significantly lower (p < 0.05) for both BM-hMSC donors with 
4.41 ± 0.14 pmol.cell-1.day-1 for M2 and 3.54 ± 1.40 pmol.cell-1.day-1 for M3. Similarly, the 
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production of lactate in the controlled microcarrier process was significantly lower (p <0.05) in 
the SFM process compared to the FBS-based process for both donor BM-hMSC lines. This result 
is once again comparable to the levels of glucose and lactate flux measured during monolayer 
(Heathman et al. 2015e) and uncontrolled microcarrier culture (Heathman et al. 2015a) using 
the same donor BM-hMSCs. As with these previous studies, the production of ammonia is more 
similar between the FBS and SFM conditions indicating that the metabolite utilisation under 
SFM conditions is more efficient, with a switch from energy production predominantly via 
anaerobic glycolysis in FBS culture to utilisation of the oxidative phosphorylation pathway under 
SFM.  
 
 
 
Figure 7.29. Metabolite consumption and production rate of two BM-hMSC donors in FBS and 
SFM. Showing the increased lactate and ammonia production for sparged culture. Data shows 
mean ± SD, n = 3 
 
 
The metabolite utilisation between BM-hMSC donors is also more consistent in controlled SFM 
microcarrier culture, with a range in the yield of lactate from glucose between M2 and M3 of 
0.12 mol.mol-1. In contrast, the yield of lactate from glucose in controlled FBS culture between 
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donors showed a range of 1.32 mol.mol-1. This increase in consistency of BM-hMSC 
characteristics between donors in controlled SFM culture offers significant advantages for 
bioprocess development and has been maintained from monolayer culture of BM-hMSCs, 
demonstrating comparable process transfer throughout development.      
 
 
 
Figure 7.30. Live metabolite concentrations of lactate dehydrogenase (LDH) and total protein 
for two BM-hMSC donors in FBS and SFM showing an increase in LDH in SFM but no increase 
in total protein. Data shows mean ± SD, n = 3 
 
The live concentrations of LDH and total protein for controlled FBS and SFM microcarrier culture 
for two BM-hMSC donors can be seen in Figure 7.30. The FBS-based controlled bioreactor 
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process demonstrated little increase in LDH or total protein over the six days of culture, 
suggesting no significant cell damage is occurring during the expansion process. The total 
protein concentration in controlled SFM expansion also showed no significant increase over the 
six days of culture, however, the LDH concentration did see a slight increase on day six, when 
the cell density is at a maximum, up to the baseline level during FBS culture. Considering that 
this occurs at increased BM-hMSC densities, this should be evaluated as the final cell density of 
BM-hMSC bioreactor processes increase, to ensure that increasing the yield does not impact the 
quality of the product.      
 
 
7.5.4 Post-harvest characterisation of BM-hMSCs 
The post-harvest characteristics from the controlled microcarrier expansion process in FBS and 
SFM have been assessed to ensure that the expansion process is not having a detrimental 
impact on the BM-hMSC characteristics. The specific outgrowth rate of BM-hMSCs from both 
the FBS and SFM controlled bioreactor processes can be seen in Figure 7.31 which shows that 
the post-harvest outgrowth kinetics of BM-hMSC have been maintained. 
 
 
Figure 7.31. Post-harvest outgrowth rate of two BM-hMSC donors in FBS and SFM expansion 
showing the increased outgrowth kinetics of BM-hMSCs from the controlled bioreactor 
particularly under SFM. Data shows mean ± SD, n = 3 
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Figure 7.32 shows the post-harvest BM-hMSC diameter which has been significantly reduced (p 
< 0.05) compared to pre-expansion, which for the FBS process was 2.1 µm for M2 and 2.2 µm 
for M3. This is in contrast to the uncontrolled spinner flask process presented in Chapter 6 which 
demonstrated a slight increase in mean cell diameter of M2 (1.2 µM) and M3 (0.4 µm) between 
post-harvest and pre-expansion.  
 
 
 
Figure 7.32. Post-harvest mean cell diameter of two BM-hMSC donors in FBS and SFM 
expansion showing the decrease in mean cell diameter from the controlled bioreactor 
process. Data shows mean ± SD, n = 3  
 
 
The benefits to the manufacturing process of producing smaller BM-hMSCs has previously been 
discussed (Heathman et al. 2015e) and smaller cells are commonly associated with increased 
proliferation, greater colony-forming efficiency and longer telomeres (Samsonraj et al. 2015). 
This highlights a key advantage of the controlled bioreactor process, which is having a beneficial 
impact on the post-harvest characteristics of the BM-hMSCs, critical for process development 
and scale up.  
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The post-harvest colony-forming potential of the BM-hMSCs can be seen in Figure 7.33, which 
shows that the CFU potential has either increased or been maintained compared to pre-
expansion. This is particularly apparent for the controlled FBS-based process, which showed a 
significant increase (p < 0.05) in the post-harvest CFU potential for both BM-hMSC donor lines. 
This is again an indication of the beneficial impact of the controlled low DO process for the two 
BM-hMSC donors in terms of CFU potential, as the uncontrolled spinner flask process presented 
in Chapter 6 did not demonstrate this increase post-harvest CFU potential.     
    
 
 
Figure 7.33. Post-harvest colony forming efficiency of two BM-hMSC donors in FBS and SFM 
expansion showing the increase in colony forming efficiency from the controlled bioreactor 
process in FBS. Data shows mean ± SD, n = 3 
 
 
The BM-hMSCs harvested from the microcarrier process must also retain their identity in 
accordance with the ISCT criteria. Figure 7.34 shows the tri-lineage differentiation potential of 
the BM-hMSC following microcarrier expansion in SFM down the adipogenic, osteogenic and 
chondrogenic lineages. This demonstrates that the BM-hMSCs have retained their tri-lineage 
differentiation potential following controlled microcarrier expansion in SFM.  
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Figure 7.34. Post-harvest tri-lineage differentiation potential of BM-hMSCs using phase 
contrast microscopy. Showing osteogenic differentiation by staining for alkaline phosphatase 
and calcium deposition, adipogenic differentiation by staining with Oil Red O and 
chondrogenic differentiation by staining with Alcian Blue. 
 
 
 
In addition to demonstration of tri-lineage differentiation potential, BM-hMSC harvested from 
the microcarrier process must also retain their immunophenotype. Figure 7.35 shows the 
multiparameter flow cytometry plots of post-harvest BM-hMSCs demonstrating the maintained 
positive co-expression of CD105, 90, 44 and 73 throughout the microcarrier expansion process. 
Further to this, BM-hMSC have retained the negative co-expression of CD45, CD34, CD11b, CD19 
and HLA-DR following the controlled microcarrier expansion process in SFM.  
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Figure 7.35. Exemplar multiparameter flow cytometry plots showing co-expression of CD90+, 
CD73+, CD105+, CD44+, CD34-, CD45-, CD11b-, CD19- & HLA-DR- for M2 expanded in SFM 
 
 
7.5.5 Process control to drive yield and consistency 
In order for these BM-hMSC therapies to successfully progress through to commercial 
production, the process cost of goods should be minimised throughout development. Driving 
yield and consistency into the BM-hMSC manufacturing process at an early stage of 
development will be critical in order to reduce the overall cost of goods and increase the cost-
effectiveness of the final BM-hMSC product. Increasing the consistency of the final product will 
reduce process costs by demonstrating a level of control over the product and reducing the risk 
of batch failure. For large-scale off the shelf processes where the capital invested per batch is 
high, increasing the consistency of product quality will reduce the risk of product batch failures 
and significantly reduce the overall production costs. For patient specific therapies where there 
is a manufacturing batch per patient, increased inter-donor consistency will again reduce the 
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probability of batch failure, increasing overall costs and would mean that a patient would go 
without treatment. All of this means that assessing the final BM-hMSC yield and donor 
consistency for various process iterations, would be highly information on the direction of future 
process development to reduce overall production costs. 
 
Currently, two of the key cost drivers for the production of cell-based therapies are in the culture 
medium and the time it takes to manufacture a product batch (Simaria et al. 2014). Therefore 
to make a basic yield comparison of each of the processes developed, the relative process yield 
in terms of number of BM-hMSCs produced as a function of the volume of culture medium and 
process time has been calculated for each of the controlled and uncontrolled systems for a 
theoretical process. In addition to this process yield estimation, a combination of the inter- and 
intra-donor variation has been assessed to get an understanding of the relative consistency 
within each process.    
 
 
 
Figure 7.36. Impact of a process control strategy on the process yield from a microcarrier 
expansion process. Showing that controlled bioreactor processes under serum-free conditions 
provide much higher yield and consistency between donors. Bars denote process yield in 
terms of number of cells produced per volume of medium per unit time and the line chart 
denotes the coefficient of variation between and within donors.    
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The results of this can be seen in Figure 7.36, which demonstrates the increased process yield 
that is achieved in controlled SFM microcarrier culture. This improvement represents an 
increase in process yield of over 300 % for the controlled SFM process compared to the 
controlled FBS based process. As the process scale increases and the manufacturing costs of the 
SFM are reduced, this improvement is likely to increase further, due to the issues associated 
with serum supply at a large-scale (Brindley et al. 2012). It can also be seen from Figure 7.36 
that the process yield is also increased by an average of around 500% for both donors under 
controlled conditions compared to uncontrolled expansion, highlighting the importance of 
systematically developing a process control strategy to increase the yield of BM-hMSC 
production on microcarriers. It is important to note that the large difference in process yield 
between monolayer and microcarrier culture at the bench-scale evaluated here, will increase as 
the scale increases, due to the improved economies of scale achievable in a suspension 
bioreactor based process.  
 
The percentage coefficient of variation has been calculated for each of the expansion processes 
in order to assess the relative amount of variation between each condition. This parameter is a 
combination of inter-donor variation, (the variation between each donor) and intra-donor 
variation (the variation between batch runs of each donor). This can also be seen in Figure 7.36, 
which shows the lowest coefficient of variation for the controlled SFM microcarrier process with 
14.7 %. A coefficient of variation of 15 % or less is in compliance with the established regulatory 
requirements (FDA 2011a; Streitz et al. 2013), demonstrating control over the product. There is 
also a clear difference between the controlled and uncontrolled processes in FBS, with process 
control reducing the coefficient of variation from 79.1 to 37.5 %. This outcome represents a 
significant reduction in process variation, via the introduction of a process control system, once 
again demonstrating the importance of developing a process control strategy for BM-hMSC 
production.        
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7.6 Chapter conclusions 
This Chapter has demonstrated that the systematic development of a process control strategy 
for the microcarrier expansion of BM-hMSCs has significantly increased the yield and 
consistency achievable in the process. Unnecessarily increasing the impeller agitation speed 
during the microcarrier expansion of BM-hMSCs decreased the growth kinetics, however, did 
not have a detrimental impact on the BM-hMSC post-harvest characteristics. Direct aeration of 
the culture medium via a sparger has also been shown to be detrimental to BM-hMSC growth 
and post-harvest quality characteristics. Sparging of the medium during bioreactor culture is 
likely to be required at the large-scale to supply oxygen to the cells and remove carbon dioxide 
and is currently the preferred method of aeration in large scale bioreactors. It will be important 
during process scale-up, therefore, to ensure that bioreactor parameters such as energy 
dissipation and sparging rates are not increased above levels which might affect the growth 
characteristics of the BM-hMSC product.    
 
Studies looking at the effect of exposing low oxygen bioreactor culture to atmospheric 
conditions during the culture period has highlighted the importance of operating closed and 
controlled processes to avoid large fluctuation of the dissolved oxygen concentration of the 
medium. Operating the microcarrier expansion process for BM-hMSCs in closed and controlled 
manner, has demonstrated improved growth and post-harvest BM-hMSC quality characteristics 
at 10 and 25 % dissolved oxygen in FBS-based medium. The introduction of serum-free medium 
into this low dissolved oxygen controlled bioreactor process has further increased the yield 
across two BM-hMSC donors, however, with reduced harvest efficiency compared to the FBS-
based process that has lower cell numbers at harvest. Considering that this was primarily due 
to cell losses in the cell-microcarrier separation step, it will be imperative to develop specific 
downstream technology to effectively separate the cells from the microcarriers, even as the 
number of BM-hMSCs per volume is increased under serum-free conditions. 
 
The development of a process control strategy has significantly increased the yield and 
consistency between BM-hMSC donors with a coefficient of variance between and within these 
donors under serum-free conditions of less than 15 %. This is in conjunction with a significant 
increase in the BM-hMSCs produced per volume of medium per unit time under serum-free 
conditions, which will be critical in increasing the economies of scale and reducing the cost of 
BM-hMSC therapies. Furthermore, the introduction of the process control strategy has 
significantly reduced the BM-hMSC inter- and intra-donor variation in FBS-based culture from 
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79.1 to 37.5 %, which will be critical for the future development of both patient specific and off-
the-shelf BM-hMSC manufacturing processes.     
 
The subsequent downstream and cryopreservation processes following the bioreactor 
expansion and harvest unit operations will have a profound impact on the scalability of the BM-
hMSC manufacturing process. This is because as the scale and BM-hMSC yield increases, the 
time required to process and formulate the additional product will also increase, which has the 
potential to negatively impact the functionality of the final product. In order to assess this, the 
focus of the next Chapter will be to determine the impact of these subsequent unit operations 
on critical BM-hMSC characteristics through the downstream and cryopreservation processes.         
 
 
Publications arising from this Chapter:     
Heathman TRJ, Rafiq QA, Coopman K, Nienow AW, Kara B, Hewitt CJ. Developing a process 
control strategy for the serum-free production of human mesenchymal stem cells on 
microcarriers. Biotechnology & Bioengineering, (2015) (in preparation) 
 
Nienow AW, Hewitt CJ, Heathman TRJ, Glyn VAM, Fonte G, Hanga MP, Coopman K, Rafiq QA. 
Agitation Conditions for the Culture and Detachment of hMSCs from Microcarriers in Multiple 
Bioreactor Platforms. Biochemical Engineering Journal, (2015) (in press)  
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8 Downstream Processing and Cryopreservation of BM-hMSCs 
 
8.1 Chapter introduction 
The successful development of a controlled serum-free microcarrier expansion and harvest 
process for BM-hMSCs in Chapter 7 has provided a consistent and potentially scalable upstream 
process for BM-hMSC production. Given the importance of maintaining critical product 
characteristics for cell-based therapies throughout the entire process (Carmen et al. 2012a; 
Heathman et al. 2015b), it is vital that the downstream process is also considered during 
development. This is because the BM-hMSCs, once harvested from the bioreactor, must be 
further processed and cryopreserved in order to decouple the manufacture from delivery and 
maximise the potential of this off-the-shelf business model. To achieve this, the downstream 
and cryopreservation process must be developed in conjunction with the upstream microcarrier 
process, taking a holistic process approach, considering the entire process from end-to-end 
(Heathman et al. 2015a). This is because any changes to the upstream process will have a direct 
impact on the downstream and cryopreservation processes and therefore must be developed 
in parallel, so that it remains cost-effective as the process scale increases (Hassan et al. 2015).   
 
Increasing the volumetric yield of BM-hMSC therapies will also be important moving forward as 
significant economic gains can be made by increasing the cell densities of microcarrier processes 
(Simaria et al. 2014). In conjunction with this, scalability in the downstream and 
cryopreservation process must be maintained, to ensure that harvested material from the 
bioreactors can be processed without impacting cell quality, as the timing of process steps 
increases. Considering process timings that would be realistic as the process scale increases will 
be important to facilitate systematic process development and highlight potential challenges at 
an early stage of development. The precise timings of these downstream processes for BM-
hMSC therapies are process specific and currently undefined, however, post-harvest washing 
and concentration is likely to be in the order of hours (Pattasseril et al. 2013), with subsequent 
manifold filling systems capable of formulating thousands of vials or bags within an hour 
(Rowley et al. 2012b). Future process development to reduce these downstream processing 
times by integrating up- and downstream unit operations and create functionally closed 
processes will also be critical, increasing the operability and scalability of BM-hMSC 
manufacturing (Cunha et al. 2015).  
       
Chapter 8: Downstream Processing and Cryopreservation of BM-hMSCs 
 
 
209 | P a g e  
 
The preservation of therapeutically active cells as part of the manufacturing process is unique 
to the cell therapy industry (Rafiq et al. 2015a). This process step is necessary to decouple the 
production from the storage, shipment and delivery of cell product to the clinic. It also allows 
for time to validate the product and complete quality assurance tests, prior to delivery. 
Considering that a number of target clinical indications for cell therapy products will be 
emergency treatments, the long term storage of these products is vital to their success. The 
cryopreservation of cell therapy products has undergone much development, with an overview 
of 66 FDA submissions for BM-hMSC products showing that > 80% considered the use of 
cryopreservation prior to product storage and transportation (Mendicino et al. 2014). Despite 
this progress much work is still required to ensure that the cryopreservation process does not 
have a detrimental impact on the cell, with some clinical studies demonstrating reduced product 
efficacy following cryopreservation (Moll et al. 2014b). 
 
This cryopreservation process is typically based on a combination of FBS and dimethylsulfoxide 
(DMSO), which acts as a cryoprotective agent (CPA) to stabilise cellular proteins (Buchanan et 
al. 2004) and the plasma membrane of the cell (Anchordoguy et al. 1991). Despite the use of 
DMSO at the laboratory scale, there are potential issues with its use for clinical delivery and it 
has been associated with the denaturation of certain proteins (Arakawa et al. 1990) as well as 
neurological toxicity when delivered to patients at high concentrations (Rodrigues et al. 2008). 
The use of FBS in cryopreservation is widespread, however should be minimised due to its 
limited supply (Brindley et al. 2012), potential for pathogen transmission and adverse immune 
response (Tuschong et al. 2002). This means that eliminating the use of FBS and reducing the 
concentration of DMSO during the BM-hMSC cryopreservation process, will be highly beneficial 
during process development (Liu et al. 2010) and therefore should be considered in conjunction 
with the downstream process following BM-hMSC expansion on microcarriers.  
 
The aim of this Chapter therefore, is to evaluate a scalable serum-free downstream and 
cryopreservation process for BM-hMSCs (Figure 8.1), following the previously developed 
controlled expansion process on microcarriers. This will evaluate the effect of relevant and 
scalable process times on BM-hMSC quality throughout the downstream process and determine 
whether the previously observed donor variation has an impact on the future development of 
BM-hMSC downstream processes. In addition, the impact of increasing process yields towards 
commercially viable cell densities on the characteristics of BM-hMSCs will be evaluated in order 
to facilitate future process development.        
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Figure 8.1. Process map for the controlled serum-free expansion, harvest, downstream and 
cryopreservation of BM-hMSC, including process timings and operating temperatures used 
here.  
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8.2 High density culture of BM-hMSCs in a controlled serum-free process 
 
8.2.1 Experimental overview 
Following the successful development of a controlled serum-free microcarrier process for the 
expansion and harvest of BM-hMSCs, the potential to increase the product yield has been 
investigated. For this, three DASbox culture vessels of 100 mL working volume per condition 
were cultured for five days (see Section 3.3.5) using BM-hMSC donor M2 with growth area of 
500 or 1000 cm2 and a constant BM-hMSC seeding density of 6000 cells.cm-2. The pH control 
set-point was 7.4, the impeller speed was controlled to 115 rpm, the temperature was 
controlled to 37 °C and the dissolved oxygen concentration was controlled to 10 %. Prior to all 
experiments, the control system on the DASGIP DASbox bioreactor platform was adjusted to 
ensure it remained stable, the process of which can be seen in Appendix E.  
 
During culture, daily medium samples were taken for analysis of glucose, lactate, ammonia, 
lactate dehydrogenase and total protein with cell counts performed each day (four samples 
were analysed per bioreactor as per Section 3.4.3) to determine cell number and attachment 
efficiency. The culture medium was supplemented with glucose for a surface area of 1000 cm-2 
up to 20 mmol.L-1, with medium exchange taking place every two days. The purpose of the 
glucose supplementation was to ensure that the culture did not deplete the available glucose 
when reaching higher cell densities. At harvest, the BM-hMSC were removed from the 
microcarriers and separated according to Section 3.3.6. The BM-hMSCs harvested from each 
condition were then assessed for mean cell diameter (Section 3.4.2), tri-lineage differentiation 
potential (Section 3.4.4) and immunophenotype (Section 3.4.5). In addition to these identity 
measurements, BM-hMSC quality characteristics of colony forming efficiency (Section 3.4.9) and 
outgrowth potential were also assessed post-harvest.   
 
 
8.2.2 Growth kinetics of BM-hMSCs at increased yield 
As mentioned previously, it will be important to increase the volumetric yield of BM-hMSC 
manufacturing processes, to reduce the number of batch runs required to meet the commercial 
demand of the product. This will likely reduce the cost of production and drive the development 
of cost-effective and reimbursable BM-hMSC therapies (Simaria et al. 2014). The final BM-hMSC 
yield can be seen in Figure 8.2 for the two processes following five days of culture, which show 
a final BM-hMSC density of 0.71 ± 0.07 · 106 cells.mL-1 and 1.04 ± 0.07 · 106 cells.mL-1 for the low 
yield and high yield processes, respectively. This represents a significant increase (p < 0.05) of 
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almost 50 % in the volumetric yield obtained after five days. Despite this however, the growth 
rate in the low yield process was higher, at 0.61 ± 0.16 day-1 compared with 0.55 ± 0.02 day-1 in 
the high yield process. This is mainly due to the increased BM-hMSC seeding density in the high 
yield process, with the increasing number of microcarriers and cells per volume, reducing the 
overall growth kinetics of the BM-hMSCs.   
 
 
 
Figure 8.2. Growth kinetics of BM-hMSCs in a controlled bioreactor process showing the 
increased cell density that can be achieved in SFM. Bioreactor control conditions: pH = 7.4, DO 
= 10% and impeller speed = 115 rpm. Data shows mean ± SD, n = 3 
 
 
 
It is clear that for the suspension culture of adherent cell-based therapies, the initial attachment 
of the BM-hMSCs to the microcarriers will be critical for successful expansion. Figure 8.3 shows 
the attachment efficiency of the BM-hMSCs in the high and low yield processes, with greater 
than 80 % BM-hMSC attachment after the first day of culture. The subsequent attachment rate 
of the BM-hMSC in both processes reaches almost 100 % attachment after the second day of 
culture, prior to the first medium exchange. It is important for the BM-hMSCs to be attached to 
the microcarriers before the medium exchange takes place, so that they are not removed in this 
process.  
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Figure 8.3. Cell attachment to microcarriers in a controlled bioreactor process showing the 
high BM-hMSC attachment rate in both serum-free conditions. Bioreactor control conditions: 
pH = 7.4, DO = 10% and impeller speed = 115 rpm. Data shows mean ± SD, n = 3 
 
 
 
Following the five days of culture, the BM-hMSCs were harvested from the reactors by 
detachment from the microcarriers and separation of the cell from the microcarriers following 
the previously described protocol (Nienow et al. 2014; Nienow et al. 2015b). The harvest 
efficiencies were calculated following this process to be 72.9 ± 7.5 % and 76.5 ± 2.9 % for the 
high yield and low yield processes, respectively. As with in Chapter 7, the BM-hMSCs were 
successfully detached from the microcarriers using the developed protocol, however cell losses 
were experienced during the microcarrier-cell separation and concentration phase. This unit 
operation requires further development to not only integrate it as a closed process (Cunha et 
al. 2015), but to also ensure that it is able to support an expansion process that is yielding 
significantly higher cell numbers under serum-free conditions.       
 
 
8.2.3 Metabolite flux of BM-hMSCs at increased yield 
As the density of BM-hMSC suspension culture is increased, the availability of nutrients and 
removal of waste products will become increasingly important, to ensure that the BM-hMSC 
expansion does not become inhibited (Schop et al. 2009b). The concentration of glucose 
throughout the culture process can be seen in Figure 8.4, which shows that the level remained 
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above 2 mmol.L-1 in both conditions. The initial concentration of glucose in the high yield process 
was increased from 5 to 20 mmol.L-1 to ensure that there was sufficient supply of glucose at 
increasing cell densities for the fed-bath process. Although this meant that the glucose 
concentration did not become limiting, it would be more desirable to control the glucose level 
during culture rather than starting with a high concentration, which is depleted throughout 
expansion. This is because maintaining stability in process parameters will be important in 
driving further consistency into the process.    
 
 
 
Figure 8.4. Glucose concentration of BM-hMSCs in a controlled bioreactor process at low and 
high yield showing the higher initial concentration and increased consumption in high yield 
culture. Data shows mean ± SD, n = 3 
 
 
The effect or increased glucose concentration has been previously investigated, which 
demonstrates that a reduction in glucose concentrations leads to decreased apoptosis, an 
increased rate of BM-hMSC proliferation and increased colony forming potential in monolayer 
(Stolzing et al. 2006) and suspension (Stolzing et al. 2012) culture. It has been suggested that 
the mechanism for this detrimental effect of high glucose may be due to the aggravation of 
oxidative stress triggered by the presence of high glucose concentrations (> 25 mmol.L-1) (Saki 
et al. 2013). Despite this, it has been shown that high glucose did not affect the secretory profile 
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of BM-hMSCs, with glucose concentrations of 20 and 30 mmol.L-1 not affecting the production 
of VEGF, HGF, or FGF2 by untreated BM-hMSCs or those treated with TNF-alpha, LPS, or hypoxia 
(Weil et al. 2009). Human MSCs have also demonstrated remarkable resistance against glucose 
concentrations as high as 40 mmol.L-1, although over time this did create a proapoptotic 
environment, which has the potential to reduce BM-hMSC functionality after chronic exposure 
during culture (Li et al. 2007). The normal physiological concentration of glucose in the blood is 
typically between 4 - 6 mmol.L-1, although patients with diabetes can experience an increase to 
levels as high as 10 mmol.L-1 (The Emerging Risk Factors 2010). Considering that BM-hMSCs 
would not typically experience glucose concentrations of 20 mmol.L-1 in vivo, a better 
manufacturing strategy might be to continuously control the glucose levels in the bioreactor to 
lower concentrations. This would form the following part of the process control strategy 
development after the DO, impeller speed and pH levels in Chapter 7, as this will be likely to 
drive further consistency, yield and potentially function into the BM-hMSC product.    
 
 
 
 
 
Figure 8.5. Lactate concentration of BM-hMSCs in a controlled bioreactor process at low and 
high yield showing the increased production in high yield culture. Data shows mean ± SD, n = 
3 
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The concentration of lactate during the five days of culture in the high and low yield processes 
can be seen in Figure 8.5. As expected, the level of lactate in the high yield culture has increased 
more rapidly, reaching a final concentration of 9.62 ± 0.68 mmol.L-1. Despite the increase in BM-
hMSC density to above 1·106 cells.mL-1 the level of lactate remained far below previously 
determined inhibitory levels of lactate at 35.4 mmol.L-1 (Schop et al. 2009b). Despite the levels 
of lactate not reaching these inhibitory levels in culture, the concentration of lactate during high 
yield expansion is still in excess of typical levels in vivo (Bakker et al. 1991) and therefore the 
effect of this on BM-hMSC functionality should be determined and the lactate levels controlled 
accordingly.  
 
  
 
Figure 8.6. Ammonia concentration of BM-hMSCs in a controlled bioreactor process at low 
and high yield showing a similar production in high and low yield culture. Data shows mean ± 
SD, n = 3 
 
 
 
In contrast to the differences in the consumption of glucose and the production of lactate, the 
production of ammonia in low and high yield culture was similar over the five days of expansion 
(Figure 8.6). The maximum ammonia concentration reached during culture was 0.56 ± 0.01 
mmol.L-1, which is again far below the previously determined inhibitory level of 2.4 mmol.L-1 
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(Schop et al. 2009b). This again demonstrates that despite increasing the cell density to above 
1·106 cells.mL-1, the fed-batch strategy employed was sufficient to maintain below-inhibitory 
levels of process metabolites. In order to control the relative level of desired nutrients and 
metabolites in the process, however, a perfusion strategy could be employed to constantly 
monitor and control these concentrations, as has previously demonstrated benefits to BM-
hMSC suspension-based expansion processes (Cunha et al. 2015).   
 
 
 
Figure 8.7. Lactate dehydrogenase concentration of BM-hMSCs in a controlled bioreactor 
process at low and high yield showing the increased production in high yield culture. Data 
shows mean ± SD, n = 3 
 
 
In addition to the levels of glucose, lactate and ammonia, the concentration of LDH and total 
protein have been monitored throughout culture. Figure 8.7 shows the concentration of LDH 
over the five days of culture which demonstrates a significant increase (p < 0.05) in the high 
yield expansion process. An increase in supernatant concentrations of LDH has previously been 
linked to rising cell stress (Lavrentieva et al. 2010b), which has previously been shown to occur 
at high BM-hMSC culture density (Song et al. 2009) and higher glucose concentrations in culture 
(Stolzing et al. 2012). The implications of this increase in LDH concentrations on BM-hMSC 
function are currently unclear, however, as the concentration of total protein or the non-viable 
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cell number during this period did not increase (Figure 8.8) it is unlikely that this increase in LDH 
is associated with cell death.  
 
 
 
Figure 8.8. Total protein concentration in the supernatant of a controlled BM-hMSC bioreactor 
process at low and high yield showing no increase in the total protein concentration 
throughout culture. Data shows mean ± SD, n = 3 
 
 
 
The per cell flux of the various metabolites can be seen in Figure 8.9, which shows clear 
differences in the metabolic pathways utilised under the different conditions. The high yield 
expansion process demonstrated significant increase in the consumption of glucose and 
production of lactate (p < 0.05) combined with a significant reduction in the production of 
ammonia (p < 0.05). This indicates a shift in the metabolic pathway utilisation between high and 
low yield cultures, with energy utilisation in the low glucose/low yield process predominantly 
by oxidative phosphorylation, whereas the high yield/high glucose process has made a relative 
shift towards energy production via anaerobic glycolysis. This effect of increased glucose 
concentrations on BM-hMSC metabolism has previously been hypothesised (Weil et al. 2009) 
but not demonstrated and the shift towards energy production by anaerobic glycolysis would 
be largely undesirable as it represents a less efficient mechanism for energy production in BM-
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hMSCs. It is important to note also that the consumption rate of glucose and the production 
rate of lactate in controlled high yield culture is still less than BM-hMSC cultured in a controlled 
FBS based process, developed in Chapter 7.      
 
 
 
Figure 8.9. Per cell metabolite concentrations of glucose, lactate, ammonia and yield of lactate 
from glucose for high and low yield culture.  Showing the increased consumption of glucose 
and production of lactate in high yield culture. Data shows mean ± SD, n = 3 
 
 
8.2.4 Post-harvest characterisation of BM-hMSCs at increased yield 
The post-harvest characteristics from the high and low yield expansion processes in SFM have 
been assessed to ensure that the expansion process is not having a detrimental impact on the 
BM-hMSC characteristics. The specific outgrowth rate of BM-hMSCs from both the high and low 
yield controlled bioreactor processes can be seen in Figure 8.10 which shows that the post-
harvest outgrowth kinetics of BM-hMSC have been maintained compared to pre-expansion and 
post-spinner flasks. The post-harvest colony-forming potential of the BM-hMSCs can also be 
seen in Figure 8.11, which shows that the CFU potential has either increased or been maintained 
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compared to pre-expansion. This is particularly apparent for the high yield process, which 
showed a significant increase (p < 0.05) in the post-harvest CFU potential.  
 
 
Figure 8.10. Post-harvest BM-hMSC specific outgrowth rate from high and low yield controlled 
bioreactor processes showing the increased post-harvest growth kinetics compared to pre-
expansion (p < 0.05). Data shows mean ± SD, n = 3 
 
 
 
Figure 8.11. Post-harvest BM-hMSC colony forming efficiency from high and low yield 
controlled bioreactor processes showing the increased post-harvest colony forming efficiency 
in high yield culture compared to low yield (p < 0.05). Data shows mean ± SD, n = 3 
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The BM-hMSCs harvested from the microcarrier process must also retain their identity in 
accordance with the ISCT criteria (Dominici et al. 2006). Figure 8.12 shows the multiparameter 
flow cytometry plots of post-harvest BM-hMSCs demonstrating the maintained positive co-
expression of CD105, 90, 44 and 73 throughout the microcarrier expansion process (Chan et al. 
2014a). Further to this, BM-hMSC have retained the negative co-expression of CD45, CD34, 
CD11b, CD19 and HLA-DR following the high yield controlled microcarrier expansion process in 
SFM.  
 
 
 
Figure 8.12. Multiparameter flow cytometry plots showing co-expression of CD90+, CD73+, 
CD105+, CD44+, CD34-, CD45-, CD11b-, CD19- & HLA-DR- for M2 expanded and harvested from 
a high yield SFM microcarrier process. Representative plots from n = 3 
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In addition to demonstration of immunophenotype expression, BM-hMSC harvested from the 
microcarrier process must also retain their tri-lineage differentiation potential. Figure 8.13 
shows the tri-lineage differentiation potential of the BM-hMSC following high yield microcarrier 
expansion in SFM down the adipogenic, osteogenic and chondrogenic lineages. This 
demonstrates that the BM-hMSCs have retained their tri-lineage differentiation potential 
following high yield controlled microcarrier expansion in SFM.  
 
 
 
 
Figure 8.13. Post-harvest tri-lineage differentiation potential of BM-hMSCs from a high yield 
SFM microcarrier process using phase contrast microscopy. Showing (A) osteogenic 
differentiation by staining for alkaline phosphatase and calcium deposition, (B) adipogenic 
differentiation by staining with Oil Red O and (C) chondrogenic differentiation by staining with 
Alcian Blue. Representative plots from n = 3 
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8.3 Serum-free downstream process for BM-hMSCs  
 
8.3.1 Experimental overview  
Following the successful development of a controlled serum-free microcarrier process for the 
high yield expansion and harvest of BM-hMSCs, the effect of a serum-free downstream process 
on two BM-hMSC donors can be evaluated. For this, three DASbox culture vessels of 100 mL 
working volume per condition were cultured for five days (see Section 3.3.5) using BM-hMSC 
donor M2 and M3. The pH control set-point was 7.4, the impeller speed was controlled to 115 
rpm, the temperature was controlled to 37 °C and the dissolved oxygen concentration was 
controlled to 10 %. Following the harvest of BM-hMSCs from each DASbox reactor system, the 
BM-hMSCs were subjected to either a long (7 h) or short (5 h) downstream process in 
accordance with Figure 8.1. Firstly, the post-harvest BM-hMSCs were held in an agitated 
suspension of PlasmaLyte-A (PLA) for two or three hours to simulate a potential holding time 
that is likely to occur as the process is scaled. Following this, the BM-hMSCs were formulated 
into three formulations (n = 6 for each). The BM-hMSCs were held in their respective 
cryopreservation solutions for one or two hours before undergoing analysis, these were: 
1. PlasmaLyte-A supplemented with 10% (v/v) DMSO 
2. PlasmaLyte-A supplemented with 5% (v/v) DMSO 
3. PlasmaLyte-A supplemented with 2% (v/v) DMSO 
4. Irvine Scientific PRIME-XV® MSC FreezIS DMSO-Free 
 
 
During this downstream process, the BM-hMSC were analysed immediately post-harvest (2 h 
total), following the agitated holding step in PLA (4 or 5 h total) and following formulation in 
each cryopreservation solution (5 or 7 h total). The BM-hMSCs were analysed for membrane 
integrity, cell aggregation, mean cell diameter (Section 3.4.2), colony forming efficiency (Section 
3.4.9) and outgrowth potential were also assessed throughout the downstream process.    
 
 
8.3.2 Short-term downstream holding process for BM-hMSCs 
For the successful development of integrated manufacturing processes for BM-hMSCs, 
sequential unit operations from expansion to cryopreservation must be evaluated in order to 
determine the accumulated detrimental effect that this process might be having on the BM-
hMSC product. Taking BM-hMSCs from a potentially scalable expansion and harvest process is 
critical for this, as the upstream process must be representative of the expansion technology 
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that will be used at the large-scale. In this sense, process development for BM-hMSC 
manufacture must be carried out using a scaled-down end-to-end process, rather than 
developing each process step independently and assuming they will successfully integrate 
together.  Previous experiments have demonstrated maintained BM-hMSC viability after 
prolonged holding for up to four (Heathman et al. 2015a) and eight hours (Pal et al. 2008), 
however breaking down the process to assess the impact of each individual process step 
provides increased insight into the effect of the downstream process on BM-hMSCs. In addition 
to breaking down the process, considering the impact of these unit operation on multiple BM-
hMSC identity and quality characteristics will provide deeper insight into the potential 
limitations on the allowable downstream processing times for large-scale off-the-shelf BM-
hMSCs manufacturing processes.  
 
 
Figure 8.14. Short-term serum-free downstream holding process for BM-hMSCs showing the 
effect of different holding times on cell membrane integrity (DAPI and acridine orange) with 
a decrease toward the end of the downstream process. Blue dots represent BM-hMSC line 
M2, red triangles represent BM-hMSC line M3. Box and whisker plots show n = 12   
 
The downstream process following the controlled serum-free microcarrier expansion and 
harvest process has been split into a short process (total of five hours) and a long process (total 
of seven hours). The effect of the short-term downstream process on BM-hMSC viability can be 
seen in Figure 8.14 across the two BM-hMSC donors, which shows a general decrease in 
membrane integrity throughout the downstream process. This is from a median post-harvest 
BM-hMSC membrane integrity of 99.6 % to 97.1 % following a two hour holding and one hour 
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formulation step in a solution containing 5 % DMSO. Figure 8.14 also demonstrates the variation 
between the M2 and M3 BM-hMSC donors in terms of membrane integrity throughout the 
downstream process and also the increase in product divergence, the longer the BM-hMSCs 
progress through the downstream unit operations. This provides the first indication that the 
BM-hMSC donor variability experienced in the initial expansion and characterisation processes 
in Chapter 4 (Heathman et al. 2015c) is also having an impact on the downstream process.   
 
 
8.3.3 Long-term downstream holding process for BM-hMSCs 
In addition to the short-term downstream process lasting five hours, a long-term process has 
also been evaluated lasting a total of seven hours, which has the potential to allow for the 
handling of commercially relevant BM-hMSC manufacturing batch sizes (Pattasseril et al. 2013), 
with an operating window of five to seven hours. Figure 8.15 shows the result of this extended 
holding process on BM-hMSC membrane integrity, which is similar to the short-term holding 
process. This demonstrates that a downstream process window of five to seven hours is 
satisfactory to maintain a BM-hMSC viability greater than 90 %, which will be critical as the 
process increases in scale towards commercially relevant batch sizes and also for patient specific 
therapies, where procedural delays may require extended product holding times.  
 
 
Figure 8.15. Long-term serum-free downstream holding process for BM-hMSCs showing the 
effect of different holding times on cell membrane integrity with a decrease toward the end 
of the downstream process. Blue dots represent BM-hMSC line M2, red triangles represent 
BM-hMSC line M3. Box and whisker plots show n = 12  
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It is important to note however, that an increase in the concentration of the cryoprotective 
agent (CPA), in this case DMSO, may contribute to a reduction in BM-hMSC membrane integrity. 
With many current BM-hMSC cryopreservation processes using up to 10 % DMSO as the CPA in 
their formulations, it will be important to consider that as these processes are scaled, that 
prolonged holding times for the product formulation unit operation may not result in the 
optimum cryopreservation strategy. This is because the cells will experience an irreversible loss 
in membrane integrity prior to the cryopreservation process, which is not considered when 
developing a cryopreservation strategy at the bench scale.       
 
 
8.3.4 Increased concentrations of cryoprotective agents in the downstream process 
As mentioned previously, the DMSO concentration in the final product has implications for the 
downstream process, with holding times for cells in DMSO (and potentially alternative CPAs) 
dictating allowable process timing and therefore overall scale. Current formulation technology 
has the ability to fill several thousand vials per hour, however, which should enable lot sizes of 
least three to five thousand vials per lot (Rowley et al. 2012b). This allowable formulation 
processing time will be dependent on the specific cell-based therapy product, the dose size 
required and how tolerant the product’s quality and functional characteristics are to prolonged 
exposure to CPAs.   
 
Figure 8.16 shows the effect of holding BM-hMSCs in a formulation containing 10 % DMSO for 
one and three hours on membrane integrity. This shows a significant drop (p < 0.05) in BM-
hMSC membrane integrity throughout this holding process to a median of 92.2 % after one hour 
and 78.4 % after three hours. Considering the time it will take to formulate a large batch of BM-
hMSC in the CPA prior to final fill and finish, this will have a dramatic impact on the potential 
scale to which a cryopreserved product can be manufactured with high concentrations of 
DMSO. It should be noted also, that the donor variability in post-formulation membrane 
integrity at a DMSO concentration of 5 % seen previously, has been further compounded with 
an increase concentration of DMSO.  
 
In the clinic, the therapeutic cells should have a minimum viability of 70% (preferably more than 
85%) (Pattasseril et al. 2013) prior to delivery into the patient. Therefore in this BM-hMSC 
downstream process containing high concentrations of DMSO, 33 % of M2 events would fail this 
criteria after one hour post-formulation and 85 % would fail after three hours post-formulation, 
before the cryopreservation process has taken place. In contrast, the M3 donor BM-hMSC line 
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would not experience any failure events based on this criteria after either one or three hours 
post-formulation. This highlights the potential donor variability that can occur, not only in the 
expansion process, but also in the downstream process of BM-hMSC manufacture, as the M3 
BM-hMSC donor line was initially considered to be far from desirable (Chapter 4).    
 
 
Figure 8.16. The effect of using 10% DMSO in a serum-free downstream process for BM-
hMSCs. Showing the dramatic loss in membrane integrity through the downstream process. 
Blue dots represent BM-hMSC line M2, red triangles represent BM-hMSC line M3. Box and 
whisker plots for n = 12 
 
Associated with this decrease in membrane integrity of BM-hMSCs post-formulation, is an 
increase in the cell aggregation, most likely caused by the release of intra-cellular proteins as 
the BM-hMSC membrane ruptures. This increase in cell aggregation will cause a number of 
further issues to the process, as aggregation is likely to cause increasing cell death throughout 
the cryopreservation process, compounding the detriment to the product. This is mainly due to 
a limitation of nutrients within the aggregates, which will cause increased cell death (Suzuki et 
al. 2012). In addition, an increase in the aggregation level of the product during the downstream 
process will increase the variation in the vialing process between batches, as the accuracy of 
current cell counting methods relies upon having an evenly distributed single-cell suspension.       
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Figure 8.17. The effect of using 10% DMSO in a serum-free downstream process for BM-
hMSCs. Showing the dramatic increase in BM-hMSC aggregation that coincides with the 
decreased membrane integrity through the downstream process. Blue dots represent BM-
hMSC line M2, red triangles represent BM-hMSC line M3. Box and whisker plots for n = 12    
 
 
The use of DMSO for the cryopreservation of BM-hMSCs has been linked to adverse effects in 
the product such as genetic mutation (Rodrigues et al. 2008) as well as potential detriment to 
the patient (Windrum and Morris 2003) once infused. Therefore, the development of 
cryopreservation processes should seek to drive down the use of DMSO to not only reduce the 
toxicity risk to the patient, but also to enable increasing scale to be achieved in the downstream 
and product formulation processes, which will be required to drive down the cost of 
manufacture.     
 
8.3.5 Effect of the downstream process on BM-hMSC characteristics 
It is clearly important to maintain an acceptable level of BM-hMSC membrane integrity 
throughout the downstream process as this will have a profound impact on the product efficacy. 
Despite this however, additional BM-hMSC characteristics should be measured in order to 
assess subtle changes to the BM-hMSCs throughout the downstream process.  
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Figure 8.18. The effect of the serum-free downstream process on the mean cell diameter of 
BM-hMSCs. Showing the increase in mean cell diameter after the holding process. Blue dots 
represent BM-hMSC line M2, red triangles represent BM-hMSC line M3. Box and whisker plots 
for n = 12  
 
 
Figure 8.19 shows the effect of the downstream process on mean BM-hMSC diameter, with a 
significant increase (p < 0.05) following the holding process in PLA, which subsequently reduces 
post-formulation. This cell swelling through the holding process should be carefully controlled 
as it will likely increase the likelihood of a loss in membrane integrity and increased cell stress 
throughout the subsequent process. This can be achieved through the development of BM-
hMSC parenteral solutions that support a consistent osmotic balance throughout the entire 
downstream process. 
 
In addition to an assessment of the BM-hMSC size throughout the downstream process, the 
BM-hMSC outgrowth kinetics have been assessed for both donors for the formulation in PRIME-
XV® SFM FreezIS. The result of this can be seen in Figure 8.19A, which shows that BM-hMSC 
donor line M3 maintained its outgrowth potential throughout the downstream process above 
0.4 day-1. In contrast, BM-hMSC donor M2 not only demonstrated a significant reduction in 
outgrowth kinetics (p < 0.05), but also showed an increasing inter-batch variation throughout 
the downstream process. This reduction in the stability of the M2 donor line through the 
downstream process raises serious concerns about the impact of donor variation, not just on 
the expansion unit operation, but on the entire manufacturing process.  
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Figure 8.19. Serum-free downstream holding process for BM-hMSCs showing the effect on 
outgrowth potential for BM-hMSC line M3 (A) and M2 (B). Demonstrating the donor 
variability in the downstream process. Box and whisker plots, n = 6 for each donor BM-hMSC 
line.   
 
 
Colony forming potential has been highlighted as an important assay for the quality of BM-hMSC 
preparations (Pochampally 2008) and has previously been shown to deteriorate as BM-hMSC 
age in culture (Stolzing and Scutt 2006). As with the outgrowth potential, the colony-forming 
potential for BM-hMSC donor M3 saw a slight decrease from a median of 19.2 % post-harvest 
to 16.2 % post hold, which subsequently stabilised post-formulation in FreezIS (Figure 8.20A). 
This supports the previous results that suggest that BM-hMSC donor M3 is able to maintain key 
characteristics throughout the downstream process following serum-free microcarrier 
expansion. In contrast, Figure 8.20B shows a significant decline (p < 0.05) in the CFU potential 
for BM-hMSC donor M2 from a median of 16.8 % post-harvest to 12.8 % post-hold and finally 
6.4 % post-formulation in FreezIS. This represents a dramatic loss in CFU potential throughout 
the downstream process as was previously seen for the membrane integrity and outgrowth 
potential of BM-hMSC donor M2.         
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Figure 8.20. Serum-free downstream holding process for BM-hMSCs showing the effect on 
colony forming efficiency for BM-hMSC line M3 (A) and M2 (B). Demonstrating the donor 
variability in the downstream process. Box and whisker plots, n = 6 for each donor BM-hMSC 
line.   
 
 
Given the impact of the cell survival during prolonged holding times has on the potential scale 
that can be achieved, careful assessment of the allowable tolerances on the BM-hMSC 
characteristics should be completed early in process development as this will determine the 
overall process scalability. For the development of an off-the-shelf BM-hMSC manufacturing 
process, it will also be important to screen potential donors through the entire process rather 
than simply having exclusion criteria based on growth and functionality through the upstream 
process. This is because initial growth and characteristics of BM-hMSC donors in the serum-
based process in Chapter 4 highlighted BM-hMSC donor M2 as a favourable donor and M3 as 
being sub-optimal for the expansion process. This conclusion has been reversed, however, after 
considering the impact of the downstream on BM-hMSC characteristics in a serum-free process. 
For future off-the-shelf process development, it would be advised to operate a scaled-down 
version of the final manufacturing and delivery process, in order to screen desirable BM-hMSC 
donors through the entire process to take forward into commercial production.            
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8.4 Serum-free cryopreservation and thaw of BM-hMSCs  
 
8.4.1 Experimental overview 
Following the evaluation of a scalable and serum-free downstream process for BM-hMSCs, the 
effect of a cryopreservation and thaw on two BM-hMSC donors has been evaluated. For this, 
BM-hMSC from M2 and M3 donors were taken through a cryopreservation and thaw process, 
following controlled microcarrier expansion, harvest and downstream processing described in 
Section 8.3. This involved a post-formulation controlled-rate freezing process from 4 °C to -80 
°C at -1 °C.min-1, followed by transfer and storage to the vapour phase of monitored liquid 
nitrogen tank at -196 °C for a least two weeks. A total of six vials were cryopreserved from each 
bioreactor (n = 18) in each of the three serum-free cryopreservation formulas, these were:    
1. PlasmaLyte-A supplemented with 5% (v/v) DMSO 
2. PlasmaLyte-A supplemented with 2% (v/v) DMSO 
3. Irvine Scientific PRIME-XV® MSC FreezIS DMSO-Free 
 
 
After at least two weeks at -196 °C, vials of 1·106 BM-hMSCs were directly thawed in a water 
bath at 37 °C, before being washed and re-suspended in SFM. Post-thaw analysis was carried 
out for n = 3 from the downstream process, for n = 3 vials and n = 2 measurements (n = 18) for 
both donors in each of the cryopreservation conditions. The BM-hMSCs from both donors were 
assessed for post-thaw membrane integrity, attachment efficiency, colony forming efficiency 
(Section 3.4.9) and outgrowth potential. 
 
 
8.4.2 Post-thaw membrane integrity and attachment efficiency of BM-hMSCs 
In order to facilitate the successful development of off-the-shelf BM-hMSC therapies, the impact 
of cryopreservation, following the controlled serum-free microcarrier expansion, harvest and 
downstream processes should be evaluated.  The post-thaw cell viability prior to clinical infusion 
into a patient should have a minimum viability of 70% (preferably more than 85%) (Pattasseril 
et al. 2013). The BM-hMSC percentage membrane integrity one hour post-thaw can be seen in 
Figure 8.21 for both BM-hMSC donors in 5 % and 2 % DMSO as well as FreezeIS, a DMSO-free 
formulation. The BM-hMSC donor M3 demonstrates a high post-thaw membrane integrity 
across all conditions with a minimum viability 80.3 % and > 94 % of thawing events above the 
preferable product viability of > 85 % for clinical delivery. In contrast, the M2 BM-hMSC donor 
line as with the stability through the downstream process, demonstrated a significant reduction 
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(p < 0.05) in post-thaw membrane integrity. This is particularly apparent at reduced DMSO 
concentrations, with 5 % DMSO supporting a similar post-thaw membrane integrity to M3, with 
only two events below the 85 % threshold.  
 
 
 
Figure 8.21. Post-thaw membrane integrity of BM-hMSCs following the serum-free 
downstream holding and cryopreservation process for M3 (A) and M2 (B). Demonstrating the 
donor variability in the post-thaw BM-hMSC characteristics following cryopreservation. Box 
and whisker plots show n = 18 for each donor BM-hMSC line in each condition 
 
 
In addition to the post-thaw membrane integrity, the BM-hMSC attachment efficiency has been 
evaluated, demonstrating the percentage of BM-hMSCs that have retained the ability to adhere 
to tissue culture plastic post-thaw. This is important, as the ability of the BM-hMSC to attach to 
the culture surface demonstrates a higher level of function than simply assessing the cell 
membrane integrity. The attachment ability of BM-hMSCs has been shown to be a critical part 
of their putative function to home to the site of injury once delivered (Karp and Leng Teo 2009; 
Sohni and Verfaillie 2013) and therefore a dramatic reduction post-thaw, prior to clinical 
delivery, would be highly undesirable. Figure 8.22 shows the post-thaw attachment efficiency 
of M2 and M3 in each of the cryopreservation solutions, which shows a lower attachment 
efficiency although a similar trend to the post-thaw membrane integrity. This generally 
represents a reduction in post-thaw attachment efficiency compared to membrane integrity of 
20 - 30 % for M3 and 30 -40 % for M2. This again demonstrates the increased stability of the M3 
BM-hMSC donor line through the downstream and cryopreservation process in all three 
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cryopreservation solutions, whereas the M2 BM-hMSC donor line demonstrated poor recovery 
and attachment, particularly at lower levels of DMSO.   
 
 
   
Figure 8.22. Post-thaw attachment efficiency of BM-hMSCs following the serum-free 
downstream holding and cryopreservation process for M3 (A) and M2 (B). Demonstrating the 
donor variability in the post-thaw BM-hMSC characteristics following cryopreservation. Box 
and whisker plots show n = 18 for each donor BM-hMSC line in each condition 
 
 
 
In addition to the instability of the M2 BM-hMSC donor throughout the downstream process, it 
can be seen that the cryopreservation process is also having a detrimental impact on the 
membrane integrity of the cells. The difference in the median post-formulation and post-thaw 
membrane integrity of the M3 BM-hMSC donor line was 3.4, 6.7 and 0.7 % for the FreezIS, 2 % 
DMSO and 5 % DMSO, respectively. In contrast, the difference in the median post-formulation 
and post-thaw membrane integrity of the M2 BM-hMSC donor line was 33.5, 23.3 and 3.7 % for 
the FreezIS, 2 % DMSO and 5 % DMSO, respectively. This demonstrates that it is not only the 
downstream process that is having a detrimental effect on the M2 BM-hMSC line, but also the 
freeze-thaw process, particularly at reduced DMSO concentrations.  
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Figure 8.23. Post-thaw membrane integrity versus attachment efficiency of BM-hMSCs 
following the serum-free downstream holding and cryopreservation process. Showing the 
improved performance in one of the donor BM-hMSC lines. Data shows n = 198  
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Figure 8.23 shows the post-thaw membrane integrity against the attachment efficiency for both 
of the BM-hMSC lines in the short-term and long-term downstream processes. This again 
demonstrates the difference between the two donors in terms of recoverability through the 
entire process. Figure 8.23 also shows the effect of the long-term downstream process on the 
M3 BM-hMSC line, which shows a slight reduction in the post-thaw membrane integrity 
compared to the short-term downstream process, although not a single event dropped below < 
70 % viability after one hour post-thaw. In contrast, almost 40 % of the thaw events for BM-
hMSC line M2 were below this 70 % viability benchmark and almost all demonstrated less than 
50 % post-thaw attachment efficiency.   
 
 
8.4.3 Post-thaw BM-hMSC characteristics  
The BM-hMSC outgrowth kinetics have also been evaluated post-thaw in each cryopreservation 
solution for both donors. The result of this can be seen in Figure 8.24 which shows a similar level 
of outgrowth potential across all conditions in M3 and a slight increase in outgrowth kinetics of 
M2 as the concentration of DMSO is increased. In terms of the difference between post-
formulation and post-thaw outgrowth kinetics, BM-hMSC donor M3 shows a median decrease 
of 12 % compared to a decrease of 72 % for the M2 BM-hMSC donor for the DMSO-free FreezIS 
cryopreservation solution. It is clear that the freeze-thaw process is also having a detrimental 
impact on the BM-hMSC outgrowth kinetics of M2, which also demonstrates increased intra-
donor variability compared to M3.  
 
 
Figure 8.24. Post-thaw outgrowth potential of BM-hMSCs following the serum-free 
downstream holding and cryopreservation process for BM-hMSC line M3 (A) and M2 (B). 
Demonstrating the donor variability in the post-thaw BM-hMSC characteristics following 
cryopreservation. Box and whisker plots show n = 9 for each donor   
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A reduction in BM-hMSC characteristics as well as an increase in variability, has the potential to 
increase the likelihood of suffering a batch failure in the product and therefore pre-selecting 
BM-hMSC donors to mitigate this risk will be critical for the development of successful 
manufacturing processes.      
 
Maintaining the CFU potential of the BM-hMSCs throughout the cryopreservation process is also 
important, as key cellular characteristics must remain present right up until the point of product 
delivery to the patient. Figure 8.25 shows the post-thaw CFU potential of M2 and M3 donor 
lines in 5 % DMSO, 2 % DMSO and DMSO-free FreezIS. This shows the relative maintenance in 
the post-thaw CFU potential for the M3 BM-hMSC donor compared with M2 across all three 
cryopreservation solutions. Despite this, the relative difference between the post-formulation 
and post-thaw CFU potential for the DMSO-free FreezIS formulation for the M3 and M2 BM-
hMSC lines was similar, with a 23 and 19 % reduction, respectively. Considering that the post-
harvest CFU potential for M3 and M2 was 19.2 and 16.8% respectively, it is clear that the 
reduction in CFU potential for the M2 BM-hMSC line has been during the downstream process, 
before cryopreservation has taken place, whereas M3 CFU potential has been maintained 
throughout. Placing limits and controls on the downstream, as well as the expansion process 
will be critical therefore to maintain BM-hMSC quality throughout the entire manufacturing 
process.      
 
 
 
Figure 8.25. Post-thaw colony forming efficiency of BM-hMSCs following the serum-free 
downstream holding and cryopreservation process for BM-hMSC line M3 (A) and M2 (B). 
Demonstrating the donor variability in the post-thaw BM-hMSC characteristics following 
cryopreservation. Box and whisker plots show n = 9 for each donor   
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8.5 Chapter conclusions   
This Chapter has demonstrated that increased BM-hMSC yield can be obtained in a serum-free 
microcarrier process to above 1·106 cells.mL-1 without having a detrimental impact on the 
product characteristics. Increasing the yield of BM-hMSC expansion processes in this way will 
drive the development of cost-effective manufacturing processes, since reduced bioreactor 
volumes will be required to manufacture commercially relevant batch sizes within a reduced 
timescale. It will also be important to control the level of glucose in the culture medium, to avoid 
requiring increased concentrations to achieve these yields in a fed batch approach. This will 
likely require the operation of perfused bioreactors, to enable online measurement and control 
of the nutrient concentration in the culture medium.  
 
Systematic investigation of the downstream and cryopreservation process following 
microcarrier expansion and harvest of BM-hMSCs has highlighted the need to develop scalable 
end-to-end processes during development. The allowable time that the BM-hMSCs are exposed 
to non-adherent conditions during the downstream process will have a significant impact on the 
potential scale the process can reach, as the product characteristics degrade through these 
downstream unit operations. It will be critical early in process development, therefore, to 
determine the allowable tolerances on the quality of the product and the allowable downstream 
exposure time that does not take the BM-hMSCs outside of this operating window. In 
conjunction with this, reducing the concentration of cryoprotective agents such as DMSO should 
be minimised, not only to avoid patient toxicity, but also because increased concentrations are 
detrimental to the product due to prolonged exposure during the product formulation stage. 
Reducing the DMSO concentration in the final product will allow for increased product 
formulation times, which will increase the number of doses that can be manufactured per batch, 
reducing the overall cost of production per dose.  
 
This Chapter has also highlighted the importance of considering the entire process before 
selection of master bank material for an off-the-shelf BM-hMSC therapy, as significant levels of 
donor variability have been experienced in the downstream and cryopreservation processes. 
Considering that the BM-hMSC donor that was most favourable in terms of growth, identity and 
quality throughout the entire production process, was evaluated due to its poor growth and 
characteristics, scaled-down versions of the entire process should be used to evaluate BM-hMSC 
donors for the product master bank that maintain functional characteristics throughout.    
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9 Conclusions and Future Work 
 
9.1 Conclusions 
 This work has first of all demonstrated the high level of variation in BM-hMSCs growth 
and characteristics from different donors in a monolayer expansion process under FBS-
based culture. This has implications for the development of both patient specific and 
off-the-shelf manufacturing processes and will likely increase the cost of production. 
These increased costs will be largely driven by this increased variation, which will 
increase the risk of product batch failure as well as reducing potential BM-hMSC 
production rates.   
 Serum-free medium has demonstrated the ability to reduce this process variability, as 
well as the potential to reduce the variation in the future supply of process raw 
materials, associated with the use of serum in the manufacturing process. The increased 
yield and convergence of BM-hMSC characteristics throughout this monolayer 
expansion process demonstrates a level of control over the product, which has the 
potential to increase the cost-effectiveness and reduce the risk in the operation of 
serum-free BM-hMSC manufacturing processes.   
 Transfer of this monolayer BM-hMSC expansion process into a scalable microcarrier-
based process has been achieved in serum-based and serum-free medium by the 
development of a fibronectin coating protocol for microcarriers. This is an important 
process transfer step as the development of a scalable microcarrier expansion process 
has the potential to take advantage of increasing economies of scale to cost-effectively 
manufacture BM-hMSCs at the lot-sizes required for commercial production.  
 Furthermore, the increased yield and donor consistency that was experienced for the 
monolayer process in HPL and serum-free medium, has also directly transferred to the 
microcarrier process, indicated that this improved efficiency has the potential to be 
carried through increasing process scales.  
 This work has also demonstrated that the BM-hMSCs harvested from this serum-free 
microcarrier process can be further processed, formulated and cryopreserved 
downstream, providing the first demonstration of successfully integrated unit 
operations for BM-hMSC production on microcarriers.    
 Unnecessarily increasing the impeller agitation speed during the microcarrier expansion 
of BM-hMSCs decreased the growth kinetics but did not have a detrimental impact on 
the BM-hMSC post-harvest characteristics.  
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 Direct aeration of the culture medium via a sparger has also been shown to be 
detrimental to BM-hMSC growth and post-harvest quality characteristics. Sparging of 
the medium during bioreactor culture is likely to be required at the large-scale to supply 
oxygen to the cells and remove carbon dioxide and is currently the preferred method of 
aeration in large-scale bioreactors. It will be important during process scale-up, 
therefore, to ensure that bioreactor parameters such as maximum energy dissipation 
and sparging rates are not increased above levels which might affect the growth and 
quality characteristics of the BM-hMSC product at the commercial scale. Alternative 
technology such as membrane based aeration could also be investigated for supplying 
oxygen to the BM-hMSC expansion process, which might be possible considering that 
the oxygen demand of these cells is far below that experienced by traditional cell 
bioprocesses.      
 The effect of exposing low oxygen bioreactor culture to atmospheric conditions during 
the culture period has highlighted the importance of operating closed and controlled 
processes to avoid large fluctuation of the dissolved oxygen concentration of the 
medium. Operating the microcarrier expansion process for BM-hMSCs in a functionally 
closed and controlled manner, has demonstrated improved growth and post-harvest 
BM-hMSC quality characteristics at 10 and 25 % dissolved oxygen in FBS-based medium. 
 The introduction of serum-free medium into this low dissolved oxygen controlled 
bioreactor process has further increased the yield across two BM-hMSC donors, 
however, with reduced harvest efficiency compared to the FBS-based process, which 
has lower cell numbers at harvest. Considering that this was primarily due to cell losses 
in the cell-microcarrier separation unit operation, it will be imperative to develop 
specific downstream technology to effectively separate the cells from the microcarriers, 
particularly as the number of BM-hMSCs per unit volume is increased during future 
process development.  
 The development of a process control strategy has also significantly increased the yield 
and consistency between BM-hMSC donors with a combined coefficient of variance 
between and within these donors under serum-free conditions of less than 15 %. This is 
in conjunction with a significant increase in the BM-hMSCs produced per volume of 
medium per unit time under serum-free conditions, which will be critical in increasing 
the economies of scale and reducing the subsequent cost of BM-hMSC therapies. 
 The introduction of the process control strategy has significantly reduced the inter- and 
intra-donor variation in FBS-based culture from 79.1 to 37.5 %, which will again be 
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critical in further reducing the development costs of both patient specific and off-the-
shelf BM-hMSC manufacturing processes.     
 This work has demonstrated that increased BM-hMSC yield can be obtained in a serum-
free microcarrier process to above 1·106 cells.mL-1 without having a detrimental impact 
on the product characteristics post-harvest. Increasing the yield of BM-hMSC expansion 
processes in this way is likely to drive the development of cost-effective manufacturing 
processes, as reduced bioreactor volumes will be required to manufacture 
commercially relevant batch sizes within a reduced timescale.  
 It will be important to control the level of glucose in the culture medium, to avoid 
requiring increased concentrations to achieve these yields in a fed batch approach. This 
will likely require the operation of perfused bioreactors, to enable online measurement 
and control of the nutrient concentration, in addition to other critical process 
parameters such as the pH and dissolved oxygen concentration of the culture medium.  
 Systematic investigation of the downstream and cryopreservation process following 
microcarrier expansion and harvest of BM-hMSCs has highlighted the need to develop 
scalable end-to-end processes during development. The allowable time that the BM-
hMSCs are exposed to non-adherent conditions during the downstream process will 
have a significant impact on the potential scale that the process can reach, as the 
product characteristics degrade through these downstream unit operations.  
 It will be critical early in process development to determine the allowable tolerances on 
the quality of the product and the allowable downstream exposure time that does not 
take the BM-hMSCs outside of this operating window. In conjunction with this, the 
concentration of cryoprotective agents such as DMSO should be minimised, not only to 
avoid patient toxicity, but also because increased concentrations are detrimental to the 
product due to prolonged exposure during the product formulation stage.  
 Reducing the DMSO concentration in the final product will allow for increased product 
formulation times, which will increase the number of doses that can be manufactured 
per batch, reducing the overall cost of production per dose.  
 Finally, this work has highlighted the importance of considering the entire process 
before selection of master bank material for an off-the-shelf BM-hMSC therapy, as 
significant levels of donor variability have been experienced in the downstream and 
cryopreservation processes. The BM-hMSC donor that was most favourable in terms of 
growth, identity and quality throughout the entire production process, was initially 
selected due to its poor growth and characteristics in FBS-based medium. It is critical 
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therefore, that scaled-down versions of the entire process are used to evaluate BM-
hMSC donors for the product master bank that maintain functional characteristics 
throughout the entire manufacturing process.     
Chapter 9: Conclusions and future work 
 
 
244 | P a g e  
 
9.2 Future work 
This work has demonstrated the increased yield and consistency that can be achieved by the 
systematic development of a process control strategy within a scalable and serum-free 
expansion, harvest, downstream and cryopreservation process for BM-hMSCs. This has 
provided important findings which can inform future development of BM-hMSC manufacturing 
processes, however a number of challenges remain: 
 
 
9.2.1 Development and operation of a functionally closed and end-to-end process 
In order to enable the successful development of commercially relevant and scalable BM-hMSC 
manufacturing processes, future process development should focus on integrating functionally 
closed unit-operations into an entire end-to-end process. The work presented in this thesis has 
demonstrated the importance of controlling the culture environment and considering the entire 
process as a sequential set of unit-operations rather than developing individual process steps in 
isolation. The key points to consider are as follows: 
 Development of scalable downstream technology specifically for microcarrier 
separation and subsequent BM-hMSCs concentration. Much of the current downstream 
technology has been adapted for this but there is an opportunity to generate 
intellectual property around separation technology specific to cells and microcarriers. 
This should ensure that BM-hMSC harvest and downstream at high cell densities can 
also be achieved, as this will continue to increase in order to reduce the manufacturing 
costs per dose, which are currently too high. 
 Part of this bioreactor and downstream development should also look to validate and 
integrate single-use components, as it is widely acknowledged for cell therapies that the 
risk vs. cost of traditional clean-in-place procedures are too high and single-use 
processes will be utilised to reduce the risk of contamination. In fact, an EPSRC-funded 
PhD student will build on the work in this PhD thesis, investigating single-use bioreactors 
for the expansion of BM-hMSCs on microcarriers in collaboration with PALL Life 
Sciences.        
 Given the importance of reduced oxygen concentrations and serum-free conditions on 
the growth and characteristics of BM-hMSCs, the initial isolation of the BM-hMSCs 
should take place under these conditions to provide material for future bioreactor 
experiments that has not been exposed to serum components. Reducing process input 
variation will be integral in driving BM-hMSC consistency throughout the entire process 
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and will act as an initial BM-hMSC selection step for each donor, for cells that adhere 
and proliferate best on fibronectin under serum-free conditions, which has been shown 
to be advantageous here.    
 Integrating the controlled bioreactor expansion process with the downstream in a 
closed manner will ensure that the BM-hMSC environment remains stable throughout. 
Developing functionally closed processes also demonstrates increased scalability, 
ensuring that unit-operations are amenable to automation, with the potential to 
replace traditional manual manipulations that are not cost-effective at the commercial 
scale.     
 During the development of these end-to-end processes, it will also be important to 
consider the regulatory requirements for this BM-hMSC manufacturing technology, to 
ensure that it has the potential to be GMP compliant. This will drastically increase the 
commercial relevance of any developed technology, which will be critical in order to 
successfully exploit any potential intellectual technology arising from this development. 
 
 
9.2.2 Integration of functional and purity assays within the end-to-end process 
Perhaps the biggest challenge facing the successful development of BM-hMSC manufacturing 
processes is the development and integration of functional BM-hMSC assays into the process. 
This is critical to the successful development of manufacturing processes, providing metrics to 
assess the impact of process unit operations on BM-hMSC quality. Setting allowable tolerances 
on these measurements will be important in order to determine downstream process timings 
and the subsequent scale that is achievable during manufacture. The development of these 
functional assays has proved difficult, however, due to the multifaceted and poorly understood 
mechanism of action of BM-hMSCs. Despite this, assays are beginning to appear that look at a 
particular aspect of BM-hMSC function such as protein secretion in response to environmental 
cues, which can be integrated into BM-hMSC characterisation. The key points to consider are as 
follows:        
 These BM-hMSC functional assays are specific to each clinical indication, therefore a 
couple of lead candidate indications can be selected as exemplars during development, 
such as immune modulation and angiogenesis that have been previously shown to be 
important to BM-hMSC function in vivo.  
 These assays can then be used to assess whether there have been any relative changes 
to these functions through the process and if so, at which point in the process. This can 
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then inform the direction of future development, to target particular unit-operations 
and minimise these product changes during manufacture.   
 In addition to measures of BM-hMSC functionality throughout the process, an 
assessment of the plastic particulate content through the microcarrier expansion, 
harvest and separation unit-operations should be made as this is becoming an 
important regulatory consideration for cell-based therapies.  
 The maintenance of acceptable levels of product purity remains a key consideration for 
microcarrier-based expansion processes and downstream technology that can remove 
plastic particulates from the product prior to formulation may be required for future 
regulatory approval.       
 It is also likely that the evolution of cell-based therapy manufacturing processes will 
have to consider the product purity in terms of virus and DNA content as has been seen 
in traditional bioprocesses. Therefore, assessment and integration of this measurement 
technology into the BM-hMSC manufacturing process will be critical for future process 
development.   
 
 
9.2.3 Control of nutrients within a perfused bioreactor process 
The control of nutrients in the microcarrier expansion process will be an important 
consideration in driving further consistency into the process, avoiding bulk fluctuations in the 
concentrations available to the cells, which has been shown to be detrimental. This will require 
the development of a perfusion bioreactor processes, where the constant measurement and 
control of key nutrients such as glucose and glutamine is possible. This will avoid having to adopt 
a fed-batch approach where large quantities of nutrients are added and depleted by the 
increasingly high BM-hMSC densities. The key points to consider are as follows: 
 The design and operation of the bioreactor perfusion loop must ensure that 
microcarriers do not pass through as this will not only cause issues in supernatant 
analysis, but can potentially cause issues as BM-hMSCs attached to microcarriers move 
through the pumping circuit. This can be achieved using an impeller spin filter, or 
initially by adopting the same filtered sample port modification demonstrated here.     
 In conjunction with this, the validation and integration of a biomass probe into the 
bioreactor system would allow for the development of a mathematical model to form 
the basis of an optimisation strategy for this nutrient control system. This is a potential 
way in which sufficient nutrients can be supplied to the system, based on BM-hMSC 
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growth kinetics and the calculated per cell flux, alleviating the need for off-line 
metabolite analysis as the basis for the control of nutrients and providing a basis for 
process optimisation.      
 This perfused bioreactor system with increased nutrient control can then be assessed 
in terms of its impact on BM-hMSC yield and consistency across multiple BM-hMSC 
donors and potentially other BM-hMSC sources (such as umbilical cord and adipose 
tissue). A comparison can then be made in terms of the number of recovered cells, per 
volume of medium, per unit time of both the perfused and fed-batch processes. 
 
 
9.2.4 Further commercial development with HPL and serum-free medium 
The work presented here has demonstrated the potential of both HPL and SFM-based processes 
for the expansion of BM-hMSCs on microcarriers. There remains, however, potential 
opportunities for further development of these formulations, continuing the current 
collaborative partnerships that have been hugely beneficial to all parties. The key points to 
consider are as follows: 
 The fibronectin coating of the microcarriers directly prior to BM-hMSC expansion would 
be undesirable due to the risk of a coating quality assurance failure impacting the 
subsequent expansion step. In order to decouple the developed fibronectin coating 
protocol of the microcarriers from the subsequent expansion of BM-hMSCs in serum-
free medium, the fibronectin coated microcarriers would have to be stored long-term. 
The development and validation of a low temperature storage method for the 
fibronectin coated microcarriers, without compromising the quality of the coating 
would be a valuable step in this process, decoupling the coating from the expansion.    
 As the field moves forward, the development of defined and custom serum-free 
medium formulations for BM-hMSC production is becoming ever more important. A 
continuation of commercial partnerships, looking at developing defined medium 
formulations and culture protocols specifically for the microcarrier culture and harvest 
of BM-hMSCs would add significant value to the field. This work would specifically look 
to drive medium costs down during manufacture and identify ways in which these 
formulations can be developed to minimised donor variation from a variety of BM-
hMSC isolation sources.    
 There is further scope to investigate the impact of HPL for the controlled expansion, 
downstream processing and cryopreservation of BM-hMSCs. This would build upon the 
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contract research projects established with Cook Regentec (USA) to focus on reduced 
quantities of HPL in the medium (5% rather than 10%) without impacting BM-hMSC 
growth and characterisation for adipose and bone marrow derived BM-hMSCs on 
microcarriers. This would from part of a wider economic assessment of the potential 
scalability of HPL in terms of available supply and batch-to-batch variation, to 
demonstrate that at reduced concentrations, it is a viable alternation to FBS at the large-
scale.  
 In terms of demonstrating the physical scalability of the serum-free and HPL-based 
processes developed here, an increase in scale of the bioreactor system by one order of 
magnitude to the litre-scale based on sound engineering principles would provide an 
invaluable demonstration of the true scalability of the system. This would be in 
conjunction with harvesting the BM-hMSC from the microcarriers in situ and separating 
the entire batch of BM-hMSCs from the microcarriers using scalable downstream 
technology, such as tangential flow filtration or fluidised bed centrifugation. 
Maintaining the relationships with commercial partners will be critical for this moving 
forward, as the cost of running these experiments is prohibitive without these valuable 
collaborative partnerships.  
 Increasing the hMSC yield during the expansion phase will also be important to drive 
future process development. A potential mechanism to achieve this would be to add 
additional microcarriers to the bioreactor during expansion, so that the BM-hMSCs have 
additional surface area to utilise and higher cell densities can be achieved with an 
increased cell expansion ratio.       
References 
 
 
249 | P a g e  
 
References 
 
Abraham EJ, Slater KA, Sanyal S, Linehan K, Flaherty PM, Qian S. 2011. Scale-up of mammalian 
cell culture using a new multilayered flask. J Vis Exp(58). 
Adams V, Challen GA, Zuba-Surma E, Ulrich H, Vereb G, Tarnok A. 2009. Where New Approaches 
Can Stem From: Focus on Stem Cell Identification. Cytometry Part A 75A(1):1-3. 
Adewumi O, Aflatoonian B, Ahrlund-Richter L, Amit M, Andrews PW, Beighton G, Bello PA, 
Benvenisty N, Berry LS, Bevan S and others. 2007. Characterization of human embryonic 
stem cell lines by the International Stem Cell Initiative. Nat Biotechnol 25(7):803-16. 
Aggarwal S, Pittenger MF. 2005. Human mesenchymal stem cells modulate allogeneic immune 
cell responses. Blood 105(4):1815-1822. 
Anchordoguy TJ, Cecchini CA, Crowe JH, Crowe LM. 1991. Insights into the cryoprotective 
mechanism of dimethyl sulfoxide for phospholipid bilayers. Cryobiology 28(5):467-73. 
Anisimov VN, Ukraintseva SV, Yashin AI. 2005. Cancer in rodents: does it tell us about cancer in 
humans? Nat Rev Cancer 5(10):807-19. 
Antwiler GD, Windmiller DA, Givens M; Terumo Bct, Inc., assignee. 2014. Method of reseeding 
adherent cells grown in a hollow fiber bioreactor system. 
Arakawa T, Carpenter JF, Kita YA, Crowe JH. 1990. The basis for toxicity of certain 
cryoprotectants: A hypothesis. Cryobiology 27(4):401-415. 
Archibald PRT, Chandra A, Thomas D, Morley G, Lekishvili T, Devonshire A, Williams DJ. 2015. 
Comparability of scalable, automated hMSC culture using manual and automated 
process steps. Biochemical Engineering Journal (In press). 
Atala A. 2012. Human embryonic stem cells: early hints on safety and efficacy. Lancet 
379(9817):689-90. 
Bakker J, Coffernils M, Leon M, Gris P, Vincent JL. 1991. Blood lactate levels are superior to 
oxygen-derived variables in predicting outcome in human septic shock. Chest 99(4):956-
62. 
Baraniak PR, Cooke MT, Saeed R, Kinney MA, Fridley KM, McDevitt TC. 2012. Stiffening of human 
mesenchymal stem cell spheroid microenvironments induced by incorporation of 
gelatin microparticles. J Mech Behav Biomed Mater 11:63-71. 
Basciano L, Nemos C, Foliguet B, de Isla N, de Carvalho M, Tran N, Dalloul A. 2011. Long term 
culture of mesenchymal stem cells in hypoxia promotes a genetic program maintaining 
their undifferentiated and multipotent status. BMC Cell Biol 12:12. 
References 
 
 
250 | P a g e  
 
Becker AJ, Till JE, McCulloch EA. 1963. CYTOLOGICAL DEMONSTRATION OF CLONAL NATURE OF 
SPLEEN COLONIES DERIVED FROM TRANSPLANTED MOUSE MARROW CELLS. Nature 
197(486):452-&. 
Beckermann BM, Kallifatidis G, Groth A, Frommhold D, Apel A, Mattern J, Salnikov AV, 
Moldenhauer G, Wagner W, Diehlmann A and others. 2008. VEGF expression by 
mesenchymal stem cells contributes to angiogenesis in pancreatic carcinoma. Br J 
Cancer 99(4):622-631. 
Beggs KJ, Lyubimov A, Borneman JN, Bartholomew A, Moseley A, Dodds R, Archambault MP, 
Smith AK, McIntosh KR. 2006. Immunologic consequences of multiple, high-dose 
administration of allogeneic mesenchymal stem cells to baboons. Cell Transplant 15(8-
9):711-21. 
Ben-David U, Benvenisty N. 2011. The tumorigenicity of human embryonic and induced 
pluripotent stem cells. Nat Rev Cancer 11(4):268-77. 
Bianco P, Barker R, Brustle O, Cattaneo E, Clevers H, Daley GQ, De Luca M, Goldstein L, Lindvall 
O, Mummery C and others. 2013a. Regulation of stem cell therapies under attack in 
Europe: for whom the bell tolls. EMBO J 32(11):1489-95. 
Bianco P, Cao X, Frenette PS, Mao JJ, Robey PG, Simmons PJ, Wang CY. 2013b. The meaning, the 
sense and the significance: translating the science of mesenchymal stem cells into 
medicine. Nat Med 19(1):35-42. 
Bianco P, Kuznetsov SA, Riminucci M, Robey PG. 2006. Postnatal skeletal stem cells. In: 
Klimanskaya I, Lanza R, editors. Adult Stem Cells. San Diego: Elsevier Academic Press Inc. 
p 117-148. 
Bianco P, Robey PG. 2004. Skeletal stem cells. In: Lanza R, editor. Handbook of Adult and Fetal 
Stem Cells. San Dieog: Academic Press. p 415-424. 
Bianco P, Robey PG, Saggio I, Riminucci M. 2010. "Mesenchymal'' Stem Cells in Human Bone 
Marrow (Skeletal Stem Cells): A Critical Discussion of Their Nature, Identity, and 
Significance in Incurable Skeletal Disease. Human Gene Therapy 21(9):1057-1066. 
Bianco P, Robey PG, Simmons PJ. 2008. Mesenchymal stem cells: Revisiting history, concepts, 
and assays. Cell Stem Cell 2(4):313-319. 
Bieback K. 2013. Platelet Lysate as Replacement for Fetal Bovine Serum in Mesenchymal Stromal 
Cell Cultures. Transfusion Medicine and Hemotherapy 40(5):326-335. 
Blashki D, Short B, Bertoncello I, Simmons P, Brouard N. 2006. Identification of stromal MSC 
canditates from multiple adult mouse tissues. International Society of Stem Cell 
Research 4th Annual Meeting 206. 
References 
 
 
251 | P a g e  
 
Bosch P, Musgrave DS, Lee JY, Cummins J, Shuler T, Ghivizzani TC, Evans T, Robbins TD, Huard. 
2000. Osteoprogenitor cells within skeletal muscle. J Orthop Res 18(6):933-44. 
Brandenberger R, Burger SR, Campbell AM, Fong T, Lapinskas E, Rowley JA. 2011. Integrating 
Process and Product Development for the Next Generation of Biotherapeutics 
BioProcess International 9(1):30-37. 
Bravery CA. 2010. Regulating interface science healthcare products: myths and uncertainties. 
Journal of the Royal Society Interface 7:S789-S795. 
Breyer A, Estharabadi N, Oki M, Ulloa F, Nelson-Holte M, Lien L, Jiang Y. 2006. Multipotent adult 
progenitor cell isolation and culture procedures. Exp Hematol 34(11):1596-601. 
Brindley DA, Davie NL, Culme-Seymour EJ, Mason C, Smith DW, Rowley JA. 2012. Peak serum: 
implications of serum supply for cell therapy manufacturing. Regen Med 7(1):7-13. 
Brooke G, Rossetti T, Pelekanos R, Ilic N, Murray P, Hancock S, Antonenas V, Huang G, Gottlieb 
D, Bradstock K and others. 2009. Manufacturing of human placenta-derived 
mesenchymal stem cells for clinical trials. Br J Haematol 144(4):571-9. 
Brown MF, Gratton TP, Stuart JA. 2007. Metabolic rate does not scale with body mass in cultured 
mammalian cells. Am J Physiol Regul Integr Comp Physiol 292(6):R2115-21. 
Bruder SP, Fink DJ, Caplan AI. 1994. MESENCHYMAL STEM-CELLS IN IN BONE-DEVELOPMENT, 
BONE REPAIR, AND SKELETAL REGENERATION THERAPY. Journal of Cellular 
Biochemistry 56(3):283-294. 
Buchanan SS, Gross SA, Acker JP, Toner M, Carpenter JF, Pyatt DW. 2004. Cryopreservation of 
stem cells using trehalose: evaluation of the method using a human hematopoietic cell 
line. Stem Cells Dev 13(3):295-305. 
Burger SR, Bravery CA. 2011. ISCT webinar: potency testing. www.celltherapysociety.org. In: 
Therapy ISfC, editor. 
Butler M. 2005. Animal cell cultures: recent achievements and perspectives in the production 
of biopharmaceuticals. Appl Microbiol Biotechnol 68(3):283-91. 
Byrne JA, Pedersen DA, Clepper LL, Nelson M, Sanger WG, Gokhale S, Wolf DP, Mitalipov SM. 
2007. Producing primate embryonic stem cells by somatic cell nuclear transfer. Nature 
450(7169):497-U3. 
Caplan AI. 1991. MESENCHYMAL STEM-CELLS. Journal of Orthopaedic Research 9(5):641-650. 
Caplan AI. 2005. Mesenchymal stem cells: Cell-based reconstructive therapy in orthopedics. 
Tissue Engineering 11(7-8):1198-1211. 
Caplan AI. 2007. Adult mesenchymal stem cells for tissue engineering versus regenerative 
medicine. Journal of Cellular Physiology 213(2):341-347. 
References 
 
 
252 | P a g e  
 
Caplan AI. 2008. All MSCs are pericytes? Cell Stem Cell 3(3):229-30. 
Caplan AI. 2009. Why are MSCs therapeutic? New data: new insight. J Pathol 217(2):318-24. 
Caplan AI. 2010. What's in a name? Tissue Eng Part A 16(8):2415-7. 
Caplan AI, Correa D. 2011. The MSC: an injury drugstore. Cell Stem Cell 9(1):11-5. 
Caplan AI, Dennis JE. 2006a. Mesenchymal stem cells as trophic mediators. Journal of Cellular 
Biochemistry 98(5):1076-1084. 
Caplan AI, Dennis JE. 2006b. Mesenchymal stem cells as trophic mediators. J Cell Biochem 
98(5):1076-84. 
Caplan AI, Sorrell JM. The MSC curtain that stops the immune system. Immunology Letters(0). 
Carlos Sepúlveda J, Tomé M, Eugenia Fernández M, Delgado M, Campisi J, Bernad A, González 
MA. 2014. Cell Senescence Abrogates the Therapeutic Potential of Human 
Mesenchymal Stem Cells in the Lethal Endotoxemia Model. STEM CELLS 32(7):1865-
1877. 
Carmen J, Burger SR, McCaman M, Rowley JA. 2012a. Developing assays to address identity, 
potency, purity and safety: cell characterization in cell therapy process development. 
Regen Med 7(1):85-100. 
Carmen J, Burger SR, McCaman M, Rowley JA. 2012b. Developing assays to address identity, 
potency, purity and safety: cell characterization in cell therapy process development. 
Regenerative Medicine 7(1):85-100. 
Carpenter MK, Frey-Vasconcells J, Rao MS. 2009. Developing safe therapies from human 
pluripotent stem cells. Nat Biotechnol 27(7):606-13. 
Chan AC, Heathman TJ, Coopman K, Hewitt C. 2014a. Multiparameter flow cytometry for the 
characterisation of extracellular markers on human mesenchymal stem cells. 
Biotechnology Letters 36(4):731-741. 
Chan AK, Heathman TR, Coopman K, Hewitt CJ. 2014b. Multiparameter flow cytometry for the 
characterisation of extracellular markers on human mesenchymal stem cells. Biotechnol 
Lett 36(4):731-41. 
Chen AK-L, Reuveny S, Oh SKW. 2013. Application of human mesenchymal and pluripotent stem 
cell microcarrier cultures in cellular therapy: Achievements and future direction. 
Biotechnology Advances 31(7):1032-1046. 
Chen K, Perez-Stable C, D'Ippolito G, Schiller PC, Roos BA, Howard GA. 2011. Human bone 
marrow-derived stem cell proliferation is inhibited by hepatocyte growth factor via 
increasing the cell cycle inhibitors p53, p21 and p27. Bone 49(6):1194-204. 
References 
 
 
253 | P a g e  
 
Cherry RS, Papoutsakis ET. 1986. Hydrodynamic effects on cells in agitated tissue culture 
reactors. Bioprocess Engineering 1(1):29-41. 
Cheuvront SN, Kenefick RW, Heavens KR, Spitz MG. 2014. A Comparison of Whole Blood and 
Plasma Osmolality and Osmolarity. Journal of Clinical Laboratory Analysis 28(5):368-
373. 
Christodoulou I, Kolisis FN, Papaevangeliou D, Zoumpourlis V. 2013. Comparative Evaluation of 
Human Mesenchymal Stem Cells of Fetal (Wharton's Jelly) and Adult (Adipose Tissue) 
Origin during Prolonged In Vitro Expansion: Considerations for Cytotherapy. Stem Cells 
Int 2013:246134. 
Cierpka K, Elseberg CL, Niss K, Kassem M, Salzig D, Czermak P. 2013. hMSC Production in 
Disposable Bioreactors with Regards to GMP and PAT. Chemie Ingenieur Technik 85(1-
2):67-75. 
Crapnell K, Blaesius R, Hastings A, Lennon DP, Caplan AI, Bruder SP. 2013. Growth, 
differentiation capacity, and function of mesenchymal stem cells expanded in serum-
free medium developed via combinatorial screening. Exp Cell Res 319(10):1409-18. 
Crigler L, Robey RC, Asawachaicharn A, Gaupp D, Phinney DG. 2006. Human mesenchymal stem 
cell subpopulations express a variety of neuro-regulatory molecules and promote 
neuronal cell survival and neuritogenesis. Exp Neurol 198(1):54-64. 
Croughan MS, Hamel JF, Wang DI. 1987. Hydrodynamic effects on animal cells grown in 
microcarrier cultures. Biotechnol Bioeng 29(1):130-41. 
Cruz HJ, Moreira JL, Carrondo MJ. 1999. Metabolic shifts by nutrient manipulation in continuous 
cultures of BHK cells. Biotechnol Bioeng 66(2):104-13. 
Cui L-l, Kerkela E, Bakreen A, Nitzsche F, Andrzejewska A, Nowakowski A, Janowski M, Walczak 
P, Boltze J, Lukomska B and others. 2015. The cerebral embolism evoked by intra-arterial 
delivery of allogeneic bone marrow mesenchymal stem cells in rats is related to cell 
dose and infusion velocity. Stem Cell Research & Therapy 6(1):11. 
Cunha B, Aguiar T, Silva MM, Silva RJ, Sousa MF, Pineda E, Peixoto C, Carrondo MJ, Serra M, 
Alves PM. 2015. Exploring continuous and integrated strategies for the up- and 
downstream processing of human mesenchymal stem cells. J Biotechnol. 
Das R, Jahr H, van Osch GJ, Farrell E. 2010. The role of hypoxia in bone marrow-derived 
mesenchymal stem cells: considerations for regenerative medicine approaches. Tissue 
Eng Part B Rev 16(2):159-68. 
Deans RJ, Moseley AB. 2000. Mesenchymal stem cells: biology and potential clinical uses. Exp 
Hematol 28(8):875-84. 
References 
 
 
254 | P a g e  
 
Deskins DL, Bastakoty D, Saraswati S, Shinar A, Holt GE, Young PP. 2013. Human Mesenchymal 
Stromal Cells: Identifying Assays to Predict Potency for Therapeutic Selection. Stem Cells 
Translational Medicine 2(2):151-158. 
Di Nicola M, Carlo-Stella C, Magni M, Milanesi M, Longoni PD, Matteucci P, Grisanti S, Gianni 
AM. 2002. Human bone marrow stromal cells suppress T-lymphocyte proliferation 
induced by cellular or nonspecific mitogenic stimuli. Blood 99(10):3838-43. 
Doherty MJ, Canfield AE. 1999. Gene expression during vascular pericyte differentiation. Crit 
Rev Eukaryot Gene Expr 9(1):1-17. 
Dolley-Sonneville PJ, Romeo LE, Melkoumian ZK. 2013. Synthetic surface for expansion of 
human mesenchymal stem cells in xeno-free, chemically defined culture conditions. 
PLoS One 8(8):e70263. 
Dominici M, Le Blanc K, Mueller I, Slaper-Cortenbach I, Marini F, Krause D, Deans R, Keating A, 
Prockop D, Horwitz E. 2006. Minimal criteria for defining multipotent mesenchymal 
stromal cells. The International Society for Cellular Therapy position statement. 
Cytotherapy 8(4):315-7. 
dos Santos F, Andrade PZ, Abecasis MM, Gimble JM, Chase LG, Campbell AM, Boucher S, Vemuri 
MC, da Silva CL, Cabral JMS. 2011a. Toward a Clinical-Grade Expansion of Mesenchymal 
Stem Cells from Human Sources: A Microcarrier-Based Culture System Under Xeno-Free 
Conditions. Tissue Engineering. Part C, Methods 17(12):1201-1210. 
Dos Santos F, Andrade PZ, Abecasis MM, Gimble JM, Chase LG, Campbell AM, Boucher S, Vemuri 
MC, Silva CL, Cabral JM. 2011b. Toward a clinical-grade expansion of mesenchymal stem 
cells from human sources: a microcarrier-based culture system under xeno-free 
conditions. Tissue Eng Part C Methods 17(12):1201-10. 
Dos Santos F, Andrade PZ, Boura JS, Abecasis MM, da Silva CL, Cabral JM. 2010. Ex vivo 
expansion of human mesenchymal stem cells: a more effective cell proliferation kinetics 
and metabolism under hypoxia. J Cell Physiol 223(1):27-35. 
dos Santos F, Campbell A, Fernandes-Platzgummer A, Andrade PZ, Gimble JM, Wen Y, Boucher 
S, Vemuri MC, da Silva CL, Cabral JMS. 2014. A xenogeneic-free bioreactor system for 
the clinical-scale expansion of human mesenchymal stem/stromal cells. Biotechnology 
and Bioengineering 111(6):1116-1127. 
Doucet C, Ernou I, Zhang Y, Llense JR, Begot L, Holy X, Lataillade JJ. 2005. Platelet lysates 
promote mesenchymal stem cell expansion: a safety substitute for animal serum in cell-
based therapy applications. J Cell Physiol 205(2):228-36. 
References 
 
 
255 | P a g e  
 
Dreher L, Elvers-Hornung S, Brinkmann I, Huck V, Henschler R, Gloe T, Kluter H, Bieback K. 2013. 
Cultivation in human serum reduces adipose tissue-derived mesenchymal stromal cell 
adhesion to laminin and endothelium and reduces capillary entrapment. Stem Cells Dev 
22(5):791-803. 
Ellington AA, Kullo IJ, Bailey KR, Klee GG. 2010. Antibody-Based Protein Multiplex Platforms: 
Technical and Operational Challenges. Clinical Chemistry 56(2):186-193. 
Erices A, Conget P, Minguell JJ. 2000. Mesenchymal progenitor cells in human umbilical cord 
blood. British Journal of Haematology 109(1):235-242. 
Estrada JC, Torres Y, Benguria A, Dopazo A, Roche E, Carrera-Quintanar L, Perez RA, Enriquez JA, 
Torres R, Ramirez JC and others. 2013. Human mesenchymal stem cell-replicative 
senescence and oxidative stress are closely linked to aneuploidy. Cell Death Dis 4:e691. 
Faris RA, Konkin T, Halpert G. 2001. Liver stem cells: a potential source of hepatocytes for the 
treatment of human liver disease. Artif Organs 25(7):513-21. 
Farrington-Rock C, Crofts NJ, Doherty MJ, Ashton BA, Griffin-Jones C, Canfield AE. 2004. 
Chondrogenic and adipogenic potential of microvascular pericytes. Circulation 
110(15):2226-32. 
FDA. 2004. PAT - A framework for Innovative Pharmaceutical Development, Manufacturing and 
Quality Assurance. In: Center of Drug Evaluation and Research FaDA, editor. 
FDA. 2008a. Content and Review of Chemistry, Manufacturing, and Control (CMC) Information 
for Human Gene Therapy Investigational New Drug Applications (INDs). In: Services 
USDoHaH, editor. 
FDA. 2009. Guidance for Industry Q8(R2) Pharmaceutical Development In: Services USDoHaH, 
editor. www.fda.gov/downloads/Drugs/Guidances/ucm073507.pdf. 
FDA. 2011a. Guidance for Industry. Potency tests for cellular and gene therapy products. In: 
Administration USFaD, editor. 
http://www.fda.gov/downloads/BiologicsBloodVaccines/GuidanceComplianceRegulat
oryInformation/Guidances/CellularandGeneTherapy/UCM243392.pdf. 
FDA U. 1997. FDA summary for basis of approval: BLA Ref No. 96-0372, Carticel. p 1-23. 
FDA U. 1998. Guidance for Industry. Guidance for Human Somatic Cell Therapy and Gene 
Therapy. . In: Services UDoHaH, editor. Rockville, MD, USA. 
FDA U. 2002. www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?fr=610.15. 
Code of Federal Regulations, general biological products standards, constituent 
materials.  
. 
References 
 
 
256 | P a g e  
 
FDA U. 2008b. Guidance for FDA Reviewers and Sponsors. Content and Review of Chemistry, 
Manufacturing, and Control (CMC) Information for Human Somatic Cell Therapy 
Investigational New Drug Applications (INDs). In: Services UDoHaH, editor. Rockville, 
MD, USA. p 1-39. 
FDA U. 2010. 21 CFR 610.12. Code of Federal Regulations, general biological products standards, 
sterility www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?fr=610.12. 
FDA U. 2011b. Final Guidance for Industry. Potency Tests for Cellular and Gene Therapy 
Products. In: Services UDoHaH, editor. Rockville, MD, USA. p 1-19. 
Festjens N, Vanden Berghe T, Vandenabeele P. 2006. Necrosis, a well-orchestrated form of cell 
demise: signalling cascades, important mediators and concomitant immune response. 
Biochim Biophys Acta 1757(9-10):1371-87. 
Friedens.Aj, Chailakh.Rk, Lalykina KS. 1970. DEVELOPMENT OF FIBROBLAST COLONIES IN 
MONOLAYER CULTURES OF GUINEA-PIG BONE MARROW AND SPLEEN CELLS. Cell and 
Tissue Kinetics 3(4):393-&. 
Friedens.Aj, Deriglas.Uf, Kulagina NN, Panasuk AF, Rudakowa SF, Luria EA, Rudakow IA. 1974. 
PRECURSORS FOR FIBROBLASTS IN DIFFERENT POPULATIONS OF HEMATOPOIETIC 
CELLS AS DETECTED BY INVITRO COLONY ASSAY METHOD. Experimental Hematology 
2(2):83-92. 
Friedens.Aj, Piatetzk, II, Petrakov.Kv. 1966. OSTEOGENESIS IN TRANSPLANTS OF BONE MARROW 
CELLS. Journal of Embryology and Experimental Morphology 16:381-&. 
Friedenstein AJ, Chailakhyan RK, Gerasimov UV. 1987. BONE-MARROW OSTEOGENIC STEM-
CELLS - INVITRO CULTIVATION AND TRANSPLANTATION IN DIFFUSION-CHAMBERS. Cell 
and Tissue Kinetics 20(3):263-272. 
Friedenstein AJ, Gorskaja UF, Kulagina NN. 1976. FIBROBLAST PRECURSORS IN NORMAL AND 
IRRADIATED MOUSE HEMATOPOIETIC ORGANS. Experimental Hematology 4(5):267-
274. 
Galipeau J. 2013. The mesenchymal stromal cells dilemma—does a negative phase III trial of 
random donor mesenchymal stromal cells in steroid-resistant graft-versus-host disease 
represent a death knell or a bump in the road? Cytotherapy 15(1):2-8. 
Ganguly J, Vogel G. 2006. Process analytical technology (PAT) and scalable automation for 
bioprocess control and monitoring—A case study. Pharmaceutical Eng 26(1):1-9. 
Gao F, He T, Wang H, Yu S, Yi D, Liu W, Cai Z. 2007. A promising strategy for the treatment of 
ischemic heart disease: Mesenchymal stem cell-mediated vascular endothelial growth 
factor gene transfer in rats. The Canadian Journal of Cardiology 23(11):891-898. 
References 
 
 
257 | P a g e  
 
Gao T, Zhang N, Wang Z, Wang Y, Liu Y, Ito Y, Zhang P. 2015. Biodegradable Microcarriers of 
Poly(Lactide-co-Glycolide) and Nano-Hydroxyapatite Decorated with IGF-1 via 
Polydopamine Coating for Enhancing Cell Proliferation and Osteogenic Differentiation. 
Macromol Biosci. 
Ge J, Guo L, Wang S, Zhang Y, Cai T, Zhao RC, Wu Y. 2014. The size of mesenchymal stem cells is 
a significant cause of vascular obstructions and stroke. Stem Cell Rev 10(2):295-303. 
Gigout A, Buschmann MD, Jolicoeur M. 2008. The fate of Pluronic F-68 in chondrocytes and CHO 
cells. Biotechnol Bioeng 100(5):975-87. 
Glacken MW. 1988. Catabolic Control of Mammalian Cell Culture. Nat Biotech 6(9):1041-1050. 
Goldring CEP, Duffy PA, Benvenisty N, Andrews PW, Ben-David U, Eakins R, French N, Hanley 
NA, Kelly L, Kitteringham NR and others. 2011. Assessing the Safety of Stem Cell 
Therapeutics. Cell Stem Cell 8(6):618-628. 
Goujon E. 1869. Recherches experimentales sur les proprietes physiologiques de la moelle des 
os. Journal de L'Anat et de La Physiol. 6:399-412. 
Grayson WL, Zhao F, Izadpanah R, Bunnell B, Ma T. 2006. Effects of hypoxia on human 
mesenchymal stem cell expansion and plasticity in 3D constructs. J Cell Physiol 
207(2):331-9. 
Guilloton F, Caron G, Menard C, Pangault C, Ame-Thomas P, Dulong J, De Vos J, Rossille D, Henry 
C, Lamy T and others. 2012. Mesenchymal stromal cells orchestrate follicular lymphoma 
cell niche through the CCL2-dependent recruitment and polarization of monocytes. 
Blood 119(11):2556-67. 
Gurdon JB. 1962. DEVELOPMENTAL CAPACITY OF NUCLEI TAKEN FROM INTESTINAL EPITHELIUM 
CELLS OF FEEDING TADPOLES. Journal of Embryology and Experimental Morphology 
10(4):622-&. 
Hampson B. 2014. Closed Processing for Cell Therapies: Engineering Risk Reduction and Patient 
Safety during Manufacturing. Genetic Engineering & Biotechnology News 34(9). 
Hampson B, Rowley J, Venturi N. 2008. Manufacturing Patient-Specific Cell Therapy Products. 
BioProcess International 6(8):60-72. 
Hare JM, Traverse JH, Henry TD, Dib N, Strumpf RK, Schulman SP, Gerstenblith G, DeMaria AN, 
Denktas AE, Gammon RS and others. 2009. A randomized, double-blind, placebo-
controlled, dose-escalation study of intravenous adult human mesenchymal stem cells 
(prochymal) after acute myocardial infarction. J Am Coll Cardiol 54(24):2277-86. 
Hartmann I, Hollweck T, Haffner S, Krebs M, Meiser B, Reichart B, Eissner G. 2010. Umbilical 
cord tissue-derived mesenchymal stem cells grow best under GMP-compliant culture 
References 
 
 
258 | P a g e  
 
conditions and maintain their phenotypic and functional properties. J Immunol 
Methods 363(1):80-9. 
Hassan S, Simaria AS, Varadaraju H, Gupta S, Warren K, Farid SS. 2015. Allogeneic cell therapy 
bioprocess economics and optimization: downstream processing decisions. 
Regenerative Medicine 10(5):591-609. 
Hatlapatka T, Moretti P, Lavrentieva A, Hass R, Marquardt N, Jacobs R, Kasper C. 2011. 
Optimization of culture conditions for the expansion of umbilical cord-derived 
mesenchymal stem or stromal cell-like cells using xeno-free culture conditions. Tissue 
Eng Part C Methods 17(4):485-93. 
Hayman EG, Pierschbacher MD, Suzuki S, Ruoslahti E. 1985. Vitronectin--a major cell 
attachment-promoting protein in fetal bovine serum. Exp Cell Res 160(2):245-58. 
Heathman T. 2015. Development of a controlled bioreactor process to drive the consistent 
manufacture of human mesenchymal stem cells from multiple donors. Cytotherapy 
17(6):S81-S82. 
Heathman TRJ, Glyn VAM, Picken A, Rafiq QA, Coopman K, Nienow AW, Kara B, Hewitt CJ. 2015a. 
Expansion, harvest and cryopreservation of human mesenchymal stem cells in a serum-
free microcarrier process. Biotechnology and Bioengineering 112(8):1696-1707. 
Heathman TRJ, Nienow AW, McCall MJ, Coopman K, Kara B, Hewitt CJ. 2015b. The translation 
of cell-based therapies: clinical landscape and manufacturing challenges. Regen Med 
10(1):49-64. 
Heathman TRJ, Rafiq QA, Chan AKC, Coopman K, Nienow AW, Kara B, Hewitt CJ. 2015c. 
Characterisation of human mesenchymal stem cells from multiple donors and the 
implications for large scale bioprocess development. Biochemical Engineering Journal 
(in press)((presented at ECI Conference on . Scale-up and Manufacture of Cell-based 
Therapies IV, San Diego, California,  January 2015)). 
Heathman TRJ, Rafiq QA, Coopman K, Nienow AW, Hewitt CJ. 2015d. Chapter 10: The scale-up 
of human mesenchymal stem cell expansion and recovery. (in Bioprocessing for Cell-
Based Therapies). In: Sons JW, editor. 
Heathman TRJ, Stolzing A, Fabian C, Rafiq QA, Coopman K, Nienow AW, Kara B, Hewitt CJ. 2015e. 
Serum-free process development: improving the yield and consistency of human 
mesenchymal stromal cell production. Cytotherapy 17(11):1524-1535. 
Heid CA, Stevens J, Livak KJ, Williams PM. 1996. Real time quantitative PCR. Genome Research 
6(10):986-994. 
References 
 
 
259 | P a g e  
 
Heiskanen A, Satomaa T, Tiitinen S, Laitinen A, Mannelin S, Impola U, Mikkola M, Olsson C, 
Miller-Podraza H, Blomqvist M and others. 2007. N-glycolylneuraminic acid xenoantigen 
contamination of human embryonic and mesenchymal stem cells is substantially 
reversible. Stem Cells 25(1):197-202. 
Herzog EL, Chai L, Krause DS. 2003. Plasticity of marrow-derived stem cells. Blood 102(10):3483-
3493. 
Hewitt CJ, Lee K, Nienow AW, Thomas RJ, Smith M, Thomas CR. 2011. Expansion of human 
mesenchymal stem cells on microcarriers. Biotechnol Lett 33(11):2325-35. 
Higuera-Sierra G, Schop D, Janssen F, Dijkhuizen-Radersma R, Boxtel vAJB, Blitterswijk vCA. 
2009. Quantifying in vitro growth and metabolism kinetics of human mesenchymal stem 
cells using a mathematical model. Tissue Engineering. Part A 15(9):2653 - 2663. 
Higuera GA, Schop D, Spitters TW, van Dijkhuizen-Radersma R, Bracke M, de Bruijn JD, Martens 
D, Karperien M, van Boxtel A, van Blitterswijk CA. 2012. Patterns of amino acid 
metabolism by proliferating human mesenchymal stem cells. Tissue Eng Part A 18(5-
6):654-64. 
Honczarenko M, Le Y, Swierkowski M, Ghiran I, Glodek AM, Silberstein LE. 2006. Human bone 
marrow stromal cells express a distinct set of biologically functional chemokine 
receptors. Stem Cells 24(4):1030-41. 
Hong SH, Gang EJ, Jeong JA, Ahn C, Hwang SH, Yang IH, Park HK, Han H, Kim H. 2005. In vitro 
differentiation of human umbilical cord blood-derived mesenchymal stem cells into 
hepatocyte-like cells. Biochem Biophys Res Commun 330(4):1153-61. 
Horwitz EM. 2008. Mesenchymal stromal cells moving forward. Cytotherapy 10(1):5-6. 
Horwitz EM, Dominici M. 2008. How do mesenchymal stromal cells exert their therapeutic 
benefit? Cytotherapy 10(8):771-4. 
Horwitz EM, Gordon PL, Koo WK, Marx JC, Neel MD, McNall RY, Muul L, Hofmann T. 2002. 
Isolated allogeneic bone marrow-derived mesenchymal cells engraft and stimulate 
growth in children with osteogenesis imperfecta: Implications for cell therapy of bone. 
Proc Natl Acad Sci U S A 99(13):8932-7. 
Horwitz EM, Prockop DJ, Fitzpatrick LA, Koo WW, Gordon PL, Neel M, Sussman M, Orchard P, 
Marx JC, Pyeritz RE and others. 1999. Transplantability and therapeutic effects of bone 
marrow-derived mesenchymal cells in children with osteogenesis imperfecta. Nat Med 
5(3):309-13. 
References 
 
 
260 | P a g e  
 
Hourd P, Chandra A, Alvey D, Ginty P, McCall M, Ratcliffe E, Rayment E, Williams DJ. 2014a. 
Qualification of academic facilities for small-scale automated manufacture of 
autologous cell-based products. Regen Med 9(6):799-815. 
Hourd P, Chandra A, Medcalf N, Williams DJ. 2008. Regulatory challenges for the manufacture 
and scale-out of autologous cell therapies. StemBook. Cambridge MA: : 2014 Paul 
Hourd, Amit Chandra, Nick Medcalf and David J. Williams. 
Hourd P, Ginty P, Chandra A, Williams DJ. 2014b. Manufacturing models permitting roll 
out/scale out of clinically led autologous cell therapies: regulatory and scientific 
challenges for comparability. Cytotherapy 16(8):1033-47. 
Huttenlocher A, Horwitz AR. 2011. Integrins in cell migration. Cold Spring Harb Perspect Biol 
3(9):a005074. 
Hwang SM, See C-j, Choi J, Kim SY, Choi Q, Kim JA, Kwon J, Park SN, Im K, Oh I-H and others. 
2013. The application of an in situ karyotyping technique for mesenchymal stromal cells: 
a validation and comparison study with classical G-banding. Exp Mol Med 45:e68. 
ICH. 2005. Quality Risk Management Q9. In: Group IEW, editor. 
International Conference on Harmonisation of Technical Requirements for Registration of 
Pharmaceuticals for Human Use I. 2008. Pharmaceutical Quality System Q10. 
Isakova IA, Dufour J, Lanclos C, Bruhn J, Phinney DG. 2010. Cell-dose-dependent increases in 
circulating levels of immune effector cells in rhesus macaques following intracranial 
injection of allogeneic MSCs. Exp Hematol 38(10):957-967 e1. 
Isakova IA, Lanclos C, Bruhn J, Kuroda MJ, Baker KC, Krishnappa V, Phinney DG. 2014. Allo-
reactivity of mesenchymal stem cells in rhesus macaques is dose and haplotype 
dependent and limits durable cell engraftment in vivo. PLoS One 9(1):e87238. 
Jaiswal N, Haynesworth SE, Caplan AI, Bruder SP. 1997. Osteogenic differentiation of purified, 
culture-expanded human mesenchymal stem cells in vitro. Journal of Cellular 
Biochemistry 64(2):295-312. 
James D. 2011. Therapies of Tomorrow Require More Than Factories from the Past. BioProcess 
International 9:4-11. 
Janowski M, Lyczek A, Engels C, Xu J, Lukomska B, Bulte JW, Walczak P. 2013. Cell size and 
velocity of injection are major determinants of the safety of intracarotid stem cell 
transplantation. J Cereb Blood Flow Metab 33(6):921-7. 
Jiang Y, Vaessen B, Lenvik T, Blackstad M, Reyes M, Verfaillie CM. 2002a. Multipotent progenitor 
cells can be isolated from postnatal murine bone marrow, muscle, and brain. Exp 
Hematol 30(8):896-904. 
References 
 
 
261 | P a g e  
 
Jiang YH, Jahagirdar BN, Reinhardt RL, Schwartz RE, Keene CD, Ortiz-Gonzalez XR, Reyes M, 
Lenvik T, Lund T, Blackstad M and others. 2002b. Pluripotency of mesenchymal stem 
cells derived from adult marrow. Nature 418(6893):41-49. 
Joeris K, Frerichs JG, Konstantinov K, Scheper T. 2002. In-situ microscopy: Online process 
monitoring of mammalian cell cultures. Cytotechnology 38(1-3):129-34. 
Johnstone B, Hering TM, Caplan AI, Goldberg VM, Yoo JU. 1998. In vitro chondrogenesis of bone 
marrow-derived mesenchymal progenitor cells. Experimental Cell Research 238(1):265-
272. 
Jones E, English A, Churchman SM, Kouroupis D, Boxall SA, Kinsey S, Giannoudis PG, Emery P, 
McGonagle D. 2010. Large-scale extraction and characterization of CD271+ 
multipotential stromal cells from trabecular bone in health and osteoarthritis: 
implications for bone regeneration strategies based on uncultured or minimally 
cultured multipotential stromal cells. Arthritis Rheum 62(7):1944-54. 
Jones EA, English A, Kinsey SE, Straszynski L, Emery P, Ponchel F, McGonagle D. 2006. 
Optimization of a flow cytometry-based protocol for detection and phenotypic 
characterization of multipotent mesenchymal stromal cells from human bone marrow. 
Cytometry B Clin Cytom 70(6):391-9. 
Jorgensen P, Tyers M. 2004. How cells coordinate growth and division. Curr Biol 14(23):R1014-
27. 
Jung S, Panchalingam KM, Rosenberg L, Behie LA. 2012. Ex Vivo Expansion of Human 
Mesenchymal Stem Cells in Defined Serum-Free Media. Stem Cells International 
2012:21. 
Jung S, Sen A, Rosenberg L, Behie LA. 2010. Identification of growth and attachment factors for 
the serum-free isolation and expansion of human mesenchymal stromal cells. 
Cytotherapy 12(5):637-57. 
Kang SG, Shinojima N, Hossain A, Gumin J, Yong RL, Colman H, Marini F, Andreeff M, Lang FF. 
2010. Isolation and Perivascular Localization of Mesenchymal Stem Cells From Mouse 
Brain. Neurosurgery 67(3):711-720. 
Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF, Redfern CH, Ferrari AC, 
Dreicer R, Sims RB and others. 2010. Sipuleucel-T immunotherapy for castration-
resistant prostate cancer. N Engl J Med 363(5):411-22. 
Karp JM, Leng Teo GS. 2009. Mesenchymal Stem Cell Homing: The Devil Is in the Details. Cell 
Stem Cell 4(3):206-216. 
References 
 
 
262 | P a g e  
 
Kasten P, Beyen I, Egermann M, Suda AJ, Moghaddam AA, Zimmermann G, Luginbuhl R. 2008. 
Instant stem cell therapy: characterization and concentration of human mesenchymal 
stem cells in vitro. Eur Cell Mater 16:47-55. 
Kasuto H, Drori-carmi N, Zohar B; Pluristem Ltd. (Haifa, IL) assignee. 2014. METHODS AND 
SYSTEMS FOR HARVESTING CELLS. 
Katagiri T, Yamaguchi A, Komaki M, Abe E, Takahashi N, Ikeda T, Rosen V, Wozney JM, 
Fujisawasehara A, Suda T. 1994. BONE MORPHOGENETIC PROTEIN-2 CONVERTS THE 
DIFFERENTIATION PATHWAY OF C2C12 MYOBLASTS INTO THE OSTEOBLAST LINEAGE. 
Journal of Cell Biology 127(6):1755-1766. 
Kedong S, Xiubo F, Tianqing L, Macedo HM, LiLi J, Meiyun F, Fangxin S, Xuehu M, Zhanfeng C. 
2010. Simultaneous expansion and harvest of hematopoietic stem cells and 
mesenchymal stem cells derived from umbilical cord blood. J Mater Sci Mater Med 
21(12):3183-93. 
Kehoe DE, Jing D, Lock LT, Tzanakakis ES. 2010. Scalable stirred-suspension bioreactor culture of 
human pluripotent stem cells. Tissue Eng Part A 16(2):405-21. 
Kern S, Eichler H, Stoeve J, Kluter H, Bieback K. 2006. Comparative analysis of mesenchymal stem 
cells from bone marrow, umbilical cord blood, or adipose tissue. Stem Cells 24(5):1294-
301. 
Kharlamova LA. 1975. INHIBITORY FORMATION OF COLONIES OF HUMAN BONE MARROW 
STROMAL CELLS UNDER THE EFFECT OF THE FACTOR FORMED IN-VITRO BY PERIPHERAL 
BLOOD LEUKOCYTES. Byulleten' Eksperimental'noi Biologii i Meditsiny 80(7):89-91. 
Kilburn DG, Webb FC. 2000. The cultivation of animal cells at controlled dissolved oxygen partial 
pressure. Reprinted from Biotechnology and Bioengineering Vol. X, Issue 6, Pages 801-
814 (1968). Biotechnol Bioeng 67(6):657-70. 
Kim J, Seong J, Lee B, Hashimura Y, Groux D, Oh D. 2013. Evaluation of a novel pneumatic 
bioreactor system for culture of recombinant Chinese hamster ovary cells. 
Biotechnology and Bioprocess Engineering 18(4):801-807. 
Kinnaird T, Stabile E, Burnett MS, Shou M, Lee CW, Barr S, Fuchs S, Epstein SE. 2004. Local 
delivery of marrow-derived stromal cells augments collateral perfusion through 
paracrine mechanisms. Circulation 109(12):1543-1549. 
Kirouac DC, Zandstra PW. 2008. The systematic production of cells for cell therapies. Cell Stem 
Cell 3(4):369-81. 
References 
 
 
263 | P a g e  
 
Klyushnenkova E, Mosca JD, Zernetkina V, Majumdar MK, Beggs KJ, Simonetti DW, Deans RJ, 
McIntosh KR. 2005. T cell responses to allogeneic human mesenchymal stem cells: 
immunogenicity, tolerance, and suppression. J Biomed Sci 12(1):47-57. 
Kocaoemer A, Kern S, Kluter H, Bieback K. 2007. Human AB serum and thrombin-activated 
platelet-rich plasma are suitable alternatives to fetal calf serum for the expansion of 
mesenchymal stem cells from adipose tissue. Stem Cells 25(5):1270-8. 
Kogler G, Sensken S, Airey JA, Trapp T, Muschen M, Feldhahn N, Liedtke S, Sorg RV, Fischer J, 
Rosenbaum C and others. 2004. A new human somatic stem cell from placental cord 
blood with intrinsic pluripotent differentiation potential. Journal of Experimental 
Medicine 200(2):123-135. 
Kolf CM, Cho E, Tuan RS. 2007. Mesenchymal stromal cells. Biology of adult mesenchymal stem 
cells: regulation of niche, self-renewal and differentiation. Arthritis Res Ther 9(1):204. 
Kubista M, Andrade JM, Bengtsson M, Forootan A, Jonak J, Lind K, Sindelka R, Sjoback R, 
Sjogreen B, Strombom L and others. 2006. The real-time polymerase chain reaction. 
Molecular Aspects of Medicine 27(2-3):95-125. 
Kuczewski M, Schirmer E, Lain B, Zarbis-Papastoitsis G. 2011. A single-use purification process 
for the production of a monoclonal antibody produced in a PER.C6 human cell line. 
Biotechnol J 6(1):56-65. 
Kuznetsov SA, Mankani MH, Gronthos S, Satomura K, Bianco P, Robey PG. 2001. Circulating 
skeletal stem cells. Journal of Cell Biology 153(5):1133-1139. 
Langheinrich C, Nienow AW, Eddleston T, Stevenson NC, Emery AN, Clayton TM, Slater NKH. 
2002. Oxygen Transfer in Stirred Bioreactors Under Animal Cell Culture Conditions. Food 
and Bioproducts Processing 80(1):39-44. 
Lavery M, Nienow AW. 1987. Oxygen transfer in animal cell culture medium. Biotechnol Bioeng 
30(3):368-73. 
Lavon N, Yanuka O, Benvenisty N. 2004. Differentiation and isolation of hepatic-like cells from 
human embryonic stem cells. Differentiation 72(5):230-8. 
Lavrentieva A, Majore I, Kasper C, Hass R. 2010a. Effects of hypoxic culture conditions on 
umbilical cord-derived human mesenchymal stem cells. Cell Communication and 
Signaling 8(1):1-9. 
Lavrentieva A, Majore I, Kasper C, Hass R. 2010b. Effects of hypoxic culture conditions on 
umbilical cord-derived human mesenchymal stem cells. Cell Commun Signal 8:18. 
References 
 
 
264 | P a g e  
 
Lavrentieva A, Majore I, Kasper C, Hass R. 2010c. Effects of hypoxic culture conditions on 
umbilical cord-derived human mesenchymal stem cells. Cell Communication and 
Signaling 8(18):1-9. 
Le Blanc K. 2006. Mesenchymal stromal cells: Tissue repair and immune modulation. 
Cytotherapy 8(6):559-61. 
Le Blanc K, Frassoni F, Ball L, Locatelli F, Roelofs H, Lewis I, Lanino E, Sundberg B, Bernardo ME, 
Remberger M and others. 2008. Mesenchymal stem cells for treatment of steroid-
resistant, severe, acute graft-versus-host disease: a phase II study. Lancet 
371(9624):1579-86. 
Le Blanc K, Rasmusson I, Sundberg B, Gotherstrom C, Hassan M, Uzunel M, Ringden O. 2004. 
Treatment of severe acute graft-versus-host disease with third party haploidentical 
mesenchymal stem cells. Lancet 363(9419):1439-41. 
Le Blanc K, Tammik C, Rosendahl K, Zetterberg E, Ringden O. 2003. HLA expression and 
immunologic properties of differentiated and undifferentiated mesenchymal stem cells. 
Exp Hematol 31(10):890-6. 
Lee B, Fang D, Croughan M, Carrondo M, Paik S-H. 2011. Characterization of novel pneumatic 
mixing for single-use bioreactor application. BMC Proceedings 5(8):1-2. 
Lefort N, Perrier AL, Laabi Y, Varela C, Peschanski M. 2009. Human embryonic stem cells and 
genomic instability. Regen Med 4(6):899-909. 
Li B, Moshfegh C, Lin Z, Albuschies J, Vogel V. 2013. Mesenchymal Stem Cells Exploit Extracellular 
Matrix as Mechanotransducer. Sci. Rep. 3. 
Li MD, Atkins H, Bubela T. 2014. The global landscape of stem cell clinical trials. Regen Med 
9(1):27-39. 
Li YM, Schilling T, Benisch P, Zeck S, Meissner-Weigl J, Schneider D, Limbert C, Seufert J, Kassem 
M, Schutze N and others. 2007. Effects of high glucose on mesenchymal stem cell 
proliferation and differentiation. Biochem Biophys Res Commun 363(1):209-15. 
Liu JY, Hafner J, Dragieva G, Burg G. 2004. Bioreactor microcarrier cell culture system (Bio-MCCS) 
for large-scale production of autologous melanocytes. Cell Transplant 13(7-8):809-16. 
Liu Y, Xu X, Ma X, Martin-Rendon E, Watt S, Cui Z. 2010. Cryopreservation of human bone 
marrow-derived mesenchymal stem cells with reduced dimethylsulfoxide and well-
defined freezing solutions. Biotechnol Prog 26(6):1635-43. 
Livak KJ, Schmittgen TD. 2001. Analysis of relative gene expression data using real-time 
quantitative PCR and the 2(T)(-Delta Delta C) method. Methods 25(4):402-408. 
References 
 
 
265 | P a g e  
 
Lo T, Ho JH, Yang M-H, Lee OK. 2011. Glucose Reduction Prevents Replicative Senescence and 
Increases Mitochondrial Respiration in Human Mesenchymal Stem Cells. Cell 
Transplantation 20:813-825. 
Lu B, Malcuit C, Wang S, Girman S, Francis P, Lemieux L, Lanza R, Lund R. 2009. Long-term safety 
and function of RPE from human embryonic stem cells in preclinical models of macular 
degeneration. Stem Cells 27(9):2126-35. 
Lubkowska A, Dolegowska B, Banfi G. 2012. Growth factor content in PRP and their applicability 
in medicine. J Biol Regul Homeost Agents 26(2 Suppl 1):3S-22S. 
Luo W, Xiong W, Zhou J, Fang Z, Chen W, Fan Y, Li F. 2011. Laminar shear stress delivers cell 
cycle arrest and anti-apoptosis to mesenchymal stem cells. Acta Biochimica et 
Biophysica Sinica 43(3):210-216. 
Lysaght MJ, Hazlehurst AL. 2004. Tissue engineering: the end of the beginning. Tissue Eng 10(1-
2):309-20. 
Majore I, Moretti P, Hass R, Kasper C. 2009. Identification of subpopulations in mesenchymal 
stem cell-like cultures from human umbilical cord. Cell Communication and Signaling : 
CCS 7:6-6. 
Majumdar MK, Thiede MA, Mosca JD, Moorman M, Gerson SL. 1998. Phenotypic and functional 
comparison of cultures of marrow-derived mesenchymal stem cells (MSCs) and stromal 
cells. J Cell Physiol 176(1):57-66. 
Mason C. 2013. House of Lords Regenerative Medicine Report. In: Committee SaT, editor. 
London. 
Mason C, Brindley DA, Culme-Seymour EJ, Davie NL. 2011. Cell therapy industry: billion dollar 
global business with unlimited potential. Regen Med 6(3):265-72. 
Mason C, Dunnill P. 2007. Translational regenerative medicine research: essential to discovery 
and outcome. Regenerative Medicine 2(3):227-229. 
Mason C, Dunnill P. 2008. A brief definition of regenerative medicine. Regen Med 3(1):1-5. 
Mason C, Hoare M. 2006. Regenerative medicine bioprocessing: the need to learn from the 
experience of other fields. Regenerative Medicine 1(5):615-623. 
Mason C, Manzotti E. 2009. Regen: the industry responsible for cell-based therapies. Regen Med 
4(6):783-5. 
Mason C, Manzotti E. 2010. The Translation Cycle: round and round in cycles is the only way 
forward for regenerative medicine. Regen Med 5(2):153-5. 
Mather ML, Crowe JA, Morgan SP, White LJ, Shakesheff KM, Howdle SM, Thomas RJ, Byrne HM, 
Waters SL, Williams DJ. 2009. Remedi: A Research Consortium Applying Engineering 
References 
 
 
266 | P a g e  
 
Strategies to Establish Regenerative Medicine as a New Industry. In: VanderSloten J, 
Verdonck P, Nyssen M, Haueisen J, editors. 4th European Conference of the 
International Federation for Medical and Biological Engineering. New York: Springer. p 
2209-2212. 
Maziarz RT, Devos T, Bachier CR, Goldstein SC, Leis JF, Devine SM, Meyers G, Gajewski JL, 
Maertens J, Deans RJ and others. 2015. Single and multiple dose MultiStem (multipotent 
adult progenitor cell) therapy prophylaxis of acute graft-versus-host disease in 
myeloablative allogeneic hematopoietic cell transplantation: a phase 1 trial. Biol Blood 
Marrow Transplant 21(4):720-8. 
Meier SJ, Hatton TA, Wang DI. 1999. Cell death from bursting bubbles: role of cell attachment 
to rising bubbles in sparged reactors. Biotechnol Bioeng 62(4):468-78. 
Meirelles LDS, Chagastelles PC, Nardi NB. 2006. Mesenchymal stem cells reside in virtually all 
post-natal organs and tissues. Journal of Cell Science 119(11):2204-2213. 
Mendicino M, Bailey AM, Wonnacott K, Puri RK, Bauer SR. 2014. MSC-based product 
characterization for clinical trials: an FDA perspective. Cell Stem Cell 14(2):141-5. 
Merten OW, Dante J, Noguiez-Hellin P, Laune S, Klatzmann D, Salzmann JL. 1997. New Process 
for Cell Detachment: Use of Heparin. In: Carrondo MT, Griffiths B, Moreira JP, editors. 
Animal Cell Technology: Springer Netherlands. p 343-348. 
Mikola M, Seto J, Amanullah A. 2007. Evaluation of a novel Wave Bioreactor® cellbag for aerobic 
yeast cultivation. Bioprocess and Biosystems Engineering 30(4):231-241. 
Mimeault M, Batra SK. 2006. Concise review: Recent advances on the significance of stem cells 
in tissue regeneration and cancer therapies. Stem Cells 24(11):2319-2345. 
Mimeault M, Hauke R, Batra SK. 2007. Stem cells: A revolution in therapeutics - Recent advances 
in stem cell biology and their therapeutic applications in regenerative medicine and 
cancer therapies. Clinical Pharmacology & Therapeutics 82(3):252-264. 
Mitchell PD, Ratcliffe E, Hourd P, Williams DJ, Thomas RJ. 2014. A quality-by-design approach to 
risk reduction and optimization for human embryonic stem cell cryopreservation 
processes. Tissue Eng Part C Methods 20(12):941-50. 
Moelker AD, Baks T, Wever KM, Spitskovsky D, Wielopolski PA, van Beusekom HM, van Geuns 
RJ, Wnendt S, Duncker DJ, van der Giessen WJ. 2007. Intracoronary delivery of umbilical 
cord blood derived unrestricted somatic stem cells is not suitable to improve LV function 
after myocardial infarction in swine. J Mol Cell Cardiol 42(4):735-45. 
Mohyeldin A, Garzón-Muvdi T, Quiñones-Hinojosa A. 2010. Oxygen in Stem Cell Biology: A 
Critical Component of the Stem Cell Niche. Cell Stem Cell 7(2):150-161. 
References 
 
 
267 | P a g e  
 
Moll G, Alm JJ, Davies LC, von Bahr L, Heldring N, Stenbeck-Funke L, Hamad OA, Hinsch R, 
Ignatowicz L, Locke M and others. 2014a. Do cryopreserved mesenchymal stromal cells 
display impaired immunomodulatory and therapeutic properties? Stem Cells 
32(9):2430-42. 
Moll G, Alm JJ, Davies LC, von Bahr L, Heldring N, Stenbeck-Funke L, Hamad OA, Hinsch R, 
Ignatowicz L, Locke M and others. 2014b. Do Cryopreserved Mesenchymal Stromal Cells 
Display Impaired Immunomodulatory and Therapeutic Properties? STEM CELLS 
32(9):2430-2442. 
Moon YJ, Lee MW, Yang MS, Kim SK, Park JS, Kim HC, Kim HS, Lee KH, Kim YJ, Choi J. 2005. 
Expression profile of genes representing varied spectra of cell lineages in human 
umbilical cord blood-derived mesenchymal stem cells. Acta Haematol 114(2):117-20. 
Mostafa SS, Gu X. 2003. Strategies for improved dCO2 removal in large-scale fed-batch cultures. 
Biotechnol Prog 19(1):45-51. 
Mullis K, Faloona F, Scharf S, Saiki R, Horn G, Erlich H. 1992. Specific enzymatic amplification of 
DNA in vitro: the polymerase chain reaction. 1986. Biotechnology (Reading, Mass.) 
24:17-27. 
Muntion S, Sanchez-Guijo FM, Carrancio S, Villaron E, Lopez O, Diez-Campelo M, San Miguel JF, 
del Canizo MC. 2012. Optimisation of mesenchymal stromal cells karyotyping analysis: 
implications for clinical use. Transfus Med 22(2):122-7. 
Naing MW, Gibson DA, Hourd P, Gomez SG, Horton RB, Segal J, Williams DJ. 2015a. Improving 
umbilical cord blood processing to increase total nucleated cell count yield and reduce 
cord input wastage by managing the consequences of input variation. Cytotherapy 
17(1):58-67. 
Naing MW, Gibson DA, Hourd P, Gomez SG, Horton RBV, Segal J, Williams DJ. 2015b. Improving 
umbilical cord blood processing to increase total nucleated cell count yield and reduce 
cord input wastage by managing the consequences of input variation. Cytotherapy 
17(1):58-67. 
Nienow AW. 1997. The suspension of solid particles. In: Harnby N, Edwards MF, Nienow AW 
(eds) Mixing in the process industries, 2nd edn.: Butterworth Heinemann, London. p 
364-393. 
Nienow AW. 2003. Aeration-biotechnology. In: Kirk Othmer encyclopaedia of chemical 
technology, 5th edn.: Wiley, New York. 
Nienow AW. 2006. Reactor engineering in large scale animal cell culture. Cytotechnology 50(1-
3):9-33. 
References 
 
 
268 | P a g e  
 
Nienow AW, Hewitt CJ, Heathman TRJ, Coopman K, Rafiq QA. 2015a. Bioreactor Engineering 
Fundamentals for Stem Cell Manufacturing (In Stem Cell Manufacturing). In: Elsevier, 
editor. 
Nienow AW, Hewitt CJ, Heathman TRJ, Glyn VAM, Fonte GN, Hanga MP, Coopman K, Rafiq QA. 
2015b. Agitation Conditions for the Culture and Detachment of hMSCs from 
Microcarriers in Multiple Bioreactor Platforms. Biochemical Engineering Journal (in 
press). 
Nienow AW, Langheinrich C, Stevenson NC, Emery AN, Clayton TM, Slater NK. 1996. 
Homogenisation and oxygen transfer rates in large agitated and sparged animal cell 
bioreactors: Some implications for growth and production. Cytotechnology 22(1-3):87-
94. 
Nienow AW, Rafiq QA, Coopman K, Hewitt CJ. 2014. A potentially scalable method for the 
harvesting of hMSCs from microcarriers. Biochemical Engineering Journal 85(0):79-88. 
Nienow AW, Rielly CD, Brosnan K, Bargh N, Lee K, Coopman K, Hewitt CJ. 2013. The physical 
characterisation of a microscale parallel bioreactor platform with an industrial CHO cell 
line expressing an IgG4. Biochemical Engineering Journal 76(0):25-36. 
Noaksson K, Zoric N, Zeng X, Rao MS, Hyllner J, Semb H, Kubista M, Sartipy P. 2005. Monitoring 
differentiation of human embryonic stem cells using real-time PCR. Stem Cells 
23(10):1460-7. 
O'Cearbhaill ED, Ng KS, Karp JM. 2014. Emerging medical devices for minimally invasive cell 
therapy. Mayo Clin Proc 89(2):259-73. 
Oh SH, Hatch HM, Petersen BE. 2002. Hepatic oval 'stem' cell in liver regeneration. Semin Cell 
Dev Biol 13(6):405-9. 
Oh SKW, Chen AK, Mok Y, Chen X, Lim UM, Chin A, Choo ABH, Reuveny S. 2009. Long-term 
microcarrier suspension cultures of human embryonic stem cells. Stem Cell Research 
2(3):219-230. 
Oh SKW, Nienow AW, Al-Rubeai M, Emery AN. 1989. The effects of agitation intensity with and 
without continuous sparging on the growth and antibody production of hybridoma cells. 
Journal of Biotechnology 12(1):45-61. 
Owen M, Friedenstein AJ. 1988. STROMAL STEM-CELLS - MARROW-DERIVED OSTEOGENIC 
PRECURSORS. Ciba Foundation Symposia 136:42-60. 
Ozturk SS, Palsson BO. 1991. Growth, metabolic, and antibody production kinetics of hybridoma 
cell culture: 2. Effects of serum concentration, dissolved oxygen concentration, and 
medium pH in a batch reactor. Biotechnol Prog 7(6):481-94. 
References 
 
 
269 | P a g e  
 
Pal R, Hanwate M, Totey SM. 2008. Effect of holding time, temperature and different parenteral 
solutions on viability and functionality of adult bone marrow-derived mesenchymal 
stem cells before transplantation. J Tissue Eng Regen Med 2(7):436-44. 
Pattappa G, Heywood HK, de Bruijn JD, Lee DA. 2011. The metabolism of human mesenchymal 
stem cells during proliferation and differentiation. J Cell Physiol 226(10):2562-70. 
Pattasseril J, Varadaraju H, Lock L, Rowley JA. 2013. Downstream Technology Landscape for 
Large-Scale Therapeutic Cell Processing. BioProcess International 11(3):38-47. 
Peault B, Rudnicki M, Torrente Y, Cossu G, Tremblay JP, Partridge T, Gussoni E, Kunkel LM, Huard 
J. 2007. Stem and progenitor cells in skeletal muscle development, maintenance, and 
therapy. Mol Ther 15(5):867-77. 
Peled A, Petit I, Kollet O, Magid M, Ponomaryov T, Byk T, Nagler A, Ben-Hur H, Many A, Shultz L 
and others. 1999. Dependence of human stem cell engraftment and repopulation of 
NOD/SCID mice on CXCR4. Science 283(5403):845-8. 
Pensler JM, Bauer BS, Christensen M, Jones JCR. 1988. DIFFERENTIATION AND FORMATION OF 
BONE TISSUE IN CELL CULTURE FROM CHICK EMBRYO MESENCHYMAL PROGENITOR 
CELLS. Surgical Forum (Chicago) 39:616-618. 
Pereira RF, Halford KW, O'Hara MD, Leeper DB, Sokolov BP, Pollard MD, Bagasra O, Prockop DJ. 
1995. Cultured adherent cells from marrow can serve as long-lasting precursor cells for 
bone, cartilage, and lung in irradiated mice. Proc Natl Acad Sci U S A 92(11):4857-61. 
Pereira RF, O'Hara MD, Laptev AV, Halford KW, Pollard MD, Class R, Simon D, Livezey K, Prockop 
DJ. 1998. Marrow stromal cells as a source of progenitor cells for nonhematopoietic 
tissues in transgenic mice with a phenotype of osteogenesis imperfecta. Proc Natl Acad 
Sci U S A 95(3):1142-7. 
Peters JM, Ansari MQ. 2011. Multiparameter Flow Cytometry in the Diagnosis and Management 
of Acute Leukemia. Archives of Pathology & Laboratory Medicine 135(1):44-54. 
Petersen BE, Bowen WC, Patrene KD, Mars WM, Sullivan AK, Murase N, Boggs SS, Greenberger 
JS, Goff JP. 1999. Bone marrow as a potential source of hepatic oval cells. Science 
284(5417):1168-70. 
Pittenger MF, Le Blanc K, Phinney DG, Chan JKY. 2015. MSCs: Scientific Support for Multiple 
Therapies. Stem Cells International 2015:2. 
Pittenger MF, Mackay AM, Beck SC, Jaiswal RK, Douglas R, Mosca JD, Moorman MA, Simonetti 
DW, Craig S, Marshak DR. 1999. Multilineage potential of adult human mesenchymal 
stem cells. Science 284(5411):143-7. 
References 
 
 
270 | P a g e  
 
Pittenger MF, Martin BJ. 2004. Mesenchymal stem cells and their potential as cardiac 
therapeutics. Circulation Research 95(1):9-20. 
Pochampally R. 2008. Colony forming unit assays for MSCs. Methods Mol Biol 449:83-91. 
Pochampally RR, Smith JR, Ylostalo J, Prockop DJ. 2004. Serum deprivation of human marrow 
stromal cells (hMSCs) selects for a subpopulation of early progenitor cells with 
enhanced expression of OCT-4 and other embryonic genes. Blood 103(5):1647-52. 
Ponomaryov T, Peled A, Petit I, Taichman RS, Habler L, Sandbank J, Arenzana-Seisdedos F, 
Magerus A, Caruz A, Fujii N and others. 2000. Induction of the chemokine stromal-
derived factor-1 following DNA damage improves human stem cell function. J Clin Invest 
106(11):1331-9. 
Prado-Lopez S, Conesa A, Armiñán A, Martínez-Losa M, Escobedo-Lucea C, Gandia C, Tarazona 
S, Melguizo D, Blesa D, Montaner D and others. 2010. Hypoxia Promotes Efficient 
Differentiation of Human Embryonic Stem Cells to Functional Endothelium. STEM CELLS 
28(3):407-418. 
Prasad VK, Lucas KG, Kleiner GI, Talano JA, Jacobsohn D, Broadwater G, Monroy R, Kurtzberg J. 
2011. Efficacy and safety of ex vivo cultured adult human mesenchymal stem cells 
(Prochymal) in pediatric patients with severe refractory acute graft-versus-host disease 
in a compassionate use study. Biol Blood Marrow Transplant 17(4):534-41. 
Preffer F, Dombkowski D. 2009. Advances in Complex Multiparameter Flow Cytometry 
Technology: Applications in Stem Cell Research. Cytometry Part B-Clinical Cytometry 
76B(5):295-314. 
Prockop DJ. 1997. Marrow stromal cells as steam cells for nonhematopoietic tissues. Science 
276(5309):71-74. 
Qu-Petersen Z, Deasy B, Jankowski R, Ikezawa M, Cummins J, Pruchnic R, Mytinger J, Cao B, 
Gates C, Wernig A and others. 2002. Identification of a novel population of muscle stem 
cells in mice: potential for muscle regeneration. J Cell Biol 157(5):851-64. 
Rafiq QA, Brosnan KM, Coopman K, Nienow AW, Hewitt CJ. 2013a. Culture of human 
mesenchymal stem cells on microcarriers in a 5 l stirred-tank bioreactor. Biotechnol Lett 
35(8):1233-45. 
Rafiq QA, Coopman K, Hewitt CJ. 2013b. Scale-up of human mesenchymal stem cell culture: 
current technologies and future challenges. Current Opinion in Chemical Engineering 
2(1):8-16. 
References 
 
 
271 | P a g e  
 
Rafiq QA, Coopman K, Nienow AW, Hewitt CJ. 2013c. A quantitative approach for understanding 
small-scale human mesenchymal stem cell culture – implications for large-scale 
bioprocess development. Biotechnology Journal 8(4):459-471. 
Rafiq QA, Heathman TRJ, Coopman K, Nienow AW, Hewitt CJ. 2015a. Chapter 10. Scale-up of 
stem cell manufacture for cell therapy needs in "Bioreactors: Design, Operation and 
Novel Applications". Wiley VCH. 
Rafiq QA, Heathman TRJ, Coopman K, Nienow AW, Hewitt CJ. 2015b. Culture of human 
mesenchymal stem cells on microcarriers in multiple stirred-tank bioreactor platforms. 
(In Bioreactors for Stem Cells Biology: Methods and Protocols). In: Biology SsMiM, 
editor. 
Rasini V, Dominici M, Kluba T, Siegel G, Lusenti G, Northoff H, Horwitz EM, Schafer R. 2013. 
Mesenchymal stromal/stem cells markers in the human bone marrow. Cytotherapy 
15(3):292-306. 
Rayment EA, Williams DJ. 2010. Concise review: mind the gap: challenges in characterizing and 
quantifying cell- and tissue-based therapies for clinical translation. Stem Cells 28(5):996-
1004. 
Reya T, Morrison SJ, Clarke MF, Weissman IL. 2001. Stem cells, cancer, and cancer stem cells. 
Nature 414(6859):105-111. 
Reyes M, Verfaillie CM. 2001. Characterization of multipotent adult progenitor cells, a 
subpopulation of mesenchymal stem cells. In: Orlic D, Brummendorf TH, Sharkis SJ, Kanz 
L, editors. Hematopoietic Stem Cells 2000 Basic and Clinical Sciences. New York: New 
York Acad Sciences. p 231-235. 
Rich IN, Hall KM. 2005. Validation and development of a predictive paradigm for hemotoxicology 
using a multifunctional bioluminescence colony-forming proliferation assay. Toxicol Sci 
87(2):427-41. 
Riekstina U, Cakstina I, Parfejevs V, Hoogduijn M, Jankovskis G, Muiznieks I, Muceniece R, 
Ancans J. 2009. Embryonic stem cell marker expression pattern in human mesenchymal 
stem cells derived from bone marrow, adipose tissue, heart and dermis. Stem Cell Rev 
5(4):378-86. 
Rodrigues JP, Paraguassu-Braga FH, Carvalho L, Abdelhay E, Bouzas LF, Porto LC. 2008. 
Evaluation of trehalose and sucrose as cryoprotectants for hematopoietic stem cells of 
umbilical cord blood. Cryobiology 56(2):144-51. 
Rowley J, Abraham E, Campbell A, Brandwein H, Oh S. 2012a. Meeting lot-size challenges of 
manufacturing adherent cells for therapy. BioProcess International 10(1):16-22. 
References 
 
 
272 | P a g e  
 
Rowley J, Abraham E, Campbell A, Brandwein H, Oh S. 2012b. Meeting Lot-Size Challenges of 
Manufacturing Adherent Cells for Therapy. BioProcess International 10(3):16-22. 
Ruan ZB, Zhu L, Yin YG, Chen GC. 2014. Karyotype stability of human umbilical cord-derived 
mesenchymal stem cells during culture. Exp Ther Med 8(5):1508-1512. 
S. Rathore A, Kapoor G, Flickinger MC. 2009. Process Analytical Technology: Strategies for 
Biopharmaceuticals. Encyclopedia of Industrial Biotechnology: John Wiley & Sons, Inc. 
Saiki RK, Gelfand DH, Stoffel S, Scharf SJ, Higuchi R, Horn GT, Mullis KB, Erlich HA. 1988. PRIMER-
DIRECTED ENZYMATIC AMPLIFICATION OF DNA WITH A THERMOSTABLE DNA-
POLYMERASE. Science 239(4839):487-491. 
Saiki RK, Scharf S, Faloona F, Mullis KB, Horn GT, Erlich HA, Arnheim N. 1985. ENZYMATIC 
AMPLIFICATION OF BETA-GLOBIN GENOMIC SEQUENCES AND RESTRICTION SITE 
ANALYSIS FOR DIAGNOSIS OF SICKLE-CELL ANEMIA. Science 230(4732):1350-1354. 
Sakaguchi Y, Sekiya I, Yagishita K, Muneta T. 2005. Comparison of human stem cells derived from 
various mesenchymal tissues: superiority of synovium as a cell source. Arthritis Rheum 
52(8):2521-9. 
Saki N, Jalalifar MA, Soleimani M, Hajizamani S, Rahim F. 2013. Adverse Effect of High Glucose 
Concentration on Stem Cell Therapy. International Journal of Hematology-Oncology and 
Stem Cell Research 7(3):34-40. 
Samsonraj RM, Rai B, Sathiyanathan P, Puan KJ, Rotzschke O, Hui JH, Raghunath M, Stanton LW, 
Nurcombe V, Cool SM. 2015. Establishing criteria for human mesenchymal stem cell 
potency. Stem Cells 33(6):1878-91. 
Santos F, Andrade PZ, Abecasis MM, Gimble JM, Chase LG, Campbell AM, Boucher S, Vemuri 
MC, Silva CL, Cabral JM. 2011. Toward a clinical-grade expansion of mesenchymal stem 
cells from human sources: a microcarrier-based culture system under xeno-free 
conditions. Tissue Eng Part C Methods 17(12):1201-10. 
Sarugaser R, Lickorish D, Baksh D, Hosseini MM, Davies JE. 2005. Human umbilical cord 
perivascular (HUCPV) cells: a source of mesenchymal progenitors. Stem Cells 23(2):220-
9. 
Schallmoser K, Bartmann C, Rohde E, Bork S, Guelly C, Obenauf AC, Reinisch A, Horn P, Ho AD, 
Strunk D and others. 2010. Replicative senescence-associated gene expression changes 
in mesenchymal stromal cells are similar under different culture conditions. 
Haematologica 95(6):867-74. 
References 
 
 
273 | P a g e  
 
Schellenberg A, Stiehl T, Horn P, Joussen S, Pallua N, Ho AD, Wagner W. 2012. Population 
dynamics of mesenchymal stromal cells during culture expansion. Cytotherapy 
14(4):401-11. 
Schop D, Janssen FW, Borgart E, de Bruijn JD, van Dijkhuizen-Radersma R. 2008. Expansion of 
mesenchymal stem cells using a microcarrier-based cultivation system: growth and 
metabolism. J Tissue Eng Regen Med 2(2-3):126-35. 
Schop D, Janssen FW, van Rijn LD, Fernandes H, Bloem RM, de Bruijn JD, van Dijkhuizen-
Radersma R. 2009a. Growth, metabolism, and growth inhibitors of mesenchymal stem 
cells. Tissue Eng Part A 15(8):1877-86. 
Schop D, Janssen FW, van Rijn LDS, Fernandes H, Bloem RM, de Bruijn JD, van Dijkhuizen-
Radersma R. 2009b. Growth, Metabolism, and Growth Inhibitors of Mesenchymal Stem 
Cells. Tissue Engineering Part A 15(8):1877-1886. 
Schwartz RE, Reyes M, Koodie L, Jiang YH, Blackstad M, Lund T, Lenvik T, Johnson S, Hu WS, 
Verfaillie CM. 2002. Multipotent adult progenitor cells from bone marrow differentiate 
into functional hepatocyte-like cells. Journal of Clinical Investigation 109(10):1291-
1302. 
Schwartz SD, Hubschman J-P, Heilwell G, Franco-Cardenas V, Pan CK, Ostrick RM, Mickunas E, 
Gay R, Klimanskaya I, Lanza R. 2012. Embryonic stem cell trials for macular 
degeneration: a preliminary report. The Lancet 379(9817):713-720. 
Seaberg RM, Smukler SR, Kieffer TJ, Enikolopov G, Asghar Z, Wheeler MB, Korbutt G, van der 
Kooy D. 2004. Clonal identification of multipotent precursors from adult mouse 
pancreas that generate neural and pancreatic lineages. Nat Biotechnol 22(9):1115-24. 
Services USDoHaH. 2004. Guidance for industry: PAT—a framework for innovative 
pharmaceutical development, manufacturing and quality assurance. 
http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/G
uidances/ucm070305.pdf Food and Drug Administration. 
Sethe S, Scutt A, Stolzing A. 2006. Aging of mesenchymal stem cells. Ageing Res Rev 5(1):91-116. 
Shaffer AL, Shapiro-Shelef M, Iwakoshi NN, Lee AH, Qian SB, Zhao H, Yu X, Yang L, Tan BK, 
Rosenwald A and others. 2004. XBP1, downstream of Blimp-1, expands the secretory 
apparatus and other organelles, and increases protein synthesis in plasma cell 
differentiation. Immunity 21(1):81-93. 
Shi S, Gronthos S. 2003. Perivascular niche of postnatal mesenchymal stem cells in human bone 
marrow and dental pulp. J Bone Miner Res 18(4):696-704. 
References 
 
 
274 | P a g e  
 
Shih DT, Lee DC, Chen SC, Tsai RY, Huang CT, Tsai CC, Shen EY, Chiu WT. 2005. Isolation and 
characterization of neurogenic mesenchymal stem cells in human scalp tissue. Stem 
Cells 23(7):1012-20. 
Siddappa R, Licht R, van Blitterswijk C, de Boer J. 2007. Donor variation and loss of multipotency 
during in vitro expansion of human mesenchymal stem cells for bone tissue engineering. 
Journal of Orthopaedic Research 25(8):1029-1041. 
Sieblist C, Hägeholz O, Aehle M, Jenzsch M, Pohlscheidt M, Lübbert A. 2011. Insights into large-
scale cell-culture reactors: II. Gas-phase mixing and CO2 stripping. Biotechnology 
Journal 6(12):1547-1556. 
Siegel G, Kluba T, Hermanutz-Klein U, Bieback K, Northoff H, Schäfer R. 2013. Phenotype, donor 
age and gender affect function of human bone marrow-derived mesenchymal stromal 
cells. BMC Medicine 11(1):1-20. 
Simaria AS, Hassan S, Varadaraju H, Rowley J, Warren K, Vanek P, Farid SS. 2014. Allogeneic cell 
therapy bioprocess economics and optimization: Single-use cell expansion technologies. 
Biotechnology and Bioengineering 111(1):69-83. 
Siminovitch L, McCulloch EA, Till JE. 1963. DISTRIBUTION OF COLONY-FORMING CELLS AMONG 
SPLEEN COLONIES. Journal of Cellular and Comparative Physiology 62(3):327-&. 
Singh V. 1999. Disposable bioreactor for cell culture using wave-induced agitation. 
Cytotechnology 30(1-3):149-158. 
Small EJ, Schellhammer PF, Higano CS, Redfern CH, Nemunaitis JJ, Valone FH, Verjee SS, Jones 
LA, Hershberg RM. 2006. Placebo-controlled phase III trial of immunologic therapy with 
sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory 
prostate cancer. J Clin Oncol 24(19):3089-94. 
Sohni A, Verfaillie CM. 2013. Mesenchymal Stem Cells Migration Homing and Tracking. Stem 
Cells International 2013:8. 
Soncini M, Vertua E, Gibelli L, Zorzi F, Denegri M, Albertini A, Wengler GS, Parolini O. 2007. 
Isolation and characterization of mesenchymal cells from human fetal membranes. J 
Tissue Eng Regen Med 1(4):296-305. 
Song I-H, Caplan AI, Dennis JE. 2009. Dexamethasone inhibition of confluence-induced apoptosis 
in human mesenchymal stem cells. Journal of Orthopaedic Research 27(2):216-221. 
Spees JL, Gregory CA, Singh H, Tucker HA, Peister A, Lynch PJ, Hsu SC, Smith J, Prockop DJ. 2004. 
Internalized antigens must be removed to prepare hypoimmunogenic mesenchymal 
stem cells for cell and gene therapy. Mol Ther 9(5):747-56. 
References 
 
 
275 | P a g e  
 
Stolzing A, Bauer E, Scutt A. 2012. Suspension cultures of bone-marrow-derived mesenchymal 
stem cells: effects of donor age and glucose level. Stem Cells Dev 21(14):2718-23. 
Stolzing A, Coleman N, Scutt A. 2006. Glucose-induced replicative senescence in mesenchymal 
stem cells. Rejuvenation Res 9(1):31-5. 
Stolzing A, Scutt A. 2006. Age-related impairment of mesenchymal progenitor cell function. 
Aging Cell 5(3):213-24. 
Streitz M, Miloud T, Kapinsky M, Reed MR, Magari R, Geissler EK, Hutchinson JA, Vogt K, 
Schlickeiser S, Kverneland AH and others. 2013. Standardization of whole blood immune 
phenotype monitoring for clinical trials: panels and methods from the ONE study. 
Transplantation Research 2:17-17. 
Stroncek DF, Jin P, Wang E, Ren J, Sabatino M, Marincola FM. 2009. Global Transcriptional 
Analysis for Biomarker Discovery and Validation in Cellular Therapies. Molecular 
Diagnosis & Therapy 13(3):181-193. 
Sun X, Long X, Yin Y, Jiang Y, Chen X, Liu W, Zhang W, Du H, Li S, Zheng Y and others. 2008. Similar 
biological characteristics of human embryonic stem cell lines with normal and abnormal 
karyotypes. Hum Reprod 23(10):2185-93. 
Sunil N, Punreddy S, Niss K, Jing D. 2014. Expansion of Human Mesenchymal Stem Cells: Using 
Microcarriers and Human Platelet Lysate. BioProcess International 12(8):74-78. 
Suzuki S, Muneta T, Tsuji K, Ichinose S, Makino H, Umezawa A, Sekiya I. 2012. Properties and 
usefulness of aggregates of synovial mesenchymal stem cells as a source for cartilage 
regeneration. Arthritis Res Ther 14(3):R136. 
Takahashi K, Tanabe K, Ohnuki M, Narita M, Ichisaka T, Tomoda K, Yamanaka S. 2007. Induction 
of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 
131(5):861-872. 
Takahashi K, Yamanaka S. 2006. Induction of pluripotent stem cells from mouse embryonic and 
adult fibroblast cultures by defined factors. Cell 126(4):663-676. 
Tamama K, Kawasaki H, Kerpedjieva SS, Guan J, Ganju RK, Sen CK. 2011. Differential roles of 
hypoxia inducible factor subunits in multipotential stromal cells under hypoxic 
condition. Journal of cellular biochemistry 112(3):804-817. 
Tan KY, Teo KL, Lim JF, Chen AK, Reuveny S, Oh SK. 2015. Serum-free media formulations are 
cell line-specific and require optimization for microcarrier culture. Cytotherapy 
17(8):1152-65. 
Tarnok A, Ulrich H, Bocsi J. 2010. Phenotypes of Stem Cells from Diverse Origin. Cytometry Part 
A 77A(1):6-10. 
References 
 
 
276 | P a g e  
 
Tavassol.M, Crosby WH. 1968. TRANSPLANTATION OF MARROW TO EXTRAMEDULLARY SITES. 
Science 161(3836):54-&. 
Tchkonia T, Zhu Y, Deursen Jv, Campisi J, Kirkland JL. 2013. Cellular senescence and the 
senescent secretory phenotype: therapeutic opportunities. The American Society for 
Clinical Investigation 123(3):966-972. 
The Emerging Risk Factors C. 2010. Diabetes mellitus, fasting blood glucose concentration, and 
risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. Lancet 
375(9733):2215-2222. 
Thomas RJ, Chandra A, Liu Y, Hourd PC, Conway PP, Williams DJ. 2007. Manufacture of a human 
mesenchymal stem cell population using an automated cell culture platform. 
Cytotechnology 55(1):31-9. 
Thomson JA, Itskovitz-Eldor J, Shapiro SS, Waknitz MA, Swiergiel JJ, Marshall VS, Jones JM. 1998. 
Embryonic stem cell lines derived from human blastocysts. Science 282(5391):1145-
1147. 
Till JE. 1961. RADIATION EFFECTS ON DIVISION CYCLE OF MAMMALIAN CELLS IN VITRO. Annals 
of the New York Academy of Sciences 95(2):911-&. 
Till JE, McCulloch EA. 1961. DIRECT MEASUREMENT OF RADIATION SENSITIVITY OF NORMAL 
MOUSE BONE MARROW CELLS. Radiation Research 14(2):213-&. 
Timmins NE, Kiel M, Gunther M, Heazlewood C, Doran MR, Brooke G, Atkinson K. 2012. Closed 
system isolation and scalable expansion of human placental mesenchymal stem cells. 
Biotechnol Bioeng 109(7):1817-26. 
Toma JG, Akhavan M, Fernandes KJ, Barnabe-Heider F, Sadikot A, Kaplan DR, Miller FD. 2001. 
Isolation of multipotent adult stem cells from the dermis of mammalian skin. Nat Cell 
Biol 3(9):778-84. 
Tondreau T, Lagneaux L, Dejeneffe M, Massy M, Mortier C, Delforge A, Bron D. 2004. Bone 
marrow-derived mesenchymal stem cells already express specific neural proteins 
before any differentiation. Differentiation 72(7):319-326. 
Trainor N, Pietak A, Smith T. 2014. Rethinking clinical delivery of adult stem cell therapies. Nat 
Biotech 32(8):729-735. 
Tremain N, Korkko J, Ibberson D, Kopen GC, DiGirolamo C, Phinney DG. 2001. MicroSAGE 
analysis of 2,353 expressed genes in a single cell-derived colony of undifferentiated 
human mesenchymal stem cells reveals mRNAs of multiple cell lineages. Stem Cells 
19(5):408-18. 
References 
 
 
277 | P a g e  
 
Trummer E, Fauland K, Seidinger S, Schriebl K, Lattenmayer C, Kunert R, Vorauer-Uhl K, Weik R, 
Borth N, Katinger H and others. 2006. Process parameter shifting: Part I. Effect of DOT, 
pH, and temperature on the performance of Epo-Fc expressing CHO cells cultivated in 
controlled batch bioreactors. Biotechnol Bioeng 94(6):1033-44. 
Tse WT, Pendleton JD, Beyer WM, Egalka MC, Guinan EC. 2003. Suppression of allogeneic T-cell 
proliferation by human marrow stromal cells: implications in transplantation. 
Transplantation 75(3):389-97. 
Tuschong L, Soenen SL, Blaese RM, Candotti F, Muul LM. 2002. Immune response to fetal calf 
serum by two adenosine deaminase-deficient patients after T cell gene therapy. Hum 
Gene Ther 13(13):1605-10. 
Uccelli A, Moretta L, Pistoia V. 2006. Immunoregulatory function of mesenchymal stem cells. 
Eur J Immunol 36(10):2566-73. 
Uccelli A, Moretta L, Pistoia V. 2008. Mesenchymal stem cells in health and disease. Nature 
Reviews Immunology 8(9):726-736. 
Unger C, Skottman H, Blomberg P, Dilber MS, Hovatta O. 2008. Good manufacturing practice 
and clinical-grade human embryonic stem cell lines. Hum Mol Genet 17(R1):R48-53. 
Veevers-Lowe J, Ball SG, Shuttleworth A, Kielty CM. 2011. Mesenchymal stem cell migration is 
regulated by fibronectin through alpha5beta1-integrin-mediated activation of PDGFR-
beta and potentiation of growth factor signals. J Cell Sci 124(Pt 8):1288-300. 
Viswanathan S, Keating A, Deans R, Hematti P, Prockop D, Stroncek DF, Stacey G, Weiss DJ, 
Mason C, Rao MS. 2014. Soliciting strategies for developing cell-based reference 
materials to advance mesenchymal stromal cell research and clinical translation. Stem 
Cells Dev 23(11):1157-67. 
von Bahr L, Batsis I, Moll G, Hagg M, Szakos A, Sundberg B, Uzunel M, Ringden O, Le Blanc K. 
2012. Analysis of tissues following mesenchymal stromal cell therapy in humans 
indicates limited long-term engraftment and no ectopic tissue formation. Stem Cells 
30(7):1575-8. 
Vrábel P, van der Lans RGJM, Luyben KCAM, Boon L, Nienow AW. 2000. Mixing in large-scale 
vessels stirred with multiple radial or radial and axial up-pumping impellers: modelling 
and measurements. Chemical Engineering Science 55(23):5881-5896. 
Wada MR, Inagawa-Ogashiwa M, Shimizu S, Yasumoto S, Hashimoto N. 2002. Generation of 
different fates from multipotent muscle stem cells. Development 129(12):2987-95. 
Wagner W, Feldmann RE, Jr., Seckinger A, Maurer MH, Wein F, Blake J, Krause U, Kalenka A, 
Burgers HF, Saffrich R and others. 2006. The heterogeneity of human mesenchymal 
References 
 
 
278 | P a g e  
 
stem cell preparations--evidence from simultaneous analysis of proteomes and 
transcriptomes. Exp Hematol 34(4):536-48. 
Wagner W, Ho AD, Zenke M. 2010. Different facets of aging in human mesenchymal stem cells. 
Tissue Eng Part B Rev 16(4):445-53. 
Wagner W, Wein F, Seckinger A, Frankhauser M, Wirkner U, Krause U, Blake J, Schwager C, 
Eckstein V, Ansorge W and others. 2005. Comparative characteristics of mesenchymal 
stem cells from human bone marrow, adipose tissue, and umbilical cord blood. Exp 
Hematol 33(11):1402-16. 
Wakitani S, Saito T, Caplan AI. 1995. MYOGENIC CELLS DERIVED FROM RAT BONE-MARROW 
MESENCHYMAL STEM-CELLS EXPOSED TO 5-AZACYTIDINE. Muscle & Nerve 
18(12):1417-1426. 
Wang HS, Hung SC, Peng ST, Huang CC, Wei HM, Guo YJ, Fu YS, Lai MC, Chen CC. 2004. 
Mesenchymal stem cells in the Wharton's jelly of the human umbilical cord. Stem Cells 
22(7):1330-1337. 
Wang M, Crisostomo PR, Herring C, Meldrum KK, Meldrum DR. 2006. Human progenitor cells 
from bone marrow or adipose tissue produce VEGF, HGF, and IGF-I in response to TNF 
by a p38 MAPK-dependent mechanism. Am J Physiol Regul Integr Comp Physiol 
291(4):R880-4. 
Wappler J, Rath B, Laufer T, Heidenreich A, Montzka K. 2013. Eliminating the need of serum 
testing using low serum culture conditions for human bone marrow-derived 
mesenchymal stromal cell expansion. Biomed Eng Online 12:15. 
Weil BR, Abarbanell AM, Herrmann JL, Wang Y, Meldrum DR. 2009. High glucose concentration 
in cell culture medium does not acutely affect human mesenchymal stem cell growth 
factor production or proliferation. Am J Physiol Regul Integr Comp Physiol 
296(6):R1735-43. 
Williams DJ, Thomas RJ, Hourd PC, Chandra A, Ratcliffe E, Liu Y, Rayment EA, Archer JR. 2012. 
Precision manufacturing for clinical-quality regenerative medicines. Philos Trans A Math 
Phys Eng Sci 370(1973):3924-49. 
Windrum P, Morris TC. 2003. Severe neurotoxicity because of dimethyl sulphoxide following 
peripheral blood stem cell transplantation. Bone Marrow Transplant 31(4):315. 
Woodbury D, Schwarz EJ, Prockop DJ, Black IB. 2000. Adult rat and human bone marrow stromal 
cells differentiate into neurons. Journal of Neuroscience Research 61(4):364-370. 
Wu J, Rostami MR, Cadavid Olaya DP, Tzanakakis ES. 2014. Oxygen Transport and Stem Cell 
Aggregation in Stirred-Suspension Bioreactor Cultures. PLoS ONE 9(7):e102486. 
References 
 
 
279 | P a g e  
 
Wuchter P, Bieback K, Schrezenmeier H, Bornhauser M, Muller LP, Bonig H, Wagner W, Meisel 
R, Pavel P, Tonn T and others. 2014. Standardization of Good Manufacturing Practice-
compliant production of bone marrow-derived human mesenchymal stromal cells for 
immunotherapeutic applications. Cytotherapy. 
Wuertz K, Godburn K, Iatridis JC. 2009. MSC response to pH levels found in degenerating 
intervertebral discs. Biochemical and biophysical research communications 379(4):824-
829. 
Yamachika E, Iida S. 2013. Bone regeneration from mesenchymal stem cells (MSCs) and compact 
bone-derived MSCs as an animal model. Japanese Dental Science Review 49(1):35-44. 
Yamaguchi A, Katagiri T, Ikeda T, Wozney JM, Rosen V, Wang EA, Kahn AJ, Suda T, Yoshiki S. 
1991. RECOMBINANT HUMAN BONE MORPHOGENETIC PROTEIN-2 STIMULATES 
OSTEOBLASTIC MATURATION AND INHIBITS MYOGENIC DIFFERENTIATION INVITRO. 
Journal of Cell Biology 113(3):681-687. 
Yang H, Acker JP, Cabuhat M, Letcher B, Larratt L, McGann LE. 2005. Association of post-thaw 
viable CD34+ cells and CFU-GM with time to hematopoietic engraftment. Bone Marrow 
Transplant 35(9):881-7. 
Yu Y, Li K, Bao C, Liu T, Jin Y, Ren H, Yun W. 2009. Ex vitro expansion of human placenta-derived 
mesenchymal stem cells in stirred bioreactor. Appl Biochem Biotechnol 159(1):110-8. 
Zeikus G; PRS Biotech, Inc., assignee. 2009. Pneumatic bioreactor. 
Zisa D, Shabbir A, Suzuki G, Lee T. 2009. Vascular endothelial growth factor (VEGF) as a key 
therapeutic trophic factor in bone marrow mesenchymal stem cell-mediated cardiac 
repair. Biochemical and Biophysical Research Communications 390(3):834-838. 
Zuk PA, Zhu M, Ashjian P, De Ugarte DA, Huang JI, Mizuno H, Alfonso ZC, Fraser JK, Benhaim P, 
Hedrick MH. 2002. Human adipose tissue is a source of multipotent stem cells. 
Molecular Biology of the Cell 13(12):4279-4295. 
Zuk PA, Zhu M, Mizuno H, Huang J, Futrell JW, Katz AJ, Benhaim P, Lorenz HP, Hedrick MH. 2001. 
Multilineage cells from human adipose tissue: Implications for cell-based therapies. 
Tissue Engineering 7(2):211-228. 
 
 
Appendices 
 
 
280 | P a g e  
 
Appendices 
 
Appendix A. Development of a quantitative osteogenesis assay 
For the development of the quantitative osteogenesis assay, a method to measure the amount 
of deposited collagen by BM-hMSCs under osteogenic differentiation must be validated. This is 
important as traditional qualitative methods of demonstrating BM-hMSC differentiation 
potential are not useful for comparing changing conditions during process development. In 
order to compare the effect of different process conditions on the osteogenic potential of BM-
hMSCs, an assay must be developed to facilitate this.    
 
 
Experimental Protocol 
The details of the osteogenic assay protocol can be found in Section 3.4.8. The aim of this 
investigation was to quantify the amount of collagen deposited under osteogenic conditions by 
producing a collagen standard and to determine whether this was more than is typically 
produced in normal culture.  
 
For the collagen standards, acid-soluble collagen Type I at 0, 0.1, 0.2 and 0.4 g.L-1 were 
formulated in sterile filtered deionised water at an n = 5. Each of these was treated with Sircol-
red dye reagent and washed three times with deionised water to dilute unbound dye reagent. 
This solution was then washed with ice-cold acid salt wash reagent to remove traces of dye 
reagent, so that only dye reagent bound to collagen remained. An alkali reagent was then added 
to each of the standards to released bound dye reagent from the collagen and five samples of 
100 µL for each concentration were transferred to a 96 well plate for analysis. This plate was 
then analysed on a plate reader at an absorbance of 555 nm and values normalised to the 
reagent blanks (0 µ.L-1 collagen).  
 
To compare the levels of collagen production under osteogenic differentiation and normal 
culture, two 12-well plates were set up with 38,000 BM-hMSCs per well, both containing six 
wells of DMEM and 10% FBS and six wells containing PRIME-XV® Serum-free Osteogenic 
Medium. The first of these 12-well plates was cultured for three days before being sacrificed 
and analysed as per the protocol in Section 3.4.8, with the other being cultured for six days with 
a complete medium exchange taking place on day three.   
 
Appendices 
 
 
281 | P a g e  
 
Results 
The results of the collagen standard can be seen in Figure 11.1 which shows a strong correlation 
of R2 = 0.975 and an equation of y = 0.3869x. Using this correlation, the actual amount of 
collagen deposition can be calculated for future experimental conditions.  
 
 
 
Figure 11.1. Collagen standard to quantify the amount of collagen produced during osteogenic 
culture of BM-hMSCs based on the plate reader absorbance 
 
 
In order to assess whether the BM-hMSCs produce more collagen under osteogenic conditions 
a comparison was made between BM-hMSCs under osteogenic conditions and under normal 
culture conditions. Figure 11.2 shows the level of expression between these conditions with the 
day three level of collagen produced under osteogenic conditions being significantly higher (p < 
0.05) than under normal culture conditions. The level of collagen under osteogenic conditions 
at day six was still higher, although not significantly so in this instance (p > 0.05). This is likely 
caused by the BM-hMSC population under normal culture conditions continuing proliferation 
and increasing the number of BM-hMSCs per well, whereas under osteogenic conditions the 
BM-hMSC proliferation is limited and there are less cells per well at day six. For a direct 
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comparison of the osteogenic potential of BM-hMSCs for different process conditions, however, 
this assay can be used as an aid to process development.  
 
 
 
Figure 11.2. The level of collagen deposition in normal culture and osteogenic culture showing 
the higher level of collagen production under osteogenic conditions   
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Appendix B. Screening of HPL concentration in DMEM 
 
Human platelet lysate (HPL) has been previously demonstrated as a viable alternative to FBS to 
supplement the culture medium for the expansion of BM-hMSCs. Prior to carrying out 
experiments using HPL, a screening study must be undertaken to find the concentration of HPL 
that best reflects the BM-hMSC performance in 10% FBS. This is important as the amount of 
serum used in culture should be minimised, without having a detrimental impact of the growth 
and characteristics of the BM-hMSCs.   
 
 
Experimental Protocol 
In order to make a direct comparison to 10% FBS, BM-hMSC line M2 was selected due to its 
stable growth characteristics in FBS culture. This was compared to 2, 5 and 10% (v/v) HPL in 
DMEM, formulated according to the protocol described in Section 3.2.1. To make this 
comparison, four T-75 flasks were seeded with M2 BM-hMSCs per experimental condition giving 
a total of 16 flasks, which were cultured for three passages according to the protocol described 
in Section 3.2.5. At the end of each passage, the cell number was determined using the protocol 
in Section 3.4.2 and the growth kinetics calculated. In conjunction with this, daily medium 
samples were taken and analysed on the Nova BioProfile FLEX for glucose, lactate and 
ammonium concentrations as described in Section 3.4.6. From the growth kinetics data and the 
relative metabolite concentrations over each passage, the net flux per cell of each metabolite 
was calculated.  
 
 
Results 
The growth kinetics of M2 BM-hMSCs can be seen in Figure 11.3 which shows the increased BM-
hMSC growth kinetics as the concentration of HPL is increased up to 10% (v/v). It is clear also 
that the BM-hMSCs undergo an adaption passage in HPL as the first passage in all concentration 
of HPL is significantly higher (p < 0.05) than the subsequent passages. This is likely due to the 
presence of residual FBS in the culture which supplies additional proteins to support BM-hMSC 
growth that is diluted out through the first passage (Dolley-Sonneville et al. 2013). Following 
this first passage, the number of population doublings stabilises for passages four and five. This 
is also an important finding as it demonstrates that one adaption passage is required prior to 
subsequent experiments involving HPL to allow the growth kinetics of the BM-hMSCs to 
stabilise.      
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Figure 11.3. Population doublings of BM-hMSCs in various concentrations of HPL compared 
with 10% FBS, showing the increased proliferation in the first passage under HPL and the 
increased proliferation at the concentration of HPL in increased. Data shows mean ± SD, n = 4 
 
 
 
 
Figure 11.4. Cumulative population doublings of BM-hMSCs in various concentration of HPL 
compared with 10% FBS over three passages. Showing a similar number of cumulative 
population doublings in 10% HPL and 10% FBS. Data shows mean ± SD, n = 4 
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The number of cumulative population doublings for each condition can be seen in Figure 11.4, 
which shows that the BM-hMSCs cultured in 2% HPL had significantly reduced cumulative 
population doublings (p < 0.01) compared to the other conditions over the three experimental 
passages. Despite the similar number of population doublings at passage three, BM-hMSCs 
cultured in 5% HPL showed a decline in growth kinetics over the subsequent two passages and 
finished with a lower number of cumulative population doublings. In contrast, BM-hMSCs 
cultured in 10% HPL demonstrated a similar number of cumulative population doublings after 
three passages (p > 0.05) compared to BM-hMSCs cultured in 10% FBS. From these data, it can 
be concluded that in terms of BM-hMSC growth kinetics over three passages, 10% HPL is the 
most comparable to 10% FBS.  
 
 
 
Figure 11.5. Phase contrast images showing the morphological changes to M2 BM-hMSCs in 
HPL compared with FBS.  
 
Appendices 
 
 
286 | P a g e  
 
The morphology of M2 BM-hMSCs in 2, 5, and 10% HPL compared with 10% FBS can be seen in 
Figure 11.5. The morphology of the BM-hMSCs cultured in HPL shows a marked difference 
compared with FBS, with BM-hMSCs in FBS demonstrating a more spindle-shaped and 
elongated morphology. It is apparent, however, that the concentration of HPL the BM-hMSCs 
are cultured in does not affect their morphology, which is similar for 2, 5 and 10% HPL. Despite 
the differences in morphology compared to FBS, this demonstrates that the concentration of 
HPL used in culture will not affect their morphology, an important characteristics for adherent 
cell expansion.  
   
 
 
Figure 11.6. Glucose consumption rate of BM-hMSCs over three passages in various 
concentrations of HPL and 10% FBS. Data shows mean ± SD, n = 4 
 
 
The net metabolite flux of BM-hMSCs between experimental conditions is an important 
parameter to assess, as it provides a quantitative indication of the effect that varying the 
concentration of HPL in culture has on the metabolic profile of BM-hMSCs. Considering that 
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metabolite concentrations are key process parameters that can be measured online, it will be 
important to ensure they remain stable under different culture conditions.  
 
Figure 11.6 shows the glucose consumption rate of M2 BM-hMSCs over the three experimental 
passages in each condition. The net glucose consumption rate in 2, 5 and 10% HPL remained 
between 10 – 12 pmol.cell-1.day-1 across the three passages, which was reduced compared with 
10% FBS. In contrast, Figure 11.7 shows that the relative lactate production rate of the BM-
hMSCs decreases as the concentration of HPL in culture is reduced. Furthermore, the net 
production rate of lactate in 10% FBS culture of BM-hMSCs is similar to 10% HPL, a further 
indication that 10% HPL supports the expansion of BM-hMSCs in a similar way to 10% FBS.  
 
 
Figure 11.7. Lactate production rate of BM-hMSCs over three passages in various 
concentrations of HPL and 10% FBS. Showing the reduction in lactate production rate as the 
level of HPL decreases. Data shows mean ± SD, n = 4 
 
The relative production rate of ammonium for BM-hMSCs in all conditions can be seen in Figure 
11.8, which in contrast to the net lactate production rate, increases as the concentration of HPL 
is decreased. This is an indication that reducing the concentration of HPL in the culture medium 
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encourages BM-hMSCs to reduce the flux through the aerobic glycolysis pathway and increase 
the utilisation of the glutamine to glutamate pathway, as demonstrated by the increase in 
ammonium production. It can be seen from Figure 11.8, however, that the net production of 
ammonium in 10% HPL is the most similar to 10% FBS, in accordance with the similarity in the 
BM-hMSC growth kinetics over the three passages.  
 
 
Figure 11.8. Ammonium production rate of BM-hMSCs over three passages in various 
concentrations of HPL and 10% FBS. Showing the increase in ammonium production rate as 
the level of HPL decreases. Data shows mean ± SD, n = 4 
 
 
The yield of lactate from glucose can be seen in Figure 11.9, with around 2 mol.mol-1 in 10% 
HPL, demonstrating that glutamine was also metabolised as a carbon source into lactate. Figure 
11.9 also shows that the net flux through the oxidative phosphorylation pathway is increased as 
the concentration of HPL is reduced, although the general trend in the data demonstrates that 
BM-hMSCs predominantly utilise aerobic glycolysis as the main metabolic pathway for energy 
production (Dos Santos et al. 2010).   
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Figure 11.9. Yield of lactate from glucose of BM-hMSCs over three passages in various 
concentrations of HPL and 10% FBS. Showing the decrease in yield of lactate from glucose as 
the level of HPL decreases. Data shows mean ± SD, n = 4 
 
 
This study has assessed the effect of various concentrations of HPL to support the proliferation 
of BM-hMSCs. From these data it is clear that 10% HPL is the most comparable to 10% FBS for 
the support of BM-hMSC proliferation in monolayer culture. Therefore, an HPL concentration 
of 10% will be used for further experiments involving BM-hMSCs with at least one adaption 
passage prior to any experiments taking place.    
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Appendix C. Assessment of PRIME-XV® SFM for BM-hMSC expansion 
 
The development of serum-free BM-hMSC manufacturing processes will be critical for future 
process development as reducing and eventually eliminating the use of FBS from the cell culture 
medium has many key benefits. In addition to lot-to-lot variability, there are further process 
constraints on the use of FBS such as limited supply, spiralling cost, potential for pathogen 
transmission, increased risk of recipient immune reaction and reduced scope for process 
optimization. All of these considerations mean that moving towards a serum-free process would 
be beneficial in achieving scalable and consistent BM-hMSC manufacturing processes. In 
addition, serum-free culture has been shown to be amenable to scalable expansion technology 
such as microcarriers and stirred bioreactors (dos Santos et al. 2011a), producing higher BM-
hMSC yields per unit time than serum-based processes, which will be important for driving down 
the production cost of BM-hMSC therapies.  
 
It is important that prior to using a serum-free medium for BM-hMSC process development, that 
it is assessed for its impact on BM-hMSC expansion to ensure that it provides a favourable 
growth and identity profile. With this in mind an experiment was designed to compare the use 
of PRIME-XV® MSC Expansion SFM to the process baseline of 10% FBS culture for two BM-hMSC 
donors to ensure that any measured effect is not donor specific.   
 
 
Experimental Protocol 
In order to make a direct comparison to 10% FBS, BM-hMSC lines M0 and M2 were selected due 
to their stable growth characteristics in FBS culture. This was compared to PRIME-XV® MSC 
Expansion SFM over three passages. To make this comparison, four T-75 flasks were seeded 
with M0 and M2 BM-hMSCs per experimental condition giving a total of 16 flasks, which were 
cultured for three passages according to the protocol described in Section 3.2.5. At the end of 
each passage, the cell number was determined using the protocol in Section 3.4.2 and the 
growth kinetics calculated. In conjunction with this, daily medium samples were taken and 
analysed on the Nova BioProfile FLEX for glucose, lactate and ammonium concentrations as 
described in Section 3.4.6. From the growth kinetics data and the relative metabolite 
concentrations over each passage, the per cell flux of each metabolite was calculated. At the 
end of the third passage, the cells were assessed for immunophenotype using the flow 
cytometry protocol described in Section 3.4.5.  
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Results 
The number of cumulative population doublings for each condition can be seen in Figure 11.10, 
which shows that both M0 and M2 BM-hMSCs cultured in SFM had between 12 -14 cumulative 
population doublings compared with 8 – 10 cumulative population doublings in FBS over the 
same time period. This represents a significantly higher number of cumulative population 
doublings in SFM (p > 0.01) compared to FBS culture. From these data, it can be concluded that 
PRIME-XV® SFM significantly increases the proliferation potential of BM-hMSCs compared to 
10% FBS. This has the potential to offer advantages during process development as more BM-
hMSCs can be produced per unit time.  
 
 
 
Figure 11.10. Cumulative population doublings of BM-hMSC lines M0 and M2 in 10% FBS and 
PRIME-XV® SFM over three passages. Showing the increased growth kinetics under serum-
free conditions. Data shows mean ± SD, n = 4 
 
 
As mentioned previously, the net metabolite flux of BM-hMSCs between experimental 
conditions is an important parameter to assess, as it provides a quantitative indication of the 
effect that different culture media has on the metabolic profile of BM-hMSCs.  
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Figure 11.11 shows the glucose consumption rate of M0 and M2 BM-hMSCs over the three 
experimental passages in SFM and FBS. The net glucose consumption rate in SFM remained 
between 5 - 7 pmol.cell-1.day-1 across the three passages, which was significantly reduced (p < 
0.01) compared with the 15 - 20 pmol.cell-1.day-1 measured in 10% FBS. Further to this, Figure 
11.12 shows that the relative lactate production rate of the BM-hMSCs in SFM is significantly 
lower (p < 0.01) than BM-hMSCs in FBS culture.  
 
 
 
 
Figure 11.11. Glucose consumption rate of BM-hMSC lines M0 and M2 over three passages in 
10% FBS and PRIME-XV® SFM. Showing the reduced glucose consumption rate in SFM. Data 
shows mean ± SD, n = 4 
 
 
This reduction in the per cell flux of both glucose and lactate demonstrates an increase in the 
metabolic efficiency of BM-hMSC culture in SFM, which has potential advantages with 
increasing process yield, as a reduced concentration of glucose will be required and the 
potential inhibitory effects of lactate build up will be reduced. 
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Figure 11.12. Lactate production rate of BM-hMSC lines M0 and M2 over three passages in 
10% FBS and PRIME-XV® SFM. Showing the reduced lactate production rate in SFM. Data 
shows mean ± SD, n = 4 
 
 
Despite the reduced consumption of glucose and production of lactate over the three passages 
in SFM, Figure 11.13 shows that the per cell flux of ammonium for both BM-hMSC lines in FBS 
and SFM are between 1 – 2 pmol.cell-1.day-1. As before, this is an indication that reducing the 
concentration of serum in the culture medium encourages BM-hMSCs to reduce the flux 
through the aerobic glycolysis pathway and increase the utilisation of the glutamine to 
glutamate pathway, as demonstrated by the measured increase in ammonium production of 
BM-hMSCs in SFM. 
 
The yield of lactate from glucose can be seen in Figure 11.14, with below 1 mol.mol-1 in SFM, 
supporting the previous statement that BM-hMSCs cultures in SFM favour the production of 
energy via oxidative phosphorylation, whereas BM-hMSCs cultured in FBS tend to increase the 
flux through the aerobic glycolysis pathway. This again demonstrates that BM-hMSCs cultured 
in SFM have a more efficient metabolic profile compared to the same BM-hMSCs cultured in 
FBS.   
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Figure 11.13. Ammonium production rate of BM-hMSC lines M0 and M2 over three passages 
in 10% FBS and PRIME-XV® SFM. Showing similar ammonium production rate in both 10% FBS 
and SFM. Data shows mean ± SD, n = 4 
 
 
 
Figure 11.14. Yield of lactate from glucose of BM-hMSC lines M0 and M2 over three passages 
in 10% FBS and PRIME-XV® SFM. Showing the decrease in yield of lactate from glucose in SFM. 
Data shows mean ± SD, n = 4 
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The morphology of M2 BM-hMSCs in SFM compared with 10% FBS can be seen in Figure 11.15. 
The morphology of the BM-hMSCs cultured in SFM demonstrate differences in morphology with 
smaller, more spindle-shaped BM-hMSCs which are also packed more tightly together in 
monolayer culture. This is likely to greatly increase the available number of BM-hMSCs per area 
in culture, which will offer advantages for the manufacture of adherent cells as the yield per 
area will also increase.  
 
 
 
Figure 11.15. Phase contrast images showing morphology of BM-hMSC line M2 in 10% FBS and 
PRIME-XV® SFM over six days of culture.  
 
 
Immunophenotype analysis of M0 and M2 after the three experimental passages can be seen 
in Figure 11.16, which demonstrates the maintenance of CD73+, CD90+, CD105+, CD34- and HLA-
DR- BM-hMSCs in SFM compared with FBS culture. There was an increase in the positive 
expression of CD34 above the 2% positive threshold, which can be attributed to an increase in 
non-specific antibody binding caused by the culture of BM-hMSCs on a fibronectin substrate, as 
the upregulation of CD34 is not biologically possible for BM-hMSCs after selection by plastic 
adherence (Wagner et al. 2005).  
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Figure 11.16. Flow cytometry plots showing expression of CD90+, CD73+, CD105+, CD34- and 
HLA-DR- at the end of passage three in 10% FBS and SFM. In all cases 10,000 events were 
measured. 
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Appendix D. Fibronectin coating in glass bioreactor vessels 
In order to transfer the microcarrier culture of BM-hMSC from a serum based process to a 
serum-free process, the coating of the plastic microcarrier surface with an attachment protein 
is required to achieve BM-hMSC attachment to the surface. This is because the serum used for 
BM-hMSC culture contains a high level of these attachment proteins that coat the microcarrier 
surface during the microcarrier conditioning phase and promote BM-hMSC attachment to the 
surface and subsequent growth. For the expansion of BM-hMSCs in PRIME-XV® SFM in 
monolayer, fibronectin has successfully been used to coat the surface of the tissue culture flask 
prior to culture and therefore will be used to coat the microcarrier surface in suspension prior 
to BM-hMSC suspension culture. This fibronectin coating of the microcarriers will take place 
immediately before the start of the BM-hMSC culture process to ensure that the coating 
substrate remains active on the surface of the microcarrier prior to BM-hMSC addition. This 
does present a challenge however, as both the coating step and the culture step will take place 
within the same spinner flask vessel to avoid the transfer of material between spinner vessels, 
reducing the potential for loss of material and culture contamination. With the coating of the 
microcarriers with fibronectin taking place in the same spinner flask, it must be confirmed that 
the fibronectin is not able to coat the internal glass surface of the spinner flask, therefore 
allowing BM-hMSCs to attach and grow on a surface other than the microcarriers in suspension. 
With this in mind, an experiment was designed to test whether the BM-hMSCs were able to 
attach to the glass surface of the spinner flask following the fibronectin coating protocol 
developed in Section 6.3.      
 
 
Experimental Protocol 
In order to test whether the fibronectin was able to coat the internal glass surface of the spinner 
flask, four experimental conditions were assessed. The first condition aimed to test the normal 
attachment of BM-hMSCs to tissue culture plastic as a positive control, with the second 
condition testing the relative BM-hMSC attachment in an ultra-low attachment well plate to 
provide a negative experimental control. To assess whether the BM-hMSC were able to attach 
to the spinner flask surface after the fibronectin coating step, the attachment assay was 
performed on a glass vessel treated with Sigmacoat before and after the fibronectin coating 
procedure. For the attachment assay, 10,000 BM-hMSCs per cm2 were seeded into each 
condition at n = 3 with an appropriate volume of culture medium and placed into an incubator 
(see Section 3.2.5) for three hours to allow for BM-hMSC attachment. After this three hour 
period, the culture vessels were removed, washed with PBS and trypsin added to remove BM-
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hMSCs attached to the surface (see Section 3.2.5). The BM-hMSCs in this solution were then 
counted (see Section 3.4.2) and the percentage of BM-hMSC that had attached was calculated 
from the amount initially seeded.      
 
 
Results 
The three hour attachment efficiency of each condition can be seen in Figure 11.17. This 
demonstrates that under normal culture conditions, a high percentage (80 – 90 %) of BM-hMSCs 
are able to attach to the culture surface within this three hour period. In contrast, the 
attachment efficiency of the BM-hMSCs in the ultra-low attachment plate was measured to be 
< 10%, the presence of this low amount of BM-hMSC is likely due to the presence of residual 
cells following the PBS washing step. It is clear from Figure 11.17 that the BM-hMSCs were not 
able to attach to either the spinner flask surface before or after the fibronectin coating step with 
< 30% attachment measured in both conditions. This is significantly lower (p < 0.01) than the 
positive control and the presence of BM-hMSCs in the final solution was likely the result of 
performing the PBS washing step in a spinner flask, which is even more inefficient than the ultra-
low attachment well plate. This is clear evidence that the fibronectin is not able to coat the 
spinner flask and therefore it is possible to perform the fibronectin coating of the microcarriers 
in the same spinner flask that the culture takes place within.   
 
 
Figure 11.17. Comparison of BM-hMSC attachment to tissue culture plastic, low-attachment 
plate, sigma-coated spinner flask and fibronectin coated spinner flask. Demonstrating that 
BM-hMSCs do not attach to the spinner flask surface after fibronectin coating. Data shows 
mean ± SD, n = 3.   
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Appendix E. Controller tuning of the DASGIP DASbox bioreactor platform 
 
The development of a process control strategy will be important to drive increased yield and 
consistency into the production of BM-hMSC in suspension. The goal of this process control 
strategy is to maintain tight control on key process parameters effecting BM-hMSC expansion 
such as dissolved oxygen concentration and the pH of the culture medium. 
 
The DASGIP DASbox bioreactor system has been selected to perform these studies as it can 
maintain the same culture volume as the spinner flasks and has physical characteristics similar 
to bioreactor systems at the litre scale, with the possibility of online monitoring and control of 
these key parameters. The DASbox bioreactor system has been primarily developed for the 
culture of mammalian cells for the production of protein and therefore must be validated for 
the expansion of BM-hMSCs. The key part of this validation is to ensure that the DASbox 
bioreactor system can maintain a tight control of key process parameters for BM-hMSC culture, 
where the consumption of oxygen and production of pH-altering substrates is far lower than 
traditional cell culture processes. With this in mind, an experiment was carried out to tune the 
settings of the pH control loop, which was initially found to be unstable. In contrast, the 
regulation of oxygen in the DASbox system was stable using the default settings and therefore 
these settings were used for all controlled BM-hMSC experiments.         
 
 
Experimental Protocol 
In order to stabilise the pH control system on the DASbox an experiment was set up with the 
system set to control at pH = 7.4 and the culture vessels sterilised, filled with 100 mL of DMEM 
supplemented with 10% FBS and connected to the DASbox bioreactor platform. Following 
calibration of the pH probes, the system was set to control at 100% dissolved oxygen and 37°C 
in order to simulate normal operating conditions. Once stabilised, the control loop parameters 
were adjusted with the software recording and allowed to stabilise to assess the pH range 
obtained under those parameters. This process was repeated until an acceptable control range 
was obtained for the pH in the bioreactor system.  
 
 
Results 
The result of this iterative process can be seen in Figure 11.18. The default settings of the 
DASbox pH controller (point A) created a pH range of 7.42 – 7.67 which is clearly very large, 
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particularly considering the sensitivity of BM-hMSCs to the pH of culture medium (Wuertz et al. 
2009), although these fluctuations are typical within an uncontrolled monolayer process. In the 
first instance, the proportional gain was doubled to 50 in order to increase the magnitude of the 
response of the controller to changes in process disturbances and the reset time was halved to 
increase the response time following a process disturbance. Additionally, the pre-set overlay of 
6% CO2 was applied to prevent the control system from dropping below this value during 
controller fluctuation.  This intervention reduced the pH range by 0.11 (see Table 11.4), however 
this range was still too large for BM-hMSC culture.  
 
 
 
Figure 11.18. Loop tuning of the DASGIP DASbox pH controller for BM-hMSCs showing the 
evolution of the control strategy to obtain a stable process control system.  
 
 
 
The second intervention was to further reduce the reset time of the controller to 300 seconds 
and therefore reduce the lag time of response to process disturbance. In addition to this, the 
auto-reset function was disabled, which is in place to protect the culture process from going 
below the control set-point (pH = 7.4). It was determined that a reduction of the pH to below 
this set-point would not be detrimental to the BM-hMSC culture (Schop et al. 2009b) and 
therefore this layer of protection could be removed as it was the main cause of the fluctuations 
in the culture pH. At this point, it was also decided that the pre-set overlay should be removed 
as this had the potential to cause issues if the pH was reduced enough during expansion that 
the CO2 concentration in the inlet gas was required to be lower than the pre-set value of 6%. 
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Table 11.4. Proportional-integral (PI) controller settings for the pH controller on the DASGIP 
DASbox bioreactor relating to Figure 11.18. Demonstrating the reduced pH range achieved 
after tuning the control settings for BM-hMSC culture on microcarriers.   
 pH set-
point 
Proportional 
gain, Kp 
Reset time, 
Ki (s) 
Deadband 
Auto 
reset 
Pre-set 
overlay 
pH range 
A 7.4 25 3600 0.02 On Off 0.25 
B 7.4 50 1800 0.02 On 6% CO2 0.14 
C 7.4 50 300 0.02 Off Off 0.04 
D 7.4 50 300 0.01 Off Off 0.02 
 
 
 
These changes to the control parameters on the DASbox system greatly reduced the control 
range of the pH to 0.04. It can be seen from Figure 11.18, however, that there was still drift in 
the pH control setting which could be mitigated. To achieve this, the deadband (or neutral zone) 
in the controller was adjusted from 0.02 to 0.01 which acts to decrease the region in which no 
control action occurs. It can be seen from Figure 11.18 that this eliminated the drift in the pH 
and halved the pH control range to 0.02. This was determined to be a satisfactory range for the 
pH controller and represented a reduction in the pH fluctuation of 0.23.  
 
